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Abstract
Background: Leukaemia is a complex disease affecting all blood cell lineages. It affects 
millions of people worldwide each year and mortality rates are high, despite considerable 
improvements in treatment. Thus, new therapies for leukaemia are urgently needed to improve 
leukaemia patients' health and survival. Since polyphenols exert pro-apoptotic effects in solid 
tumours, our study investigated the effects of polyphenols in haematological malignancies.
Methods: The effects of eight polyphenols (quercetin, chrysin, apigenin, emodin, aloe-emodin, 
rhein, cis-stilbene and trans-stilbene) was studied on cellular proliferation, the induction of 
apoptosis and cell cycle progression in four lymphoid (JURKAT, MOLT-3, CCRF-CEM and 
U937) and four myeloid (HL-60, THP-1, K562 and KG-la) leukaemia cells lines, together 
with normal haematopoietic control cells (CD34+ HSC and CD133+ HSC) from cord blood. 
Further to this, an investigation was made of the effects of the most promising polyphenols 
used in combination with nine standard chemotherapeutic agents (etoposide, doxorubicin, 
cyclophosphamide, chlorambucil, cisplatin, methotrexate, 6-mercaptopurine, 5-fluorouracil 
and imatinib). For this polyphenol and chemotherapy combination work four leukaemia cells 
lines were used: the two most sensitive (JURKAT and CCRFM-CEM) and two most resistant 
(KGla and THP-1) to polyphenol treatment. Subsequently, an investigation was undertaken to 
identify potential mechanisms of action of these polyphenol when used alone and in 
combination with chemotherapeutics. The extrinsic and intrinsic apoptotic pathways were 
investigated together with effects on glutathione levels and DNA damage.
Results: Emodin, quercetin, and cis-stilbene were the most effective polyphenols at decreasing 
cell viability and inducing apoptosis. Lymphoid cell lines were normally more sensitive to 
polyphenol treatment compared to myeloid cell lines; however those myeloid (KG-la and 
K562) cell lines which were most polyphenol resistant; were however affected by emodin and 
quercetin at micromolar treatment doses. Non-tumour cells were less sensitive to all 
polyphenols compared to the leukaemia cells. Mechanistically, most polyphenols alone 
depleted glutathione (GSH) levels associated with a direct activation in caspase 8 and/or 
caspase 9 in leukaemia cell lines at 24 h. Polyphenols also had differential capacities to induce 
DNA damage in the leukaemia cell lines. Polyphenols acted synergistically in lymphoid cell 
lines and differently in myeloid cell lines producing either synergistic, additive, competitive 
antagonistic or antagonistic effects; when they were combined with toposiomerase inhibitor 
agents (etoposide and doxorubicin) and alkylating agents (cyclophosphamide and chlorambucil, 
cisplatin). In contrast, they worked antagonistically with anti-metabolites agents (methotrexate 
and 6-mercaptopurine) in both lymphoid and myeloid leukaemia cell lines. Mechanistically the 
synergistic induction of apoptosis observed following the combination of polyphenols with
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chemotherapeutic agents was caused by the direct activation of intrinsic or /and extrinsic 
apoptotic pathway through the up-regulation of caspase 8 or caspase 9 within the lymphoid and 
myeloid leukaemia cell line. Furthermore, it has been shown the synergistic effects observed 
when polyphenols and chemotherapy agents were combined was correlated with down 
regulation of GSH levels and an induction of DNA damage which drove apoptosis. 
Alternatively where there was an antagonist effect there was an up-regulation of GSH levels, a 
reduction in DNA damage and the level of apoptosis.
Conclusions: These findings demonstrate that polyphenols induce apoptosis and arrest cell 
cycle in leukaemia cell lines which could translate to anti-cancer activities in leukaemia, 
although the effects were dependant on polyphenol type and origin of the cell line investigated. 
Importantly, the differential sensitivity of emodin, quercetin, and cis-stilbene between 
leukaemia and normal cells suggests that polyphenols are potential therapeutic agents for 
leukaemia. Furthermore, this study concluded that the efficacy of standard chemotherapeutic 
agents were differentially modulated by polyphenols, producing either synergistic, additive or 
competitive antagonistic/antagonistic effects, which was dependent on type of polyphenol, 
chemotherapy agent and cell line. Interestingly the study showed that synergistic or 
antagonistic effects observed following the combination treatments were strongly dependent 
on the modulation of glutathione levels in association with the formation of y-H2AX nuclear 
foci and DNA damage in leukaemia cell lines.
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Chapter 1 
Introduction.
1.1 Introduction to Cancer
Cancer is considered as a leading cause of disease worldwide. In 2012, there were an estimated
14.1 million cancer cases and 8.2 million cancer deaths in the world (American Cancer society, 
2014; Cancer Research UK, 2014). Approximately 7.4 million cases (53%) and 4.7 million 
deaths (57%) were estimated in males; and 6.7 million cases (47%) and 3.5 million deaths 
(43%) were estimated in females, giving a male: female ratio of 10:9 of cancer cases and 10:8 
of cancer mortality (Cancer Research UK, 2014). There are more than 200 different types of 
cancer, but the top four most common cancers worldwide are lung cancer, breast cancer, 
colorectal cancer and prostate cancer, together accounting for 53% of all cancer cases and 46% 
of all cancer deaths. Furthermore the ten most common cancers in men and women based on 
the estimation of UK in 2011 (Cancer Research UK, 2014) and USA in 2014 (American 
Cancer society, 2014) are summarised and showed in Table 1.1.
Cancer is caused by both external (chemicals, radiation tobacco and infectious) and internal 
factors (inherited mutations, hormones, immune conditions, and mutations that occur from 
metabolism) (Cancer Research UK, 2014). These factors may act together or in sequence to 
initiate or promote the development of cancer (Cancer Research UK, 2014). Cancer is defined 
as a group of diseases characterised by the uncontrolled growth and spread of abnormal cells. 
In fact, the abnormal growth of cancer cells is usually derived from a single abnormal cell that 
has lost normal control mechanisms. When cancer cells abnormally grow and multiply, they 
form a mass of cancerous cells called a tumour. Most tumours appeared as a solid mass, and 
can be classified as either benign (non-cancerous) or malignant (cancerous) tumours (Cancer 
Research UK, 2014).
The benign tumours are not cancer and non-life threatening. They can be removed in most 
cases, and usaully do not return. Most importantly, cells from benign tumours do not invade 
neighbouring tissues, or spread throughout the body. However, they can sometimes continue to 
grow and cause a problem by pressing on the surrounding organs or tissues. Papilloma (a 
projecting mass on the skin), adenoma (a tumour that grows in and around the glands), lipoma 
(a tumour in fatty tissue), osteoma (a tumour originating in the bones), myoma (a tumour of 
muscle tissue), angioma (a tumour composed of small blood or lymph vessels) and nevus (a 
skin tumour); are the most common examples of benign tumours (Cancer Research UK, 2014).
In contrast, malignant tumours are cancer and life threatening. They have the capacity to 
spread by either invasion to adjacent tissues; or by the formation of metastasis which spread 
the cancer throughout the body via the lymphatic and blood systems giving rise to secondary 
cancerous tumours. Malignancies or cancers can be divided based on the tissue type and cell 
type that are affected. They include: sarcomas (derived from connective tissues), carcinomas
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(derived from epithelial tissues), lymphoma and leukaemia (which arising from hematopoietic 
blood cells), germ cell tumours (derived from pluripotent cells of the testis and ovaries), and 
blastoma (derived from immature precursor cells; or embryonic tissue) (American Cancer 
society, 2014). Each type of cancer can behave very differently, because they grow at different 
rates and respond differently to treatment (American Cancer society, 2014).
M en W om en
UK (2011) USA (2014) UK (2011) USA (2014)
Prostate
(25% cases; 13% deaths)
Prostate
(26% cases; 6% deaths)
Breast
(30% cases; 15% deaths)
Breast
(29% cases; 15% deaths)
Lung
(14% cases; 23% deaths)
Lung
(14% cases; 28% deaths)
Lung
(12% cases; 21% deaths)
Lung
(13% cases; 28% deaths)
Colon and Rectum
(14% cases; 10% deaths)
Colon and Rectum
(8% cases; 8% deaths)
Colon and Rectum
(11 % cases; 10% deaths)
Colon and Rectum
(8% cases; 9% deaths)
Urinary Bladder
(4% cases; 4% deaths)
Urinary Bladder
(7% cases; 4% deaths)
Uterus
(5% cases; 3% deaths)
Uterine corpus
(6% cases; 3% deaths)
Malignant Melanoma
(4% cases)
Malignant Melanoma
(5% cases)
Ovary
(4% cases; 5% deaths)
Thyroid
(6% cases)
Kidney and Renal 
pelvis (4% cases; 3% 
deaths)
Kidney and Renal pelvis
(5% cases; 3% deaths)
Non-Hodgkin Lymphoma
(4% cases; 3% deaths)
Non-Hodgkin Lymphoma
(4% cases; 3% cases)
Non-Hodgkin
Lymphoma
(4% cases; 3% deaths)
Non-Hodgkin lymphoma
(4% cases; 3% deaths)
Malignant Melanoma
(4% cases)
Malignant Melanoma
(4% cases)
Oesophagus
(3% cases; 6% deaths)
Oesophagus
(4% cases; 4% deaths)
Brain
(3% cases; 3% deaths)
Kidney and Renal pelvis
(3% cases; 4% deaths),
Leukaemia
(3% cases; 3% deaths)
Leukaemia
(4% cases; 5% deaths)
Pancreas
(3% cases; 6% deaths)
Pancreas
(3% cases; 7% deaths)
Brain
(3% cases; 3% deaths)
Liver and Intrahcpatic 
Bile duct
(3% cases; 5% deaths)
Leukaemia
(2% cases; 3% deaths)
Leukaemia
(3% cases; 4% deaths)
Table 1.1: A Summary for Ten Most Common Cancers with their Percentage Estimated Cases 
and Deaths For Men and Women in UK (2011) and USA (2014) from the Latest Data Available. 
Summarised from American Cancer society, 2014; Cancer Research UK, 2014.
1.2 Normal and Leukaemia Haematopoiesis
1.2.1 Normal Haematopoiesis
Hematopoietic stem cells (HSCs) give rise to all blood cells during the process of 
haematopoiesis (Sachs, 1996; Passegue et al, 2003; Kondo, 2010). Blood cell production is 
highly regulated; insuring homeostatic maintenance of the blood cell population (Sachs, 1996; 
Passegue et al, 2003; Kondo, 2010). HSCs are mostly found in bone marrow (Passegue et al, 
2003). HSCs are capable of self-renewal with the ability to divide, produce daughter cells with 
identical characteristics and retain all of their proliferative and developmental potential. HSCs 
can differentiate into all classes of blood cells (Figure 1.1) (Passegue et al, 2003).
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During self-renewal, HSCs have the ability to form two sub-populations: (i) Long-term 
haematopoietic stem cells, which have prolonged self-renewal ability; and (ii) short term 
haematopoietic stem cells, which have limited self-renewal ability (Figure 1.1) (Passegue et al, 
2003). Self-renewal ensures that the HSC pool is protected and not used up. HSCs develop into 
multipotent progenitors cells which subsequently divide and differentiate into either common 
myeloid or common lymphoid progenitor cells (Figure 1.1) (Passegue et al, 2003). Each cell 
type can then go on to differentiate into one or more specific blood cell types (Figure 1.1) 
(Passegue et al, 2003).
The common myeloid progenitors give rise to erythrocytes, megakaryocytes and some 
classifications of white blood cell or granulocytes (neutrophils, eosinophils, basophils), 
monocytes which in turn form macrophages and dendritic cells (Figure 1.1) (Passegue et al, 
2003; Kondo, 2010). The common lymphoid progenitors give rise to T-and B-lymphocytes and 
Natural Killer (NK) cells (Figure 1.1) (Passegue et al, 2003). B-cells are commonly 
synthesised in bone marrow and subsequently differentiate into plasma cells within the lymph 
nodes. Once formed the plasma cells do not divide further (Passegue et al, 2003).
1.2.1 Aberrant Haematopoiesis and Leukaemia Development
Normally, during haematopoiesis there is a regulation of cellular proliferation, differentiation 
and release of cells from the bone marrow into blood (Passegue' et al, 2003). This ensures that 
there is the correct compliment of each blood cell type within blood and that a state of 
homeostasis and optimal function is maintained (Passegue' et al, 2003). Therefore, aberrant 
production of blood cells is associated with the onset of leukaemia (Jones et al, 2008). 
Typically, aberrant haematopoiesis in leukaemia results in an enormous overproduction of a 
sub-group of blood cells or alternatively the production of immature cells that fail to 
differentiate into their mature state (Jones et al, 2008).
Leukaemia often develops from accumulation of mutations in HSCs. This leads to the 
production of non-functional immature HSCs or multi-potent progenitors cells. These 
immature cells are often referred to as leukaemia stem cells (Figure 1.2) (Jones et al, 2008). 
These stem cells retain some of the properties of normal HSCs: their capacity for self-renewal, 
proliferation and prolonged survival, but fail to terminally differentiate (Figure 1.2) (Jones et al, 
2008). This increase in proliferation and/or survival is believed to be caused by gene mutations 
in the RAS family members; which is the name specified to a family of related proteins that is 
ubiquitously expressed in all cell lineages and organs; and the tyrosine kinase receptors that 
drive growth: c-Kit (tyrosine-protein kinase Kit) and FLT-3 (Fms-like tyrosine kinase 3) 
amongst others (Jones et al, 2008).
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Normal Haem atopoiesis
Bone Marrow
O
Long-Term Haematopoietic Stem Cells (LT-HSCs)
Short -Term Haematopoietic Stem Cells (ST-HSCs)
*
O
Multipotent  Progenitors (MPPs)
o o
Common Lymphoid Progenitors (CLP) Common Myeloid Progenitors (CMP)
o
Lymhoblast
m m
Erythrocytes Myeloblast Megakaryocyte
▼ V ▼o o o
T-Lymphocytc B-Lymphocyte Natural Killer
|  (NK) Cell
Granulocytes
Cells Passed into Blood
C i----------------------- 1----------------------  Monocytei  I
Plasma Cc" fa Q
Basophil Neutrophil Eosinophil ,
Blood Macrophages
3
i
•Q
Platelets
Figure 1.1: Schematic representation of the haematopoietic hierarchy. This figure represents 
the generation of mature myeloid and lymphoid haematopoietic cells from long-term 
haematopoietic stem cells. Modified from Passegue et al, 2003.
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Aberrant Haematopoiesis and Leukaemia Development
Bone M a r r o w
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ii c
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Figure 1.2: Schematic representation of the aberrant haematopoietic and initiation of 
leukaemia stem cells (LSCs) that caused extensive self-renewal. Modified from Passegue et al, 
2003.
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1.3 Leukaemia
Leukaemia is a malignant neoplasm affecting the hematopoietic system. It is defined as a 
cancer of the myeloid or lymphoid blood cells (Passegue' et al, 2003; Pokhare, 2012; Wagner 
et al, 2012). Leukaemia is generally characterised by: i) increased cell survival caused by the 
up-regulation of Bcl-2, Bcl-x and down-regulation of Fas-receptor signalling pathways (FAS); 
ii) increased proliferation capacity caused by aberrant c-Myc, Cyclin D l, and BCR-ABL gene 
expression amongst others; and iii) increased self-renewal capacity as a result of up-regulation 
of HOX, WNT and NOTCH pathways; genomic instability, deregulated signalling pathways 
and impaired differentiation (Passegue' et al, 2003).
1.3.1 Classic Classification of Leukaemia
Leukaemia is a complicated disease. Initially, it was classified according to stage of disease 
progression as either acute or chronic. Acute leukaemia is characterised by the large number of 
immature blood cells or blast cells, the disease progression is rapid and the prognosis is 
generally poor. Chronic leukaemia is characterised by a large number of precursor cells that 
are more differentiated than blast cells, the disease progression rate is relatively slow and is 
fatal in months to years if untreated (Passegue' et al, 2003; Pokhare, 2012). Acute and chronic 
leukaemias are further sub-divided according to lineage as either myeloid or lymphoid. Four 
main categories of leukaemia can be identified based on differentiation and lineage: acute 
myeloid leukaemia (AML); chronic myeloid leukaemia (CML); acute lymphoid leukaemia 
(ALL) and chronic lymphoid leukaemia (CLL) (Table 1.2). The first three of these types arise 
from haematopoietic progenitor cells, whilst CLL is derived from mature lymphocytes 
(Passegue' et al, 2003; Pokhare, 2012). This classification system has been updated by the 
World Health Organisation and the current classification system involves a number of specific 
subdivisions which take into account the cell lineage, stage of disease and presence of 
cytogenetic abnormalities which has led to tailored treatment regimens for specific leukaemia 
subclasses (Harris et al, 2000; Tefferi and Vardiman, 2008; Vardiman et al, 2009; Claudia et al, 
2011).
Myeloid Lymphoid
Acute Acute Myeloid Leukaemia (AML) Acute Lymphocytic Leukaemia (ALL)
Chronic Chronic Myeloid Leukaemia (CML) Chronic Lymphocytic Leukaemia (CLL)
Table 1.2: Leukaemia Classification According to the rate of disease progression, and due to 
their HSC lineage.
21
1.3.2 Use of Leukaemia Cells in the Laboratory
A number of cell lines have been developed from leukaemia patients that can be essential for 
initial investigations into new treatments and understanding leukaemia pathogenesis in the 
laboratory. Cell lines representing the different types of leukaemia are commercially available 
and used routinely in the laboratory (Table 1.3).
Cell Line Name HI.60 THP-1 K562 KG-la i Jurkat Molt-3 CCRF-CEM U937
Human
Acute Acute Chronic Acute
Acute T cell 
leukaemia
Acute Acute leukaemia
Description promyelocytic monocytic myelogenous myelogenous lymphoblastic lymphoblastic monocyte
leukaemia leukaemia leukaemia leukaemia leukaemia leukaemia lymphoma cell
line
Year of 
Establishment
1976 1978 1970 1977 1976 1971 1964 1974
Cell phenotype Promyeloblast Monocytes Lymphoblast Myeloblast T Lymphoblast T Lymphoblast T Lymphoblast Monocytes
Initially AML r — -1- - - ALL with
Diffuse
Patient Disease
M3, laier 
changed to
AM LM 5 s CML
Erythroleukem
iatoA M L
ALL
i
receiving
multidrug
Lymphosarcom 
to ALL
histiocytic
lymphoma
— - -- -------- - AML M2 ......-..... - - - - - - .^.- ........ .. chemotherapy —  —  ..... -  -
Disease Status At diagnosis At relapse At blast crisis At relapse At Is1 relapse At relapse At relapse Refractory
Patent Data
36 year old - 1 year old- 53 year old : 59 year old - ■ 14 year old - 19 year o ld - 3 year o ld - 37 year o ld -
female male female male male male female male
Source of cell
Peripheral
blood
Peripheral
blood
Pleural effusion Bone marrow
Peripheral
blood
Peripheral
blood
Peripheral
blood
Pleural effusion
Doubling Time 
in culture
25-40 h 35-50 h 24-30 h 40-50 h 25-35 h 40 h 24-30 h 30-40 h
Primary
References
Collins etal, 
1977
Tsuchiya etal, 
1980
Lozzio1 and 
Lozzio2, 1975;
Koefllerand  
Golde, 1978
Schneider, 1977
Minowada,
1972
Foley, 1965
Sundstrom and 
Nilsson, 1976
p53 statues Null Null Null Null Null Wild type Mutant Null
p53 statues 
References
An et al, 2000; 
Durland and 
Resiman, 2002
Durland and 
Resiman, 2002
Durland and 
Resiman, 2002
Durland and 
Resiman, 2002
An et al, 2000 Cai e ta /, 2001
Gelcy etal, 
1997; 
Anagnostopulo 
setal, 2005
An etal, 2000
Table 1.3: Summary of eight leukaemia cell lines, including their history, clinical data, p53 
status. All leukaemia cell lines except MOLT-3 are p53-deficient, being either null, or containing 
mutant p53. MOLT-3 cells express wild type p53.
1.3.3 Epidemiology of Leukaemia
1.3.3.1 Incidence
In 2012 approximately 352,000 people were diagnosed with leukaemia worldwide (Cancer 
Research UK, 2014). The highest incidence rates were in Australia and New Zealand, and the 
lowest rates are in Western Africa (Cancer Research UK, 2014). From the latest data available, 
the diagnosis of new cases of leukaemia were around 8,616 cases in the UK in 2011, 82,300
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cases in Europe in 2012 (Cancer Research UK, 2014), and 52,380 cases in the USA in 2014 
(Leukaemia & lymphoma Research, 2014). Both the UK (2011) (Cancer Research UK, 2014) 
and USA (2014) Leukaemia & lymphoma Research, 2014) reports showed that the incidence 
rates of leukaemia were higher in males than females. In the UK there were around 5,014 
(58%) male cases and 30,100 (57%) female cases (Cancer Research UK, 2014). In the USA 
there were around 3,602 (42%) male cases and 22,280 (43%) female cases (Leukaemia & 
lymphoma Research, 2014). This produced a male: female ratio of around 14:10 (Cancer 
Research UK, 2014). In the UK in 2011, leukaemia incidence was the 9th most common cancer 
in males and the 10th most common cancer in females (Cancer Research UK, 2014). In the UK, 
8% of all leukaemias were ALL, 34% AML, 38% CLL and 8% CML (Cancer Research UK, 
2014). Thus in the UK CLL was the most common subtype of leukaemia and ALL the least 
common (Cancer Research UK, 2014).
Leukaemia is considered to be largely a disease of adulthood which increases in incidence with 
age (Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). Age-specific 
incidence rates increase sharply from 45-49 years onwards, with the highest rates of 
occurrence being after 75 years (Cancer Research UK, 2014). However when considering the 
four major classification of leukaemia it can be seen that there is not always an increase in 
disease occurrence with ages (Cancer Research UK, 2014). Indeed when considering ALL, it 
can be seen that diagnosis normally occurs during early adulthood, in individuals under 20 
years old (Table 1.4) (Cancer Research UK, 2014). AML has a more bi-modular rate of 
incidence; it is either diagnosed in early adulthood in individuals between 25 to 29 years or in 
adults between 50 and 75 years or over (Table 1.4) (Cancer Research UK, 2014). Both CLL 
and CML are adult diseases being once again mostly diagnosed in adults between 55 and 75 
years, or older (Table 1.4) (Cancer Research UK, 2014).
Some racial variation in the occurrence of leukaemia has been observed in the USA. The 
highest incidence rates for leukaemia are found in the non-Hispanic white populations, whilst 
the lowest rates are found in American-Asian, American-Indian and Alaska Native populations 
(Leukaemia & lymphoma Research, 2014).
13.3.2 Relative Survival Rate
Commonly, relative survival rates of leukaemia depend on the type of leukaemia, the patient’s 
age, gender and treatment regime (Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014). From the latest data available, the overall survival rates 5 years post­
diagnosis for leukaemia were 44.3%; in the UK (between 2005 and 2009) and 59.2% in the 
USA (between 2003 and 2009) (Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014).
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In the USA (between 2003 and 2009) the 5-year relative survival rates for each major type of 
leukaemia were: 58.6% for all ages in CML patients; 83.1% for all ages in CLL patients; 
24.9% for adults and 64.8% for children and adolescents (younger than 15 years) in AML 
patients; and 68.8% for adults, 91.7% for children and adolescents (younger than 15 years), 
and 92.6% for children younger than 5 years in ALL patients (Leukaemia & lymphoma 
Research, 2014).
1.3.3.3 Mortality
Worldwide, leukaemia is the 10th most common cause of cancer deaths with more than 
265,000 deaths in 2012 (Cancer Research UK, 2014; Leukaemia & lymphoma Research, 
2014). Mortality of leukaemia was around 53,800 deaths in the Europe in 2012, 4,807 deaths in 
the UK in 2011 (Cancer Research UK, 2014); and 24,090 deaths in the USA during 2014 
(Leukaemia & lymphoma Research, 2014).
In the UK in 2012, leukaemia was the 9th most common cause of cancer death among males 
and females (Cancer Research UK, 2014). Whilst in the USA (between 2010 until 2014), 
leukaemia was the 5th most common cause of cancer deaths in males and the 6th most common 
in females (Leukaemia & lymphoma Research, 2014). A comparison of the major types of 
leukaemia (AML, ALL CLL and CML) showed that AML caused the greatest number of 
deaths, both in the UK (2011) and the USA (2014) (Table 1.5) (Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014).
The leukaemia mortality is strongly correlated with increasing age, in both males and females 
(Cancer Research UK, 2014). In the UK between 2010 and 2012, 56% of deaths from 
leukaemia were in individuals aged 75 or over, whilst only 4% were in those aged 35 years or 
under (Cancer Research UK, 2014). However in both the UK and the USA, leukaemia was 
responsible for more deaths than any other type of cancers in children, adolescents and young 
adults less than 20 years old (Cancer Research UK, 2014; Leukaemia & lymphoma Research, 
2014). In the USA between 2006 and 2010, it was estimated that the rate of deaths from 
leukaemia was 7.4 per 100,000 in the non-Hispanic whites population; 7.3 per 100,000 in the 
whites at population and 6.1 per 100,000 in the black population (Leukaemia & lymphoma 
Research, 2014).
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Number Cases 
of Leukaemia in 
UK (2011)
Number Cases of 
Leukaemia in the 
USA (2014)
Most Common Age of Diagnosis
ALL 650 cases 6,020 cases Children and young adults aged less than 20yrs
AML 2,900 cases 15,720 cases Aged between 25 and 29; or 55 and 75, or older
CLL 3,200 cases 18,860 cases Older adults aged between 55 and 75, or over
CML 680 cases 5,980 cases Older adults aged between 55 and 75, or over
Table 1.4: The major types of leukaemia and rates of occurrence in the UK and USA; along 
with the typical ages of diagnosis. (Cancer Research UK, 2014 and Leukaemia & lymphoma 
Research, 2014).
Number of Deaths 
for Leukaemia in 
UK (2011)
Number of 
Deaths for 
Leukaemia in the 
USA (2014)
Common Age at Which Death Occurred
ALL 218 deaths 1,440 deaths Children and young adults aged less than 20
AML 2,310 deaths 10,460 deaths Older adults aged 75 and over
CLL 1,136 deaths 4,600 deaths Older adults aged 75 and over
CML 248 deaths 810 deaths Older adults aged 75 and over
Table 1.5: A summary of the number of death caused by major types of leukaemia in the 
UK and USA; along with the common ages at which death occurred. This is summarised 
from the Cancer Research UK, 2014 and Leukaemia & Lymphoma Research, 2014.
1.3.4 Aetiology of Leukaemia
The exact cause of leukaemia in most patients remains unknown, however, there are a number 
of factors associated with increased risk of disease (Buffler and Kwan, 2005; Belson et al, 
2007; Kumar, 2011; Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014). Leukaemia has described as having a multifactorial aetiology resulting from: 
a) general factors (e.g. age, gender and ethnicity); b) environmental factors (e.g. exposure to 
chemical agents such as benzene or smoking related carcinogen ionising radiation, 
chemotherapy and viral infection); and/or c) genetic factors (e.g. congenital disease such as 
Down Syndrome, or genetic abnormality due to specific chromosomal mutations e.g. mutation 
of chromosome 22, (the Philadelphia chromosome) is linked to CML; or a family history of
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leukaemia) (Buffler and Kwan, 2005; Belson et al, 2007; Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014).
13.4.1 Environmental Factors
A number of environmental factors have been implicated in the aetiology of leukaemia: 
smoking, exposure to high levels of radiation, exposure to chemical agents such as benzene, 
prior chemotherapy or radiotherapy treatment or viral infection (Buffler and Kwan, 2005; 
Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). Smoking has a strong 
association with leukaemia. It has been shown to increase the risk of AML by 50%; although it 
may not be a direct cause of the disease (Cancer Research UK, 2014). Furthermore, smoking in 
leukaemia patients has been linked to higher relapse rates and an increased genetic instability 
of leukaemia cells (Chelghoum et al, 2002). Exposure to ionisation radiation and long term 
exposure to the chemicals such as benzene are considered to be a potential risk factors for most 
types of leukaemia (ALL, AML, CLL, CML) (Belson et al, 2007). Indeed, exposure to 
ionizing radiation has been significantly linked with both ALL and AML; but not CLL and 
CML (Belson et al, 2007). The use of chemotherapy agents for treatment of a previous primary 
cancer have been also linked to an increased occurrence of leukaemia. There is a subset of 
AML called secondary AML or therapy related myeloid leukaemia which occurs following 
cancer treatment with chemotherapy agents, such as the alkylating agents (cyclophosphamide, 
chlorambucil and cisplatin), and topoisomerase II inhibitor agents (etoposide and doxorubicin) 
(Pokhare, 2012). Unfortunately, the prognosis for secondary AML is poor; when compared to 
that of primary AML (Pokhare, 2012).
Viral infection has also been linked to some forms of leukaemia. For example, infection with 
human T-cell lymphotropic virus-1 (HTLV-I) is associated to the development of Adult T-cell 
leukaemia/lymphoma (ATLL), a cancer of activated mature T lymphocytes. The occurrences 
of ATLL however are largely restricted geographically to Japan, the Caribbean basin and parts 
of South America and Africa (Pokhare, 2012). Most cases of chronic leukaemia (CLL and 
CML) have no clear cause and there is no way to prevent them (Pokhare, 2012; Cancer 
Research UK, 2014; Leukaemia & lymphoma Research, 2014). The risk of developing CLL 
and CML does not seem to be associated with smoking, exposure to chemicals, or indeed as a 
result of an infection (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014). However, it is important to note that the exposure to some environmental 
agents may be linked with relatively specific clonal chromosome aberrations; which in turn 
may lead to chronic leukaemias. For example; an epidemiological study has reported that 
prolonged exposure to organic solvents is linked with Philadelphia chromosome positive CML 
(Cancer Research UK, 2014).
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1.3.4.2 Genetic Factors: Genetic Risk Verses Genetic Aberrations in Leukaemia
1.3.4.2.1 Hereditary Genetic Factors
Most leukaemias have an abnormal genetic component which contributes to the disease state. 
These genetic abnormalities are however not generally inherited (Leukaemia & lymphoma 
Research, 2014). Only very occasionally, does CLL occur within the same family group and 
may be present in a parent and child, or in two siblings (Kumar, 2011). Likewise in genetically 
identical twins, if one is diagnosed with AML or ALL there is a greater risk of disease in the 
second twin, however this is related to congenital abnormalities, rather than a shared 
predisposition to sporadic cancer (Kumar, 2011). Genetically, Down syndrome is the most 
common genetic mutation that is significantly associated with the development of acute 
leukaemias, especially AML (Xavier et al, 2009).
1.3.4.2.2 Acquired Genetic Factors
Leukaemia can also be caused by other genetic mutations which result in the inactivation of 
tumour suppressor genes, activation of oncogenes, or general genomic instability. This in turn 
causes inappropriate cellular proliferation, and differentiation which disrupts cell death 
pathways leading to the development of cancer. The many genetic abnormalities and risk 
factors associated with the incidence of leukaemia are shown in Table 1.6 (Johansson et al, 
2002; Shet et al, 2002; Akagi et al, 2009; Meijerink et al, 2009; Kumar, 2011; Leukaemia & 
lymphoma Research, 2014; Puiggros et al, 2014). Most genetic abnormalities and mutations 
occur spontaneously, or as a result of exposure to carcinogens or radiation; rather than being 
inherited (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 
2014). In fact, identification of these genetic abnormalities and mutations helps in the 
understanding of the pathophysiology and classification of the leukaemia; and hence the 
identification of the most appropriate treatment (Table 1.6) (Pokhare, 2012).
(A) Genetic Abnormalities and Mutations in Leukaemia
Generally, leukaemia is characterised by multiple random cytogenetic abnormalities including: 
chromosomal abnormalities such as translocations, deletions, inversions, duplication or 
substitutions, and/or gene mutations through the activation of oncogenes and/or deactivation of 
tumour suppressor genes, all of which contributed directly to malignant transformation 
(Johansson et al, 2002; Shet et al, 2002; Akagi et al, 2009; Meijerink et al, 2009; Kumar, 
2011; Leukaemia & lymphoma Research, 2014; Puiggros et al, 2014). Most types of 
leukaemia (ALL, AML, CLL, AML) are mainly associated with chromosomal translocations 
(Table 1.6) (Johansson et al, 2002; Shet et al, 2002; Akagi et al, 2009; Meijerink et al, 2009; 
Kumar, 2011; Leukaemia & lymphoma Research, 2014; Puiggros et al, 2014). However, it is
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possible to have a variety of alternative genetic mutation which can result in leukaemia 
(Puiggros et al, 2014).
ALL
>  T ranslocation betw een chrom osom e 1 and 19.
>  Translocation betw een chrom osom e 4  and 11.
>  T ranslocation betw een chrom osom e 11 and 19.
>  T ranslocation betw een chrom osom e 8 and 14.
>  Translocation betw een chrom osom e 22 and 9. (Philadelphia 
chrom osom e).
>  H yperdiploid (> 46 chrom osom es).
>  H ypodiploid (< 46 chrom osom es).
>  M ost com m on m utations occur in FLT3, SHP-2 and RA S/M A PK  
genes.
>  O ther m utations also can be  occurred in  N O TC H  1, JA K 1 and 
H O X 1 1 genes w hich are com m only seen in T-ALL; and m utations 
in the JA K2 gene are occurred com m only in B-ALL.
M eijerink et al, 2009; 
Leukaem ia & 
lym phom a Research, 
2014.
AML
>  Translocation betw een chrom osom es 8 and 21. Translocation 
betw een chrom osom es 15 and 17
>  Inversion in chrom osom e 16.
>  T risom y o f  chrom osom e 8 o r 21.
>  M onosom y in chrom osom e 7 or 21 and/or a loss o f  an X  or Y  
chrom osom e.
>  M utations in FLT3, N P M 1, c- K IT  and/or RAS genes.
Akagi et al, 2009; 
K um ar, 2011; 
Leukaem ia & 
lym phom a Research, 
2014.
CLL
>  D eletion in chrom osom e 13
>  M utation in chrom osom e 11 and 17,
>  T risom y o f  chrom osom e 12
>  M utations in P53, NO TCH 1 and SF3B1 genes
D ierlam m  et al, 1997; 
D ohner et al, 2000; 
Leukaem ia & 
lym phom a Research, 
2014; Puiggros et al, 
2014.
CML
>  Translocation between chrom osom e 22 and 9. (Philadelphia 
chrom osom e). T he Ph chrom osom e gives rise to a constitutively 
active fusion gene betw een the BCR gene on chrom osom e 22 and 
the ABL1 locus on chrom osom e 9.
>  M utations in the tum our suppressor genes R B 1, and P53.
Johansson et al, 2002; 
Shet et al, 2002; 
Leukaem ia & 
lym phom a R esearch, 
2014.
Table 1.6: The most common chromosomal abnormalities and genetic mutations that is 
associated with the classical type of leukaemia. This information is summarised from 
Johansson et al, 2002; Shet et al, 2002; Akagi et al, 2009; Meijerink et al, 2009; Kumar, 2011; 
Leukaemia &  lymphoma Research, 2014 and Puiggros et al, 2014.
13.4.3 Epigenetic Alterations in Leukaemia
Recent studies have demonstrated that the complexity of leukaemogenesis can not be 
accounted by chromosomal aberrations and gene mutations alone, but also involves epigenetic 
modifications in processes such as DNA methylation and histone modifications, which 
normally regulate gene transcription (Chen et al, 2010; Polakova et al, 2013). Changes in DNA 
methylation state and histone modification pattern lead to permanent changes in the genes 
expression that regulate the leukemogenic phenotype (Chen et al, 2010; Polakova et al, 2013).
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(A) Alterations in DNA Methylation in Leukaemia
DNA methylation is usually mediated by DNA methyltransferases (DNMTs) which catalyse 
the conversion of cytosine residues that preceed guanosine (CpG) to 5-methylcytosine, by the 
covalent addition of a methyl (CH3) group at the carbon 5 position of the cytosine (Ostrosky et 
al, 2007; Chen et al, 2010). DNMT is commonly responsible for maintaining DNA 
methylation patterns. DNMTs are usually over expressed and contribute to the pathogenesis of 
leukaemia by inducing aberrant regional hypermethylation (Ostrosky et al, 2007). 
Furthermore, leukaemia might be characterised by a general deregulation of CpG island 
methylation (Ostrosky et al, 2007). In normal cells, CpG residues cluster particularly in 
promoter regions of genes, and this is described as a CpG island. These CpGs, are commonly 
unmethylated, and are linked with hyperacetylated histones, and have an open chromatin 
configuration; which assist accessibility to transcription factors and transcriptional activation 
(Chen et al, 2010). However if the CpG islands are methylated in the promoter regions of 
genes this normally led to transcriptional repression, gene silencing and a condensed chromatin 
state (Chen et al, 2010).
Compared to the normal and leukaemic cells; show that the later exhibit either DNA 
hypermethylation, hypomethylation or aberrant methylation of CpG islands within gene 
promoters regions. Subsequently, this leads to the inactivation of tumour suppressor genes 
and/or activation of oncogenes (Chen et al, 2010).
Aberrant DNA hypermethylation in some genes has been shown to play a critical role in 
leukaemogenesis. (Ostrosky et al, 2007). For example, AML is associated with aberrant 
hypermethylation of tumour suppressor genes such as cyclin-dependent kinase inhibitor 2B 
(CDKN2B) gene, which encodes for p l5 INK4b. This gene tended to express higher levels in the 
presence of DNMT (REF). This phenomenon has been described well, and it is consequently 
associated with transcriptional silencing, and the recruitment of methyl-binding proteins and 
HDACs to regions surrounding the transcriptional initiation sites (Chen et al, 2010). 
Consequently, DNA hypermethylation has been suggested as one of the more important 
therapeutic targets in AML (Ostrosky et al, 2007). Furthermore, 95% of AML and ALL cases 
are associated with hypermethylation of the calcitonin gene, which is associated with an 
unfavourable clinical outcome specifically in ALL (Ostrosky et al, 2007). Likewise, CML is 
significantly linked with hypermethylation in the ABL1 promoter of the BCR-ABL fusion 
gene (Ostrosky et al, 2007). In constrast, CLL transformation is commonly associated with a 
massive hypomethylation phenomenon frequently affecting the enhancer regions (Martin et al,
2013).
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(B) Histones Modifications in Leukaemia
Leukaemia is not only associated with methylation of DNA, but also changes in histone 
modifications (Polakova et al, 2013). Histone modifications are an integral part of gene 
regulation and transcription as well as other nuclear processes (Polakova et al, 2013). Histone 
modifications involve acetylation, methylation, phosphorylation and other post-translational 
modifications of chromatin accessibility, DNA integrity and repair, transcription and 
replication (Polakova et al, 2013). The acetylation state of the histone tail is reversibly and 
regulated by two classes of enzymes: histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (Ostrosky et al, 2007). Leukaemia is often associated with a decreased 
of histone acetylation by increased histone deacetylase activity (HDACs), which can also lead 
to epigenetic silencing of tumour suppressor gene (Ostrosky et al, 2007). For instance, 
hypoacetylation of the p21wafl/c,fl promoter results in its silencing in acute leukaemia, and can 
be reversed by HD AC inhibitors (Ostrosky et al, 2007). Histone acetylation is normally linked 
to transcriptional activation, while histone deacetylation is linked to transcriptional silencing. It 
is reported that there is a strong link between aberrant histone acetylation and carcinogenesis 
(Ostrosky et al, 2007). In particular, histone hypoacetylation is commonly observed and linked 
to the initiation and/or progression of leukaemia mainly in AML (Ostrosky et al, 2007). Thus 
inhibition of histone deacetylation represents a new interesting concept in the treatment of 
haematological malignancies (Ostrosky et al, 2007).
Furthermore, leukaemia is often associated with chromatin changes in histone 
methyltransferase (HMTs) (Peters et al, 2011). The best known example of alterations in 
HMTs is called the mixed lineage leukaemia (MLL) gene, which is a frequent partner for 
recurrent translocations mainly in acute leukaemias (AML and ALL), and is a H3 lysine 4 
(H3K4) methyltransferase (Peters et al, 2011). In normal cells, MLL positively regulates gene 
expression of many genes, including HOX  genes (Peters et al, 2011). However in leukaemia, 
the MLL1 fusion proteins act as constitutively active chimeric transcription factors (Peters et al, 
2011). This fusion proteins in leukemic cells have lost the H3K4 methyltransferase activity, 
resulting in up-regulation of downstream homeobox (HOX) genes and activation of several 
leukaemogenic pathways such as RAS and fins-related tyrosine kinase 3 (FLT3), and 
transformation into leukaemic stem cells (Peters et al, 2011). MLL leukaemias is used as a 
unique transcriptional signature and associated usually with a poor prognosis (Peters et al, 
2011).
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1.4 Hallm arks of Cancer
In 2011, Hanahan and Weinberg defined ten essential hallmarks of cancer these included: 1) 
reprogramming energy metabolism and abnormal metabolic pathways; 2) sustaining 
proliferative signalling; 3) evading growth suppressors; 4) resisting cell death (apoptosis); 5) 
enabling replicative immortality; 6) evading the immune system; 7) genome instability and 
mutation; 8) tumour-promoting inflammation; 9) inducing angiogenesis and 10) activating 
invasion and metastasis (Figure 1.3) (Hanahan and Weinberg, 2011). A discussion is made 
here of the first seven of these hallmarks; excluding those which related only to solid 
malignancies; rather than haematological malignancies. Those excluded are inflammation, 
angiogenesis, invasion and metastasis.
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Figure 1.3: Hallmarks of Cancer. Modified from Hanahan and Weinberg, 2011.
1.4.1 Reprogramming Energy Metabolism and Abnormal Metabolic Pathways
Cellular energy metabolism is one of the major processes affected during the transition from 
normal to cancer cells, and it is an essential determinant of cell proliferation or cell death 
(Hanahan and Weinberg, 2011; Ward and Thompson, 2012; Jang et al, 2013). As a support for 
rapid proliferation, cancer cells choose to use glycolysis even in the presence of oxygen, this 
phenomenon, known as Warburg effect. Cancer cells use fuel macromolecules to synthesis 
nucleotides, fatty acids, and amino acids for accelerated mitosis, rather than to fuel the 
tricarboxylic acid cycle (TAC) and oxidative phosphorylation (Jang et al, 2013). This is 
described as “ aerobic glycolysis” . This phenomena was first identified by Warburg in 1956 
(Jang et al, 2013). Preferential aerobic glycolysis in cancer cells is associated with, and caused 
by several mechanisms including: 1) mitochondrial defects; 2) adaptation to hypoxic
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environment in cancer tissues via activating the hypoxia-inducible factor (HIF); 3) activation 
of oncogenic signals such as PI3K, MYC, RAS; 4) loss or mutation of tumour suppressors 
such as p53 and 6) abnormal expression of metabolic enzymes (Cairns et al, 2011).
Usually, ATP generation via glycolysis is far less efficient (two ATP per glucose) than through 
oxidative phosphorylation (36 ATP per glucose) (Pelicano et al, 2003). Cancer cells consume 
far more glucose than normal cells to provide and maintain sufficient ATP supply for their 
active metabolism and proliferation (Pelicano et al, 2003). As such, maintaining very high 
level of glycolytic activity is crucial for cancer cells to survive and grow (Pelicano et al, 2003). 
In this respect, inhibition of glycolytic capacity may contribute to an anti-cancer effect on 
cancer cells (Jang et al, 2013). As a result, cancer cell metabolism is generally characterised by 
an enhanced uptake and utilisation of glucose, which has been reported in many human cancers 
such as leukaemia and glioma (Jang et al, 2013). Additionally, cancerous cells have higher 
metabolic rates than normal cells, allowing them to sustain higher proliferative rates (Hanahan 
and Weinberg, 2011). Therefore, cancer cells need more nutrients and excrete more waste 
products than normal tissues. This leads to an accumulation of metabolites inside the cell, and 
develops a more hostile environment around the cancer cells (Hanahan and Weinberg, 2011). 
Subsequently, cells require more lipids, proteins, nucleotides and energy (in the form of ATP) 
for their bioenergetics and anabolic process to divide more, increase their size, and replicate 
DNA (Hanahan and Weinberg, 2011). These metabolic alterations create a phenotype that is 
essential for cancerous cell development and survival (Hanahan and Weinberg, 2011). As a 
result, dysregulated metabolic pathways have become attractive targets for cancer therapeutics 
(Hanahan and Weinberg, 2011; Jang et al, 2013). For this reason the reprogramming of energy 
metabolism and abnormal metabolic pathway is emerging as an important molecular hallmark 
of cancer cells (Hanahan and Weinberg, 2011).
1.4.2 Sustaining Proliferative Signalling
In normal cells, proliferative signalling is a tightly regulated process; this ensures cellular 
homeostasis. Normal tissues regulate production and release of growth promoting signals, 
which control entry and progression of the cell cycle (Hanahan and Weinberg, 2011). 
Normally, growth promoting signals are carried by growth factors binding to cell surface 
receptors which classically contain intracellular tyrosine kinase domains (Hanahan and 
Weinberg, 2011). The tyrosine kinase domain conveys signals by downstream signalling 
pathways to regulate normal cellular homeostasis (Hanahan and Weinberg, 2011). However, in 
cancer cells there is dysregulation of these proliferation signals resulting in sustained 
unregulated proliferation (Hanahan and Weinberg, 2011). This is achieved through four 
mechanisms: 1) production of growth factors and autocrine stimulation such as transforming
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growth factor-alpha (TGF-a) and platelet-derived growth factor (PDGF); 2) promotion of 
stromal cells proliferation; 3) increased growth factor receptor expression on cell surface; 4) 
altered receptors signalling mechanisms such as constitutive activation (Hanahan and 
Weinberg, 2011).
For example the epidermal growth factor receptor (EGFR) is often over-expressed in 
gastrointestinal and lung tumours and the HER2/neu receptor is commonly over-expressed in 
breast cancer (Hanahan and Weinberg, 2011). Both receptors activate the Ras-Raf-MAP 
kinase pathway, enhancing cell proliferation (Hanahan and Weinberg, 2011). Interleukin 1 
(IL-1) has also been identified as an autocrine growth factor which is over-expressed in acute 
myeloid leukaemia cells, and is responsible for increased cell proliferation (Cozzolino et al, 
1989). Similarly, it is well known that tyrosine kinase receptors are over-expressed in CML; 
this is associated with up regulation and activation of several major downstream effectors such 
as Ras, PI3K and protein kinase B (AKT), all of which promote an increase in cell 
proliferation (Bacco et al, 2000).
1.4.3 Evading Growth Suppressors
In normal cells, p53 and pRb (Sections 1.5.2) are important part of large network proteins that 
regulate cell proliferation, cell cycle process and apoptosis (Hanahan and Weinberg, 2011). In 
cancer cells, these proteins are commonly dysregulated, inactivated or mutated, leading to 
uncontrolled growth and proliferation (Hanahan and Weinberg, 2011). For example, Zen et al, 
(2010) reported that a p53 mutation in patients with CLL was associated with poor prognosis 
(Zen et al, 2010). In addition, inactivation of p53 was extensively linked with the initiation of 
aggressive AML, which was resistant to chemotherapy agents, and associated with p53 role in 
limiting aberrant self-renewal of myeloid progenitor cells (Zen et al, 2010).
1.4.4 Resisting Cell Death: Apoptosis
Resisting programmed cell death (Section 1.6) plays a vital role in cancer cell survival 
(Hanahan and Weinberg, 2011). In particular, cancer cells can develop resistance to apoptosis 
through multiple mechanisms by: 1) modulating or loss the function of p53 tumour suppressor 
protein (Bouillet and Strasser, 2002; Junttila et al, 2009; Hanahan and Weinberg, 2011); 2) 
increased expression of anti-apoptotic regulators such as Bcl-2, and Bcl-xl; 3) decreased 
expression of pro-apoptotic regulators such as Bax, Bim and Puma; 4) increased expression of 
survival signals such as IL-3 and IL-1 (within leukaemia cells) finally by interrupting the 
extrinsic apoptotic pathway (Hanahan and Weinberg, 2011). In addition, cancer cells resist cell 
death by changing normal cellular autophagy and necrosis (Hanahan and Weinberg, 2011). 
Autophagy is a self-digestive process that ensures the lysosomal degradation of superfluous or
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damaged organelles and mis-folded proteins. Normally, autophagy helps to maintain 
homeostasis by contributing to protein and organelle turnover. In cancer, the role of autophagy 
is quite complicated and still controversial; it appears to be tumour suppressive during cancer 
development, while it can also contribute to tumour cell survival during cancer progression. In 
addition, cancer cells can use autophagy to resist anti-cancer therapies (Hanahan and 
Weinberg, 2011). Finally, necrotic cell death results in rupture of the cell membrane which 
releases intracellular contents which results in pro-inflammatory signals to the surrounding 
microenvironment, which results in inflammation, which promotes tumour growth (Hanahan 
and Weinberg, 2011).
1.4.5 Enabling Replicative Immortality: Telomeres and Telomerase
Normal cells have a limited lifespan, which go through a limited number of cell divisions 
before they undergo senescence (Section 1.5.2.5) and subsequent crisis and cell death (Shay 
and Wright, 2001). During replication in normal cells, telomeres shorten with each cell 
division eventually resulting in replicative senescence (Shay and Wright, 2001). However, 
cancer cells can re-express embryonic telomerase, which is a cellular ribonucleoprotein reverse 
transcriptase that stabilises the telomere length by adding hexameric telomere repeats 
(TTAGGG) to the telomeric ends of the chromosomes. This permits continued cell division; 
thus preventing senescence and hence makes the cells ‘immortal’ (Shay and Wright, 2001). 
About 90% of immortalised cells in human cancers are capable of increasing their telomere 
length due to over expression of telomerase (Hahn, 2003). A number of leukaemia cell lines 
such as HL-60 and U937 have higher levels of telomerase activity compared to normal bone 
marrow mononuclear cells (Seol et al, 1998). This suggests that understanding the 
manipulation of telomeres and telomerase biology can lead to clinically significant applications 
in the diagnosis, prevention, and treatment of cancer (Hanahan and Weinberg, 2011).
1.4.6 Evading the Immune System
The immune system functions as a vital barrier to tumour formation and progression, and the 
capability to evade and escape from immunity, which is a hallmark of cancer development 
(Hanahan and Weinberg, 2011). Pre-clinical studies have reported that an active immune 
system continuously identifies and eliminates most cancer cells before they establish 
themselves and form a tumour (Cavallo et al, 2011). However, cancer cells can evade the 
immune system through three key phases: elimination; equilibrium and escape (Cavallo et al,
2011). During the elimination phase the immune system recognises and eliminates cancer cells 
(Cavallo et al, 2011). Those cells that avoid the elimination, progress to the equilibrium phase, 
in which the immune system regulates cancer cell growth; but does not totally eliminate the 
transformed cells (Cavallo et al, 2011). Tumour cells not susceptible to the immune
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destruction, progress to the escape phase, in this phase the “escaped” tumour clones are not 
effectively recognised and destroyed by the immune system (Cavallo et al, 2011). Cancer cells 
that successfully cross these phases acquire the capability to evade the immune system.
Cancer cells usually shed surface antigens into circulation; this triggers CD8+ cytotoxic T 
lymphocytes, natural killer cells and macrophage production (Cavallo et al, 2011). The 
immune system is believed to provide continuous surveillance, with subsequent elimination of 
cells that undergo malignant transformation (Cavallo et al, 2011). However, deficiencies in the 
action or development of CD4+ Thl helper T cells, CD8+ cytotoxic T lymphocyte, or natural 
killer cells can each lead to a significant increase in cancer incidence (Hanahan and Weinberg,
2011). Furthermore, highly immunogenic cancer cells may evade immune destruction via 
inactivating components of the immune system (Hanahan and Weinberg, 2011). This occurs 
through recruitment of inflammatory cells, including regulatory T cells and myeloid-derived 
suppressor cells, that both actively suppress the actions of cytotoxic lymphocytes (Cavallo et 
al, 2011; Hanahan and Weinberg, 2011). As a result, there are three emerging immune 
hallmarks for cancer cells which have the capability to: increase the chronically inflamed 
microenvironment; evade immune recognition and suppress immune reactivity (Cavallo et al, 
2011).
1.4.7 Genome Instability and Mutation
Random genetic mutations occur very rarely throughout all the cells in the body; these confer a 
selective advantage on single cells, permitting overgrowth and dominance in local tissue 
environments (Negrini et al, 2010). Multistep carcinogenesis is a consequence of successive 
clonal expansions of pre-malignant cells, each expansion being induced by acquisition of 
normally random facilitating genetic mutations (Negrini et al, 2010). In normal cells, cellular 
DNA repair mechanisms are highly effective, and almost all spontaneous mutations are 
repaired (Negrini et al, 2010). The process of DNA repair is very important to maintain 
genome integrity (Negrini et al, 2010; Shen et al, 2011). There are four mechanisms that 
maintain genomic stability during normal cell division: 1) A high fidelity of DNA, which must 
be replicated in S-phase, condensed, and separated during each cell division; 2) cells must 
respond too and repair both endogenous and exogenous DNA damage; 3) precise distribution 
of chromosomes among daughter cells during mitosis, and 4) control of the cell cycle 
progression, checkpoints and cell fate, including apoptosis and senescence (Shen et al, 2011). 
Any dysregulation in these mechanisms can create genomic instability and mutations, and 
contribute to the development of cancer (Shen et al, 2011).
In cancer cells, the accumulation of mutations can be enhanced and accelerated by 
compromising the surveillance systems that usually monitor genomic integrity and pushes
genetically damaged cells into either senescence or apoptosis (Negrini et al, 2010; Shen et al,
2011). Typically, genetic instability can occur due to: a) deficiencies in one of three types of 
DNA repair systems (mismatch repair, nucleotide excision repair or recombination repair); b) a 
loss or gain of chromosomes or c) large scale chromosomal reorganisation (Shen et al, 2011). 
Accumulation of the genomic instability leads to multiple mutations in chromosomes, genes or 
within the nucleotide sequences; and can cause dysregulation of cell division, imbalance 
between cells proliferate and death, which can led to cancer (Shen et al, 2011). Genomic 
instability is often associated with a vast majority of cancers (Negrini et al, 2010). 
Furthermore, it is not only considered as a hallmark of cancer, but it could be considered as an 
indicator to how tumours develop (Hanahan and Weinberg, 2011). Many studies suggest that 
genomic instability and its molecular pathways and components, are good therapeutic targets 
for the treatment of cancer (Negrini et al, 2010; Shen et al, 2011; Hanahan and Weinberg, 
2011; Muvarak et al, 2012).
Tumour cells can progress from a less malignant to a more malignant state according to the 
inherent genomic instability (Muvarak et al, 2012). For example, CML is characterised by 
changes in their DNA damage responses, DNA repair and cell-cycle checkpoints, all of which 
are crucial for cell survival, progression, and resistance to genomic instability (Muvarak et al,
2012). Consequently, this genomic instability leads to genomic deletions, rearrangements, and 
point mutations, as well as the gain or loss of whole chromosomes (aneuploidy), which are 
commonly observed in CML (Muvarak et al, 2012). For this reason, identification and 
targeting of particular factors that cause genomic instability is an attractive therapeutic 
approach, with particular relevance to CML in which tyrosine kinase inhibitor (TKI) therapy 
has failed (Muvarak et al, 2012). It is important to mention that aneuploidy mutation is one of 
the most common types of genomic instability seen in leukaemia, is likely to be linked with 
loss of function of the mitotic checkpoints, centrosome dysfunction, or both (Muvarak et al,
2012). Generally, cellular DNA undergoes continuous damage and re-synthesis. DNA damage 
could result from environmental sources and the environmental agents that damage DNA and 
have been demonstrated to be mutagens and most are carcinogens (Hanahan and Weinberg,
2011). The association between environmental factors and genetic alterations and how these 
mutations could be acquired in leukaemia are discussed in Sections 13.4.2.
1.5 Cell Cycle
1.5.1 Overview of the Cell Cycle
The cell cycle is a sequence of events that occur in a cell leading to its growth, DNA
replication and cell division resulting in duplication (Garrett, 2001; Schwartz and Shah, 2005).
Fundamentally, the cell cycle occurs in two distinct phases: interphase, during which the cell
grows and replicates its DNA, followed by mitosis in which the cell divides to generate two
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daughter cells (Figure 1.4) (Schwartz and Shah, 2005). Interphase can be further sub-divided 
into: Gap 0 (Go), Gap 1 (Gi); Synthesis (S) and Gap 2 (G2) phases (Figure 1.4), during 
interphase cells actively prepare for mitosis by collecting nutrients, amplifying organelles, 
proteins and other cellular contents and are metabolically active to mitotic phase (M); which is 
a relatively brief period of nuclear and cellular division (O'Connor, 2008).
1.5.2 Cell Cycle Regulation
The cell cycle is coordinated and regulated by a number of molecular mechanisms that depend 
on a cascade of protein phosphorylations, which include: (1) cyclins and cyclin-dependent 
kinases (CDKs), (2) cyclin-dependent kinase inhibitors (CDKIs), (3) checkpoints and (4) 
tumour suppressor genes (Garrett, 2001; Vermeulen et al, 2003). CDKs are controlled 
positively by cyclins and controlled negatively by naturally occurring CDK dependent kinase 
inhibitors (CDKIs) (Figure 1.4) (Vermeulen et al, 2003). Each protein is carefully controlled as 
any mutations in the components can lead to tumour development (Vermeulen et al, 2003).
1.5.2.1 Cyclins and Cyclin-Dependent Kinases (CDKs)
The cyclin-dependent kinases (CDKs) are a family of serine/threonine rich kinases which have 
a central role in cell cycle (Malumbres and Barbacid, 2009). They require the co-localisation of 
a regulatory cyclin subunit and a catalytic kinase subunit (Figure 1.4 and Table 1.7) 
(Malumbres and Barbacid, 2009). The progression of cells through cell cycle is controlled by 
the binding of cyclins with CDKs, which are activated at specific points of the cell cycle 
(Figure 1.4 and Table 1.7) (Garrett, 2001). There are four major regulatory cyclin-CDK 
complexes each defined by the phases of cell cycle: (1) Cyclins D l, D2, D3 bind to CDK4 and 
CDK6, these complexes are important for cellular entry in Gi phase, (2) Cyclin E bind to 
CDK2 at the end of Gi phase and the beginning of S phase, and this complex is regulates 
progression through the R point from Gj into S phase and commits the cell to DNA synthesis, 
(3) Cyclin A bind to CDK2, which regulates S phase, (4) Cyclin A binds to CDK1 in late G2 
phase and early M phase to promote entry into mitosis, (5) Cyclin B binds to CDK1 and this 
complex is required to initiate mitosis (Figure 1.4 and Table 1.7) (Malumbres and Barbacid,
2009).
1.5.2.2 Cyclin Dependent Kinases Inhibitors (CDKIs)
CDKs activity can be counteracted by cell cycle inhibitory proteins, called cyclin dependent 
kinase inhibitors (CDKIs). These can bind to CDK alone or to the CDK-cyclin complex and 
prevents cell cycle progression (Malumbres and Barbacid, 2009). There are two main protein 
families that can bind to and inhibit CDKs (Garrett, 2001). The first are inhibitors of CDK4 
(INK4) and alternative reading frame (ARF), which include about five family members:
37
pl6 lnk4a, p l5 lnk4b, p l4Arf, p l8 lnk4c, and p l9  lnk4d/Arf. These bind to and inhibit the activity of 
CDK4 (cyclin D/CDK4) and CDK6 (cyclin D/CDK 6) complexes, leading to Gj phase cell 
cycle arrest (Figure 1.4 and Table 1.8) (Malumbres and Barbacid, 2009). The second family of 
CDK inhibitors are the CDK Interacting Protein/Kinase Inhibitory Protein (CIP/KIP), which 
include three family members: p21wafl/cipl, p27kipl, and p57kip. These bind to and inhibit CDKs 
alone or in combination with cyclins; this leads to cell cycle arrest phases, particularly in S 
phase (Figure 1.4 and Table 1.8) (Malumbres and Barbacid, 2009).
The progression of cell cycle can be arrested by the inhibition of cell specific mechanisms in 
each phase of the cell cycle. Gi phase arrest occurs through the inhibition of Cyclin D/CDK4 
and Cyclin D/CDK6 complexes. S phase arrest is triggered by DNA damage and a reduction in 
expression of Cyclin A/CDK2 and Cyclin E/CDK2. Indeed, DNA damages causes up- 
regulation of p53 oncogenes and Transforming Growth Factor (TGF- P). These in turn cause 
the upregualtion of p21wafl/c,pl and p27kipl which reduce Cyclin A/CDK2 and Cyclin E/CDK2 
and causes S phase arrest. G2/M phase arrest is caused by the inhibition of Cyclin B/CDK1 
kinase activity through normal activation of p53 (Malumbres and Barbacid, 2009).
1.5.2.3 Checkpoints
The movement through each phase of the cell cycle and transition from one phase to the next is 
tightly controlled at a number of checkpoints (Garrett, 2001). These checkpoints in the cell 
cycle are very important to minimize errors (Garrett, 2001). Typically, checkpoints act as 
control mechanisms for cell cycle progression to ensure that chromosomes are intact, and that 
each phase of the cell cycle is completed, before the next phase is started (Malumbres and 
Barbacid, 2007). Checkpoints can inhibit cell cycle progression at specific points, permitting 
confirmation of necessary phase process and repair DNA damage via sensor mechanisms. The 
cells cannot proceed to the next phase until checkpoint requirements have been met. Briefly, 
when checkpoints are activated, for example by DNA damage, a signal is transmitted to the 
cell cycle-progression machinery (Garrett, 2001). This causes a slow progression in cycle until 
' the risk of mutation has been removed or repaired (Garrett, 2001). Failure to repair the DNA 
damage results in cell cycle arrest (Schwartz and Shah, 2005).
There are three major checkpoints responsible for regulation the cells transition from phase to 
phase: (1) Gi Checkpoint (Restriction (R) point), (2) Gj/S Checkpoint, (3) S Checkpoint, (4) G2  
Checkpoint and (5) M Checkpoint (metaphase to anaphase checkpoint) (Figure 1.4) (Foster et 
al, 2011). These checkpoints are designed to ensure that the appropriate environment to 
support cell growth exists and that damaged or incomplete DNA is not passed on to daughter 
cells. The Gj Checkpoint (R point) is defined as a point of no return in GI, following which 
the cell is committed to enter the cell cycle (Figure 1.4) (Foster et al, 2011). The second
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checkpoint is located at the end of Gi phase and the beginning of S phase, and this checkpoint 
ensures the correct environment exists and adequate growth factors are provided (Figure 1.4) 
(Foster et al, 2011). The third checkpoint is located in the middle of S phase repairing any 
damage to DNA before entering to the G2 phase (Figure 1.4) (Foster et al, 2011). The fourth 
checkpoint is located at G2 phase which monitors the fidelity of DNA replication. It ensures all 
the chromosomes have been replicated and that the replicated DNA is not damaged before the 
cell enters mitosis. If DNA damage is detected the cell will attempt repair using its DNA repair 
mechanisms, and will return the cell to S phase to re-synthesis the DNA. If this fails controlled 
cell death (apoptosis) will be triggered (Figure 1.4). A fifth checkpoint is located during M 
phase, where it checks that mitotic spindle has formed correctly (Malumbres and Barbacid, 
2007). These checkpoints have a key role to monitor the integrity of the genome throughout 
the cell cycle (Malumbres and Barbacid, 2007). These checkpoints are controlled by two major 
tumour-suppressor proteins p53 and pRb (Gollas et al, 2004).
1.5.2.4 Tumour Suppressor Genes: p53 and Rb
(A) p53
p53 is a transcription factor that plays a crucial role in cell cycle regulation and apoptosis. p53 
is a phosphoprotein made of 393 amino acids, containing four domains: a domain to activate 
transcription factors; a domain to recognise specific DNA sequences; a core domain 
responsible for tetramerization of proteins and finally a domain which recognises DNA 
damage (Zilfou and Lowe, 2009). p53 is described as "the guardian of the genome", preserving 
genome stability, and preventing mutations (Ryan et al, 2001). Defective p53 permits 
abnormal cells to proliferate and the formation of cancer; as such p53 is described as a tumour- 
suppressor gene. In fact p53 is the most frequently mutated gene in cancer seen in more than 
50% of all human cancers (Sherr et al, 2002). In normal cells, the p53 protein is unstable and 
short lived. However if DNA is damaged, p53 becomes stabilised increasing its activity, 
resulting in growth arrest, DNA repair or apoptosis (Sherr et al, 2002). The action of p53 is 
normally inactivated by the Mouse Double Minute 2 (MDM2) gene, which is responsible for 
encoding a protein known as negative regulator for p53 (Mendoza-Rodriguez and Cerbon, 
2001).
p53 regulates cell cycle via the activation of the p2lwafl/cipl genes that inhibits most CDKs if 
DNA damage is detected (Figure 1.5) (Gollas et al, 2004). If DNA damage is detected which 
cannot be repaired, p53 triggers apoptosis (Section 1.6.3.4) (Gollas et al, 2004). Tumour cells 
lacking normal p53 have a reduced ability to regulate cell cycle following DNA damage (Sherr 
et al, 2002).
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(B) Retinoblastom a (Rb)
Retinoblastoma (RBI) is a tumour suppressor gene producing Retinoblastoma protein (pRb). 
This plays a vital role in the control of the cell cycle and tumour progression (Genovese et al, 
2006; Giacinti and Giordano, 2006). One critical function of pRb is the control of the Gj-to-S 
phase checkpoint of the cell cycle (R point) (Figure 1.6) (Giacinti and Giordano, 2006). 
Whilst pRb is hypophosphorylated it sequesters E2F transcription factors (E2Fs); E2Fs binding 
sites are found in the promoters of many genes that are necessary for cell cycle progression, 
thus the sequestration by pRb inhibits transcription of cell cycle-promoting genes; preventing 
progression of the cell cycle from Gi to S phase (Figure 1.6) (Giacinti and Giordano, 2006). 
During Gi phase if environmental conditions are suitable, Cyclin D/CDK4, Cyclin D/CDK6 
phosphorylate pRb, which is further Phosphorylated by Cyclin E/CDK2, once pRb becomes 
hyperphosphorylated pRb dissociates from E2Fs, permitting their action and induces S phase 
(Figure 1.6) (Genovese et al, 2006).
In addition, pRb suppress transcription by remodelling chromatin structure through interaction 
with proteins such as histone deacetylase 1 (HDAC1), brahma-related gene-1 (BRG1), and 
histone-lysine N-methyltransferase SUV39H1; which are involved in histone
acetylation/deacetylation, nucleosome remodelling and methylation, respectively (Giacinti and 
Giordano, 2006). Loss of regulation of pRb can induce cell cycle deregulation and
subsequently lead to malignant phenotypes (Giacinti and Giordano, 2006). Gene inactivation 
of pRb through chromosomal mutations is one of the major reasons for retinoblastoma tumour 
development, as well as, other human cancers including; lung, brain, liver cancers and 
leukaemia (Giacinti and Giordano, 2006). For example, a study in 35 patients with CLL of B- 
cell origin (B-CLL) showed a significantly higher frequency of the RBI deletion (Stilgenbauer 
et al, 1993). In addition, it has been found that RBI inactivation is more frequently seen in
AML than in ALL (Tang et al, 1992).
1.5.2.5 Irreversible Cell Cycle Arrest: Senescence
Cellular senescence is persistent and irreversible cell cycle arrest, its function is to control the 
lifecycle of mammalian cells and inhibits unlimited cellular proliferation (Campisi, 2000). It is 
for this reason that cellular senescence is also known as replicative senescence (Campisi, 
2000). Normal cells have a limited lifespan, which go through a limited number of cell 
divisions (known as Hayflick limit) before they undergo senescence (Collado and Serrano,
2010). Senescence is important as it prevents the continual proliferation of cells which could 
result in DNA damage due to shortening of DNA during each cell replication resulting in 
telomere shortening. Aging is not the only cause of senescence, it can also be triggered by
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DNA double strand breaks (DSB), and premature telomere shortening during oxidative stress 
(Blasco, 2005).
Telomeres are repeating nucleotide sequences (TTAGGGG) at the ends of chromosomes 
which protect the coding DNA, which are shortened during each replication of DNA. This 
leads to a loss of telomeric repeats which once the telomeres reach a critical size, cellular 
senescence is initiated (Collado and Serrano, 2010). Similarly, if  telomeres were completely 
lost this would result in loss of genes at the end of a chromosome or abnormal chromosomal 
replication. This would lead to DNA damage and consequent activation of pRb and p53 
(Section 1.5.2.4 and 1.6.3.4) pathways (Ferbeyre et al, 2002); which would initiate senescence. 
Likewise reactive oxygen species (ROS) generated by oxidative stress can cause also DNA 
damage (Ferbeyre et al, 2002) and subsequent stress induced premature senescence (SIPS) 
(Collado and Serrano, 2010).
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Figure 1.4: Cell Cycle Phases and Regulators. Cell cycle has four basic phases: G] phase 
(growth), S phase (replication), G2 phase (preparation for division) and M phase (mitosis) The 
progression of cell cycle is regulated by a cyclins and cyclin-dependent kinases (CDKs), cyclin- 
dependent kinase inhibitor (CDKIs) and checkpoints. Modified from Vermeulen et al, 2003; and 
Malumbres and Barbacid, 2007.
Gj phase Cyclin D1,D2, D3 CDK4
G] phase Cyclin D1,D2, D3 CDK6
G(/S phase transition Cyclin E CDK2
S-phase Cyclin A CDK2
G2/M phase transition Cyclin A CDK1 (cdc2)
M phase Cyclin B CDK1 (cdc2)
Table 1.7: The summary of the cyclins and cyclin dependent kinases (CDKs) activated in
each phase of the cell cycle. Modified from Vermeulen et al, 2003.
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INK4 family
pi 6
Inactivate Cyclin D/CDK4 and Cyclin D/CDK6. Gl phase 
inhibitors.
pl5lnk4b
pl8lnk4c
| g 1 nk4d/Arf
CIP/KIP family
p 2 |wap|^ c*pi
Inactivate or inhibit all the CDKs alone or Cyclin/CDKs 
complexes. S phase inhibitors.
p27kipl
p57kip
Table 1.8: Cyclin dependent kinases inhibitors (CKIs) bind to Cyclin Dependent Kinases 
(CDKs) alone; or to the CDK-cyclin complex and regulate CDK activity. Modified from 
Vermeulen et al, 2003.
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Figure 1.5: The major role of p53 in cell cycle regulation. p53-induced cell-cycle arrest in 
response to DNA damage. The normally unstable p53 protein is stabilized by damaged DNA, so its 
concentration increases. Acting as a transcription factor active p53 upregulates the expression level 
of p2 lwafl,cipl and a cyclin-kinase inhibitor that inhibits all Cyclins/CDKs complexes (Figure 1.4). 
Binding of p21up to these Cyclins/CDKs complexes leads to cell cycle arrest in G] and G2 phases, 
allowing DNA repair prior to replicate and cell division. Modified from Gollas et al, 2004, and 
Zilfou and Lowe, 2009.
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Figure 1.6: Major role of pRb in cell cycle regulation. pRb exists in two states of 
phosphorylation: hypophosphorylated, and hyperphosphorylated, their activity is regulated by 
specific phosphorylations in response to DNA damage. In G0and early Gi, the hypophosphorylated 
state occurs when pRb binds interacts with the E2F family transcription factors such that E2F. 
Rb/E2F complex normally induces expression of genes that required for DNA synthesis. So, pRb 
becomes hyperphosphorylated after the activation of cyclins and CDK complexes, at this point in 
late Gi, E2F dissociates from pRb and can initiate the transcription of genes required for 
progression into S phase. Modified from Stone et al, 2011.
1.6 Apoptosis
Apoptosis is described as type I programmed cell death (PCD). It is vital for cellular self- 
destruction essential to biological processes ranging from embryogenesis to ageing, from 
normal tissue homeostasis to many human diseases (Elmore, 2007). The name apoptosis was 
first coined by Kerr et al, in 1972 to describe a morphologically distinct form o f cell death 
(Kerr et al, 1972). Normally, apoptosis occurs as a homeostatic mechanism to maintain cell 
populations throughout development and aging (Elmore, 2007). Furthermore, apoptosis takes 
place as a protection process when cells are damaged by disease or immune reactions (Elmore, 
2007). There are several physiological and pathological stimuli or conditions that can initiate 
apoptosis, however, not all cells can undergo apoptosis in response these stimuli (Elmore, 
2007; Wong, 2011).
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1.6.1 Mechanisms of Apoptosis
The mechanisms of apoptosis are sophisticated and highly complex, involving an energy 
dependent cascade of molecular events (Figure 1.7). There are two main apoptotic pathways: 
1) the extrinsic or death receptor pathway and 2) the intrinsic or mitochondrial pathway 
(Elmore, 2007). These two pathways converge on the same point and trigger the execution 
pathway (Figure 1.7) (Elmore, 2007). The intrinsic and extrinsic pathways can be distinguished 
by the differences in adapters and initiator caspases involved in each pathway (Figure 1.7) 
(David et al, 2013). Caspases are central to the mechanism of apoptosis as they are both the 
initiators and executioners that are responsible for destruction of the cell (Figure 1.7) (Elmore, 
2007).
1.6,1.1 The Extrinsic (or Death Receptor) Pathways o f  Type I  and Type I I  Apoptosis
The extrinsic pathway is initiated by the activation of death receptors, which are cell surface 
receptors including: tumour necrosis factor receptor (TNFR), first apoptosis signal (Fas) also 
known as CD95 or APO-1 receptor, and death receptors (DRs 3, 4 or 5). The death receptors 
belong to the tumour necrosis factor receptor (TNFR) superfamily, each has a cysteine rich 
extracellular subdomain which permits them to recognise and specifically bind to ligands 
(TNF-a, FasL, TRAIL, respectively). Following ligand binding trimerisation of receptors occur 
resulting in its activation (Figure 1.7). The cytoplasmic part of the death receptor, known as 
the death domain (DD) binds to adaptor proteins such as Fas-associating Death Domain 
Protein (FADD) or Tumour Necrosis Factor Receptor 1-associated Death Domain Protein 
(TRADD), which each have their own death domains (DD) and death effector domains (DED) 
(Figure 1.7). This results in dimerization of the death effector domains (DED) with either 
procaspase 8 or 10 and the formation a death-inducing signalling complex (DISC). This DISC 
formation results in autocatalysis of procaspase 8 or 10 releasing active caspase 8 or 10 into 
the cytoplasm (Figure 1.7). Once caspase 8 or 10 are activated, apoptosis has begun and hence 
they are known as initiator caspases. Caspase 8 or 10 stimulate the execution phase of 
apoptosis through cleavage and activation of effector caspases 3, 6 and 7 (Figure 1.7). 
Cleavage of caspase substrates ultimately leads to the characteristic morphological and 
biochemical features of apoptosis (Figure 1.7) (Elmore, 2007; Tait and Green, 2010).
The extrinsic (or death receptor mediated) apoptosis can be negatively regulated by Cellular 
FLICE-Like Inhibiting Protein (c-FLIP) (Section 1.6.3.1) which can bind to adaptor proteins 
such as FADD or TRADD, or bind to caspase 8 to inhibit the extrinsic pathway and hence 
apoptosis (Figure 1.7) (Elmore, 2007). In some cell systems, this direct activation of caspase 
activity is sufficient to elicit apoptosis on its own. This is described as Type 1 apoptotic 
signalling (Figure 1.7). However, in other systems the signal coming from the DISC is
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insufficient for execution of cell death on its own. In this case, the signal requires amplification 
of the signal by proteolytic activation of B-cell lymphoma-2 (Bcl-2) family member Bid, 
which is cleaved by caspase 8 to its truncated form tBid. This is conveyed to the mitochondria; 
where under the action of pro-apoptotic Bcl-2 family members such as Bax and Bak induces 
the release of cytochrome c and other mitochondrial pro-apoptotic factors into the cytosol. This 
interacts with the intrinsic apoptotic pathway (Section 1.6.1.2); this is called Type 2 apoptotic 
signalling (Figure 1.7). Now the extrinsic and intrinsic pathways converge at the level of the 
effector (executioner) caspases, and cross talk can occur between the two pathways (Figure
1.7) (Tait and Green, 2010).
1.6.1,2 The In trinsic  (or M itochondrial) Apoptotic Pathway
The intrinsic or mitochondrial apoptotic pathway is triggered by multiple stimuli including: 
viral infections; DNA damage; oxidative stress; heat shock proteins; ischemia; hypoxia; UV 
radiation. Irradiation or anti-cancer drugs commonly results in DNA damage in cells, which 
can lead to apoptotic death through a /?53-dependent pathway (Figure 1.7). After receiving the 
initial stimuli, there is the production of pro-apoptotic proteins such as Bax, Bad and Bid 
(Section 1.6.3.3) within the cytoplasm. These can then bind to the outer membrane of the 
mitochondria changing it permeability by the opening of the mitochondrial permeability 
transition (MPT) pores. This causes a loss in the mitochondrial transmembrane potential, 
which subsequently releases cytochrome c, Smac/Diablo, and Omi/HtrA2 from the 
mitochondria into the cytoplasm (Figure 1.7). These proteins activate the caspase dependent 
mitochondrial pathway. Cytochrome c binds to adaptor protein called apoptotic protease 
activating factor-1 (Apaf-1). Apaf-1 along with adenosine triphosphate (dATP/ATP) induces 
oligomerization of cytochrome-c and the formation of a heptametric structure resembling a 
wheel, whose core contains seven N-terminal CARDs called "apoptosome complex"; which is 
now capable of caspase activation (Figure 1.7). The formation of the apoptosome complex 
allows interaction of pro-caspase 9 with Apaf-1, leading to the cleavage of procaspase 9 to its 
activated caspase 9 form (Figure 1.7). Active caspase 9 now becomes an initiator caspase 
causing the activation of the effector (or executioner) caspases: caspase 3 and 7; this now 
completes the execution pathway of apoptosis (Figure 1.7) (Tait and Green, 2010; Ouyang et 
al, 2012; Rajguru et al, 2012).
The intrinsic pathway can be negatively regulated by inhibitor of apoptosis proteins (IAPs) 
(Section 1.6.3.2) which cause the neutralisation of activated caspase 9 and 3 (Figure 1.7). 
Furthermore, Smac/Diablo and Omi/HtrA2 are also reported to promote apoptosis by directly 
interacting with the IAPs and disrupting their ability to inactivate with these caspases (Figure
1.7). In addition to IAPs, the intrinsic pathway can be negatively controlled by the anti-
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apoptotic Bcl-2 family members (Section 1.6.3.3) such as Bcl-2 and Bcl-xl, which can directly 
bind and subsequently inhibit the role of pro-apoptotic proteins Bax and Bad (Figure 1.7) 
(Rajguru et al, 2012).
1. 6.1.3 The Execution Phase o f  Apoptosis
The extrinsic and intrinsic pathways both converge at the execution phase of apoptosis (Figure
1.7) (Jain et al, 2014). Here there is the activation of a series of caspases, which are activated 
at the caspase recognition site by proteolytic cleavage between the large and small domains 
forming heterodimers. Caspases are sub-divided into initiator caspases (caspase 8, 9 and 10) 
which have long pro-domains and executioner caspases (caspase 3, 6, and 7) which have short 
pro-domains (Jain et al, 2014) (Figure 1.7). The executioner caspases coordinate the 
destruction of cell structural proteins and activate enzymes that cause the dramatic 
morphological and biochemical changes characteristic of apoptosis (Section 1.6.2) (Figure 1.7 
and 1.8).
Caspase 3 is considered to be the most important executioner caspase and is activated by the 
initiator caspases (Figure 1.7) (Belloc et al, 2000). Therefore activation of caspase 3 pathway 
is considered as a hallmark of apoptosis and its measurement is often considered to indicate 
early apoptosis prior to the appearance of the typical morphological changes of apoptosis 
(Belloc et al, 2000). The precursor form of caspase 3 is predominantly synthesised in the 
cytoplasm, and activated caspase 3 is translocated from the cytoplasm into the nucleus of the 
cell by diffusion. This causes disruption of nuclear-cytoplasmic barrier leading to the nuclear 
morphological changes seen during apoptosis (Belloc et al, 2000).
When caspase 3 is activated, it is also play a crucial role in the destruction of the nucleus of the 
cell through several substrates: 1) The cleavage the Inhibitor of Caspase activated DNAse 
(ICAD) of the Caspase-Activated Deoxyribonuclease (CAD) that responsible for chromosomal 
DNA degradation within the nuclei, resulting in nuclear condensation. 2) Breakdown of 
structural nuclear proteins (nuclear lamina) further driving chromatin condensation and nuclear 
fragmentation. 3) Cleavage of cytoskeletal proteins and the cleavage of poly (ADP-ribose) 
polymerase (PARP); which allows DNA to fragment without repair. Together these actions of 
caspase 3 contribute to the typical morphological changes seen in apoptosis (Section 1.6.2) 
(Elmore, 2007).
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Figure 1.7: Apoptosis pathways, (a) The extrinsic apoptosis pathway - activated by the 
binding of a ligand to a death receptor, (b) The intrinsic pathway- activated by cellular stress.
Each pathway activates its own initiator caspase (8, 9 or 10) which will activate caspase 3. The 
execution pathway results in characteristic features of apoptosis. This can be negatively regulated by 
Bcl-2, c-FLIP and IAPs proteins. Modified from Elmore, 2007 and Wong, 2011.
1.6.2 Morphological Features of Apoptosis
During apoptosis the cell shrinks and chromatin condenses; the cell membrane blebs and 
fragments giving rise to pyknotic apoptotic bodies (Figure 1.8) (Doonan et al, 2008). The 
typical features of apoptosis can be visualised using Hoechst 33342 staining and fluorescence 
microscopy.
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1.6.3 Regulators of Apoptosis
When considering the physiological importance of apoptotic responses, it is clear that tight 
regulations of the signalling cascades are required. Three major regulators of apoptosis 
signalling have been identified including Cellular FLICE-inhibitory protein (c-FLIPs), Bcl-2 
family members, Inhibitors of Apoptosis Proteins (IAPs) and p53 (Figure 1.7) (Portt et al, 
2011).
Generally, the regulation of apoptosis pathways is controlled by a balance between pro- 
apoptotic and anti-apoptotic proteins (Gewies, 2003). The extrinsic (death receptor) pathway is 
regulated by the death inhibitory molecule: c-FLIP, which controls the expression of activating 
ligands and cytoplasmic adapter molecules such as FADD and TRADD which are needed for 
procaspase 8 or 10 activation (Fridman and Lowe, 2003). The intrinsic pathway is regulated by 
the pro- and anti- apoptotic members of the Bcl-2 family, within the mitochondria (Gewies, 
2003). The IAPs provides a further level of control at the interface between the intrinsic and 
extrinsic pathways (Fridman and Lowe, 2003). p53 regulates apoptosis via modulation of key 
control points in both extrinsic and intrinsic pathways (Fridman and Lowe, 2003; Gewies,
2003). The tumour suppressor protein p53 has a critical role in regulation of Bcl-2 family of 
proteins; however the exact mechanisms have not yet been completely interpreted (Fridman 
and Lowe, 2003).
1.6.3.1 Cellular F L IC E  -Inh ib ito ry  Protein (c-FLIP)
Cellular FLICE-inhibitory protein (c-FLIP) is a master anti-apoptotic regulator for the extrinsic 
pathway (Figure 1.7) (Safa et al, 2008; Portt et al, 2011; Safa, 2012). Functionally, c-FLIP 
binds to FADD and/or caspase 8 or 10 and TRAIL receptor 5 (DR5) in a ligand-dependent and 
ligand-independent fashion, which in turn inhibits DISC formation and subsequent activation 
of the caspase cascade. This protects cells from the death receptor mediated apoptosis (Figure
1.7) (Safa et al, 2008; Portt et al, 2011; Safa, 2012). In addition, c-FLIP can also suppress 
induction of apoptosis triggered by chemotherapy agents in cancer (Safa, 2012). c-FLIP can be
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expressed as a long (c-FLIP-L) or a short (c-FLIP-S) protein; each being structurally and 
functionally different (Safa et al, 2008; Safa, 2012). c-FLIP-L is similar to caspase 8, it 
contains two DEDs at its N-terminal, and a large and small caspase-like domain without 
catalytic activity; however, c-FLIP-S contains only two DEDs and a small C-terminus (Safa et 
al, 2008). Particularly, c-FLIP-S prevents the initial step of pro-caspase 8. Whilst c-FLIP-L 
permits the first cleavage step, releasing the small subunit of caspase 8, while preventing the 
second cleavage between the large caspase subunit and the DED domains (Safa et al, 2008; 
Safa, 2012). c-FLIP has been shown to have multifunctional roles in a number of signalling 
pathways. It is capable of activating and/or up-regulating many cytoprotective and pro-survival 
signalling proteins, such as Nuclear factor-KB (NF-kB), Protein kinase B (PKB) (also known 
as Akt) and extracellular-signal-regulated kinase (ERK) (Portt et al, 2011; Safa, 2012). Over 
expression of c-FLIP has been shown to strongly activate the transcriptional factor NF-kp and 
might therefore have a role in regulation of NF-kp dependent gene expression; which could 
affect cellular proliferation in response to stimulation of death receptors (Safa et al, 2008; Portt 
et al, 2011; Safa, 2012). Furthermore, up- regulation of c-FLIP has been reported in numerous 
tumour types including those of colon carcinoma, melanoma and Hodgkin lymphoma (Safa,
2012). For this reason, c-FLIP has been considered as an important target for cancer therapy 
(Safa et al, 2008; Safa, 2012).
1.6.3.2 Inhibitors o f  Apoptosis (IAPs)
Both the extrinsic and intrinsic apoptotic pathways converge on a common pathway of caspase 
activation, which is directly regulated by inhibitors of apoptosis (IAPs) (Figure 1.7) (Nachmias 
et al, 2004; Mannhold et al, 2010; Portt et al, 2011). IAPs are a group of structurally related 
proteins which were originally recognised in baculoviruses (Nachmias et al, 2004). IAP 
family members have one or more repeats of a highly conserved 70 amino acids domain called 
the baculovirus IAP repeat (BIR) sequence, which is located at the amino-terminus (Nachmias 
et al, 2004). To date, eight human IAPs have been identified: XIAP, c-IAPl, C-IAP2, survivin, 
NAIP, Bruce, ILP-2, and livin (Nachmias et al, 2004). The most-well characterised of IAPs is 
XIAP or X-linked IAP, which is the most potent human inhibitor of caspases (Portt et al, 2011). 
These proteins inhibit apoptosis in two ways: they bind to pro-caspases and prevent their 
activation, or they bind directly to the caspases and inhibit their activity (Figure 1.7) (Portt et 
al, 2011). In particular, IAPs directly inhibited the effector caspases: 3, 6 and 7. They act 
through suppression of caspase catalytic activity (Figure 1.7) (Portt et al, 2011). Furthermore, 
LAPs can inhibit the initiator caspases such as caspase 9, which is activated after the release of 
cytochrome c (Figure 1.7) (Nachmias et al, 2004). IAPs can also be upregulated by proteolytic 
cleavage mediated by effector caspases (Figure 1.7) (Nachmias et al, 2004). Alternatively, 
they can also be down regulated by Smac/Diablo and Omi/HtrA2 (Figure 1.7) (Nachmias et al,
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2004). Additionally, IAPs expression is regulated by survival signals from growth factor 
receptors (Mannhold et al, 2010). An overexpression of IAPs has been observed in a number 
of cancers, and believed to be associated with a resistance to apoptosis in cancer cells. Thus, 
IAPs are considered as one of the potential targets for cancer therapy (Mannhold et al, 2010).
1.6.3.3 Bcl-2 Fam ily M em bers
The Bcl-2 family of proteins include pro-apoptotic and anti-apoptotic proteins, which play an 
essential role in the regulation of apoptosis, particularly in intrinsic apoptosis; as they reside 
upstream of irreversible cellular damage and act mainly at the mitochondria level (Czabotar et 
al, 2014). To date, a total of 20 genes have been recognised in the Bcl-2 family (Czabotar et al, 
2014). All the Bcl-2 members are positioned on the outer mitochondrial membrane and 
responsible for mitochondrial membrane permeability. The Bcl-2 family of proteins can be 
recognised by the presence of sequence motifs that are known as Bcl-2 homology domains 
(BH1 to BH4) (Gewies, 2003). The function of the Bcl-2 family members depends on their 
Bcl-2 homology (BH) domains. They are classified into three groups: (1) Anti-apoptotic 
proteins such as Bcl-2, Bcl-x, Bcl-xl, Bcl-xs, Bcl-w, Mcl-1 and BAG, which contain all four 
BH domains and protect the cell from apoptotic stimuli. (2) The pro-apoptotic proteins group 
contain only BH-3 domain these include: Bid, Bim, Noxa, Puma, Bad, Bmf, Hrk, and Bik, 
these regulate the anti-apoptotic Bcl2 proteins and are the promoter of apoptosis; and final (3) 
the pro-apoptotic proteins group contain all four BH domains; which include Bax, Bak, and 
Bok which are the promoter of apoptosis (Czabotar et al, 2014). Indeed, the maintenance of 
mitochondrial membrane potential depends, on the ratio and activity balance between pro- 
apoptotic and anti-apoptotic signals of the Bcl-2 family members (Ouyang et al, 2012; 
Czabotar et al, 2014). These proteins can help determine if the cell is committed to apoptosis 
or can escape apoptosis (Elmore, 2007). It is believed that the major mechanism of action of 
the Bcl-2 family of proteins is the regulation of small pro-apoptotic molecules such as 
cytochrome c, Smac/DIABLO, and Omi/HtrA2 that release from the mitochondria during 
changes in the mitochondrial membrane permeability (MMP) (Figure 1.7) (Ouyang et al, 2012; 
Czabotar et al, 2014). Bax is considered the key pro-apoptotic Bcl-2 family member and can 
induce cell death via mitochondrial permeabilisation (MMP) (Figure 1.7) (Ouyang et al, 2012). 
The Bcl-2 family is commonly over-expressed in cancers including leukaemia, specifically in 
chronic lymphocytic leukaemia (CLL) (Ouyang et al, 2012). It is important to note that the 
reduction of Bcl-2 expression may promote apoptotic responses to anti-cancer drugs; however 
an increase in expression can lead to resistance to chemotherapeutic drugs and even radiation 
therapy (Ouyang et al, 2012).
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1.6.3.4 The Role o f  p53 Tumour Suppressor Gene in Apoptosis
p53 (Section 1.5.2.4) was first tumour suppresser gene linked to apoptosis (Bai and Zhu, 2006). 
A variety of stimuli activate p53 which then regulates cell-cycle arrest (Section 1.5.2.4), DNA 
repair, apoptosis and differentiation, through transcriptional activation of specific target genes 
that carry p53 DNA binding sites (Bai and Zhu, 2006). The different functions of activated p53 
are sophisticate and highly dependent on co-expression of the other factors which are affected 
by cell type and by the severity and persistence of conditions of cell stress and genomic 
damage. In regard of induction of apoptosis, p53 can directly or indirectly regulate the 
expression and/or release of pro-apoptotic and anti-apoptotic proteins that control both 
extrinsic and intrinsic apoptotic pathways (Fridman and Lowe, 2003; Hu and Kavanagh, 2003). 
Accumulation of p53 within the cell nucleus is often seen after DNA damage. During this 
DNA damage, p53 protein will arrest the cell cycle allowing time for cells to repair the DNA. 
If the damage cannot be repaired, then p53 acts as pro-apoptotic signal (Fridman and Lowe, 
2003). Activated p53 can positively regulate the pro-apoptotic proteins including Apaf-1, Bax 
and multiple BH3-proteins such as Noxa, Puma and Bid. These induce cytochrome c release 
from the mitochondria and induce the intrinsic apoptotic pathway (Figure 1.7) (Fridman and 
Lowe, 2003; Bai and Zhu, 2006). p53 can also bind to one or more anti- apoptotic 
mitochondrial proteins such as Bcl-xl, and suppress Bax/ Bak mitochondrial pore formation 
and the release of cytochrome c (Figure 1.7) (Fridman and Lowe, 2003; Bai and Zhu, 2006). 
Furthermore, p53 can also trigger expression of death receptors, such as Fas and DR5, which 
results in activation of extrinsic apoptosis (Figure 1.7) (Fridman and Lowe, 2003; Bai and Zhu). 
The cellular concentration of p53 is tightly regulated by Mouse double minute 2 (Mdm2) 
protein, which itself is a transcriptional target of p53 and can trigger the degradation of p53 by 
the proteasome-ubiquitin system (Bai and Zhu, 2006).
Loss of p53 function confers genomic instability, diminished cell cycle regulation, and 
impaired apoptosis (Ouyang et al, 2012). Alteration of p53 is the most common mutation in 
human cancer including leukaemia, especially in myeloid leukaemia (Ouyang et al, 2012). The 
loss of p53 in myeloid progenitor’s cells is associated with a high risk of developing AML, 
since p53 has a role in controlling cell proliferation through limiting self-renewal of normal 
HSCs (Ouyang et al, 2012). Tumours that maintain wild type p53 have a better prognosis, as 
well as a better response to therapy. p53 is an essential pro-apoptotic factor and tumour 
inhibitor, thus several anti-tumour drugs can exert their roles by targeting p53-related 
signalling pathways (Ouyang et al, 2012).
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1.7 Therapeutic Intervention in Leukaemia: Role in Targeting the Cell Cycle and 
Apoptosis
Many chemotherapy drugs affect DNA synthesis, the mechanism of action however varies 
between drugs, although they all interfere with biochemical processes that control cellular 
replication, which ultimately lead to arrest of cell cycle and induction of apoptosis (Wu, 2006; 
Sak, 2012; Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma Research,
2014). Chemotherapeutic agents can be classified according to their chemicals structure and 
site of action on DNA synthesis (Figure 1.9) (Sak, 2012; Pokhare, 2012; Mohan et al, 2013; 
Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). The major classes of 
chemotherapeutic agents are: topoisomerase inhibitor agents; alkylating agents; anti-metabolite 
agents; and mitosis inhibitors (Figure 1.9) (Pokhare, 2012; Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014). These chemotherapeutic agents are further sub­
divided due to their affect on the cell cycle into cell cycle-specific drugs and non-cell cycle- 
specific drugs (Figure 1.9) (Lamson and Brignall, 1999; Wu, 2006; Cancer Research UK, 
2014; Leukaemia & lymphoma Research, 2014).
1.7.1 Topoisomerase Inhibitors Agents
Normally, topoisomerases are responsible for controlling the 3D structure of DNA. They 
regulate the cleavage, unwinding and re-joining of DNA. Furthermore, they are involved in 
DNA replication, chromatid segregation and transcription. Inhibition of topoisomerase 
enzymes results in inhibit of DNA replication and results in DNA damage and cell death. 
Hence topoisomerase inhibitors agents have been applied therapeutically for the treatment of 
cancer (Hande, 1998; Baldwin et al, 2005; Thakur, 2011; Thom et al, 2011; Tacar et al, 2013). 
There are two classes: Topoisomerase I inhibitors such as topotecan and irinotecan, which 
binds to the enzyme-DNA complexes, stabilizing it and preventing DNA replication; and 
Topoisomerase II inhibitors such as etoposide and doxorubicin, which stabilize the complex 
between topoisomerase II and DNA that causes strand breaks and eventually inhibit DNA 
replication and led to programmed cell death (apoptosis) (Hande, 1998; Baldwin et al, 2005; 
Thakur, 2011; Thom et al, 2011; Pokhare, 2012; Tacar et al, 2013). The class of topoisomerase 
II inhibitors are commonly used to treat leukaemias, mainly acute leukaemia types, including 
ALL and AML.
1.7.1.1 Etoposide
Etoposide is approved for the treatment of acute leukaemia (Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014). It works by inhibiting the topoisomerase II 
enzymes. It prevents the re-ligation, synthesis, replication and transcription of DNA, thus 
generating double-strand DNA breaks which induces apoptosis (Hande, 1998; Baldwin et al,
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2005; Thakur, 2011; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). 
Etoposide also induces caspase 8 activity, which results in mitochondrial damage and 
subsequent downstream activation of caspase 9 and 3, and DNA fragmentation and the 
morphological indicative of apoptosis (Thakur, 2011). Topoisomerase II exists as two highly 
homology isoforms (alpha- and beta-topoisomerase II) (Thakur, 2011). Etoposide specifically 
targeted the alpha-topoisomerase II enzyme (Thakur, 2011). This isoform is usually highly 
formed and produced during G2 /M phase of cell cycle process, for this reason etoposide is 
considered and sub-classified as cell cycle specific chemotherapy agent as it causes cell cycle 
arrest at the G2 /M phase (Figure 1.9) (Thakur, 2011).
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Figure 1.9: Major targets and mechanism of action of chemotherapy agents, (a) Chemotherapy 
agents are classified according to their mechanism of action on DNA synthesis, (b) Chemotherapy 
agents are sub-classified also according to their effect on cell cycle.
1.7.1.2 Doxorubicin
Doxorubicin is approved for treatment of acute leukaemia (Thom et al, 2011; Tacar et al, 
2013; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). It has three 
mechanisms of action: 1) It becomes intercalated in the spaces between the nucleotides of 
DNA or RNA, thus inhibiting DNA and RNA synthesis (Takimoto and Calvo, 2008; Thorn et 
al, 2011; Pokhare, 2012; Tacar et al, 2013); 2) it inhibits topoisomerase II, preventing the 
relaxing of supercoiled DNA and thus blocking DNA transcription and replication, resulting in 
DNA damage and cell death (apoptosis) (Pommier et al, 2010); and 3) it generates free oxygen 
radicals that damage DNA, proteins and the cell membrane, triggering apoptosis and cell death 
(Thom et al, 2011). Doxorubicin is also sub-classified as a cell cycle non-specific drug, as it 
can arrest cells in any phases of cell cycle (Figure 1.9) (Takimoto and Calvo, 2008; Thom et 
al, 2011; Pokhare, 2012). Doxorubicin is one of the most widely used chemotherapeutic agents
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and is generally prescribed in combination with cyclophosphamide and cisplatin (Cancer 
Research UK, 2014).
1.7.2 Alkylating Agents
Alkylating agents work by modification of DNA bases. They interfere with DNA replication 
and transcription which leads to DNA mutations (Takimoto and Calvo, 2005; Pokhare, 2012; 
Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). Alkylating agents act 
via two different mechanisms: 1) the alkyl groups (CnH2n+i) of the drug attaches to the DNA 
bases at the N7 position of a guanine, resulting in fragmentation of the DNA by repair enzymes 
as they attempt to replace the alkylated bases. This prevents DNA synthesis and RNA 
transcription. Alternatively 2) alkylating agents form intra-strand and inter-strand crosslinks 
between DNA; this prevents DNA synthesis or transcription (Takimoto and Calvo, 2005). Both 
mechanisms disrupt DNA synthesis and transcription and ultimately resulting in cell death 
(Takimoto and Calvo, 2005; Pokhare, 2012; Leukaemia & lymphoma Research, 2014). These 
alkylating chemotherapy agents can be further characterised as being non-cell cycle specific 
agents, as they can induced arrest of the cell cycle in any phases (Figure 1.9). 
Cyclophosphamide (Takimoto and Calvo, 2005; Shanafelt et al, 2007), chlorambucil (Rai et al, 
2000) and cisplatin (Florea and Busselberg, 2011; Praveen et al, 2013) are typical alkylating 
chemotherapy agents approved for the treatment of leukaemia (Figure 1.9).
1.7.2.1 Cyclophosphamide
Cyclophosphamide is approved for all types of leukaemia (Shanafelt et al, 2007; Pokhare, 
2012; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). 
Cyclophosphamide is a nitrogen mustard alkylating agent that forms DNA crosslinks and 
inhibits DNA synthesis and induces apoptosis (Hall and Tilby, 1992; Shanafelt et al, 2007). 
For leukaemia treatment, cyclophosphamide is commonly applied alone, or in combination 
with other chemotherapy agents such as doxorubicin or rituximab and/or with radiotherapy for 
the treatment of CLL (Leukaemia & lymphoma Research, 2014).
1.7.2.2 Chlorambucil
Chlorambucil is approved to treat most types of leukaemia, but it is mainly applied for the 
treatment of patients with CLL (Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014). Chlorambucil is a nitrogen mustard alkylating agent that formed DNA 
crosslinks, resulting in inhibition of DNA synthesis, induction of apoptosis and arresting the 
cell cycle by up-regulation of p53 (Rai et al, 2000).
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1.7.2.3 Cisplatin
Cisplatin is approved to treat all types of leukaemia and can be used alone or in combination 
with other drugs (Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). The 
mechanism of action of cisplatin is mediated by its direct interaction with DNA. It forms intra­
strand cross-links between the DNA, resulting in inhibition of DNA synthesis, induction of 
apoptosis and arrest of the cell cycle (Siddik, 2003; Florea and Busselberg, 2011). Cisplatin 
can decrease the activity of ATPase and altered the cellular transports mechanisms, which can 
cause mitochondrial damage (Siddik, 2003). It also causes direct or indirect damage of the 
proteins such as p53, Bax, Bcl-2, and caspases; which are involved in the apoptotic; which 
leads to cell death (Siddik, 2003).
1.7.3 Anti-Metabolite Agents
Anti-metabolite agents are a group of molecules that become incorporated into DNA and RNA 
synthesis (Kaye, 1998; Sorbello and Brtino, 2001; Sahasranaman et al, 2008; Pokhare, 2012; 
Rossi, 2013). Anti-metabolite agents are structurally related to native nucleosides, amino acids 
or vitamins (Pokhare, 2012). Most anti-metabolite agents have a similar structure to 
nucleosides, which are the building blocks of DNA and RNA (Pokhare, 2012; Cancer Research 
UK, 2014; Leukaemia & lymphoma Research, 2014). Nucleoside has three functional groups: 
a nucleobase, a sugar and a phosphate group (Pokhare, 2012; Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014). The nucleobase is normally classified into purines 
including guanine and adenine; and pyrimidines including cytosine, thymine and uracil 
(Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). Anti­
metabolite agents are commonly incorporated into these nucleobases or nucleosides of the 
DNA or RNA, thus inhibiting the DNA polymerase, kinases and enzymes (Pokhare, 2012; 
Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). This results in 
inhibition of the DNA synthesis and an induction of cell death by apoptosis (Pokhare, 2012; 
Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). Anti-metabolite agents 
are sub-classified as cell cycle specific agents because their maximal cytotoxic effects are 
specifically in S phase. Anti-metabolites are considered as one of the first effective 
chemotherapeutic agents discovered and are classified into three types according to the 
substances with which they interfere (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia 
& lymphoma Research, 2014). They include: folic acid analogues such as methotrexate, which 
inhibits dihydrofolate reductase (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & 
lymphoma Research, 2014). Purine analogues like 6 -mercaptopurine that inhibits 
interconversion of purine nucleotide (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia 
& lymphoma Research, 2014). Finally, pyrimdine analogues like 5-fluorouracil, which inhibits
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thymidylate synthase (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014). Anti-metabolite agents are commonly applied to the treatment of leukaemia 
and lymphoma (Leukaemia & lymphoma Research, 2014), but are also used for the treatment 
of some solid tumours such as breast cancer (Pokhare, 2012; Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014).
1.7.3.1 Methotrexate
Methotrexate is approved, alone or with other drugs for the treatment of all type of leukaemia, 
however in practise they are mainly used for treating ALL that has spread to the central 
nervous system (CNS) or to prevent this from occuring (Kaye, 1998; Sorbello and Brtino, 
2001; Chabner and Roberts, 2005; Rossi, 2013; Cancer Research UK, 2014; Leukaemia & 
lymphoma Research, 2014). Normally, folic acid is an important element for the synthesis of 
nucleotides (Chabner and Roberts, 2005). It was empirically observed in patients with 
leukaemia, that diets low in folate produced lower white cell counts than observed in 
leukaemia patients on normal folate diets (Chabner and Roberts, 2005). Methotrexate is a folic 
acid antagonist that inhibiting dihydrofolate reductase and prevents the conversion of 
dihydrofolate to the tetrahydrofolate required for purine and pyrimidine synthesis; which are 
both essential for DNA or RNA synthesis and cell division (Figure 1.9) (Kaye, 1998; Sorbello 
and Brtino, 2001; Rossi, 2013). Subsequently, the inhibition of dihydro folate reductase results 
in inhibition of cells proliferation, induction of cell death (apoptosis) and arresting the cell 
cycle at S phase (Figure 1.9) (Kaye, 1998).
1.7.3.2 6-Mercaptopurine
6 -Mercaptopurine is approved to treat childhood leukaemias, especially ALL and AML; and 
sometimes CML (Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). 6 - 
Mercaptopurine is a thiopurine analogue of the native purine bases and nucleotides of guanine 
within DNA (Sahasranaman et al, 2008). Mercaptopurine is applied primarily for the 
maintenance of patients in remission with ALL and is given in combination with MTX for this 
purpose (Leukaemia & lymphoma Research, 2014). 6 -Mercaptopurine is activity metabolised 
by hypoxanthine-guanine phosphoribosyl transferase (HGPRT) to form 6 -thioinosinic acid and 
6 -methylmercaptopurine ribonucleotide (MMPR), which in turn inhibits a number of the 
enzymes of purine nucleotides inter-conversion. This results in an alteration of the DNA and 
RNA synthesis and function; which subsequently leads to DNA damage, apoptosis and cell 
cycle arrest at S phase (Figure 1.9) (Sahasranaman et al, 2008). 6 -MP can induce apoptosis 
through the activation of intrinsic pathway via an up-regulation of p53 expression 
(Sahasranaman et al, 2008).
57
1.7.4 Mitotic Inhibitor Agents
Cancer cells divide more rapidly than normal cells, for this reason they are more susceptible to 
inhibition of mitosis (Jiang et al, 2006; Chan et al, 2012). Mitotic inhibitor such as vincristine 
is approved for acute leukaemias (Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014). Vincristine is a mitotic spindle poison which acts by binding to tubulin and 
thus inhibits assembly of the spindle during mitosis and arrests the cells at metaphase (Chan et 
al, 2012). The use of mitotic inhibitor chemotherapy agents are commonly associated with 
peripheral nerve damage leading to paraesthesia, loss of reflexes and weakness (Leukaemia & 
lymphoma Research, 2014). It can cause also other side effects including, nausea, vomiting, 
alopecia and mylosuppression (Cancer Research UK, 2014; Leukaemia & lymphoma 
Research, 2014).
1.7.5 Targeted Therapy
Targeted therapy is the type of treatment that uses drugs or other substances to work by 
interfering with specific molecules, which are specifically associated with cancer growth. They 
commonly attack cancer cells more specifically than traditional chemotherapy agents 
(Downing, 2008). There are some targeted therapies have been approved by the FDA for 
leukaemia treatment. Examples of these targeted therapies include, immunotherapy, tyrosine 
kinase inhibitor therapy (e.g. Imatinib) and proteasome inhibitor therapy (e.g. Bortezomib) 
(Downing, 2008; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014).
17.5.1 Tyrosine Kinase Inhibitor Therapy: Imatinib
Tyrosine kinase inhibitors such as Imatinib are designed to specifically inhibit translocated 
Bcr-abl, the latter containing a tyrosine kinase domain. Tyrosine kinases are typically 
responsible for the activation of many proteins that regulate signal transduction, growth, 
proliferation and survival of hematopoietic and cancer cells (Gilhot, 2004). Imatinib ultimately 
inhibits cell proliferation and induces apoptosis (Patel 1 et al, 2010). Imatinib is sub-classified 
as a cell cycle non-specific agent; as it can arrest cells at any phase of the cell cycle (Gilhot,
2004). Imatinib is approved to treat newly diagnosed adult and paediatric patients with chronic 
phase Philadelphia-chromosome positive chronic myeloid leukaemia (Ph+ CML). These are 
patients with Philadelphia-chromosome-positive chronic myeloid leukaemia (Ph+ CML) in 
blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy 
(Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). In addition, it is FDA 
approved to be used in combination with chemotherapy, to treat adult patients with relapsed or 
refractory Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) and
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in paediatric patients with newly diagnosed Philadelphia chromosome-positive acute 
lymphoblastic leukaemia (Ph+ ALL) (Leukaemia & lymphoma Research, 2014).
1.7.5.2 Proteasome Inhibitor Therapy
Proteasomes are multi-enzyme complex found in all cells. Normally, the proteasome plays an 
important role in control of degrading of more than 80% of ubiquitin-tagged cellular proteins, 
which control the functions of cellular division, growth, cell cycle and cell death (Niewerth et 
al, 2013; Koyama et al, 2014; Liu et al, 2014). In particular, proteasome control cyclins, 
cyclin-dependent kinases, cyclin-dependent kinase inhibitors, tumour suppressor genes, 
oncogenes, and transcriptional activators and inhibitors (Niewerth et al, 2013; Koyama et al, 
2014; Liu et al, 2014). The major function of proteasomes is the activation of the transcription 
factor nuclear factor-kB (NF-kB) (Fuchs et al, 2009). Hence, proteasomes are important in 
maintaining normal cellular function and homeostasis. Clinically, proteasome inhibitor agents 
such as bortezomib are being used as monotherapy or in combination with standard therapies 
for the treatment of haematological malignancies, particularly multiple myeloma (Liu et al, 
2014). Both pre-clinical and clinical studies reported that cancer cells are more sensitive to 
proteasome inhibitor agents than normal hematopoietic cells (Fuchs et al, 2009; Niewerth et al, 
2013; Koyama et al, 2014; Liu et al, 2014).
1.7.5.2.1 Bortezomib
Bortezomib (Velcade) is the first proteasome inhibitor approved for the treatment of multiple 
myeloma and mantle cell lymphoma (Cancer Research UK, 2014). It is considered also as 
novel treatment strategy in acute leukaemias (ALL and AML) (Niewerth et al, 2013; Cancer 
Research UK, 2014). Functionally, bortezomib inhibits proteasome by binding reversibly to 
the chymotrypsin-like site in the 26S-core of the proteasome (Niewerth et al, 2013). 
Commonly, bortezomib-mediated proteasome inhibition affects the stability o f multiple 
signalling pathways (Fuchs et al, 2009). In particular, bortezomib leads to decreased NF-kB 
activity, and an increased p53-mediated transcription of genes involved in apoptosis and 
dysregulation of the cell cycle. This includes increased p21- and p27-mediated induction of 
cell cycle arrest, and promotion of apoptosis via Bax-mediated inhibition of Bcl-2 (Fuchs et al,
2009). This drives the activation of apoptosis and cell death pathways (Fuchs et al, 2009). 
Cancer cells are more susceptible to the effects of bortezomib than normal cells, due to the 
reversibility of proteasome inhibition in normal cells (Fuchs et al, 2009). However, sometimes 
when bortezomib is insufficient, it may inconsistently activate NF-kB (Fuchs et al, 2009). This 
reversal of bortezomib activity can result in drug resistance mediated through P-glycoprotein 
(Fuchs et al, 2009). In addition, bortezomib is associated with moderate side effects including 
fatigue, diarrhoea, painful peripheral neuropathy, thrombocytopenia, bleeding, anaemia and
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neutropenia (Cancer Research UK, 2014). Additionally, it can increase the infection risk due to 
a drop in the number of white blood cells (Cancer Research UK, 2014).
1.7.6 Major Problems of Current Leukaemia Treatments
1.7.6.1 Side Effects
The current leukaemia treatments are associated severe side effects (Table 1.9). The specific 
side effects for each treatment are represented in Table 1.8.
1.7.6.2 Resistance to Anti-Cancer Treatments
Drug resistance is considered as a major problem for leukaemia therapy. Resistance can occur 
to standard chemotherapy drugs, targeted therapy agents or even radiation treatment; 
(Luqmani, 2005; Mohan et al, 2013). Drug resistance can develop through a number of 
pathways: (a) An expression of multidrug resistance (MDR1) gene and an up-regulation of p- 
glycoprotein membrane transporters which remove chemotherapy drug from the cancer cells, 
resulting in a reduced intracellular drug accumulation and loss of therapeutic efficacy, (b) Drug 
inactivation due to conjugation with cellular glutathione, (c) Up regulation of survival factors 
such as NF-kB transcription factor and/or the anti-apoptotic proteins Bcl-2 and Bcl-xl. (d) 
Mutations in the p53 tumour suppressor gene which leads to an increased cell cycle and 
resistance to cell death. And finally (e) An increased in DNA repair in cells by nucleotide 
excision repair (NER) mechanisms (Luqmani, 2005). Each anti-cancer agent has a different 
resistance mechanisms and this shown in Table 1.10.
1.7.6.3 Disease Recurrence
In the case of chronic cancer such as CML, recurrence may be expected as part of the cycle of 
the disease. In other cases, recurrence may be unexpected, particularly if  the remission has 
lasted a significant amount of time. For instance, current chemotherapy treatment in patients 
with AML will result in complete remission in 50% to 90% of patients; but between 10% and 
25% of patients will have primary refractory disease and the majority of those who gain 
remission will relapse within 3 years of diagnosis. The treatment of relapsed leukaemia is 
complex and well-controlled trails in this group of patients are uncommon. In addition, more 
than 80% of children with AML experience complete remission (CR), but later more than 30% 
of these children suffer recurrence, and the long-term survival rate is only about 50%. After 
relapse, the survival is very poor and ranges from 21% to 33% (Cancer Research UK, 2014; 
Leukaemia & lymphoma Research, 2014). Together, this indicates that effective and new 
leukaemia therapies are urgently needed. One such strategy, which could hold promise for the 
future of leukaemia therapies, is by using none-toxic bioactive compounds such as polyphenols 
that are isolated from natural sources (fruits and vegetables).
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M ajor side effects: A lopecia, fatigue, 
nausea, vom iting, stom ach ache, diarrhoea, 
haem orrhagic cystitis and suppression o f  
haem atopoiesis.
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M ajor side effects: Nausea, vom iting, 
diarrhoea, fatigue, m yelosuppression, 
gastritis, acute pneum onitis and kidney 
failure.
Kaye, 1998; Sorbello  and 
B rtino, 2001; Rossi, 2013.
it**
O '
High doses can led to dam age to the central 
nervous system.
R ossi, 2013.
OJ
■ O '
■5
0  '
<
6-Mercaptopurine
M ajor side effects: Sore throat and m outh, 
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vom iting, diarrhoea and skin rash, , 
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C ancer Research U K , 2014; 
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Research, 2014.
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Increases the risk o f  a second cancer 
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Doxorubicin
Other side effects: Fatigue, nausea, 
vom iting, diarrhoea, alopecia, fever, oral 
m ucositis, esophagitis, skin rashes, liver 
dysfunction and suppression o f  
haem atopoiesis.
R ossi, 2013; T acar et al, 
2013.
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Vincristine
M ajor side effects: W eakness, nausea, 
vom iting, alopecia, peripheral nerve 
dam age leading to paraesthesia, loss o f  
reflexes, and m yelosuppression.
Jiang et al, 2006; C hen et 
al, 2012; C ancer R esearch 
UK , 2014; L eukaem ia & 
L ym phim a R esarch  2014.
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Imatinib
M ajor side effects: N ausea, vom iting, 
diarrhoea, oedem a, m uscle cram ps, and 
skin rash.
G ilhot, 2004; D olly and 
A postolia, 2009; Patel et al, 
2010; L eukaem ia & 
Lym phim a R esarch 2014.
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Bortezomib
(Veicade)
M ajor side effects: Fatigue, diarrhoea, 
painful peripheral neuropathy, 
throm bocytopenia, bleeding, anaemia and 
neutropenia and increased the infection risk 
due to a drop in the num ber o f  w hite blood 
cells.
Fuchs et al, 2009; C ancer 
R esearch UK, 2014.
Table 1.9: Summary of side effects and toxicities of the current leukaemia treatments.
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Agents
Resistance Mechanisms References
Alkylating Agents: 
Cyclophosphamide
9
Chlorambuci & 
Cisplatin
Resistance to alkylating agents can arise through multiple
mechanisms:
>  Increased D N A  repair
>  Reduced cellu lar uptake and accum ulation
>  D ecreased cellular perm eability  to  the drug
>  Increased efflux
>  Increased drug inactivation
>  Increased in the synthesis o f  g lutathione (GSH) through 
conjugation reactions with glutathione S-transferase (G ST) w hich is 
protective against D N A  dam age
>  Inhibition o f  transm ission o f  DN A dam age recognition signals to 
the apoptotic pathway.
Hall and Tilby, 1992; 
Siddik, 2003; Florea 
and Biisselberg,
2011; C ancer 
R esearch UK, 2014; 
L eukaem ia & 
lym phom a Research, 
2014.
Anti-Metabolite
Agents:
Methotrexate
Resistance to methotrexate can arise through multiple mechanisms:
>  Im paired transport into cell
>  Increased efflux due to overexpression o f  m ulti-drug resistance 
protein (M D R)
>  Increased target expression o f  thym idylate synthase
>  Increased in dihydrofolate reductase (DH FR) concentration due to 
gene am plification and altered affinity o f  m ethotrexate to  DH FR
>  A ctivation o f  survival pathw ays such as ERBB signalling pathw ays
>  Increased expression o f  anti-apoptotic proteins e.g. FLIP, and Bcl-2
Kaye, 1998; Sorbello 
and B rtino, 2001; 
C habner and R oberts, 
2005; C ancer 
R esearch UK, 2014; 
L eukaem ia & 
lym phom a R esearch, 
2014.
Anti- Metabolite 
Agents: 
6-Mercaptopurine
Resistance to 6-mercaptopurine can arise through two mechanisms:
>  D ecrease in the  activity o f  hypoxanthine-guanine phosphoribosyl 
transferase (HG PRT).
>  E levated the alkaline phosphatase levels, w hich dephosphorylate 
thiopurines nucleotides resulting in cellular loss o f  ribonuceosides, 
particularly  occurred in acute leukaem ia.
Sahasranam an et al, 
2008; C ancer 
R esearch UK , 2014; 
Leukaem ia & 
lym phom a R esearch, 
2014.
Topoisomerase 11 
Inhibitor Agents: 
Etoposide &  
Doxorubicin
Resistance to topoisomerase I I  inhibitor agents can arise through
multiple mechanisms:
>  O verexpressed o f  m ulti-drug resistance protein (M DR).
>  Reduced cellular uptake and accum ulation, resulting from  
overexpression o f  a cell surface perm eability  glycoprotein.
>  A ltered topoisom erase II activity prevents doxorubicin and 
etoposide binding the topoisom erase-D N A  complex, allow ing the 
broken strands to be  repaired.
>  D ecreased apoptosis due to  m utation o f  p53.
>  Increased in the synthesis o f  glutathione (GSH) through glutathione 
S-transferase (GST) w hich is protective against D N A  dam age
Thakur, 2011; T hom  
et al, 2011; C ancer 
R esearch UK, 2014; 
Leukaem ia & 
lym phom a R esearch, 
2014.
Mitotic Inhibitor 
Agent: Vincristine
Resistance to mitotic inhibitor agent such as vincristine can arise 
through multiple mechanisms:
>  O verexpressed o f  m ulti-drug resistance protein (M D R 1).
>  R educed cellular uptake and accum ulation
>  M utations in Tubulin
>  Chrom osom al instability
Jiang et al, 2006; 
C han et al, 2012; 
C ancer R esearch U K , 
2014; Leukaem ia & 
lym phom a R esearch, 
2014.
Targeted therapy: 
Imatinib
Resistance to Imatinib can arise through multiple mechanisms:
> O verexpressed o f  m ulti-drug resistance protein (M D R 1).
>  R educed intracellular uptake o f  imatinib.
> Point m utation in BCR-ABL, w hich interferes w ith binding.
>  Bcr-abl gene am plification o r overexpression at the m R N A  and 
protein levels.
>  Chrom osom al aberrations.
D olly and A postolia, 
2009; C ancer 
Research UK, 2014; 
Leukaem ia & 
lym phom a R esearch, 
2014.
Targeted Therapy: 
Bortezomib 
(Velcade)
Resistance to bortezomib can arise through multiple mechanisms:
> Overexpressed o f  m ulti-drug resistance protein (M D R 1) m ediated 
through P-glycoprotein.
> R educed intracellular uptake o f  bortezom ib.
>  Insufficient doses o f  bortezom ib, which m ay inconsistently  activate 
survival factor such as NF-kB.
> M utation in the binding site for bortezomib.
> Enhanced anti-apoptotic m echanism s.
Fuchs et al, 2009; 
C ancer R esearch U K , 
2014.
Table 1.10: Summary of resistance mechanisms to current anti-cancer leukaemia treatments
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1.8 Potential of Naturally Sourced Polyphenols
There has been great interest in bioactive agents from natural sources which have anti- 
cancerous activity (Giovannini et al, 2007; Dai et al, 2010). The bioactive components that 
have shown the most potential include polyphenols and polyacetylenes (Huang et al, 2007; 
McDougall et al, 2010; Zaini et al, 2011; Dahlawi et al, 2012, Spagnuolo et al, 2012; Zaini et 
al, 2012; Dahlawi et al, 2013). Epidemiological data has shown that diets rich in polyphenols 
significantly improve the survival and quality of life in patients with cancer (Giovannini et al, 
2007; Dai et al, 2010). Furthermore, these compounds are well tolerated with few side effects 
(Dai et al, 2010).
1.8.1 Polyphenols Overview
Polyphenols are the biggest group of phytochemicals and considered as one of the most 
numerous and ubiquitous group of plant metabolites (Giovannini et al, 2007; Sharif et al, 
2010; Tsao, 2010). They are an essential part of the human diet (Giovannini et al, 2007). 
Generally, polyphenols can be extracted from fruits (e.g. rhubarb, cherries, berries, apples, 
citrus); vegetables (e.g. onion, soy beans, celery); herbs, roots, spices (e.g. turmeric, gingko); 
and green and black tea (Giovannini et al, 2007; Huang et al, 2007; Yang et al, 2008; 
Jaganathan and Mandal, 2009; Dai et al, 2010). Polyphenols have received great attention 
among nutritionists, food scientists and medical researches due to their roles in human health 
(Dai et al, 2010; Sharif et al, 2010; Tsao, 2010). Studies over the years strongly support a role 
for polyphenols in the prevention of degenerative diseases, particularly cancers, cardiovascular 
diseases and neurodegenerative diseases (Dai et al, 2010; Sharif et al, 2010; Tsao, 2010). They 
have been identified that polyphenols are strong antioxidants, which can defend against 
oxidative stress caused by excess reactive oxygen species (ROS) (Dai et al, 2010; Sharif et al, 
2010; Tsao, 2010). Subsequently, in the last few years, the recognition and development of 
such agents for the treatment of cancer has become a major area of research (Patel et al, 2007; 
Dai et al, 2010; Sharif et al, 2010; Tsao, 2010). Polyphenols have great potential for the 
treating cancer as they are widely availability in foods; they have low toxicity and biological 
benefits (Dai et al, 2010). Furthermore, in recent in vivo and in vitro studies polyphenols have 
been shown to have anti-mutagenic, anti-inflammatory, anti-proliferative, anti-progression 
properties; and are capable of inducing cell cycle arrest and cell death through multiple 
signalling pathways (Dai et al, 2010).
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1.8.2 The Main Classification of Polyphenols
Dietary polyphenols are the most abundant antioxidants in human diets with over 8,000 
structural variants and different compounds (Giovannini et al, 2007; Han et al, 2007; Huang et 
al, 2007; Yang et al, 2008; Jaganathan and Mandal, 2009; Dai et al, 2010; Tsao, 2010). They 
are secondary metabolites of plants and are characterised by having at least one aromatic 
ring(s) bearing one or more hydroxyl moieties and are described as polyhydroxylated 
phytochemicals or polyphenols (Figure 1.11) (Dai et al, 2010). Polyphenols are classified into 
groups based on their chemical structure, particularly according to the number of phenolic 
rings and by the structural elements that link the phenolic rings. The major classification 
include: 1) Flavonoids; 2) Anthaquinones; 3) Stilbenes; 4) Phenolic acids; 5) Tannins and 6 ) 
Lignans (Dai et al, 2010). The most abundant polyphenols in plants are flavonoids, phenolic 
acids, stilbenes and anthaquinones, of which flavonoids account for 60% of dietary 
polyphenols (Han et al, 2007; Dai et al, 2010). The considerable diversity of their chemical 
structures influences their bioavailability, biological properties, anti-oxidant activity and 
specificity to react with enzymes and cell receptors (Giovannini et al, 2007). This study 
focuses on three classes of polyphenols: Flavonoids, Anthaquinones and Stilbenes; and from 
these classes eight compounds have been selected for investigation based on their previously 
shown anti-proliferative, pro-apoptotic and/or growth inhibitory affects in solid tumours; and 
thus may have potential in the treatment of leukaemia. The selected polyphenols include: 
flavonoids (e.g. quercetin, apigenin and chrysin); anthraquinones (e.g. emodin, aloe-emodin 
and rhein); and stilbenes (e.g. cis-stilbene and trans-stilbene).
Figure 1.10: Basic structure of polyphenols (Phenol) (Han et al, 2007).
1.8.2.1 Flavonoids
Flavonoids are extensively distributed among the plant kingdom (Sandha et al, 2011; Kumar 
and Pandey, 2013). Flavonoids are the most abundant polyphenols in human diets and 
represent the most important polyphenolic class, with more than 4000 compounds (Huang et al,
2007). They are found in fruits (e.g. Apples, blueberries), vegetables (e.g. Onions, broccoli, 
parsley, and celery), nuts, seeds, flowers and tea (Sandha et al, 2011). These polyphenols are 
an integral part of our daily diet (Sandha et al, 2011). The presence of flavonoids in food is 
commonly responsible for taste, colour, prevention of fat oxidation, as well as enzymes or
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vitamins degradation (Sandha et al, 2011). Flavonoids are low molecular weight bioactive 
polyphenols which play a crucial role in photosynthesis (Sandha et al, 2011). Chemically, 
flavonoids are based upon a fifteen-carbon skeleton consisting of two benzene rings (A and B) 
linked by a heterocyclic pyrane ring (C) (Figure 1.11) (Tsao, 2010; Kumar and Pandey, 2013). 
Most flavonoids bear this type of 2-phenyl-benzo-y-pyrane structure (Tsao, 2010; Kumar and 
Pandey, 2013). Due to the B ring relative to the C ring, as well as the hydroxylation pattern and 
variations in the C ring (such as functional groups (ketones, hydroxyls) and presence of a 
double bond or not in the C ring); flavonoids can be further divided into different sub-classes 
such as flavonols (e.g. quercetin and kaempferol), flavones (e.g. apigenin and chrysin), 
flavanones (e.g. hesperetin, and naringenin) (Table 1.11) (Tsao, 2010; Kumar and Pandey, 
2013). Their general structures are shown in Table 1.11. The most abundant flavonoids in the 
diet are flavanols (e.g. quercetin) and flavones (e.g. apigenin) (Sandha et al, 2011; Kumar and 
Pandey, 2013). The general dietary intake of flavonoids is estimated to be 1-2 g/day (Kumar 
and Pandey, 2013). The average intake of flavonols and flavones was reported to be 23 mg/day, 
among which, flavonol quercetin contributed 16 mg/day (Kumar and Pandey, 2013). The basic 
structures of flavonoids are aglycones; while in plants, most of these compounds exist as 
glycosides (Figure 1.11) (Kumar and Pandey, 2013). The biological activities of the flavonoid 
compounds are usually dependent on both the structural difference and the glycosylation 
patterns (Kumar and Pandey, 2013). These flavonoids exhibit a wide range of biological 
activities including: antioxidant, anti-inflammatory, anti-allergic, anti-bacterial, anti-viral, anti­
tumour activities, they are cytotoxic and have been used as a treatment of neurodegenerative 
diseases and used as a vasodilator (Sandha et al, 2011; Kumar and Pandey, 2013).
Figure 1.11: Basic Flavonoid Structure 
(Kumar and Pandey, 2013).
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Table 1.11: Chemical
structure of major types 
of flavonoids and their 
representative compounds 
used in this study (Kumar 
and Pandey, 2013).
1.8.2.2 Anthaquinones
Anthraquinones are a group of functionally diverse aromatic chemicals structurally related to 
anthracenes. The basic chemical structure of anthraquinone is an anthracene ring (tricyclic 
aromatic) with two ketone groups in position C-9 and C-10 (Figure 1.12) (Dave and Ledwani, 
2012). In plant, anthraquinones are mostly present as sugar derivatives such as glycosides, but 
they are also present in the free glycones (Huang et al, 2007). Anthraquinones are found 
mainly in medical rhubarb (Huang et al, 2007; McDougall et al, 2010), or herbs (e.g., senna, 
purslane and aloe); plus peas, cabbage, lettuce and beans (Dave and Ledwani, 2012). Six key 
anthraquinones have therapeutic potential in the treatment of cancer included aloe-emodin, 
emodin, rhein, chrysophanol, physcion and danthron, aloe, senna and purslane (Huang et al, 
2007; McDougall et al, 2010; Zhang et al, 2010). The major anthraquinone derivatives 
including, emodin (1, 3, 8-trihydroxy-6-methylanthraquinone, -2.6% ), aloe-emodin (1, 8- 
dihydroxy-3-hydroxyl-methyl anthraquinone, -1.8%), rhein (1, 8-dihydroxy-3- 
carboxyanthraquinone, -1.9% ) (Figure 1.13) (Huang et al, 2007). Anthraquinone compounds 
are commonly used as laxative, or for the treatment of fungal infections (Dave and Ledwani, 
2012). Recent studies have indicated that a number of anti-neoplastic effects could be found 
among studied anthraquinones, including emodin, aloe-emodin, and rhein (Zhang et al, 2010; 
Dave and Ledwani, 2012).
Figure 1.12: Basic chemical structure 
of anthraquinone (Huang et al 2007).
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Figure 1.13: Chemical structures of the major anthraquinones: Emodin, Aloe-emodin and 
Rhein (Huang et al 2007).
1.8.2.3 Stilbenes
Stilbenes are an important class of plant polyphenols that have been shown to have anti-fimgal 
and anti-microbal effects and are synthesised in plants in response to injury or infection 
(Pandey and Rizvi, 2009). Stilbenes are mainly found in grapes and peanuts (Han et al, 2007); 
thus they make up a relatively small part of human diet, (0.3-7mg as aglycones and 15 mg as 
glycosides in grapes). Stilbenes are found in such low quantities, any protective effect of this 
molecule is unlikely via normal nutritional intakes (Shen et al, 2009). Stilbenes have been 
found to have diverse bioactivity; they have been shown to have antioxidant, anti-malarial, 
anti-microbial, anti-inflammatory and cytotoxic properties (Shen et al, 2009). They have also 
been shown to be hepatoprotective, and are currently being evaluated for the treatment of 
Alzheimer’s disease and tumour formation (Shen et al, 2009).
Stilbenes contain two phenyl moieties connected by a two-carbon methylene bridge; the basic 
backbone for stilbenes is a C6-C2-C6 structure (Shen et al, 2009). Structurally, the stilbenes 
are characterised by the presence of a 1 , 2 -diphenylethylene nucleus with hydroxyls substituted 
on the aromatic rings, and can be divided into two isomers (Figure 1.14). The first isomer is 
called ^rafls’-stilbene or (£)-stilbene {trans-1, 2-diphenylethylene) (Figure 1.14); and the 
second isomer is called c/s-stilbene or (Z)-stilbene (cis-1, 2-diphenylethylene) (Figure 1.14) 
(Shen et al, 2009). C/s-stilbene and rra/w-stilbene are structurally very similar the only 
difference is in the potency of their biological effect (Gosslau et al, 2008). The small 
difference in their configuration affects cell uptake and hence their biological activity (Gosslau 
et al, 2008).
Figure 1.14: Typical structure of 
stilbene isomers: (A) 7ra/is-stilbene 
and (B) Cis-stilbene (Gosslau et al,
2008).
m-stilhenc
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1.8.3 Polyphenols - Bioavailability
The most abundant dietary polyphenols in our diet do not necessary have the best 
bioavailability profile (D’Archivio et al, 2010; Manach et al, 2004), because they may have a 
lower intrinsic activity, a poor absorptive rate from the intestine, or are highly metabolised, or 
rapidly elimination from the body (Manach et al, 2004). So, it is not only necessary to know 
how much of polyphenol is present in specific food, but to also know if its bioavailable 
(D’Archivio et al, 2010).
In general, bioavailability of polyphenols is mostly influenced by their chemical structure and 
their molecular size; as this will determine the rate and extent of intestinal absorption (Manach 
et al, 2004; Williamson and Manach, 2005; D’Archivio et al, 2010; Mendoza et al, 2011). In 
food, some polyphenols are present as aglycones or glucosides (with no sugar group); these 
can be directly absorbed from the small intestine without requiring hydrolysis (Manach et al, 
2004; Williamson and Manach, 2005; D’Archivio et al, 2010; Mendoza et al, 2011). 
However, most of the polyphenols present as glycosides, polymers or esters forms, and these 
native forms cannot be absorbed until they hydrolysed by intestinal enzymes or by the colonic 
microflora (Manach et al, 2004; Williamson and Manach, 2005; D’Archivio et al, 2010; 
Mendoza et al, 2011). The gut microflora once they have hydrolysed the glycosides into 
aglycones; these can then be metabolised into aromatic acids (Manach et al, 2004; D’Archivio 
et al, 2010). During the course of absorption, polyphenols are conjugated firstly in the small 
intestine and later in the liver (Manach et al, 2004; D’Archivio et al, 2010).
Once in the liver the polyphenols are subjected to three main types of conjugation: 
methylation, sulphation, and glucuronidation (Manach et al, 2004; D’Archivio et al, 2010). All 
these modifications deeply affect the biological activity of polyphenols (D’Archivio et al,
2010). Subsequently, circulating polyphenol metabolites are not free in blood; they are instead 
bound to albumin (Manach et al, 2004; D’Archivio et al, 2010; Mendoza et al, 2011). 
Generally, the physiological concentrations of polyphenols metabolites within blood plasma do 
not exceed lOpM (Manach et al, 2004; D’Archivio et al, 2010).
In order to enter the tissues, polyphenols are metabolised. Metabolites of polyphenols are 
eliminated in bile or urine depending of the size of the conjugated metabolites (Manach et al, 
2004; D’Archivio et al, 2010; Mendoza et al, 2011). Particularly, large conjugated metabolites 
are more likely to be eliminated in the bile, while small conjugates are preferentially excreted 
in urine (Manach et al, 2004; D’Archivio et al, 2010; Mendoza et al, 2011). However it is 
important to note that the total amount of polyphenols metabolites excreted in urine is directly 
correlated to plasma concentrations (Manach et al, 2004).
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Previous studies in human showed that the most readily absorbed polyphenols were phenolic 
acid, catechins, flavanones, and quercetin glucoside. However kinetics of this absorptive 
process was different for each polyphenol (Manach et al, 2004; D’Archivio et al, 2010). The 
least well absorbed polyphenols are large molecular weight polyphenols such as the 
anthocyanins (Han et al, 2007; D’Archivio et al, 2010). A few researchers have investigated 
the kinetics and extent of polyphenol absorption by measuring plasma concentrations and/or 
urinary excretion among adults after the ingestion of a single dose of polyphenol, provided as 
pure compound, a plant extract, or whole food/beverage (Williamson and Manach, 2005; 
Mendoza et al, 2011). To date, the data available on bioavailability of polyphenols however is 
still very limited, but there is evidence that flavonoid compounds such quercetin consumed in a 
normal diet can result in micromolar concentrations in blood plasma (Hollman et al, 1997; 
Mendoza et al, 2011). Furthermore, quercetin has showed to have a relatively long plasma 
half-life of 11-28 h, and a 50-100 mg dose would lead to concentrations of up to 0.75-1.5 pM 
in plasma (Manach et al, 2004; D’Archivio et al, 2010; Mendoza et al, 2011). However, 
further investigations are required to determine whether the effects of the polyphenols in vitro 
are relevant to their clinical use, and to consider their bioavailability and whether these 
treatment concentrations are achievable in plasma.
18.4 Evidence of the Potential of Polyphenols in the Treatment of Cancers
18.4.1 The Potential o f  Flavonoids in the Treatm ent o f  Cancer 
(A) Quercetin
Previous studies demonstrated that quercetin has anti-proliferative effects in breast (MDA- 
MB-231 and MCF-7), cervical (HeLa), liver (HepG2), lung (A-549) and in two leukaemia 
(HL60 and K562) cell lines (Choi et al, 2008; Chien et al, 2009; Chou et al, 2010; Huang et al, 
2009; Zhang et al, 2009; Priyadarsini et al, 2010;,Serrano et at, 2006) (Robaszkiewicz et al, 
2007; and Csokay et al, 1997; Kang et al, 1997). These studies reported a range of IC50 values 
for quercetin between 20-278 pM (Kang et al, 1997; Chien et al, 2009) (Table 1.12). In the 
majority of these studies quercetin induce apoptosis by the activation of the mitochondrial- 
and caspase 3-dependent apoptotic pathways (Choi et al, 2008; Chien et al, 2009; Huang et al, 
2009; Zhang et al, 2009; Chou et al, 2010; Priyadarsini et al, 2010) (Table 1.12). Quercetin 
was shown to induce apoptosis through inhibition of the major survival signals such as Akt, 
and extracellular regulated kinase (ERK) and NF-kappa B in hepatoma cell lines (HepG2) 
(Serrano et at, 2006); and through the inhibition of cytosolic protein kinase C (PKC) and 
phosphoinositol-3-kinase (P13K) in two leukaemia cell lines (HL60 and K562) (Csokay et al, 
1997; Kang et al, 1997) (Table 1.12). In addition, quercetin has been shown to induce S-phase 
arrest in breast cancer cell lines (MCF-7) by decreasing the level of CDK2, cyclins A and B 
proteins and increasing the levels of the p53 and p57 protein (Chou et al, 2010). It also induced
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G2/M phase arrest in cervical cancer cell lines (HeLa) (Huang et al, 2009; Zhang et al, 2009; 
Priyadarsini et al, 2010) (Table 1.12).
Quercetin
Cancer Cell Lines IC50 Values Targets and Mechanisms of Action References
Breast Cancer Cell 
Lines 
(MDA-MB-435)
100 pM  at 24 h
Inhibited cells proliferation.
(Choi et al, 
2008)Induced the apoptosis through m itochondrial- and 
caspase 3-dependent pathways.
Breast Cancer Cell 
Lines 
(MDA-MB-231)
278 pM  at 24 h
Inhibited cells proliferation.
(Chien et al, 
2009)Induced the apoptosis through m itochondrial- and 
caspase 3-dependent pathways.
Breast Cancer Cell 
Lines 
(MCF-7)
92.4 pM  at 48 h
Inhibited cells proliferation.
(C hou et al, 
2010)
A rrested cell cycle at S phase by decreasing the level 
o f  CD K 2, cyclins A  and B proteins; and increasing 
the  levels o f  the p53 and p57 protein.
Induced the apoptosis through m itochondrial- and 
caspase 3-dependent pathw ays.
Cervical Cancer Cell 
Lines (HeLa) 50 pM  at 24 h
Inhibited cells proliferation.
(H uang et al, 
2009)
A rrested cell cycle at G2/M  phase.
Induced apoptosis via an up-regulation o f  pro- 
apoptotic B cl-2 fam ily proteins, cytochrom e c, Apaf-1 
and caspase 3 activity, dow n-regulation o f  anti- 
apoptotic Bcl-2 proteins, and reduction o f  
m itochondrial m em brane potential; by increase the 
levels o f  the p53 and p57 protein.
Cervical Cancer Cell 
Lines (HeLa) 20 pM  at 24h
Inhibited cells proliferation.
(Zhang et al, 
2009)
A rrested cell cycle at G2/M  phase.
Induced apoptosis via an up-regulation o f  pro- 
apoptotic Bcl-2 fam ily proteins, cytochrom e c, Apaf-1 
and caspase 3 activity, p lus dow n-regulation o f  anti- 
apoptotic Bcl-2 proteins, and reduction o f  
m itochondrial m em brane potential.
Cervical Cancer Cell 
Lines (HeLa) 80 pM  at 24 h
Inhibited cells proliferation.
(Priyadarsini et 
a I, 2010)
Induced apoptosis via an up-regulation o f  pro- 
apoptotic B cl-2 fam ily proteins and caspase 3 activity; 
p lus dow n-regulation o f  anti-apoptotic B cl-2 proteins, 
and reduction o f  m itochondrial m em brane potential.
Hepatoma Cell Lines 
(HepG2) 87pM  at 18 h
Inhibited cells proliferation.
(Serrano et at, 
2006)
Induced apoptosis associated w ith inhibition o f  the 
m ajor survival signals like Akt, and extracellular 
regulated k inase (ERK); JNK/AP-1 activation and 
inhibition o f  N F-kappa B.
Lung Cancer Cell 
Lines (A-549) 50 pM  at 24 h
Inhibited cells proliferation. (R obaszkiew icz 
et al, 2007)A rrested cell cycle at S and G2/M  phases
Promyeolytic 
Leukaemia Cell Lines 
(HL-60)
20 - 30 iiM  at 
24 h
Inhibited cells proliferation.
(K ang et al, 
1997)
Induced apoptosis v ia inhibition o f  cytosolic  protein 
kinase C (PK C ) and m em brane TPK , and reduction o f  
phosphoinositol-3-kinase (P13K).
Chronic Myeloid 
Leukaemia Cell Lines 
(K562)
5.5 pM at 12h
Inhibited cells proliferation
(C sokay et al, 
1997)
Induced apoptosis via inhibition o f  cytosolic protein 
kinase C (PK C), and reduction o f  phosphoinositol-3- 
k inase (P13K).
Table 1.12: The potential of quercetin in the treatment of cancer based on previous studies.
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(B) Apigenin
Apigenin has been targeted as a candidate in the development of non-cytotoxic anti-cancer 
medicines (Choi and Kim, 2009; Shukla and Gupta, 2010). Previous studies demonstrated that 
apigenin has anti-proliferative and pro-apoptotic effects on colorectal (SW480, HT-29 and 
Caco-2) (Wang et al, 2000), human cervical (HeLa), neuroblastoma (NUB-7 and LAN-5), 
hepatoma (HepG2, Hep3B, PLC/PRF/5) (Zheng et al, 2005), human breast cancer (MDA-MB- 
453 and MCF-7) (Way et al, 2004; Choi and Kim, 2009) and six leukaemia (THP-1, U937, 
HL60, JURKAT, K562 and NIH3t3) cell lines (Vrago et al, 2006) (Table 1.13). Apigenin was 
reported as having an IC50 values ranging between 40-70pM in colon, cervical and breast 
cancer cell lines (Wang et al, 2000; Way et al, 2004; Zheng et al, 2005; Choi and Kim, 2009) 
and between 30-50pM in the leukaemia cell line (Vrago et al, 2006) (Table 1.13). Most of the 
previous studies found that apigenin was a potent apoptotic agent. It was reported that apigenin 
inhibited cell growth and induced apoptosis via inhibition of the PI3K, and activitation of the 
Akt kinase and HER2/neu signalling pathways in MDA-MB- 453 and MCF-7 breast cancer 
cell lines (Way et al, 2004) (Table 1.13). In the MDA-MB-453 breast cells apigenin was 
shown to induce apoptosis via both the intrinsic and extrinsic pathways by the activation of 
caspases 3, - 8  and -9 (Choi and Kim, 2009). Apigenin was also shown to induce apoptosis in 
six leukaemia cell lines (THP-1, U937, HL60, JURKAT, K562 and NIH3t3) through activation 
of the intrinsic pathway via an increased caspase 3 and 9 activity. It was also shown to increase 
reactive oxygen species (ROS) levels in these leukeamia cells and inhibited the activation of 
cytosolic protein kinase C (PKC) (Vrago et al, 2006) (Table 1.13). Apigenin has also been 
shown to induce G0/G 1 arrest in human cervical cancer (HeLa) cells through elevating of p53, 
p21 wafi/cip 1 (£heng et al, 2005) and G2/M arrest in human colon carcinoma (SW480, HT-29 and 
Caco-2) through inhibition in p34 (cdc2) kinase, and cyclin B1 proteins levels (Wang et al, 
2000) (Table 1.13).
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Apigenin
Cancer Cell Lines IC50 Values Targets and Mechanisms of Action References
Human Colon 
Carcinoma Cell lines 
(SW480, HT-29, and 
Caco-2).
40 //M  at 24 h 
for SW 480
50 ftM at 24 h 
for HT-29
70 //M  at 24 h 
for Caco-2
Inhibited cells proliferation.
(W ang et al, 
2000)
A rrested cell cycle at G2/M  through inhibition in p34 
(cdc2) kinase, and cyclin B1 proteins levels.
Breast Cancer Cell Lines 
(MDA-MB- 453 and 
MCF-7)
40 //M  at 24 h
Inhibited cells proliferation.
(W ay et al, 
2004)Inhibition the H ER2/neu-overexpressing accom panied 
by the induction o f  apoptosis processes
Breast Cancer Cell Lines 
(MDA-MB-453)
59.44 at 
24 h
Inhibited cells proliferation.
(Choi and 
K im , 2009)Induced apoptosis via both the intrinsic and extrinsic 
pathw ays by  the activation o f  caspases-3,-8 and -9.
Cervical Cancer Cell 
Lines (HeLa),
Neuroblastoma Cell 
Lines (NUB-7 and LAN- 
5),
Hepatoma Cell Lines 
(HepG2, Hep3B, 
PLC/PRF/5)
3 5 .8 9 //M  at 
24 h
Inhibited cells p roliferation.
(Zheng et al, 
2005)
Arrested cell cycle at G q/G , phase in hum an cervical 
cancer (H eLa) cells through elevating o f  p53,
p 2 1 \vafl/cip l
Induced apoptosis.
Leukaemia Cell Lines 
(THP-1, U937, HL60, 
JURKAT, K562 and 
NIH3t3)
30 and 50 pM 
at 24h
Inhibited cells proliferation
(V rago et al, 
2006)
Induced apoptosis by intrinsic pathw ay via increased 
caspase 3 and -9 activity p lus an increase in reactive 
oxygen species (ROS) level, phosphorylation o f  the 
M A PK s and p38 kinase expression and activation o f  
cytosolic Protein K inase C (PKC).
Table 1.13: The potential of apigenin in the treatment of cancer based on previous studies.
(C) Chrysin
Previous studies demonstrated that chrysin has anti-proliferative and pro-apoptotic effects in 
gastric (SGC-7901), colorectal (HT-29 and HCT-116), cervical (HeLa), hepatic (HepG2), 
nasopharyngal (CNE1) (Li et al, 2011), breast (MDA-MB-231), prostate (PC3) (Parajuli et al,
2009), glioma (U87-MG and U-251, C6 ) (Weng et al, 2005; Parajuli et al, 2009), and three 
leukaemia (U937, THP-1 and HL60) cell lines (Monasterio et al, 2004; Rmos and Aller, 2008) 
(Table 1.14). The reported IC50 values for chrysin in the solid tumours were between 16 and 
100 pM (Weng et al, 2005; Parajuli et al, 2009; Li et al, 2011); and in the leukaemia cell lines 
were between 16 and 35 pM (Monasterio et al, 2004; Rmos and Aller, 2008) (Table 1.14). 
These studies reported that chrysin was able to induce apoptosis through caspase activation 
involving caspase 8  and 3 (Monasterio et al, 2004; Li, et al, 2011); and through inactivation of 
the Akt signalling (Monasterio et al, 2004; Ramos and Aller, 2008) (Table 1.14). Chrysin was 
also shown to significantly inhibite cell proliferation, induced apoptosis through inhibition of
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proteasome activity and caused arrested the cell cycle at Go/Gi phase in breast (MDA-MB- 
231), glioma (U87-MG U-251 and C6 ) and prostate (PC3) cell lines (Weng et al, 2005; 
Parajuli et al, 2009) (Table 1.14). This was accompanied by a reduction in the levels of 
phosphorylation of pRb; inhibition in the activity of cyclin dependent kinase-2 (CDK2) and -4 
(CDK4); and elevation in the levels of cyclin dependent kinase inhibitor (p21waf7, cipl); without 
any change in p53 protein levels (Weng et al, 2005; Parajuli et al, 2009) (Table 1.14).
Cancer Cell Lines IC50Values Targets and Mechanisms o f Action References
Human Gastric 
Adenocarcinoma (SGC-7901),
Colorectal Adenocarcinoma 
(HT-29 and HCT-116),
Cervical Cancer Cell Lines 
(HeLa),
Hepatoma Cells Lines 
(HepG2),
Human Nasopfaaryngal 
Carcinoma Cell Lines (CNE1).
40 fiM at 
2 h
Inhibited cells proliferation.
(Li et al, 
2011)
Induced apoptosis through the caspase cascade 
activation by  increasing the activity levels o f  caspase 8 
and caspase 3.
Glioma Cell lines (C6).
50 /*M at 
2 4 ,4 8  
and 72 h
Inhibited cells proliferation.
(W eng et al, 
2005)
A rrested cell cycle at G0/Gj phase by a reduction in 
the levels o f  phosphorylation o f  R etinoblastom a (Rb) 
proteins, inhibition the activity o f  cyclin dependent 
kinase 2 (CD K 2) and 4 (CDK4).
Induced apoptosis.
Breast Cancer Cell Lines 
(MDA-MB-231),
Malignant Glioma (U87-MG 
and U-251),
Prostate Cancer Cell Lines 
(PC3).
100 pM  
at 24 h
Inhibited cells proliferation.
(Parajuli et al, 
2009)
Arrested cell cycle at G0/Gj phase by a reduction  in 
the levels o f  phosphorylation o f  R etinoblastom a (Rb) 
proteins, inhibition the activity o f  cyclin dependent 
kinase 2 (CD K 2) and 4 (CDK 4); and elevation in  the 
levels o f  cyclin dependent k inase inhibitor (p21wafl/cipl) 
w ithout any change in p53 protein level.
Induced apoptosis through inhibition the activity o f  
proteasom e.
Histiocytic Lymphoma 
Leukaemia Cell Lines (U937)
16 pM  at 
24 h
32 pM  at 
48 h
Inhibited cells proliferation.
(M onasterio  
et al, 2004)
A ccum ulated cells in sub-G] phase o f  cell cycle.
Induced apoptosis by increasing the activity  levels o f  
caspase 8 and caspase 3 via the over expression o f  
BCL-2 levels; and through reduction in the level o f  the 
m em ber inhibitor o f  apoptosis pro teins XIA P and 
inactivation o f  Akt phosphorylation.
Histiocytic Lymphoma 
Leukaemia Cell Lines (U937)
Promyeolytic Leukaemia Cell 
Lines (HL-60)
Acute Monocytic Leukaemia 
Cell Lines (THP-1)
25 pM  at 
8 h
16 pM  at 
24 h
Inhibited cells proliferation
(R m os and 
A ller, 2008)
Induced apoptosis via a decrease the Akt 
phosphorylation and m itochondrial dysfunction.
Table 1.14: The potential of chrysin in the treatment of cancer based on previous studies.
73
1.8.4.2 The Potential o f  Anthraquinones Compounds: Aloe-emoditt, Emodin and Rhein in 
the Treatment o f  Cancer
The anti-cancer activity of emodin has been the most highly investigated anthraquinone (Table 
1.14). Emodin has been shown to inhibit cells proliferation, arrested the cell cycle at Go/Gi 
phase and induced apoptosis in HL-60 promyeolytic leukaemia cell lines through with 
activation of caspase 3, up-regulation of p53 and p21 and down regulation the activation of the 
tyrosine kinase, phosphoinositol-3-kinase (P13K), protein kinase C (PKC), NF-kappa B (NF- 
k B ) and mitogen-activated protein kinase (MAPK) signalling cascade (Chen et al, 2002) 
(Table 1.15). Additional studies reported that emodin was able to induce the apoptosis in 
JURKAT and WEHI-3 leukaemia cell lines through the activation of caspase cascade 
involving caspase 9 and caspase 3, up-regulation of PARP expressions and elevation the 
reactive oxygen species (ROS) (Wei et al, 2009; Chang et al, 2011) (Table 1.15). Similarly 
emodin along with aloe-emodin and rhein has been shown to have anti-cancer activity in 
human tongue cancer (SCC-4) (Chen et al, 2010). These anthraquinones have been shown to 
inhibit cell proliferation, arrest the cell cycle and induce the apoptosis, through the production 
of reactive oxygen species (ROS) and mitochondria-dependent pathways (Table 1.15) (Chen et 
al, 2010). Based on this simgle study, emodin has shown to be one of the most potent 
ployphenols, with an IC50 of 30 pM. This is considerabily lower than the IC50 for aloe-emodin 
and rhein which were 100 pM, at 24 and 48 h (Chen et al, 2010) (Table 1.15).
Anthraquinones
I Cancer Cell Lines 1 1C  ^Values | Targets and Mechanisms of Action 1 References |
Human Tongue 
Cancer Cell Lines 
(SCC-4).
30 pM  at 24 h and 
48 h for emodin.
100 at 24 h a n d  48 
h for aloe-em odin 
and rhein.
Inhibited cell proliferation.
(C hen et al, 
2010)
Arrested the cell cycle at G 0/G 1
Induced apoptosis, through the production o f  reactive 
oxygen species (ROS) and m itochondria-dependent 
pathways.
HL-60 - 
Promyeolytic 
Leukaemia Cell lines
40 pM  at 24 h
Inhibited cell proliferation.
(Chen et al, 
2002)
Arrested the cell cycle at Go/Gi
Induced apoptosis through with activation o f  caspase 3, 
up-regulation o f  p53 and p21 and down regulation the 
activation o f  the tyrosine kinase, phosphoinositol-3- 
kinase (P13K ), protein kinase C (PK C ), N F-kappa B 
(NF-kB) and m itogen-activated protein k inase (M A PK ) 
signalling cascade.
T-lymphocytic 
leukaemia Cell Lines 
(JURKAT)
20 pM  at 24 h
Inhibited cell proliferation.
(W ei et al, 
2009)
Induced apoptosis through the activation o f  caspase 9 
and caspase 3, up-regulation o f  PA RP expressions; 
elevated ROS.
Murine Leukaemia 
Cell Lines (WEHI-3)
100 pM  at 24h and 
48 h
Inhibited cell proliferation.
(C hang et 
al, 2011)
Induced apoptosis through the  activation o f  caspase 9 
and caspase 3, up-regulation o f  PA RP expressions; 
elevated ROS.
Table 1.15: The potential of anti 
treatment of cancer based on previo
hraquinones (emodin, aloe-emodin and rhein) in the 
us studies.
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1.8.4.3 The Potential o f Stilbenoids in the Treatment o f Cancer
The stilbenoids have been shown to inhibit cell proliferation and induce apoptosis in lung 
(A549) (Lee et al, 2004; Weng et al, 2009), prostate (DU145 and PC3) (Shankar et al, 2007), 
breast (BT-549), colon (HT29) (Yang et al, 2002) and one leukaemia (HL60) cell lines (Saiko 
et al, 2006; Simoni et al, 2006). Cis-stilbene and trans-stilbene have also been shown to be 
effective at inhibiting growth of human lung cancer cells. The reported IC50 of trans-stilbene 
and cis-stilbene in human lung cancer (A549) cells, were 6.36 and 0.03 pM, respectively, at 24 
h (Lee et al, 2004). Cis-stilbene was found to be more effective than trans-stilbene and shown 
to inhibit cell growth, induce cell cycle arrest at G2/M, through the down-regulation of 
checkpoint protein cyclin B 1 and induce apoptosis through an elevation of the pro-apoptotic 
protein p53, the cyclin-dependent kinase inhibitor p21, and the release of cytochrome c in the 
cytosol in lung cancer (A549) cells [(Lee et al, 2004), and S phase in leukaemia (HL60) cells 
(Simoni et al, 2006; Saiko et al, 2006). Similarly in lung (A549 and CH27) (Weng et al, 2009) 
and prostate cancer (DU145 and PC3) cell lines (Shankar et al, 2007). Trans-stilbene was 
shown to induce apoptosis through reduction of mitochondrial membrane potential, elevation 
the Bax/Bcl-2 ratio, activation of caspase 9 and 3, and subsequent cleavage of PARP (Shankar 
et al, 2007; Weng et al, 2009); causing the generation of reactive oxygen species (ROS) 
(Shankar et al, 2007). An evaluation of a series /rans-stilbene benzenesulfonamide derivatives 
on 60 human cancer cell lines showed that /rans-stilbene compounds were more potent on 
breast cancer (BT-549) and colon cancer (HT29) cell lines with IC50 values as low as 0.20 and 
0.55 pM at 24 h, respectively (Yang et al, 2002) (Table 1.16).
I Cancer Cell Lines IC50 Values Targets and Mechanisms of Action References |
Lung Cancer Cell Lines 
(A549) & Lung Squamous 
Carcinoma Cell Lines 
(CH27)
92pM  at 24 h for 
A 549 cells & 39 
pM  at 24 h for 
CH27 cells.
Induced the apoptosis through reduction o f  
m itochondrial m em brane potential, e levation the 
Bax/Bcl-2 ratio , activation o f  caspase 9 and 3, 
and cleavage o f  PA RP
(W eng et al, 
2009)
Prostate Cancer Cell Lines 
(DU145 and PC3) 25 pM  at 48 h.
Inhibited cell growth.
Induced apoptosis through reduction o f  
m itochondrial m em brane potential via elevation 
the B ax/Bcl-2 ratio, activation o f  caspase 9 and 
3, and cleavage o f  PA RP generating reactive 
oxygen species.
(Shankar et 
al, 2007)
Breast Cancer Cell Lines 
(BT-549) & Colon Cancer 
Cell Lines (HT29)
0.20 pM  at 24 h 
for BT-549 
cells.&  0.55 pM  
at 24 h for H T29 
cells.
Inhibited cell growth. 
Induced apoptosis.
(Y ang et al, 
2002)
Promyelocytic Leukaemia 
Cell Lines (HL-60) 0.15 pM  at 24 h.
Inhibited cell growth.
Arrested cell cycle at S phase & apoptosis.
(S im oni et 
al, 2006)
Promyelocytic Leukaemia 
Cell Lines (HL-60) 12 pM  at 24 h.
Inhibited cell growth.
Arrested cell cycle at S phase & apoptosis.
(Saiko et al, 
2006)
Table 1.16: The potential of Stilbenoids in the treatment of cancer based on previous 
studies.
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1.8.5 The Potential of Polyphenols in the Treatment of Leukaemia
Polyphenols can affect the overall process of carcinogenesis in many ways. In particular, 
polyphenols contribute to counteracting oxidative stress and the prevention of the onset of 
cancer (Lambert et al, 2005). Polyphenols have been shown to suppress cell proliferation and 
hence growth of many cancer cell lines; induce apoptosis or/and arrest the cell cycle. From the 
previous in vitro studies, it can be seen that polyphenols can activate the signalling pathways 
and regulate cell cycle proteins (Cyclin D1 as an example), growth factors (e.g. EGF, HER-2), 
transcription factors (e.g. NF-kB, PPAR, p53), protein kinases (e.g. PKC, PI3K, IKK, Akt, 
MAPK), pro-apoptotic proteins (caspases, PARP, Bax and Bak) and anti-apoptotic proteins 
(e.g. Bcl-2 and Bcl-xl) that are important in the control of cancer (Han et al, 2007; Dai et al,
2010). Previous studies clearly show the potential of these molecules in the treatment of 
cancer (Table 1.12, 1.13, 1.14, 1.15 and 1.16). Much of the work undertaken has demonstrated 
the pro-apoptotic and anti-cancerous activity of these polyphenols has focused on the treatment 
of solid tumours cancers, of the breast, colon, and liver; however this evidence led us to 
believe that these molecules may have potential in the treatment of leukaemia. A few studies 
using one or two leukaemia cell lines have shown that this may be possible, although more 
detailed work is required. It is essential to study the effects on polyphenols in a number of 
leukaemia cells lines, including cell lines that are representative of both acute and chronic 
myeloid and lymphoid leukaemia. Further it is important to determine the IC50 values of each 
studied polyphenol in each cell lines as this will enable a direct comparison of the effectiveness 
of each in the treatment of leukaemia; and the identification of the most potent polyphenols for 
treatment of each leukaemia type. From this is may be possible to produce a short-list of 
polyphenols that could be use alongside standard leukaemia chemotherapy and determine if 
they could be used as an adjunctive treatment. In this fashion it can be determined whether 
any synergistic, additive, or antagonistic action of this polyphenols on the action of standard 
chemotherapy treatments.
The evidence so far suggests that it may be possible for the polyphenols to enhance action of 
the standard chemotherapy treatments; and thus it may be possible to help in overcoming 
resistance to standard chemotherapy treatments, improve their performance and help in 
reducing treatment dosages and toxic side effects, all of which are critical in improving patient 
prognosis. So, based on evidence from solid tumours and some leukaemia cell lines, it is 
possible that polyphenols and related bioactive molecules may have potential in the treatment 
of leukaemia; furthermore they could be used individually or in combination with existing 
therapies. However, it is necessary to expand this knowledge, to look at all types of leukaemia 
including: acute and chronic, lymphoid and myeloid leukaemia.
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1.9 General Hypothesis
1.9.1 Polyphenols Modulate Apoptotic and Proliferative Responses to Chemotherapy 
Agents in Leukaemia Cells
The general hypotheses of this research are: Polyphenols inhibit cellular proliferation and have 
a pro-apoptotic effect on leukaemia cell lines vs. non-tumour cells, and they work 
synergistically with standard chemotherapeutic agents; and this action is reliant on a 
modulation in glutathione (GSH) levels within the leukaemia cells. Using a hypothesis-driven 
approach we aim to evaluate the potential for polyphenols in the treatment of leukaemia.
1.9.2 General Aims
The specific aims for this study were to:
(1) Investigate the effect of 8  polyphenols: quercetin, chrysin, apigenin, emodin, aloe-emodin, 
rhein, cis-stilbene and trans-stilbene on cellular proliferation, cell cycle and apoptosis (Chapter 
2). These polyphenols have been specifically selected as they have been shown in previous 
studies to have the most potential in the treatment of solid cancer tumours, and are 
representative of the major polyphenol sub-classes. These polyphenols were tested on a panel 
of leukaemia cells lines, including human myeloid (KGla, HL60, THP-1 and K562) and 
lymphoid (JURKAT, CCRF-CEM, MOLT-3 and U937) leukaemia cell lines, which are 
representative of the different leukaemia types. Unlike other studies, two control hematopoietic 
stem cell sources were also tested (CD34+HSC and CD133+HSC progenitor cells from cord 
blood), to investigate the effects of our treatments on normal health blood cells, which is 
fundamental when developing new chemotherapy treatments. Determine which polyphenols 
were the most effective at reducing ATP levels as an indicator for cell viability and inducing 
apoptosis in each of the eight leukemic cell lines, whilst having a limited effect on the non­
tumour cells. A direct comparison was made of effectiveness of each polyphenol, an IC50 and 
AP50 values were determined for each polyphenol in each cell line.
(2) Investigate the effect of the combination treatment of the most effective polyphenols with 
the standard chemotherapeutic agents on ATP levels, apoptosis and cell cycle in the two most 
sensitive leukaemia cell lines (JURKAT and CCRF-CEM) and in the two most resistance 
leukaemia cell lines (THP-1 and KG-la) (Chapter 3).
(3) Identify the potential mechanistic pathways for the synergetic and antagonistic 
combination treatments of polyphenols and chemotherapeutic agents through investigating the 
extrinsic and intrinsic apoptotic pathways, glutathione levels and DNA damage; in two 
lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) and two myeloid leukaemia cell 
lines (THP-1 and KG-la) (Chapter 4).
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Chapter 2
Effects of Polyphenols on Proliferation 
and Apoptosis in Human Myeloid and 
Lymphoid Leukaemia Cell Lines.
78
2,1 Introduction
The problems with current treatments have led to the search for new compounds for the 
treatment of leukaemia. One area that has received great interest is the use of bio-active agents 
from natural sources (McDougall et al, 2010; Zaini et al, 2011; Dahlawi et al, 2012; Dahlawi 
et al, 2013). Two groups of bioactive components that have shown potential are the 
polyphenols (Dahlawi et al, 2012; Dahlawi et al, 2013) and polyacetylenes (Zaini et al, 2011). 
Epidemiological data has shown that diets rich in polyphenols significantly improve the quality 
of life (Han et al, 2007) and survival rates (Dai et al, 2013) of patients with a range of chronic 
diseases, including cancer. Furthermore, these polyphenols are found naturally in a variety of 
foods and are well tolerated, with few side effects (Dai et al, 2013). The selected polyphenols 
used in this study are representative of 3 different classes of polyphenols, which have been 
previously shown to have anti-proliferative, pro-apoptotic and/or prevent the progression of 
solid tumours (Huang et al, 2007; Han et al, 2007; Patel et al, 2007; Jaganathan et al, 2009; 
Sharif et al, 2010; Shukla et al, 2010; Dai et al, 2013) and a handful of leukaemia cell lines, 
with the most commonly studied being the human promyleocytic: HL-60 cells (Kang et al, 
1997; Saiko et al, 2006; Simoni et al, 2006; Vargo et al, 2006; Ramos et al, 2008). The 
polyphenols investigated include the flavonol (quercetin), flavones (apigenin and chrysin), 
anthraquinones (emodin, aloe-emodin and rhein); and two stilbene isomers (m-stilbene and 
frww-stilbene) (Section 1.8.2).
Previous work has demonstrated the pro-apoptotic and anti-cancerous activity of polyphenols 
in a number of solid tumours (Han et al, 2007; Patel et al, 2007; Jaganathan et al, 2009; Sharif 
et al, 2010; Shukla et al, 2010; Dai et al, 2013) and a selection of leukaemia cell lines (Kang et 
al, 1997; Saiko et al, 2006; Simoni et al, 2006; Vargo et al, 2006; Ramos et al, 2008). 
However, there has not been a comprehensive comparison of the action of polyphenols within 
a wide range of leukaemia cell lines. From previous studies, it is difficult to determine which 
polyphenols have the greatest potential for the treatment of leukaemia. There are no direct 
comparisons of the IC50 values (the concentration which inhibits 50% of cell proliferation) or 
AP50 values (the concentration at which 50% of cells undergo apoptosis) for each polyphenol. 
Furthermore, it is unclear whether a single polyphenol is affective in all leukaemia types; or 
whether specific polyphenols are only useful in a single type or subset of leukaemia. For this 
reason we compared the anti-proliferative and pro-apoptotic effects of the 8  polyphenols that 
have previously shown potential in solid cancer cell lines, on a panel of leukaemic cell lines 
that represent the major leukaemia types. These included four myeloid (KG-la, HL-60, THP-1 
and K562), three lymphoid (JURKAT, CCRF-CEM and MOLT-3) human leukaemic cell lines 
and one histocytic lymphoma cell line (U937). In addition, for the first time we evaluated the
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action of these polyphenols on two non-tumour hematopoietic stem progenitor cells (CD34+ 
HSC and CD133+HSC) from cord blood.
The purpose of this study was to determine which polyphenols were the most effective at 
inhibiting cell proliferation and inducing apoptosis in each of the eight leukaemic cell lines, 
whilst having a limited effect on the non-tumour cells. A direct comparison was made of the 
IC50 and AP50 values of each polyphenol in each cell line. Furthermore, we determined the 
action of each polyphenol on cell-cycle progression.
2.1.1 Hypothesis
This study tested the hypothesis that: Polyphenols reduce ATP levels, induce apoptosis and/or 
arrest cell cycle progression in leukaemia cell lines.
2.1.2 Aims
The major aims of this study were to investigate the effects of eight polyphenols (quercetin, 
apigenin, chrysin, emodin, aloe-emodin, rhein, m-stilbene and frwzs-stilbene) on: (1) ATP 
levels using CellTiter-Glo® luminescent cell viability assay; (2) apoptosis using the NucView 
caspase 3 activity assay and flow cytometry; and morphological assessment with Hoechst 
33342 stained cells and (3) progression of the cell cycle using PI staining and flow cytometry 
in four human lymphoid leukaemia cell lines (JURKAT, CCRF-CEM, MOLT-3 and U937), 
four human myeloid leukaemia cell lines (HL60, THP-1, K562 and KG la) and two non­
tumour hematopoietic stem progenitor cells (CD34+ HSC and CD133+HSC).
2.2 Material and Methods
2.2.1 Preparation of Polyphenols
Polyphenols: quercetin (Enzo), chrysin, apigenin, emodin, aloe-emodin, rhein, cis-stilbene and 
trans-stilbene (Sigma) were dissolved in ethanol (Sigma). A stock solution of 100 mMol was 
prepared in 10% (v/v) ethanol (Sigma) in serum free media (Invitrogen) to generate 
concentrations 0.4, 2, 10, 50, 250, 500 pMol.
2.2.2 Cell Lines and Culture Conditions
Four human myeloid leukaemia cell lines (HL-60 (promyelocytic leukaemia) (ATCC: CCL- 
240), THP-1 (acute monocytic leukaemia) (ATCC: TIB-202), K562 (chronic myeloid 
leukaemia) (ATCC: CCL-243) and KG-la (acute mylogenous leukaemia) (ATCC:CCL-243)]; 
and three human lymphoid cell lines [JURKAT (peripheral blood T cell leukaemia) (ATCC: 
TIB-152), MOLT-3 (acute lymphoblastic leukaemia from a patient relapsed following 
chemotherapy) (ATCC: CRL- 1552), and CCRF-CEM (acute lymphoblastic leukaemia)
(ATCC: CCL-119)]) and one histocytic lymphoma cell line (U937) (ATCC: CRL-1593.2) 
(Section 1.3.2); together with two non-tumour hematopoietic stem progenitor cells (CD34+ 
HSC and CD133+HSC) from cord blood (Stem cell Technologies) were used in this study. All 
leukaemia cell lines except MOLT-3 were p53-deficient, being either null, or containing 
mutant p53 (An et al, 2000; Durland and Reisman, 2002; Geley et al, 1997). MOLT-3 cells 
express wild type p53 (Cai et al, 2001), but are mutant for PTEN (Medyouf et al, 2010). All 
cell lines were tested regularly for mycoplasma contamination using the MycoAlert TM 
mycoplasma detection kit (Lonza) and were all tested negative throughout the study. Cells 
were seeded in T75cm2 flasks (Invitrogen) in 90% of Roswell Park Memorial Institute medium 
1640 (RPMI 1640) (Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS), 
1.5mM L-Glutamine and 100 pg/ml penicillin/streptomycin. The cultures were maintained at 
37°C with 5% C 02 in air.
2.2.2.1 Mycoplasma Analysis Using MycoAlert™ Mycoplasma Detection (Lonza)
One of the most common contaminants present in cell cultures are mycoplasma infections, 
which can lead to many serious alterations in cell viability, morphology, metabolic function, 
and gene expression (Uphoff and Drexler, 2005; Young et al, 2010; Volokhov et al, 2011). 
The first sign that a cell culture is contaminated with mycoplasma is a reduction in cell 
proliferation, cell aggregation and a change in cell morphology (Volokhov et al, 2011). Thus, 
regular testing of cell cultures for mycoplasma is essential (Uphoff and Drexler, 2005; Young 
et al, 2010; Volokhov et al, 2011). The MycoAlert™ mycoplasma detection assay (Lonza) 
was used check for mycoplasma contamination monthly (Uphoff and Drexler, 2005; Young et 
al, 2010; Volokhov et al, 2011).
The MycoAlert™ assay is a selective biochemical test that uses the activity of certain 
mycoplasmal enzymes. Any viable mycoplasma is lysed and the mycoplasma enzymes react 
with the MycoAlert™ substrate, catalyzing the conversion of ADP to ATP. The resultant ATP 
causes the mono-oxygenation of luciferin in the presence of luciferase, oxygen (O2 ) and 
magnesium (Mg2+) to oxyluciferin, AMP, carbon dioxide and energy in the form of a 
luminescent signal. This can be measured by a luminometer, and is an indication of the 
amount of ATP and hence the amount of mycoplasma infection. Briefly, a 2 ml sample of cell 
culture suspension was removed from each flask of cells into a 20 ml centrifuge tube, and 
centrifuged at 200 g for 5 minutes. Then, lOOpl of culture supernatant was transferred into 
triplicate wells of a white 96 well plate (Fisher Scientific). One hundred microliters of 
MycoAlert™ reagent (reconstituted in MycoAlert Buffer from Lonza) was added to each well 
and incubated at room temperature (RT) for 5 minutes. Luminescence was measured using a 
Wallac Victor 2 14020 (Reading A). Finally 100 pL of MycoAlert™ substrate (reconstituted
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in MycoAlert Buffer, Lonza) was added to each well and the plate incubated at RT for 10 
minutes prior to luminescence detection on the Wallac Victor 2 14020 (Reading B). The ATP 
level in a test sample should be measured before (Reading A) and after (Reading B) addition 
of the MycoAlert™ substrate, this produces a ratio of ATP levels, indicating the presence or 
absence of mycoplasma. The MycoAlert ratio was calculated for each well: the equation: 
Calculate ratio = Reading B/Reading A. A ratio of less than 0.9 was considered to have no 
mycoplasma contamination.
2.2.3 Analysis of Adenosine-5’-triphosphate (ATP) Levels as Indicator of Cell Viability 
Using CellTiter-Glo® Luminescent Cell Viability Assay
ATP is essential for the control of intracellular energy and is fundamental for all metabolic 
process of the cell, and indicative of normal cell function (Gilbert et al, 2011). ATP provides 
energy to sustain protein synthesis, biomass accumulation, growth, and cellular proliferation 
(Pelicano et al, 2003; Gilbert et al, 2011). In addition, ATP can mediate a variety of biological 
functions, including the induction of programmed cell death (apoptosis) (Gilbert et al, 2011). 
Cellular proliferation and apoptosis are energy dependent processes use ATP, during 
proliferation ATP levels increase in proportion with cell number (Gilbert et al, 2011). While, 
although apoptosis requires ATP, ATP levels will decrease during the loss of metabolic 
functions until cell death occurs (Gilbert et al, 2011). Measuring the ATP levels has been used 
as an indicator for number of viable cells (Gilbert et al, 2011; Lee et al, 2012). There are a 
number of methods for measuring ATP, however the most reliable and sensitive assay is a 
bioluminescent method based on the luciferin-luciferase reaction (Gilbert et al, 2011; Lee et al, 
2012). One such assay is the CellTiter-Glo® Luminescent Cell Viability Assay which unlike 
traditional colourmetric viability assays such as MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide), this assay measures ATP levels as a luminescent signal rather 
than a colour change, which can be particularly useful if agents under investigation are 
coloured.
2.2.S.2 CellTiter-Glo® Luminescent Cell Viability Assay
The CellTiter-Glo® Luminescent Cell Viability Assay utilises the mono-oxygenation of 
luciferin in the presence of luciferase, ATP, oxygen (O2 ) and magnesium (Mg2+) to 
oxyluciferin, AMP, carbon dioxide and energy in the form of light (Figure 2.1). The 
luminescent signal can then be measured by a luminometer detector (Figure 2.1), where the 
luminescent signal is proportional to the amount of ATP (Lee et al, 2012; Promega, 2013).
For ATP analysis, cells were seeded into white 96-well plates (Fisher Scientific) at 2.5 x 103 
cells per well and treated with each polyphenol (quercetin, apigenin, chrysin, emodin, aloe- 
emodin, rhein, c/s-stilbene and trans stilbene) (Sigma) at concentrations of 0.4, 2, 10, 50, 250,
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500 pMol, together with ethanol vehicle controls at 0.1 % (v/v). Treated cells were incubated 
at 37°C with 5% C 0 2, for 24, 48 and 72 h. Following treatments, 25pl of CellTiter-Glo® 
Reagent from CellTiter-Glo® Luminescent Cell Viability Assay Kit (Promega) was added to 
each well and mixed for 2 min on an orbital shaker and incubated at room temperature (RT) for 
10 min to stabilise luminescent signal. The luminescence was measured using Wallac Victor 2 
1420 luminescence detector (PerkinElmer, Waltham, USA). The luminescent signal was 
proportional to the amount of ATP present in the sample. The average from three luminescence 
readings was calculated and all treated samples were normalised to the controls. All treatments 
were performed in triplicate, in three independent experiments. The IC50 was determined for 
each polyphenol in each cell line. This was defined as the treatment concentration at which 
50% reduction in ATP levels was observed. This was calculated from a linear regression 
equation of each standard curve for each polyphenol with each cell line. The IC25 was also 
determined in order to provide treatment ranges for apoptosis detection, and cell cycle 
treatments, but were not used to determine the effectiveness of treatments.
Figure 2.1: Schematic of the 
CellTiter-Glo® Luminescent Cell 
Viability Assay. CellTiter-Glo® 
Reagent was added to cells cultured 
in serum-supplemented medium. 
This caused cell lysis and the 
release of ATP. Luciferin in the 
presence of luciferase, ATP, oxygen
(0 2) and magnesium (Mg2+) is 
converted to oxyluciferin, AMP, 
carbon dioxide (C02) and energy in 
the form of a luminescence which 
can be measured by a luminometer. 
Modified from Lee et al, 2012 and 
Promega, 2013.
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2.2.4 Apoptosis Analysis
2.2.4.1 NucView Caspase 3 Activity Assay Determination by Flow Cytometiy
Activation of the caspase 3 is a hallmark of apoptosis, thus determining levels of active 
caspase 3 is widely applied in cellular assays to identify induction of apoptosis (Lavrik et al,
2005). NucView™ 488 caspase 3 substrate is a novel cell membrane-permeable fluorogenic 
caspase substrate designed by Biotium (Cambridge Biosciences, UK) for detecting active
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caspase 3. NucView™ 488 caspase 3 substrate consists of a DNA-fluorogenic dye and a 
DEVD peptide moiety (with an amino acid sequence of Asp-Glu-Val-Asp). This amino acid 
sequence corresponds to a sequence within PARP; which is cleaved specifically by caspase 3 
(Figure 2.2) (Cen et al, 2008; Skommer et al, 2010; Smith et al, 2012). The NucView™ 488 
substrate is initially is non-functional, until the DEVD peptide (which is highly negatively 
charged) attaches to a DNA-fluorogenic dye (which is positively charged). Once this occurs 
the substrate rapidly crosses the cell membrane to enter the cell cytoplasm, where it is cleaved 
by intracellular caspase 3 activation to release the high-affmity DNA dye; which migrates to 
the cell nucleus and stains it fluorescent green. This can be measured at 488 nm and analysed 
by a flow cytometer using FITC settings (Figure 2.2) (Cen et al, 2008; Skommer et al, 2010; 
Smith et al, 2012). Using this method, it was possible to determine the AP5 0  concentrations for 
each polyphenol in each leukaemia cell line. This was defined as the treatment concentration at 
which 50% of treated cells had undergone apoptosis.
For analysis o f caspase 3 activity, cells were treated with each polyphenol at the range of IC2 5  
and I C 5 0  concentrations as shown determined previously by the CellTiter-Glo® assay. The 
treatment concentrations for emodin, quercetin and cw-stilbene were 0, 0.4, 2, 10, 50 pM; and 
for apigenin, chrysin, aloe-emodin, rhein and /ra/7 5 -stilbene they were 0, 10, 50, 250 pM.
Following treatments, 200 pi of each cell suspension was transferred to a flow cytometry tube
and 5 pi of caspase 3 activity assay (0.2 mM) (Promega) was added. This was incubated for 10 
min in the dark, and each sample was analysed by flow cytometer using a BD FACS Calibur 
instrument (BD). Ten thousand events were acquired per sample and the data was analysed 
with Flow Jo software (Tree Star).
Figure 2.2: The principle of
NucViewT!M488 Caspase 3 
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fo r  c a sp a se  3. T h is  su b s tra te  is 
o r ig in a lly  n o t f lu o re s c e n t a n d  n o n ­
fu n c tio n a l u n til  th e  D E V D  p e p tid e  
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2.2.4.2 Hoechst 33342 Nuclear Morphological Analysis by Fluorescence Microscopy
Apoptotic cells and nuclear morphology was assessed by fluorescence microscopy following 
Hoechst 33342 nucleic acid staining. During apoptosis, the cell shrink and the chromatin 
content condenses. The cell membrane blebs and fragments giving raise to pyknotic apoptotic 
bodies (Doonan et al, 2007; Elmore, 2007). The typical features of apoptosis can be visualised 
following Hoechst 33342 staining using a fluorescence microscopy. Hoechst 33342 is a 
permeable blue-fluorescent stain that binds strongly to Adenine-Thymine rich regions in the 
minor groove of double-stranded DNA (Breusegem et al, 2002; Martin et al, 2005; Gilbert et 
al, 2011). The fluorescence of Hoechst 33342 stain is very sensitive to DNA conformation and 
chromatin state in cells. The fluorescence of this stain is enhanced based upon binding to 
dsDNA AT stretches of at least three AT base pairs (Martin et al, 2005). Once the Hoechst 
33342 stain is bound to DNA, it generates a 30 fold increase in fluorescence which can be 
observed by fluorescent microscope (Martin et al, 2005; Gilbert et al, 2011). Hoechst can enter 
live and apoptotic cells easily, and the level of fluorescence is proportional to the DNA content. 
Hoechst 33342 dye provides a brighter staining of the condensed chromatin of apoptotic cells; 
whilst normal live cells appear round and diffusely stained (Martin et al, 2005; Gilbert et al, 
2011). Using this stain it is possible to identify and quantify the number of apoptotic cells.
For analysis of morphological changes of apoptosis, cells were seeded in 12 well plates 0.5 x 
106 cells per well and treated for 24 h with each of the polyphenols at wide concentrations of 
0.4, 2, 10, 50, 250, 500 pMol, together with ethanol vehicle controls at 0.1 % (v/v). Following 
polyphenol treatments, cells from each culture well was transferred to eppendorf tubes and 
centrifuged for 5 min at 400 g at 4°C. The supernatant was removed, and cells washed in 100 
pi PBS. The cells were fixed in 4% (w/v) paraformaldhyde/PBS and cytospins formed 
(Shandon Cytospin 3 Centrifuge, Thermo). Samples were air dried and stained in 50 pi of 10 
pg/ml Hoescht 33342 stain (Sigma) for 10 min in the dark. Slides were mounted in immersion 
oil and examined using a fluorescence microscope (Olympus). Two hundred cells (live and 
apoptotic) were counted and the percentage of apoptotic nuclei determined for each sample. 
Images were captured using Lab Works 4.0 (UVP Bioimaging Systems).
2.2.5 Cell Cycle Analysis using Propidium Iodide (PI) and Flow Cytometry
The effect of polyphenols on the progression of cell cycle was studied using a fluorescent 
DNA-intercalating dye propidium iodide (PI) and analysed by flow cytometery. PI is a red- 
fluorescent stain that binds to all double stranded nucleic acids, including that of the major 
groove of double stranded DNA and RNA (Darzynkiewicz, 2010; Darzynkiewicz, 2011). It is
85
able to quantify the proportion of cells in each phase of cell cycle (Go/Gi, S and G2/M); and 
determine whether cells are accumulated in a specific phase (Figure 2.3) (Thomas, 1993; Tao 
et al, 2004; Leo et al, 2011). When analysing cell cycle progression, cell are initially 
permeabilized and then stained with PI stain together with RNase. The RNase removes any 
RNA so that the PI can only bind to DNA (Darzynkiewicz, 2010; Darzynkiewicz, 2011). The 
PI stain once bound to DNA, fluoresces with a broad emission between 600 and 637 nm that 
can be excited at 488nm and detected using a flow cytometer (Darzynkiewicz, 2010; 
Darzynkiewicz, 2011). As DNA content increases as cell cycle progresses, cell cycle stage can 
be easily determined from the concentration of DNA within each cell (Figure 2.3).
For cell cycle analysis, cells were seeded in 12 well plates at 0.5 x 106 cells per well and 
treated for 24 h with dose ranges between IC25 and IC50 for each polyphenol as shown in the 
CellTiter-Glo® assay. The treatment doses were 2, 10, 50 pM for quercetin, emodin and cis- 
stilbene (Sigma); 10, 50 250 pM for apigenin (Sigma), and 50, 250, 500 pM for chrysin, aloe- 
emodin, rhein and trans-sXiVoQWQ (Sigma). Following treatment cells were harvested and 
centrifuged at 400 g for 5 min. The supernatant was removed, and cells were washed twice in 
100 pi cold PBS. Cells were fixed in 100 pi of 80% ethanol/H20  (v/v) and stored overnight at - 
20°C. Then, cells were washed twice with cold PBS prior to addition of 300 pi of 50 pg/mL PI 
(Sigma) and 50 pi of 0.1 unit/mL RNase (Sigma). Samples were PI stained overnight at 4°C 
and analysed on the flow cytometer with BD FACS Calibur instrument. Ten thousand events 
were acquired per sample and the DNA histogram of cell cycle phase was analyzed with 
Flow Jo software using the Waston (pragmatic) equation (Tree Star).
Figure 2.3: The
relationship between the 
cell cycle and DNA 
histogram. Left picture 
showed the distribution of 
the DNA content within 
different stages of the cell 
cycle. Right picture showed 
Flow Jo analysis of three 
stages of cell cycle using 
the Waston (pragmatic) 
equation (Tree Star).
The means and standard deviations (STD) were calculated for CellTiter-Glo®, caspase 3 
activity and Hoechst 33342 assays. The median with ranges were calculated for Cell Cycle 
analysis. Stats Direct software (Stats Direct Ltd, England) was used to test for normality using 
a Shapiro-Wilks test. The data was non-parametric; a Kruskal-Wallis and Conover-Inman post
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2.2.6 Statistical Analysis
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hoc test was used to determine statistical significance of the data. Results were considered 
statistically significant when p < 0.05.
2.3 Results
2.3.1 Effects of Polyphenol Treatments on ATP Levels in Leukaemia Cell Lines at 24, 48, 
72 h
Treatment with polyphenols for 24, 48, 72 h resulted in reduced cell ATP levels in all 8  
leukaemia cell lines to a greater extent than in non-tumour cell lines (Figure 2.4, 2.5, 2.6). The 
lowest dose of polyphenols at which there was a significant inhibition on cellular ATP levels 
(Table 2.1, 2.3, 2.5), and the IC50 values was determined for each polyphenol in each cell line 
at 24, 48, 72 h (Table 2.2, 2.4, 2.6). Using this data, it was possible to rank the polyphenols in 
order of effectiveness. Over the different time points, the most effective polyphenols at 
significantly reducing ATP levels compared to vehicle controls were emodin, quercetin, and 
cw-stilbene (p<0.05) (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). A more moderate affect was 
shown by apigenin and rhein; and the least effective polyphenols were aloe-emodin, trans- 
stilbene and chrysin. Both lymphoid and myeloid leukaemia cell lines were sensitive to emodin, 
quercetin, and cA-stilbene treatment (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). However, it 
is important to note that each leukaemia cell line demonstrated differing sensitivity with the 
remaining polyphenols. Generally, the lymphoid cell lines were more sensitive to polyphenol 
treatment than myeloid cell lines (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6).
Emodin consistently gave the lowest IC50 values (5-22 pM at 24 h) (Table 2.2), (3-20 pM at 48 
h) (Table 2.4), (2-10 pM at 72 h) (Table 2.6); showing a significant reduction on ATP levels of 
all leukaemia cell lines (p<0.05), with a slightly greater effect on lymphoid than myeloid cells. 
Emodin also significantly reduced ATP levels in the non-tumour cell lines (CD34+ HSC and 
CD133+ HSC) (p<0.05). However, the IC50 in the CD34+ HSC and CD133+ HSC cells (-150 
and 250 pM at 24 h) (Table 2.2), (-125 and 160 pM at 48 h) (Table 2.4), (-85 and 95 pM at 72 
h) (Table 2.6) were much greater than that seen for all the leukaemia cells, demonstrating 
selectivity towards malignant verses non-transformed cell lines (Figure 2.4, 2.5, 2.6 and Table 
2.2, 2.4, 2 .6 ). Similarly, quercetin had a more potent effect on lymphoid cell line (IC50 values 
of 8-20 pM at 24 h, 4.5-10 pM at 48 h and 4-10 pM at 72 h) than myeloid cell lines (IC50  
values of 33-155 pM at 24 h, 25-100 pM at 48 h and 20-50 pM at 72 h) (Figure 2.4, 2.5, 2.6 
and Table 2.2, 2.4, 2.6). The least sensitive leukaemia cell line to quercetin treatment with an 
IC50 of 155 pM at 24 h, 100 pM at 48 h, and 50 pM at 72 h was the acute myelogenous 
leukaemia KG-la cell line (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). However, the human 
promyelocytic leukaemia (HL-60) cell line had a much lower IC50 values ( 8  pM at 24 h, 4 pM 
at 48 h and 3 pM at 72 h ), which were similar to those values seen in lymphoid cells (Figure 
2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). In addition, quercetin did not affect the ATP levels of the
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non-tumour cell lines, until the treatment dose reached 500 pM at 24 and 48 h, and 250 pM at 
72 h (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). C/s-stilbene had IC50 values of 25-85 jj.M at 
24 h, 25-80 pM at 48 h and 15-75 pM at 72 h, and affected both lymphoid and myeloid cells 
equally (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). C/s-stilbene also did not affect the ATP 
levels of the non-tumour cell lines, until the treatment dose exceeds 350 pM over the three 
time points (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6).
Apigenin and rhein had a moderate effect at reducing ATP levels. Apigenin demonstrated a 
greater effect on the lymphoid cells (IC50 values of 140-195 pM at 24 h, 120-160 pM at 48 h 
and 60-145 pM at 72 h) compared to the myeloid cells (IC50 values of 100-500 pM at 24 h, 
100-480 pM at 48 h, 60-400 pM at 72 h) (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). In non­
tumour cell lines (CD34+HSC and CD133+ HSC), they did not reach a 50% inhibition of ATP 
levels until apigenin treatment exceeded 500 pM over the three time points (Figure 2.4, 2.5, 2.6 
and Table 2.2, 2.4, 2.6).
Rhein demonstrated a significant decrease on ATP levels of all leukaemia cell lines with IC50  
values of 135-380 pM at 24 h, 120-260 pM at 48 h and 90-250 pM at 72 h with a similar effect 
seen in both lymphoid and myeloid cell lines. In the non-tumour cell lines the IC50 values were 
350-380 pM at 24 h, 260 pM at 48 h and 250 pM at 72 h (p<0.05), (Figure 2.4, 2.5, 2.6 and 
Table 2.2, 2.4, 2.6).
Aloe-emodin, chrysin and Jraws-stilbene were the least effective polyphenols at reducing ATP 
levels. Aloe-emodin had IC50 values between 185-450 pM at 24 h, 180-450 pM at 48 h and 
170-380 pM at 72 h (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). These were more than ten 
times higher than emodin. Aloe-emodin, like emodin, showed a greater effect on lymphoid cell 
lines than myeloid cell lines (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). Similarly, chrysin 
demonstrated comparatively high IC50 values, and again was more effective on lymphoid cells 
(IC50 values of 128-217 pM at 24 h, 100-200 pM at 48 h and 75-150 pM at 72 h) compared to 
the myeloid cells (IC50 values of 328-500 pM at 24 h, 300-500 pM at 48 h and 270-400 pM at 
72 h) (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6).
7raws-stilbene had some of the highest IC50  values ranging between 109-500 pM at 24 h, 100- 
500 pM at 48 h, 95-500 pM at 72 h (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6). These were 
much higher than those values found with its isomer, c/s-stilbene (Figure 2.4, 2.5, 2.6 and 
Table 2.2, 2.4, 2.6). Despite the differing effects on the leukaemia cells, aloe-emodin, chrysin 
and trans-stilbene did not cause any significant reduction in ATP levels of the non-tumour cell 
lines, until the treatment dose reached 500 pM (Figure 2.4, 2.5, 2.6 and Table 2.2, 2.4, 2.6).
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Figure 2.4: Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe- 
emodin, m-stilbene and trans-stilbene) on ATP levels of three lymphoid leukaemia (CCRF- 
CEM, MOLT-3, JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four 
human myeloid leukaemia cell lines (K562, HL-60, KG-la , THP-1; blue lines), and two non­
tumour normal progenitor cells (CD34+HSC, CD133+ HSC; black lines) at 0, 0.4, 2, 10, 50, 
250, 500 pM for 24 h. This was evaluated by CellTiter-Glo® assay. Data was normalised to the 
vehicle control which was assigned 100% cell viability. The data is expressed as mean ± STD 
(three independent experiments, each in triplicate). The statistical significance was determined by 
comparison with the vehicle control; statistical significance was set at p<0.05. Statistical results are 
summarised in Table 2.1 which shows the lowest dose that induced significant inhibition compared 
to vehicle control at 24 h. All concentrations above these points were also statistically significant. 
The IC5o for each polyphenol in each cell line at 24 h were determined and shown in Table 2.2.
Cell Types
The Lowest Dose of Polyphenols (pM) At Which There Was a 
Significant Inhibition of ATP Levels Compared to The Vehicle Control
At 24 h.
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbene
Trans-
Stilbene
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia JURKAT 2 50 50 50 2 50 2 50
CCRF-
CEM 2 10 50 50 2 50 10 50
MOLT-3 2 50 50 50 2 50 2 50
M
ye
lo
id
le
uk
ae
m
ia
HL60 2 10 50 50 2 50 2 50
THP-1 2 10 250 50 2 250 2 250
K562 2 10 250 50 2 50 2 50
KGla 10 10 250 50 2 50 2 50
H
is
to
cy
tic
L
ym
ph
om
a
U937 2 10 50 50 2 50 2 50
Co
rd
 
bl
oo
d 
ce
lls
N
on
-T
um
ou
r 
C
on
tr
ol
 C
el
ls CD34+
HSC 250 500 500 250 50 500 250
250
CD133+
HSC 250 50 500 250 50 500 250
250
Table 2.1: The lowest dose of polyphenols that induced a significant decrease in ATP levels 
compared to the vehicle controls, p<0.05. Polyphenol treatments were: 0, 0.4, 2,10, 50, 250, 500 
pM for 24 h. The polyphenols were ranked in order of activity with respect to significant reduction 
of cellular proliferation in lymphoid cells (emodin = quercetin > m-stilbene > apigenin > rhein = 
fra/w-stilbene = aloe-emodin = chrysin); and in myeloid cells (emodin = m-stilbene > quercetin > 
apigenin > rhein > aloe-emodin = PYm-stilbene > chrysin). Note that the treatment doses that 
caused significant inhibition of cellular proliferation in all leukaemia cell lines were much lower 
than in the non-tumour cells (CD34+ HSC and CCD133+HSC) at 24 h. Due to the wide range of 
concentrations used and the number of cell lines investigated, it was not possible to indicate 
significance levels on Figure 2.4 and thus, Table 2.1 indicates the lowest dose of polyphenol at 
which significance was obtained for each cell line, providing the statistical analysis for Figure 2.4.
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Cell Types
Polyphenols IC50 in pM at 24 h
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbene
Trans-
Stilbenc
Ce
ll 
L
in
es
L
ym
ph
oi
d
le
uk
ae
m
ia
JURKAT 10 143 180 277 9 185 38 163
CCRF-
CEM
10 195 128 140 22 211 53 109
MOLT-3 20 140 217 158 8 220 25 180
M
ye
lo
id
le
uk
ae
m
ia
HL60 8 100 328 150 5 225 32 135
THP-1 37 180 500 158 10 450 45 380
K562 33 350 500 380 13 309 53 500
KGla 155 500 335 169 15 310 85 250
H
is
to
cy
tic
L
ym
ph
om
a
U937 8 160 217 135 7 250 30 340
Co
rd
 
bl
oo
d 
ce
lls
N
on
-T
um
ou
r 
C
on
tr
ol
 C
el
ls CD34+
HSC
>500 >500 >500 380 150 >500 390 500
CD133+
HSC
500 >500 >500 350 250 >500 350 500
Table 2.2: The IC50 values responsible for 50% inhibition of ATP levels in each leukaemia 
and non-tumour control cell line following 24 h treatment with each polyphenols. This was 
determined by CellTiter-Glo® Luminescent assay. The polyphenols were ranked in order of 
activity with respect to inhibition of 50% proliferation in lymphoid cells (emodin = quercetin > cis- 
stilbene > apigenin > fraw.s-stilbene > chrysin = rhein > aloe-emodin); and in myeloid cells (emodin 
= c/s-stilbene > quercetin > apigenin = rhein > aloe-emodin = /raws-stilbene = chrysin). Non­
tumour cells (CD34+ HSC and CD133+HSC) did not reach 50% inhibition until the polyphenol 
treatments excessed 500 pM; the only exceptions were emodin, rhein and c/s-stilbene. Note that the 
highest doses of aloe-emodin, chrysin, rhein and /raws'-stilbene would be clinically impractical, 
while IC50 for quercetin emodin, c/s-stilbene had much lower doses and thus are potentially more 
clinically useful.
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Figure 2.5: Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe- 
emodin, c/s-stilbene and trans-stilbene) on ATP levels of three lymphoid leukaemia (CCRF- 
CEM, MOLT-3, JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four 
human myeloid leukaemia cell lines (K562, HL-60, KG-la , THP-1; blue lines), and two non­
tumour normal progenitor cells (CD34+HSC, CD133+ HSC; black lines) at 0, 0.4, 2, 10, 50, 
250, 500 pM for 48 h. This was evaluated by CellTiter-Glo® assay. Data was normalised to the 
vehicle control which was assigned 100% cell viability. The data is expressed as mean ± STD 
(three independent experiments, each in triplicate). The statistical significance was determined by 
comparison with the vehicle control; statistical significance was set atp<0.05. Statistical results are 
summarised in Table 2.3 which shows the lowest dose that induced significant inhibition compared 
to vehicle control at 48 h. All concentrations above these points were also statistically significant. 
The IC50 for each polyphenol in each cell line at 48 h were determined and shown in Table 2.4.
Cell Types
The Lowest Dose of Polyphenol 
Significant Inhibition of ATP Levels
At 41
s (pM) At Which There Was a 
Compared to The Vehicle Control 
3h.
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbene
Trans-
Stilbene
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia JURKAT 2 10 10 10 0.4 10 2 50
CCRF-
CEM 2 10 10 2 2 10 10 50
MOLT-3 2 2 50 10 2 10 2 50
M
ye
lo
id
le
uk
ae
m
ia
HL60 2 10 50 10 0.4 10 2 50
THP-1 2 10 50 10 2 50 2 250
K562 2 10 10 10 2 50 2 50
KGla 2 10 10 10 2 10 2 50
H
is
to
cy
tic
L
ym
ph
om
a
U937 2 2 50 10 2 10 10 50
Co
rd
 
bl
oo
d 
ce
lls
N
on
-t
um
ou
r  
co
nt
ro
l 
ce
lls CD34+
HSC 50 50
50 250 10 50 10 250
CD133+
HSC 50
50 50 10 10 50 10 250
Table 2.3: The lowest dose of polyphenols that induced a significant decrease in ATP levels 
compared to the vehicle controls, p<0.05. Polyphenol treatments were: 0, 0.4, 2,10, 50, 250, 500 
pM for 48 h. The polyphenols were ranked in order of activity with respect to significant reduction 
of cellular proliferation in lymphoid cells (emodin = quercetin > c/s-stilbene > apigenin > rhein = 
trans-stilbene = aloe-emodin = chrysin); and in myeloid cells (emodin = c/s-stilbene > quercetin > 
apigenin > rhein > aloe-emodin = /ra/is-stilbene > chrysin). Note that the treatment doses that 
caused significant inhibition of cellular proliferation in all leukaemia cell lines were much lower 
than in the non-tumour cells (CD34+ HSC and CCD133+HSC) at 48 h. Due to the wide range of 
concentrations used and the number of cell lines investigated, it was not possible to indicate 
significance levels on Figure 2.5 and thus, Table 2.3 indicates the lowest dose of polyphenol at 
which significance was obtained for each cell line, providing the statistical analysis for Figure 2.5.
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rVII Tvnp«
Polyphenols IC50 in pM at 48 h
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stiibcnc
Trans-
Stilbene
■o «
JURKAT 7.5 120 160 250 8 180 30 160
S’ 55 E ■“
J  s
CCRF-
CEM
10 160 100 120 20 210 50 100
MOLT-3 10 140 200 120 3 190 25 175
HL60 4 100 300 135 4 200 31 160
oJR «  .5 
1  E_ 0
THP-1 25 170 500 150 9 450 40 400
O
V §  g K562 25 300 320 260 11 300 50 500
KGla 100 480 320 200 9 310 80 250
H
is
to
cy
tic
L
ym
ph
om
a
U937 4.5 150 160 120 4.5 250 28 280
Co
rd
 
bl
oo
d 
ce
lls
U Vi
n
CD34+
HSC
>500 >500 500 260 125 >500 400 500
h t !
e e  
0  0  
Z, U
CD133+
HSC
500 >500 500 260 160 >500 350 500
Table 2.4: The IC50 values responsible for 50% inhibition of ATP levels in each leukaemia 
and non-tumour control cell line following 48 h treatment with each polyphenols. This was 
determined by CellTiter-Glo® Luminescent assay. The polyphenols were ranked in order of 
activity with respect to inhibition of 50% proliferation in lymphoid cells (emodin = quercetin > cis- 
stilbene > apigenin > /ra/w-stilbene > chrysin = rhein > aloe-emodin); and in myeloid cells (emodin 
= c/s-stilbene > quercetin > apigenin = rhein > aloe-emodin = /ra/w-stilbene = chrysin). Non­
tumour cells (CD34+ HSC and CD133+HSC) did not reach 50% inhibition until the polyphenol 
treatments excessed 500 pM; the only exceptions were emodin, rhein and ds-stilbene. Note that the 
highest doses of aloe-emodin, chrysin, rhein and /ra/?y-stilbene would be clinically impractical, 
while IC50 for quercetin emodin, ds-stilbene had much lower doses and thus are potentially more 
clinically useful.
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Figure 2.6: Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe- 
emodin, c/s-stilbene and trans-stilbene) on ATP levels of three lymphoid leukaemia (CCRF- 
CEM, MOLT-3, JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four 
human myeloid leukaemia cell lines (K562, HL-60, KG-la , THP-1; blue lines), and two non­
tumour normal progenitor cells (CD34+ HSC, CD133+ HSC; black lines) at 0, 0.4, 2, 10, 50, 
250, 500 pM for 72 h. This was evaluated by CellTiter-Glo® assay. Data was normalised to the 
vehicle control which was assigned 100% cell viability. The data is expressed as mean ± STD 
(three independent experiments, each in triplicate). The statistical significance was determined by 
comparison with the vehicle control; statistical significance was set atp<0.05. Statistical results are 
summarised in Table 2.5 which shows the lowest dose that induced significant inhibition compared 
to vehicle control at 72 h. All concentrations above these points were also statistically significant. 
The IC50 for each polyphenol in each cell line at 72 h were determined and shown in Table 2.6.
Cell Types
The Lowest Dose of Polyphenols (pM) At Which There Was a 
Significant Inhibition of ATP Levels Compared to The Vehicle Control
At 72 h.
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stiibene
Trans-
Stilbene
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia JURKAT 0.4 10 10 10 0.4 10 0.4 10
CCRF-
CEM 2 10 10 2 2 10 2 10
MOLT-3 2 2 10 10 0.4 10 2 10
M
ye
lo
id
le
uk
ae
m
ia
HL60 2 10 10 10 0.4 10 2 50
THP-1 2 10 50 50 2 50 2 250
K562 2 10 10 10 2 50 2 50
KGla 2 10 10 10 2 10 2 50
H
is
to
cy
tic
L
ym
ph
om
a
U937 2 2 50 10 2 10 10 50
Co
rd
 
bl
oo
d 
ce
lls
N
on
-T
um
ou
r  
C
on
tr
ol
 C
el
ls CD34+
HSC 50 50 10 50 10 50 10 250
CD133+
HSC 50 50 50 10 10 10 10 50
Table 2.5: The lowest dose of polyphenols that induced a significant decrease in ATP levels 
compared to the vehicle controls,p<0.05. Polyphenol treatments were: 0, 0.4, 2, 10, 50, 250, 500 
pM for 72 h. The polyphenols were ranked in order of activity with respect to significant reduction 
of cellular proliferation in lymphoid cells (emodin = quercetin > c/s-stilbene > apigenin > rhein = 
trans-stilbene = aloe-emodin = chrysin); and in myeloid cells (emodin = c/s-stilbene > quercetin > 
apigenin > rhein > aloe-emodin = trans-stilbene > chrysin). Note that the treatment doses that 
caused significant inhibition of cellular proliferation in all leukaemia cell lines were much lower 
than in the non-tumour cells (CD34+ HSC and CCD133+HSC) at 72 h. Due to the wide range of 
concentrations used and the number of cell lines investigated, it was not possible to indicate 
significance levels on Figure 2.6 and thus, Table 2.5 indicates the lowest dose of polyphenol at 
which significance was obtained for each cell line, providing the statistical analysis for Figure 2.6.
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Cell Types
Polyphenols IC50 in pM at 72 h
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbcne
Trans-
Stilbene
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia JURKAT 4.9 100 150 200 4.5 170 19 160
CCRF-
CEM 10 145 75 90 18 195 50 95
MOLT-3 9 60 150 100 2 100 15 100
M
ye
lo
id
le
uk
ae
m
ia
HL60 3 60 270 125 3 200 20 100
THP-1 20 160 400 130 7 380 40 390
K562 20 280 280 250 10 250 50 500
KGla 50 400 260 160 9 250 75 200
H
is
to
cy
tic
L
ym
ph
om
a
U937 4 145 95 100 3.5 235 15 200
Co
rd
 
bl
oo
d 
ce
lls
1
N
on
-T
um
ou
r 
C
on
tr
ol
 C
el
ls CD34+
HSC 450 >500 500 250 85 >500 355 500
CD133+
HSC 250 >500 450 250 95 500 300 490
Table 2.6: The IC5 0 values responsible for 50% inhibition of ATP levels in each leukaemia 
and non-tumour control cell line following 72 h treatment with each polyphenols. This was 
determined by CellTiter-Glo® Luminescent assay. The polyphenols were ranked in order of 
activity with respect to inhibition of 50% proliferation in lymphoid cells (emodin = quercetin > cis- 
stilbene > apigenin > Jran.s-stilbene > chrysin = rhein > aloe-emodin); and in myeloid cells (emodin 
= m-stilbene > quercetin > apigenin = rhein > aloe-emodin = /raws-stilbene = chrysin). Non­
tumour cells (CD34+ HSC and CD133+HSC) did not reach 50% inhibition until the polyphenol 
treatments excessed 500 pM; the only exceptions were emodin, rhein and m-stilbene. Note that the 
highest doses of aloe-emodin, chrysin, rhein and frwis-stilbene would be clinically impractical, 
while IC50 for quercetin emodin, m-stilbene had much lower doses and thus are potentially more 
clinically useful.
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2.3.2 Induction of Apoptosis Following Polyphenol Treatments in Leukaemia Cells at 24 
h
The effectiveness of polyphenols in inducing apoptosis was assessed by caspase 3 activity 
assay using flow cytometry and Hoechst 33342 nuclear staining using a fluorescence 
microscope; these two methods were indicative of early and late phases of apoptosis. For the 
measurement of caspase 3 activity, the leukaemia cell lines were treated with polyphenols at 
the IC25 and IC50 treatment ranges (0.4, 2 , 10, 50 pM of quercetin, emodin and czs-stilbene, 1 0 , 
50, 250 pM of apigenin, 50, 250 pM of chrysin and aloe-emodin, 50, 250, 500 pM of trans- 
stilbene) as determined by CellTiter-Glo® assay for 24 h. For Hoechst 33342 nuclear staining, 
the leukaemic cell lines were treated with all polyphenols at a wide range of concentrations (0 , 
0.4, 2, 10, 50, 250, 500 pM) as previously used in CellTiter-Glo® assay for 24 h; This enabled 
an examination of the differential effects of each polyphenols on the morphological changes of 
apoptosis plus help to confirm the CellTiter-Glo® results. Using the results from both assays, it 
was possible to determine the lowest dose of polyphenol (pM) which significant induction of 
apoptosis (Table 2.7, 2.8); plus the AP50 values (Table 2.9) the dose at which there was 50% of 
apoptosis. By using the AP50 values of caspase 3 activity and Hoechst 33342 assays it was 
possible to rank the polyphenols in order of effectiveness for apoptosis induction (Table 2.9). 
The morphological assessment of apoptosis by Hoechst 33342 staining confirmed the 
induction of apoptosis shown by the caspase 3 activity assays. However it is important to note 
that the AP50 values determined using the caspase 3 activity were lower than those determined 
by the Hoechst staining, as the later is indiciative of late stages of apoptosis (Figure 2.7, 2.8 
and Table 2.9).
All eight polyphenols induced significantly higher levels of apoptosis determined by caspase 3 
activity (Figure 2.7) and Hoechst 33342 staining (Figure 2.9) in all leukaemia cell lines 
compared to the non-tumour cells (p<0.05) (Table 2.9). The leukaemia cell lines demonstrated 
differing sensitivity to the polyphenols. In particular, quercetin (Figure 2.10), chrysin (Figure 
2.11), apigenin (Figure 2.12), emodin (Figure 2.13), aloe-emodin (Figure 2.14), cw-stilbene 
(Figure 2.15) had a greater toxicity towards lymphoid leukaemia cell lines than myeloid 
leukaemia cell lines with AP50 values of caspase 3 activity and Hoechst 33342 assays ranging 
between 19-50 pM for quercetin, 35-130 pM for chrysin, 30-250 pM for apigenin, 2-27 pM for 
emodin, 50-195 pM for aloe-emodin, 8-50pM for cw-stillbene (Figure 2.7, 2.8 and Table 2.9). 
Emodin, quercetin, c/s-stilbene and apigenin were the most effective polyphenols at inducing 
apoptosis according to their AP50 values in lymphoid cell lines (Figure 2.7, 2.8 and Table 2.9). 
The HL-60 cells were the only myeloid cells which were sensitive responded to quercetin, 
apigenin, chrysin, emodin, aloe-emodin, ds-stilbene treatments with AP50 values of caspase 3 
activity and Hoechst 33342 assays 50 pM, 75-175 pM, 84-129 pM, 6-8.5 pM, 185-190 pM, 
31-49 pM respectively (Figure 2.7, 2.8 and Table 2.9). In addition, the THP-1 myeloid cell line
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was only sensitive to apigenin and emodin, with AP50 values of 110-225 pM (Figure 2.7, 2.8 
and Table 2.9). K562 and KGla were resistant to the most of polyphenol treatments (quercetin, 
chrysin, emodin, aloe-emodin, cA-stilbene treatments), while they were sensitive to apigenin 
treatment with AP5o values between 150-190 pM in K562 cells and 89-235 pM in KGla cells 
(Figure 2.7, 2.8 and Table 2.9). Consequently, apigenin was the only effective polyphenol at 
inducing apoptosis in all myeloid cell lines with AP50 values ranging between 84-235 pM. 
Rhein (Figure 2.7, 2.8, 2.12) and frYms-stilbene (Figure 2.7, 2.8, 2.16), demonstrated similar 
sensitivity to both myeloid and lymphoid cell lines with AP50 values of caspase 3 activity and 
Hoechst 33342 assays ranging between 60-265 pM and 40-400 pM respectively (Table 2.9).
In accordance with their AP50 values emodin, quercetin, czs-stilbene and apigenin were the 
most effective polyphenols at inducing apoptosis in most of leukaemic cell lines (Figure 2.7,
2.8 and Table 2.9). Emodin induced 50% apoptosis in 5 of the 8  leukaemia cell lines (JURKAT, 
MOLT-3, HL-60, THP-1 and U937) (Figure 2.7, 2.8, 2.13 and Table 2.9). Quercetin was also a 
potent polyphenol inducing apoptosis with AP50 value ranging between 19-50 pM in lymphoid 
cell lines and 50-205 pM in myeloid cell lines. Quercetin differential induction of apoptosis in 
each leukaemia cell line although the AP50 values were consistently low (Figure 2.7, 2.8, 2.9 
and Table 2.9).
C/s-stilbene induced caspase 3 activity of early apoptosis and morphological changes 
characteristic of late apoptosis in the majority of leukaemia cell lines. In particular Czs-stilbene 
showed AP50 values ranging between 8-50 pM in three lymphoid cell lines (JURKAT, MOLT- 
3, and U937) and between 31-49 pM in one myeloid cell line (HL-60); the remaining cell 
lines were more resistant, and did not reach 50% apoptosis even when treated with a maximal 
treatment dose (500 pM) (Figure 2.7, 2.8, 2.15 and Table 2.9).
Apigenin was shown to induce apoptosis in all leukaemia cell lines, with AP50 values ranging 
between 35-130 pM in lymphoid cell lines and 84-235 pM in the myeloid cell lines. In contrast 
to quercetin, apigenin was capable of inducing both an increase in caspase 3 indicating early 
apoptosis, plus morphological evidence of late apoptosis, in all leukaemia cells lines; including 
the KG-la and K562 cells which were resistant to emodin, quercetin and cA-stilbene treatment. 
The other polyphenols investigated; chrysin, rhein, aloe-emodin, ^ra/zs-stilbene induced 
apoptosis in some leukaemia cell lines, however the AP50 values were much higher compared 
to other polyphenols (Figure 2.7, 2.8 and Table 2.9).
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Figure 2.7: Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe 
emodin, m-stilbene and frans-stilbene) on apoptosis of three lymphoid leukaemia (CCRF- 
CEM, MOLT-3, JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four 
human myeloid leukaemia cell lines (K562, HL-60, KG-la , THP-1; blue lines), and two non­
tumour normal progenitor cells (CD34+ HSC, CD133+ HSC; black lines). Apoptosis was 
assessed using a caspase 3 activity assay and analysed by flow cytometry. Cells were treated with 
each polyphenol at ranges of IC25 and IC50 doses as determined by CellTiter-Glo® assay for 24 h. 
The treatment concentrations for emodin, quercetin and c/s-stilbene were 0, 0.4, 2, 10, 50 pM; and 
for apigenin, chrysin, aloe-emodin, rhein and /ra/?5 -stilbene were 0, 10, 50, 250 pM. All data was 
normalised to the vehicle-only control, which was assigned a 0% apoptotic level. The data is 
expressed as mean ± STD (three independent experiments, each in triplicate). The statistical 
significance was determined by comparison with the vehicle control, statistical significant was set 
at p<0.05. Statistical results are summarised in Table 2.7 which shows the lowest dose that induced 
a significant increase in caspase 3 activity compared to vehicle control. All concentrations above 
these points were also significant. The AP50 for each polyphenol in each cell line were determined 
and shown in Table 2.9.
Cell Types
The lowest dose of polyphenols (pM) at which there was a significant 
induction of apoptosis compared to the vehicle control by caspase 3 
activity assay at 24 h.
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbene
Trans-
Stilbene
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia
JURKAT 2 50 50 50 2 50 10 50
CCRF-
CEM
2 10 50 50 10 50 50 50
MOLT-3 10 50 50 50 2 50 10 50
M
ye
lo
id
le
uk
ae
m
ia
HL60 10 50 50 50 10 50 10 50
THP-1 10 10 250 50 2 50 50 250
K562 10 10 250 50 2 50 50 50
KGla 10 10 250 50 2 50 10 50
H
is
to
cy
tic
L
ym
ph
om
a
U937 2 50 50 50 2 50 2 50
Co
rd
 
bl
oo
d 
ce
lls
N
on
-t
um
ou
r 
co
nt
ro
l 
ce
lls
CD34+
HSC
50 250 250 50 10 250 250 250
CD133+
HSC
50 250 50 250 50 50 10 250
Table 2.7: The lowest dose of polyphenols which induced significant induction of caspase 3 
activity, compared to the control (p<0.05). Apoptosis was assessed by caspase 3 activity assay. 
The polyphenols were ranked in order of activity with respect to significant induction of apoptosis 
in lymphoid cells (emodin = quercetin > c/s-stilbene > apigenin > rhein = fran.s-stilbene = aloe- 
emodin = chrysin); and in myeloid cells (emodin > quercetin > c/s-stilbene = apigenin > rhein = 
aloe-emodin > /raw.s-stilbene > chrysin). Note that the treatment doses which caused significant 
induction of apoptosis in all leukaemia cell lines were much lower than of the non-tumour cells 
(CD34+). Due to the wide range of concentrations used and the cell lines investigated, it was not 
possible to indicate significance levels on (Figure 2.7) and thus Table 2.7 provides the lowest doses 
of polyphenol at which significance was obtained.
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Figure 2.8: Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe- 
emodin, c/s-stilbene and trans-stilbene) on apoptosis of three lymphoid leukaemia (CCRF- 
CEM, MOLT-3, JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four 
human myeloid leukaemia cell lines (K562, HL-60, KG-la , THP-1; blue lines), and two non­
tumour normal progenitor cells (CD34+ HSC, CD133+ HSC; black lines). Apoptosis was 
assessed using a Hoechst 33342 staining and examined by fluorescence microscopy. Cells were 
treated with each polyphenol at 0, 0.4, 2, 10, 50, 250, 500 pM for 24 h. All data was normalised to 
the vehicle-only control, which was assigned a 0% apoptotic level. The data is expressed as mean ± 
STD (each in triplicate). The statistical significance was determined by comparison with the 
vehicle control; statistical significant was set atp<0.05. Statistical results are summarised in Table
2 . 8  which shows the lowest dose that caused significant induction of apoptosis compared to vehicle 
control. All concentrations above these points were also significant. The AP50 for each polyphenol 
in each cell line were determined and shown in Table 2.9. An example of the morphological 
assessment of apoptosis for polyphenols showed in following figures; quercetin (Figure 2.9), 
chrysin (Figure 2.10), apigenin (Figure 2.11), rhein (Figure 2.12), emodin (Figure 2.13), aloe- 
emodin (Figure 2.14), two m-stilbene (Figure 2.15),and /rans-stilbene (Figure 2.16).
Cell Types
The Lowest Dose of Polyphenols (pM) at Which There Was a 
Significant Induction of Apoptosis Compared to The Vehicle Control 
Using Hoechst 33342 Staining
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbene
Trans-
Stilbene
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia
JURKAT 2 2 10 10 2 10 10 10
CCRF-CEM 2 2 2 10 10 10 50 2
MOLT-3 10 10 2 10 2 2 2 10
M
ye
lo
id
le
uk
ae
m
ia
HL60 10 2 2 10 2 2 10 2
THP-1 10 50 250 10 2 10 10 50
K562 50 50 250 50 10 250 50 50
KGla 50 250 250 10 2 250 10 10
H
is
to
cy
tic
L
ym
ph
om
a
U937 2 2 2 2 2 2 2 2
Co
rd
 
bl
oo
d 
ce
lls
N
on
-t
um
ou
r 
C
on
tr
ol
 c
el
ls CD34+
HSC
250 250 50 50 250 250 50 250
CD133+
HSC
250 250 50 250 250 250 50 250
Table 2.8: The lowest dose of polyphenols which caused significant induction of apoptosis 
morphological changes, compared to the control (p<0.05). Apoptosis was assessed by Hoechst 
33342 staining and fluorescence microscopy. The polyphenols were ranked in order of activity with 
respect to significant induction of apoptosis in lymphoid cells (emodin = quercetin > c/s-stilbene > 
apigenin > rhein = /ra/w-stilbene = aloe-emodin = chrysin); and in myeloid cells (emodin > 
quercetin > m-stilbene = apigenin > rhein = aloe-emodin > tra/tf-stilbene > chrysin). Note that the 
treatment doses which caused significant induction of apoptosis in all leukaemia cell lines were 
much lower than of the non-tumour cells (CD34+ HSC). Due to the wide range of concentrations 
used and the cell lines investigated, it was not possible to indicate significance levels on (Figure 
2.8), and thus Table 2.8 provides the lowest doses of polyphenol at which significance was 
obtained.
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Cell Types
Polyphenols AP50 in pM
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbcne
Trans-
Stilbene
C3 Hoe C3 Hoe C3 Hoe C3 Hoc C3 Hoe C3 Hoe C3 Hoe C3 Hoe
Ce
ll 
lin
es
L
ym
ph
oi
d
le
uk
ae
m
ia
JURKAT 19 25 35 90 40 30 >250 >500 2 9 50 130 31 50 250 310
CCRF-
CEM
50 50 50 100 250 40 200 250 >10 >500 50 150 >50 >500 >500 200
MOLT-3 50 50 50 125 140 38 200 265 5 9 50 150 44 50 350 400
M
ye
lo
id
L
eu
ka
em
ia
HL60 50 50 84 129 175 75 >250 >500 8.5 6 185 190 31 49 40 50
THP-1 >50 >500 110 220 >250 >500 50 60 7.8 10 >250 283 >50 >500 >500 >500
K562 >50 205 150 190 >250 >500 >250 >500 >10 >500 >250 500 >50 410 >500 460
KGla >50 125 89 235 >250 >500 >250 >500 >10 >500 >250 360 >50 350 >500 360
H
is
to
cy
tic
ly
m
hp
om
a
U937 50 50 45 130 150 32 60 140 4 27 50 195 8 20 200 225
Co
rd
 
bl
oo
d 
ce
lls
N
on
-t
um
ou
r 
co
nt
ro
l 
ce
lls CD34+HSC
>50 >500 >250 >500 >250 >500 >250 >500 >50 >500 >250 > 500 >50 >500 >500 >500
CD133+
HSC
>50 >500 >250 >500 >250 >500 >250 >500 >50 >500 >250 >500 >50 >500 >500 >500
Table 2.9: The AP50 values responsible for 50% induction of apoptosis, determined by: 
Caspase 3 activity assay (C3) (Figure 2.7) and Hoechst 33342 staining (Hoe) (Figure 2.8). The
polyphenol were ranked in order of induction of 50% apoptosis in lymphoid cells (quercetin > 
emodin = c/s-stilbene > apigenin > aloe-emodin > chrysin > rhein > /raws-stilbene). The HL-60 
human promyelocytic leukaemia cell line was the only myeloid cell to reach an AP50. The non­
tumour cells (CD34+HSC and CD133+HSC) did not reach 50% apoptosis with any of the treatment 
doses investigated. THP-1, K562 and KG-la myeloid cell lines were the most resistant cell lines, 
although did they reached an AP50 with apigenin treatment.
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Quercetin
Control
Figure 2.9: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with quercetin at 10, 50, 
250, 500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and 
MOLT-3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines 
(HL-60, THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their 
irregular shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic 
bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead cells 
appear pink. Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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Chrysin
Control
Figure 2.10: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with chrysin at 10, 50, 250, 
500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and MOLT- 
3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines (HL-60, 
THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their irregular 
shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic bodies. 
Normal cells were round and pale blue stained, and late apoptotic cells and dead cells appear pink. 
Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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Figure 2.11: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with apigenin at 10, 50, 250, 
500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and MOLT- 
3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines (HL-60, 
THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their irregular 
shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic bodies. 
Normal cells were round and pale blue stained, and late apoptotic cells and dead cells appear pink. 
Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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Rhein
Control 250 pM
Figure 2.12: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with rhein at 10, 50, 250, 
500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and MOLT- 
3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines (HL-60, 
THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their irregular 
shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic bodies. 
Normal cells were round and pale blue stained, and late apoptotic cells and dead cells appear pink. 
Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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Emodin
Control
Figure 2.13: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with emodin at 10, 50, 250, 
500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and MOLT- 
3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines (HL-60, 
THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their irregular 
shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic bodies. 
Normal cells were round and pale blue stained, and late apoptotic cells and dead cells appear pink. 
Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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Aloe-Emodin
Control 250 mM
lOnm
Figure 2.14: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with aloe-emodin at 10, 50, 
250, 500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and 
MOLT-3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines 
(HL-60, THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their 
irregular shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic 
bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead cells 
appear pink. Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
1 1 0
C/s-Stilbene
Control
Figure 2.15: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with c/s-stilbene at 10, 50, 
250, 500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and 
MOLT-3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines 
(HL-60, THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their 
irregular shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic 
bodies. Nonnal cells were round and pale blue stained, and late apoptotic cells and dead cells 
appear pink. Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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Figure 2.16: An example of the morphological assessment of apoptosis using Hoechst 33342 
nuclear staining using a fluorescence microscope, after treatment with trans-stilbene at 10, 50, 
250, 500 pM for 24 h on three lymphoid leukaemia cell lines (JURKAT, CCRF-CEM and 
MOLT-3), one histocytic lymphoma (U937) and four human myeloid leukaemia cell lines 
(HL-60, THP-1, K562 and KGla). Scale bar = 10 pm. Apoptotic cells were identified by their 
irregular shape, intensely stained nuclei, chromatin condensation and the formation of apoptotic 
bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead cells 
appear pink. Green star (*) indicates to the treatment doses that induce 50% of apoptosis.
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2.3.3 Cell Cycle Accumulation Following Polyphenol Treatments in Leukaemia Cells at 
24 h
When assessing the effect of polyphenols of the progression of the cell cycle the IC25 and IC50  
of polyphenols treatment doses as determined by CellTiter-Glo® assay for 24 h were used: 2, 
10, 50 pM for quercetin, emodin and ds-stilbene, 10, 50, 250 pM for apigenin, and 50, 250, 
500 for chrysin, aloe-emodin and ^rans-stilbene. These treatment doses significantly induced 
cell cycle arrest in all leukaemia cell lines (p<0.05) (Table 2.10). There was however no 
significant arrest in cell cycle with most polyphenols in the non-tumour progenitor cells 
(CD34+ HSC and CD133+HSC) (Table 2.10). The only exceptions was observed with rhein, 
which caused significant arrest at G2/M phase in CD34+ and CD133+HSC normal cells when 
used at the highest treatment dose of 500 pM (p<0.05) (Figure 2.23, 2.24 and Table 2.10), and 
with aloe-emodin and toms-stilbene, which caused significant arrest at S phase in CD133+ 
HSC cells when treatment doses of 250 and 500 pM were used (p<0.05) (Figure 2.27, 2.28, 
2.31, 2.32 and Table 2.10). It is important to note that these doses at which there was 
significant arrest for normal cells would be clinically impractical. The phase of cell cycle 
accumulation varied according to polyphenol treatment and cell line (Table 2.10). While in 
general, polyphenols appeared to cause G0/G 1 phase accumulation in most of leukaemia cell 
lines (Table 2.10).
Emodin at 2, 10, 50 pM (Figure 2.29, 2.30) caused a more consistent effect significantly 
increasing the accumulation of cells in G0/G1 phase in all leukaemia cell lines (p<0.05) (Figure 
2.25, 2.26 and Table 2.10). Similarly m-stilbene at 2, 10, 50 pM (Figure 2.29, 2.30) and 
chrysin at 250 and 500 pM (Figure 2.19, 2.20) also significantly induced cells accumulation at 
G0/G 1 phase in 7 out of the 8  leukaemia cell lines (p<0.05) (Table 2.10). Similarly, by rhein at 
50, 250, 500 pM also significantly induced cells accumulation in G0/G 1 phase of cell cycle in 6  
out of the 8  leukaemia cell lines (p<0.05) (Figure 2.23, 2.24 and Table 2.10).
Quercetin, apigenin, aloe-emodin and rrans-stilbene treatments caused differential effects on 
arresting the cell cycle phases within the IC25 and IC50 treatment ranges (Table 2.10). 
Quercetin (Figure 2.17, 2.18) produced a consistent effect on all myeloid cell lines 
significantly accumulating cells at G0/G 1 phase with treatment doses of 2, 10, 50 pM (p<0.05); 
while it acted differently on lymphoid cell lines in which significantly accumulated the cells at 
S phase in JURKAT and CCRF-CEM cells, and G2/M phase in MOLT-3 and U937 cells with 
10, 50 pM treatmetn doses (p<0.05) (Figure 2.17, 2.18 and Table 2.10).
Apigenin (Figure 2.21, 2.22) induced varied effects on cell cycle within the leukaemia cell 
lines. In particular, apigenin significantly accumulated in the cells in G0/G 1 phase for CCRF- 
CEM, U937, HL60 cells at treatment dose of 50 and 250 pM; in S phase for JURKAT and 
MOLT-3 cells at treatment dose of 50 and 250 pM, K562 cells at treatment dose of 250 and
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500 pM, and KGla cells at treatment dose of 50, 250 500 pM; and finally in G2/M phase for 
THP-1 cells at treatment dose of 50 and 250 pM (p<0.05) (Figure 2.21, 2.22 and Table 2.10).
Aloe-emodin (Figure 2.27, 2.28) and ^ra/7 5-stilbene (Figure 2.31, 2.32) had similar effects on 
cell cycle within the leukaemic cell lines. Both treatments caused significant accumulation in 
cells in G0/G 1 phase for CCRF-CEM, MOLT-3, THP-1 and U937 cell lines; plus S phase 
accumulation for JURKAT, HL60 and THP-1 cells; and finally G2/M phase accumulation for 
K562 cells mostly at treatment doses of 250 and 500 pM (p<0.05) (Table 2.10). The only 
difference seen between these two polyphenol treatment was shown in KGla cells, which were 
significantly arrested at G0/G1 phase with aloe-emodin and at G2 /M phase with rrans-stilbene at 
250 and 500 pM treatment doses (p<0.05) (Table 2.10).
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Figure 2.17: Effect of quercetin on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). This was analysed by propidium iodide staining and flow 
cytometry. Cell were treated with quercetin at the range of IC2 5 and IC5 0  doses (at 2, 10, 50 250 pM 
for KGla cell lines and at 2, 10, 50 pM for all other cell lines) as determined by CellTiter-Glo® 
assay for 24 h. The percentage of cells in each phase was analysed with Flow Jo software using 
Waston pragmatic model. The data is expressed as median with range (each in triplicate). The 
statistical significance was determined by comparison with the vehicle control; statistical 
significance was set at p<0.05. The green star (*) indicates where there is a significant increase in 
the accumulation of cells in a phase of the cell cycle; while the black star (*) indicates a significant 
decrease in the accumulation of cells in a phase of the cell cycle. The effects of all polyphenols on 
the cell cycle progression in all the cell lines are summarised in table 2 .1 0 .
Quercetin
Control
Go/Gi=52.1 
S=36.1 
G2/M= 10
Control
Go/Gi=41.9 
S=47.9 
G2/M= 7.8
10 pM
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G2/M= 7.4
Control
Go/Gl=64.4 
S= 24.7 
G2/M= 7.38
10 pM
Go/Gl=60.2 
S=26.1 
G2/M= 12.7
Control
Go/Gl=44.03 
S=40.1 
G2/M= 19.1
Figure 2.18: An example of histograms for cell cycle phases (G0/G|, S, G2/M) for quercetin 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.19: Effect of chrysin on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). This was analysed by propidium iodide staining and flow 
cytometry. Cell were treated with chrysin at the range of IC2 5 and IC5 0 doses (at 50, 250, 500 pM 
for all other cell lines) as determined by CellTiter-Glo® assay for 24 h. The percentage of cells in 
each phase was analysed with Flow Jo software using Waston pragmatic model. The data is 
expressed as median with range (each in triplicate). The statistical significance was determined by 
comparison with the vehicle control; statistical significance was set at p<0.05. The green star (*) 
indicates where there is a significant increase in the accumulation of cells in a phase of the cell 
cycle; while the black star (*) indicates a significant decrease in the accumulation of cells in a 
phase of the cell cycle. The effects of all polyphenols on the cell cycle progression in all the cell 
lines are summarised in table 2 .1 0 .
Control
Go/Gi=52.1
S= 36.1
G2/M= 10
<N©•G
Vcn
H
+-t
ft
©
VONJ
H
Chrysin
250 pM
Go/Gl=65 
S=24.1 
G2/M= 10.2
290 400
Control
Go/Gi=64.4 
S=24.7 
G2/M= 7.38
250 pM
Go/Gj=69 
S=25.6 
G2/M= 4.9
J ,
| Control
Go/Gl=57.3
j S=33.4
.
| G2/M= 9.23
250 pM
Go/Gl=46.2 
S= 45.5 
G2/M= 10.5
J rH -
Control
Go/Gi=53.7 
S=32.1 
G2/M= 13.6
M l
250 pM
Go/Gi=?9.3 
S=29.1 
G2/M= 9.83
200 400
: Control
Go/Gi=56.1
S= 29.2
G2/M=17
A
250 pM
Go/Gi=55 
S= 28 
G2/M= 18.5
Control 250 pM
Go/G 1=49.4Go/Gl=41.9 
S=47.9 
G2/M= 7.8
S =42.6
G2/M= 7.1
u
C/3
ft
+
ftu
Control
Go/Gl=44.03 
S=40.1 
G2/M= 19.1
250 pM
Go/Gi=72.4 
S= 15 
G2/M= 11.62
Control
Go/Gi=42.3 
S=31.2 
G2/M= 26.4
500 pM
Gfl/G)=52 
S=31.6 
G2/M= 14.8
M l
Control
Go/Gi=44.2 
S=34.6 
G2/M= 18.9
M l
250 pM
G«/Gi=50.1 
S=30.1 
G2/M= 18.1
Control
Go/Gl=48.3 
S=33.3 ;
G2/M= 23.9 !’
250 pM
j Go/Gl=47.9
S=33.6
G2/M= 20.16
1m
Figure 2.20: An example of histograms for cell cycle phases (G0/Gi, S, G2/M) for chrysin 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.21: Effect of apigenin on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). This was analysed by propidium iodide staining and flow 
cytometry. Cell were treated with apigenin at the range of IC2 5  and IC5 0 doses (at 10, 50 250, 500 
pM for K562 and KGla cell lines, and at 10, 50, 250 pM for all other cell lines) as determined by 
CellTiter-Glo® assay for 24 h. The percentage of cells in each phase was analysed with Flow Jo 
software using Waston pragmatic model. The data is expressed as median with range (each in 
triplicate). The statistical significance was determined by comparison with the vehicle control; 
statistical significance was set at p<0.05. The green star (*) indicates where there is a significant 
increase in the accumulation of cells in a phase of the cell cycle; while the black star (*) indicates a 
significant decrease in the accumulation of cells in a phase of the cell cycle. The effects of all 
polyphenols on the cell cycle progression in all the cell lines are summarised in table 2 .1 0 .
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Figure 2.22: An example of histograms for cell cycle phases (G0/G|, S, G2/M) for apigenin 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.23: Effect of rhein on cell cycle progression of three lymphoid leukaemia (JURKAT, 
CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines 
(HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor cells (CD34+ HSC, 
CD133+ HSC). This was analysed by propidium iodide staining and flow cytometry. Cell were 
treated with rhein at the range of IC25 and IC50 doses (at 50, 250, 500 pM for all other cell lines) as 
determined by CellTiter-Glo® assay for 24 h. The percentage of cells in each phase was analysed 
with Flow Jo software using Waston pragmatic model. The data is expressed as median with range 
(each in triplicate). The statistical significance was determined by comparison with the vehicle 
control; statistical significance was set at p<0.05. The green star (*) indicates where there is a 
significant increase in the accumulation of cells in a phase of the cell cycle; while the black star (*) 
indicates a significant decrease in the accumulation of cells in a phase of the cell cycle. The effects 
of all polyphenols on the cell cycle progression in all the cell lines are summarised in table 2.10.
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Figure 2.24: An example of histograms for cell cycle phases (G0/Gi, S, G2/M) for rhein 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.25: Effect of emodin on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). This was analysed by propidium iodide staining and flow 
cytometry. Cell were treated with emodin at the range of IC2 5 and IC50 doses (at 2 , 10, 50 pM for 
all other cell lines) as determined by CellTiter-Glo® assay for 24 h. The percentage of cells in each 
phase was analysed with Flow Jo software using Waston pragmatic model. The data is expressed as 
median with range (each in triplicate). The statistical significance was determined by comparison 
with the vehicle control; statistical significance was set at p<0.05. The green star (*) indicates 
where there is a significant increase in the accumulation of cells in a phase of the cell cycle; while 
the black star (*) indicates a significant decrease in the accumulation of cells in a phase of the cell 
cycle. The effects of all polyphenols on the cell cycle progression in all the cell lines are 
summarised in table 2 .1 0 .
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Figure 2.26: An example of histograms for cell cycle phases (G„/G|, S, G2/M) for emodin 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.27: Effect of aloe-emodin on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). This was analysed by propidium iodide staining and flow 
cytometry. Cell were treated with aloe-emodin at the range of IC2 5 and IC5 0 doses (at 50, 250, 500 
pM for all other cell lines) as determined by CellTiter-Glo® assay for 24 h. The percentage of cells 
in each phase was analysed with Flow Jo software using Waston pragmatic model. The data is 
expressed as median with range (each in triplicate). The statistical significance was determined by 
comparison with the vehicle control; statistical significance was set at p<0.05. The green star (*) 
indicates where there is a significant increase in the accumulation of cells in a phase of the cell 
cycle; while the black star (*) indicates a significant decrease in the accumulation of cells in a 
phase of the cell cycle. The effects of all polyphenols on the cell cycle progression in all the cell 
lines are summarised in table 2 .1 0 .
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Figure 2.28: An example of histograms for cell cycle phases (G0/Gi, S, G2/M) for aloe-emodin 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.29: Effect of c/s-stilbene on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). This was analysed by propidium iodide staining and flow 
cytometry. Cell were treated with m-stilbene at the range of IC95 and IC5 0 doses (at 2, 10, 50, 250 
pM for KGla cell lines, and at 2, 10, 50 pM for all other cell lines) as determined by CellTiter- 
Glo® assay for 24 h. The percentage of cells in each phase was analysed with Flow Jo software 
using Waston pragmatic model. The data is expressed as median with range (each in triplicate). 
The statistical significance was determined by comparison with the vehicle control; statistical 
significance was set at p<0.05. The green star (*) indicates where there is a significant increase in 
the accumulation of cells in a phase of the cell cycle; while the black star (*) indicates a significant 
decrease in the accumulation of cells in a phase of the cell cycle. The effects of all polyphenols on 
the cell cycle progression in all the cell lines are summarised in table 2 .1 0 .
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Figure 2.30: An example of histograms for cell cycle phases (G0/G 1, S, G2/M) for c/s-stilbene 
treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF-CEM, 
MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, THP-1, 
K562, KGla), and two non-tumour normal progenitor cells (CD34+HSC, CD133+HSC). The
percentage of cells in each phase was analysed using the Flow Jo software with the Waston 
pragmatic model. The statistical significance was set at p<0.05. The phase with green text is 
indicated for significant increase of cells accumulation compared to vehicle control.
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Figure 2.31: Effect of trans-stilbene on cell cycle progression of three lymphoid leukaemia 
(JURKAT, CCRF-CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid 
leukaemia cell lines (HL-60, THP-1, K562, KGla), and two non-tumour normal progenitor 
cells (CD34+ HSC, CD133+ HSC). T h i s  w a s  a n a l y s e d  b y  p r o p i d i u m  i o d i d e  s t a i n i n g  a n d  f l o w  
c y t o m e t r y .  C e l l  w e r e  t r e a t e d  w i t h  / r a / 75 - s t i l b e n e  a t  t h e  r a n g e  o f  I C 25 a n d  I C 50 d o s e s  ( a t  5 0 ,  2 5 0 ,  5 0 0  
p M  f o r  a l l  o t h e r  c e l l  l i n e s )  a s  d e t e r m i n e d  b y  C e l l T i t e r - G l o ®  a s s a y  f o r  2 4  h .  T h e  p e r c e n t a g e  o f  c e l l s  
i n  e a c h  p h a s e  w a s  a n a l y s e d  w i t h  F l o w  J o  s o f t w a r e  u s i n g  W a s t o n  p r a g m a t i c  m o d e l .  T h e  d a t a  i s  
e x p r e s s e d  a s  m e d i a n  w i t h  r a n g e  ( e a c h  i n  t r i p l i c a t e ) .  T h e  s t a t i s t i c a l  s i g n i f i c a n c e  w a s  d e t e r m i n e d  b y  
c o m p a r i s o n  w i t h  t h e  v e h i c l e  c o n t r o l ;  s t a t i s t i c a l  s i g n i f i c a n c e  w a s  s e t  a t  p < 0 . 0 5 .  T h e  g r e e n  s t a r  ( * )  
i n d i c a t e s  w h e r e  t h e r e  i s  a  s i g n i f i c a n t  i n c r e a s e  i n  t h e  a c c u m u l a t i o n  o f  c e l l s  i n  a  p h a s e  o f  t h e  c e l l  
c y c l e ;  w h i l e  t h e  b l a c k  s t a r  ( * )  i n d i c a t e s  a  s i g n i f i c a n t  d e c r e a s e  i n  t h e  a c c u m u l a t i o n  o f  c e l l s  i n  a  
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Figure 2.32: An example of histograms for cell cycle phases (G0/Gi, S, G2/M) for trans- 
stilbene treatment at the IC50 doses at 24 h in three lymphoid leukaemia (JURKAT, CCRF- 
CEM, MOLT-3), one histocytic lymphoma (U937), four myeloid leukaemia cell lines (HL-60, 
THP-1, K562, KGla), and two non-tumour normal progenitor cells (CD34+ HSC, CD133+ 
HSC). T h e  p e r c e n t a g e  o f  c e l l s  i n  e a c h  p h a s e  w a s  a n a l y s e d  u s i n g  t h e  F l o w  J o  s o f t w a r e  w i t h  t h e  
W a s t o n  p r a g m a t i c  m o d e l .  T h e  s t a t i s t i c a l  s i g n i f i c a n c e  w a s  s e t  a t  p < 0 . 0 5 .  T h e  p h a s e  w i t h  g r e e n  t e x t  
i s  i n d i c a t e d  f o r  s i g n i f i c a n t  i n c r e a s e  o f  c e l l s  a c c u m u l a t i o n  c o m p a r e d  t o  v e h i c l e  c o n t r o l .
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Cell lines
The Phases of Cell Cycle at Which There Was a Significant Accumulation 
of Cells Following 24h I C 2 5  and IC50 Polyphenol Treatment
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin
Cis-
Stilbene
Trans-
Stilbene
L
ym
ph
oi
d
L
eu
ka
em
ia
JURKAT S S Go/G, S Go/G, S Go/G, S
CCRF-
CEM s G0/G1 Go/G, Go/G, Go/G, Go/G, Go/G, Go/G,
MOLT-3 g 2/m s Go/G, G«/G, Go/G, Go/G, g 2/m Go/G,
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L
eu
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ia
HL60 Go/G, Go/G, S Go/G, Go/G, S Go/G, S
THP-1 Go/G, g 2/m Go/G, Go/G, Go/G, Go/G, Go/G, G«/G,
K562 G0/G1 S Go/G, S Go/G, g 2/m Go/G, g 2/m
KGla G0/G1 s Go/G, Go/G, Go/G, Go/G, Go/G, g 2/m
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<50pM
No Arrest 
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No
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<500pM
No
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No
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No
Arrest
<500pM
No
Arrest
<50pM
No Arrest 
<500pM
CD133+
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No Arrest 
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No
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No
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No
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S
No
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S
Table 2.10: A summary of the cell cycle phases in which there was significantly accumulation 
of cells following IC2 5 and IC50 polyphenol treatments for 24 h in eight leukaemia cell lines 
and two non-tumour control cells. The cell cycle was assessed using propidium iodide (PI) 
staining and flow cytometric. The percentage of cells in each phase was analysed using the Flow Jo 
software with the Waston pragmatic model. The phase of cell cycle accumulation varied according 
to polyphenol treatment and cell line. While in general, polyphenols appeared to cause G0/Gi phase 
accumulation in most of leukaemic cell lines. No significant arrest in cell cycle was observed in the 
non-tumour progenitor cells (CD34+HSC and CD133+ HSC) with most polyphenols within the IC25 
and IC50 ranges that used to treat the leukaemia cell lines, the only exception was observed with 
aloe-emodin and trans-stilbene for CD133+HSC normal cells.
2.4 Discussion
Over the past 10 years, researchers have confirmed that polyphenols are capable of inhibiting 
cell proliferation, inducing cell cycle arrest and apoptosis in a number of solid tumour cell 
lines (Dai et al, 2013; Han et al, 2007; Jaganathan et al, 2009; Patel et al, 2007; Sharif et al, 
2010; Shukla et al, 2010), however there has not been a direct comparison of the effect of 
polyphenols on leukaemia cell lines and non-tumour cells. Here, we directly compared the 
effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe-emodin, 
c/sstilbene and /raws-stilbene) on four lymphoid and three myeloid leukaemia cell lines; one 
histocytic leukaemia cell line; and two non-tumour blood progenitor cells (CD34+ HSC and 
CD133+ HSC). In particular, we studied the effect of polyphenols on cell ATP levels as 
indication of cell viability at 24, 48 and 72 h. From this data, it was able to determine the IC50  
values for each polyphenol in each cell line at each time point (Tables 2.2, 2.4, 2.6). A
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comparison of this data shows that there is little variation between the time points. With this in 
mind all further assessment including, cell cycle, caspase 3 activity, and Hoechst 33342 
nuclear stain of apoptosis was completed at 24 h. So for this discussion, we used the IC50  
values that determined at 24 h only (Tables 2.2) to determine effectiveness of polyphenols on 
leukaemia cell lines in comparison with other assays (Table 2.9, 2.10). The effects of these 
polyphenols were shown to be greater in leukaemia cells compared to non-tumour blood 
progenitor cells (CD34+ HSC and CD133+ HSC), indicating no effect on their viable cells. 
When non-tumour cells were treated with quercetin and cz's-stilbene, chrysin, apigenin and 
aloe-emodin, there was no significant decrease on ATP levels until the treatment concentration 
increased to 250-500 pM. There was a significant decrease on ATP levels of non-tumour cells 
when treated with >250 pM of emodin, rhein and /razzs-stilbene; however this is 5-10 times 
higher than the IC50 values reported for all leukaemia cells (Tables 2.2). Consequently, we 
have shown that each of the polyphenols caused a decrease in ATP levels and hence cell 
viability in all leukaemia cell lines and can be ranked according to their effectiveness: emodin 
> quercetin > czs-stilbene > apigenin > rhein > aloe-emodin > PY/zzs-stilbene > chrysin. 
However, it is important to note that this ranking did vary between individual cell lines (Table 
2 .2).
Emodin was the most effective polyphenol at reducing ATP levels. It was by far the most 
effective of the anthraquinones investigated. The structural differences between the 
anthraquinones are slight and, indeed, emodin and aloe-emodin have the same structural 
formula (C15H10O5), although the orientations of the functional groups vary. The IC50 values 
for emodin (5-22 pM) were the lowest of all the studied polyphenols; and were comparable 
with those previously reported in squamous cell carcinoma cell lines (SCC-4) cells (Chen et al, 
2010). Emodin was shown to consistently induce accumulation of cells at G0/G 1 phase in all 
leukaemia cell lines, and induced 50% apoptosis in 5 of the 8  leukaemia cell lines (JURKAT, 
MOLT3, HL-60, THP-1 and U937). This is consistent with previous studies in which emodin 
induced apoptosis in HL-60 (Chen et al, 2002) and SCC-4 (Chen et al, 2010) cell lines.
Quercetin was also a potent polyphenol, with IC50 value ranging between 8-33 pM and 
induction of apoptosis with AP50 value ranging between 19-50 pM. Quercetin was the most 
effective of the flavonoids tested and was routinely 5-10 times more potent than apigenin and 
chrysin. The IC50 values noted are at the lower end of values previously reported (20-278 pM), 
in cancer cell lines of breast (MDA-MB-231 and MDA-MB-453) (Chien et al, 2009; Choi and 
Kim, 2009) and (MCF-7) (Chou et al, 2010); cervical (HeLa) (Huang et al, 2009; Vidya et al, 
2010; Zhang et al, 2009), liver (HepG2) (Granado et al, 2006), lung (A-549) (Robaszkiewicz 
et al, 2007); and two leukaemia cell lines (HL-60 and K562) (Kang et al, 1997;Csokay et al, 
1997). Lymphoid cell lines were more susceptible to quercetin treatment than myeloid
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leukaemia cells. The only exception being the promyelocytic leukaemia cells (HL-60), which 
showed the same level of sensitivity as lymphoid cells. Quercetin demonstrated a differential 
induction of apoptosis in each leukaemia cell line although the AP50 values were consistently 
low. Previously, quercetin has been reported to induce apoptosis in a range of solid tumours, 
via a caspase 3-dependent mechanism (Chien et al, 2009; Chou et al, 2010; Choi et al, 2008), 
and in HL-60 cells via decreased PI3K/AKT pathway activity (Yuan et al, 2012). However, 
there are no reported AP50 values for these studies. Quercetin was found to have a differential 
effect on the cell cycle in myeloid and lymphoid cell lines. Inducing accumulation of cells at 
G0/G1 phase in all myeloid cell lines, and either S phase (JURKAT and CCRF-CEM) or G2/M 
phase (U937 and MOLT3) accumulation in the lymphoid cell lines (Table 2.10). This varied 
effect of quercetin has been previously observed, where it induced accumulation in S phase in 
breast cancer cell lines (MCF-7) (Chou et al, 2010) and in G2/M phase in cervical cancer cell 
lines (HeLa) (Huang et al, 2009; Vidya et al, 2010). Together with our study, this suggests that 
quercetin causes differential effects on cell cycle dependant on cell type, even in comparatively 
similar leukaemia cell lines. This may reflect expression of different molecular targets in 
myeloid and lymphoid cell lines; or a differential effect on the same pathway in different cell 
lineages.
C/.s'-stilbene was much more effective than its isomer Jrans’-stilbene in all leukaemia cell lines. 
This is reflected in IC50 values for c/s-stilbene (25-85 pM) and /‘ra/zs-stilbene (109-500 pM); 
however, these values were considerably higher than those previously reported in solid 
tumours (Shankar et al, 2007; Yang et al, 2002). Very few studies have investigated the effects 
of stilbenoids on cell cycle. C/s-stilbene has been reported to induce cells accumulation in 
G2 /M phase in the lung cancer cell lines (A549) (Lee et al, 2004), and in S phase in one 
leukaemia cell lines (HL-60) (Saiko et al, 2006). Our results have shown that c/s-stilbene 
consistently caused cell accumulation at G0/G 1 phase in 7 of the 8  cell lines including the HL- 
60 cell line. This contrasts with the finding that HL-60 cells when treated with the stilbene 
derivate 3, 3', 4, 4', 5, 5'-hexahydroxystilbene induced S phase accumulation (Saiko et al, 
2006). A less consistent effect was found with /rans-stilbene treatment, which caused cell 
accumulation at different phases of cell cycle in all leukaemia cell lines. Both cis- and trans- 
stilbene induced caspase 3 activity of early apoptosis and morphological changes characteristic 
of late apoptosis in the majority of leukaemia cell lines. C/s-stilbene was able to induce 
apoptosis in three lymphoid cell lines (JURKAT, MOLT3, and U937) with AP50 values 
ranging between 20-50 pM, the remaining cell lines were more resistant, and did not reach 
50% apoptosis even when treated with a maximal treatment dose (500 pM). Similarly, trans- 
stilbene induced apoptosis in the same three lymphoid cell lines, however the AP50 values were 
much higher (40-460 pM), there was also a similar resistance to treatment in the remaining
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lymphoid cell lines. Czs-stilbene did not show any significant effect on ATP levels of the non­
tumour cells, however, /nms'-stilbene did, but only at high treatment concentration in excess of 
250 pM. Previous work has shown that stilbenoids can inhibit cell proliferation and induce 
apoptosis in cancer cell lines of lung (A549) (Lee et al, 2004; Weng et al, 2009), prostate 
(DU 145 and PC3), breast (BT-549), colon (HT-29) (Shankar et al, 2007; Yang et al, 2002) and 
one leukaemia (HL-60) (Saiko et al, 2006; Simoni et al, 2006). Trans-stilbene had a reported 
IC50 values of 25-98 pM at 24 h in two lung cancer cell lines (A549 and CH27) (Weng et al, 
2009). A direct comparison of czs-stilbene and /rans-stilbene in cancer cell lines of lung 
(A549) (Lee et al, 2004) and leukaemia (HL-60) (Saiko et al, 2006); demonstrated that cis- 
stilbene was more effective than frans-stilbene with IC50 values of 0.03 pM and 6.25 pM, 
respectively, at 24 h (Saiko et al, 2006; Lee et al, 2004). This supports the finding of this study 
that czs-stilbene is more potent than /‘rans-stilbene in the treatment of leukaemia cells. 
However, the reason for this difference is not clear, but may be related to the stability o f the 
trans- and c/s-isomers in culture.
A moderate effect was seen in leukaemia cells treated with apigenin, with IC50 values between 
100-500 pM. However, in other cell types lower IC50 values have been reported, including 36 
pM in human cervical cancer cells (HeLa) (Zheng et al, 2005) and 70 pM in colorectal cancer 
cells (SW480, HT-29 and Caco-2) following 24 h treatments (Wang et al, 2000) suggesting 
differential activity within tumour types. In addition, apigenin induced variable effects on cell 
cycle, which was dependant on the cell lines investigated. This phenomenon has also been seen 
in solid tumour cell lines, where apigenin induced G0/G1 arrest in human cervical cancer cell 
lines (HeLa) (Zheng et al, 2005) and G2/M arrest in human colon cancer cell lines (SW480, 
HT-29 and Caco-2) (Wang et al, 2000). Apigenin was shown to induce apoptosis in all 
leukaemia cell lines, with AP50 values ranging between 35-130 pM in lymphoid cell lines and 
84-235 pM in the myeloid cell lines. In contrast to quercetin, apigenin was capable of inducing 
both an increase in caspase 3 activity indicating early apoptosis, plus morphological evidence 
of late apoptosis, in all leukaemia cells lines; including the KG-la and K562 cells which were 
resistant to emodin, quercetin and c/s-stilbene treatment. This pro-apopotic action of apigenin 
has been previous demonstrated in MDA-MB-453 breast cells (Choi and Kim, 2009). The 
other polyphenols investigated; rhein, chrysin, aloe-emodin demonstrated a low potency and 
thus are unlikely to be of clinical use in leukaemia treatment. Similar low potency has also 
been shown in solid tumours, for example the reported IC50 for chrysin in solid tumour cell 
lines are between 40 and lOOpM (Li et al, 2011; Khoo et al, 2010; Parajuli et al, 2009).
Within all the polyphenols agents tested, the leukaemia cells were more sensitive than the non­
tumour cell lines (CD34+ HSC and CD133+ HSC). Interestingly, the ATP levels and 
percentages of G0/G 1 population were comparable in all untreated leukaemia and non-tumour
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control cells, suggesting sensitivity rates were not related to ATP levels and hence cell viability. 
The order of sensitivity within the leukaemia cells was shown to be dependent on the 
polyphenol investigated. For example, U937 cells were one of the most affected cell lines 
when treated with quercetin, emodin and c/s-stilbene; however they were least affected cell 
line when treated with apigenin. This demonstrates that no single polyphenol is active on all 
cell lines and that specific polyphenols should be selected for each type of leukaemia.
The cell cycle arrest data showed predominately Go/Gi arrest, however some treatments 
arrested cells in S phase and G2/M. It is well known that cell cycle is regulated by the 
coordinated activity of family of protein kinases: cyclin-dependent kinase (CDKs), cyclins and 
CDK inhibitors (CDKIs) (Malumbres and Barbacid, 2009). Cell-cycle can be arrested via 
protein kinase inhibitors (CDKIs), such as p21wafl and p27kipl, upon binding to cyclins and 
CDK complexes and indeed modulation of their activities could be possible targets for the 
polyphenols. The stage of cell cycle arrest induced by phenolic agents can indicate the 
molecular mechanisms of action. For example it is well known that cells arrested in Gi phase 
can be via inhibition of CDK4 and/or CDK6  (Malumbres and Barbacid, 2009). S phase arrest 
can be caused by inhibition of Cyclin A and Cyclin E through the activation of p21 {via p53 in 
the presence of DNA damage) and p27 (induced by Transforming Growth Factor of p (TGF- 
P)) (Malumbres and Barbacid, 2009). Arrest of cells in G2/M phase can be caused by 
inactivation of cyclin B1 with Cdc2 kinase activity through p53-mediated induction of p21 
(Malumbres and Barbacid, 2009).
Here, we demonstrated that the majority of polyphenols investigated induce G0/G 1 arrest, 
suggesting that they may inhibit CDK4 and/or -6 , however this requires confirmation. Hur, 
et.al (2004) showed that JURKAT cells and T lymphocytes stimulated with rosmarinic acid 
induce p5 6lck (Lck) protein kinase-dependant apoptosis, through the mitochondrial pathway 
(Hur et al, 2004). P561ck is a lymphoid-specific protein tyrosine kinase and is usually 
expressed on T lymphocytes (Hur et al, 2004). This may explain why the lymphoid cell lines 
were more sensitive than myeloid cell lines. In addition, recent investigations showed that 
polyphenols such as the flavonoids (apigenin and quercetin) can act as a p5 6lck (Lck) protein 
kinase inhibitors (Hur et al, 2004; Fassihi and Sabet, 2008). As p561ck is an essential regulator 
of the cell cycle; modulation of this kinase could lead to the G0/G 1 arrest. However, further 
investigation is essential to determine the molecular mechanisms of each polyphenol. It is well 
established that tumour suppressor gene p53 has a role in the regulation of the cell cycle, as 
well as in the initiation of apoptosis. However the majority of our cell lines were either null or 
mutated for p53, with the exception of MOLT-3 which express wild type p53 (An et al, 2000; 
Durland and Reisman, 2002; Geley et al, 1997; Cai et al, 2001). MOLT-3 cells however, 
display PTEN mutations, which results in constitutive activity of AKT (Medyouf et al, 2010).
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p53 induces Bax, which leads to activation of the intrinsic apoptotic pathway. AKT promotes 
pro-apoptotic Bad to be sequestered. Therefore a lack of p53 or PTEN both lead to an 
insensitivity to apoptosis with respect to the intrinsic pathway (Deininger et al, 2000). This 
suggests that the p53 status does not influence the effect of polyphenol treatment in this study.
To determine whether the effects of these polyphenols in vitro are relevant to their clinical use, 
it is essential also to consider their bioavailability and whether these treatment concentrations 
are achievable in plasma. It has been suggested that physiological concentrations of plasma 
metabolites will not exceed 10 pM (D’Archivio et al, 2010; Hollman et a\, 1997; Manach et al, 
2004). Our study has shown that quercetin, emodin and cis- stilbene induced significant affects 
at low doses (between 2 to 10 pM) following 24 h of treatment in most of leukaemia cell lines. 
The data available on bioavailability of polyphenols however is still limited, but there is 
evidence that quercetin obtained from plant products can result in micromolar concentrations 
in blood plasma (Hollman et a\, 1997; Mendoza et al, 2011), supporting the idea that in vivo 
effects may be possible, through diet. However, quercetin has a reported plasma half-life of 
11-28 h; with a 50-100 mg dose causing a plasma concentration of 0.75-1.5 pM in plasma 
(D’Archivio et al, 2010; Hollman et al, 1997; Manach et al, 2004; Mendoza et al, 2011). This 
is further complicated as abundant dietary polyphenols do not necessarily have the best 
bioavailability profile (D’Archivio et al, 2010; Manach et al, 2004) and they are extensively 
metabolized by intestinal and hepatic enzymes and microflora (D’Archivio et al, 2010; 
Manach et al, 2004). The absorption of polyphenols depends primarily on their chemical 
structure, and molecular size as well as the degree of glycosylation, esterification, and 
polymerization with other polyphenols (D’Archivio et al, 2010; Manach et al, 2004; Mendoza 
et al, 2011; Manach et al, 2004; Perez-Jimenez et al, 2011).
2.5 Conclusion
In conclusion, we have shown that the effectiveness of polyphenols varied depending on the 
leukaemia cell lineage (lymphoid vs. myeloid) and in some cases within the cell lines from the 
same lineage. We have shown that myeloid cell lines (K562 and KG-la) were particularly 
resistant even to the most active polyphenols. This suggests that the molecular mechanism of 
action of the polyphenols may vary in each cell line and this requires further investigation. 
Furthermore, we have demonstrated that polyphenols with similar molecular structures such as 
emodin and aloe-emodin, and even cis- and /rans-stilbene do not have the same effect on 
leukaemia cells. These findings suggest that polyphenols have anti-tumour activity against 
leukaemia cells with differential effects. The observed differential sensitivity between 
leukaemia and normal cells suggests that polyphenols have potential in treatment of leukaemia. 
The most potent polyphenols are emodin, quercetin, and cw-stilbene; these polyphenols may 
have potential in treating leukaemia.
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Chapter 3
Modulation of Chemotherapeutic 
Activity by Polyphenols.
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3.1 Introduction
Chemotherapy is the major treatment for leukaemia, which is targeted according to specific 
diagnosis, genetic abnormalities identified, the type of leukaemia, age and overall health of the 
patient (Pokhare, 2012; Cancer Research UK, 2014; Leukaemia & lymphoma Research, 2014). 
Chemotherapeutic agents are classified according to the chemical structure and mechanisms of 
action (Sak, 2012; Mohan et al, 2013). The major classes of chemotherapeutic agents are: (1) 
Topoisomerase inhibitor agents such as etoposide (ETP) (Section 1.7.1.1) (Hande, 1998; 
Baldwin et al, 2005; Thakur, 2011) and doxorubicin (DOX) (Section 1.7.1.2) (Thom et al, 
2011; Tacar et al, 2013); (2) Alkylating agents such as cyclophosphamide (CYCLO) (Section
1.7.2.1) (Shanafelt et al, 2007; Huttunen et al, 2011), chlorambucil (CLB) (Section 1.7.2.2) 
(Rai et al, 2000) and cisplatin (CSP) (Section 1.7.2.3) (Siddik, 2003; Florea and Biisselberg, 
2011; Praveen et al, 2013); (3) Anti-metabolite agents such as methotrexate (MTX) (Section
1.7.3.1) (Kaye, 1998; Sorbello and Brtino, 2001; Rossi, 2013), 6 -mercaptopurine (6 -MP) 
(Section 1.7.3.2) (Sahasranaman et al, 2008), and 5-fluorouracil (5-FLU); and (4) Tyrosine 
kinase inhibitor agents such as imatinib (IM) (Section 1.7.5.1) (Dolly and Apostolia, 2009). 
These chemotherapeutic agents are further sub-divided due to their effect on the cell cycle 
(Lamson and Brgnall, 1999; Wu, 2006). They can be classed as: (1) cell cycle-specific drugs 
(e.g. MTX, 6 -MP, 5-FLU are S-phase specific, whilst ETP is G2/M-phase specific) or (2) non­
cell cycle-specific dmgs (e.g. CYCLO, CLB, CSP, DOX, and IM all of which can arrest cell 
cycle at any phase) (Section 1.7) (Lamson and Brignall, 1999; Wu, 2006). Each chemotherapy 
drug has a unique target and mechanism of action (Section 1.7), although they all interfere with 
biochemical process controlling cellular replication and ultimately lead to arrest of cell cycle 
and induction of apoptosis (Sak, 2012;Wu, 2006).
All these agents are currently used clinically and in most cases providing temporary 
prolongation of patient’s life and relief from symptoms, although some can result in complete 
remission (Gerber, 2008; Ramos, 2008; Mohan et al, 2013). However, they are expensive and 
many are themselves mutagenic, carcinogenic or teratogenic (Gerber, 2008; Ramos, 2008; 
Mohan et al, 2013). Many are cytotoxic to normal cells especially liable cells: haematopoietic, 
keratinocytes and intestinal epithelial cells (Gerber, 2008; Ramos, 2008; Mohan et al, 2013). 
These chemotherapeutic agents induce considerable side effects including: nausea; vomiting; 
fatigue; diarrhoea; alopecia; skin rashes and myelosuppression; which can be so severe, that 
patients withdraw themselves from treatment, which can result in development of drug 
resistance and remission (Gerber, 2008; Mohan et al, 2013).
Drug resistance is considered as a major issue for cancer treatments and can occur through 
multiple pathways (Ferreira et al, 2006; Mohan et al, 2013). Some chemotherapies can alter
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membrane transportation and expression of multidrug resistance (MDR1) gene (Ferreira et al, 
2006; Mohan et al, 2013). These genes mediated by P-glycoprotein (P-gp), which can increase 
the glutathione (GSH) levels resulting in increased drug efflux and reduced intracellular drug 
accumulation and loss of therapeutic efficacy (Ferreira et al, 2006; Mohan et al, 2013). Drug 
resistance is found commonly in ALL patients when treated with etoposide or doxorubicin, as 
well as in CML patients when treated with imatinib (Ferreira et al, 2006; Mohan et al, 2013). 
Alternatively chemotherapeutic agents can also activate NF-kB transcription factor gene, 
which leads to up regulation of pro-survival factors such as Bcl-2 and Bcl-xl (Mohan et al, 
2013) or induce mutations in cell cycle proteins such as p53 leading to increased cell cycle and 
resistance to cell death (Florea and Biisselberg, 2011; Mohan et al, 2013). Increased DNA 
repair in cells via activation of nucleotide excision repair (NER) mechanisms has also been 
shown to lead to drug resistance (Mohan et al, 2013).
In order to overcome some of these problems with chemotherapy treatments, combination 
treatments are under investigation. Where, multiple anti-cancer agents are used, which target 
different anti-cancer mechanisms. These agents have been used in combination at a reduced 
treatment concentration to avoid side effects. The use of combination treatments can enhance 
the efficacy of standard chemotherapy agents, and decrease development of drug resistance, 
toxicity and side effects (Florea and Biisselberg, 2011; Sandeep et al, 2012; Mohan et al, 2013). 
For example: cyclophosphamide has been used successfully in combination with doxorubicin 
or rituximab in the treatment of lymphoblastic leukaemia and non-Hodgkin lymphoma 
(Sandeep et al, 2012; Mohan et al, 2013). Demonstrating the combination treatment was more 
effective than each treatment alone; there was also reduced drug resistance, and fewer side 
effects (Sandeep et al, 2012; Mohan et al, 2013). It is for this reason, that it is important to 
develop new combination treatments that could improve the response to chemotherapy, clinical 
outcome and patient survival rates.
Previous studies have shown that polyphenols possess a broad range of biological properties 
(Ramos, 2008; Mohan et al, 2013). They can inhibit cell proliferation; induce apoptosis; cause 
cell cycle arrest and inhibit several protein kinases (e.g. PKC and tyrosine kinases). They have 
also been shown to have anti-oxidant, anti-inflammatory, anti-viral and anti-cancer activities 
(Han et al, 2007; Dai et al, 2013). Due to these properties, polyphenols have been under 
investigation as potential chemotherapeutic agents (Han et al, 2007; Dai et al, 2013; Mohan et 
al, 2013). Work to date has shown that polyphenols have potential in the treatment of 
leukaemia, with quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) and cis-stilbene 
(CIS) shown to induce apoptosis and arrest cell cycle particularly in lymphoid leukaemia cells 
lines; with limited effects seen in normal hematopoietic cells (Mahbub et al, 2013; Chapter 2). 
These agents have also been shown to interact with the actions of chemotherapeutic agents,
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quercetin potentiated the induction of apoptosis by cisplatin and doxorubicin in human 
laryngeal carcinoma (Hep-2) cells (Kuhar et al, 2007), human cervical cancer (HeLa) cells 
(Zhang et al, 2008) and human breast cancer (MCF7) cells (Staedler et al, 2011). Combination 
treatments were found to activate caspase 9 and caspase 3, and reduce anti-apoptotic proteins 
Bcl-2 and Bcl-x (Kuhar et al, 2007; Zhang et al, 2008; Staedler et al, 2011). In addition, 
quercetin when used in combined with cisplatin or doxorubicin depleted levels of glutathione 
(GSH) and inhibited the expression of nuclear translocation and multidrug resistance protein 
(MDR), leading to the reduction of drug resistance and increase the efficacy of therapy (Kuhar 
et al, 2007; Zhang et al, 2008; Staedler et al, 2011; Mohan et al, 2013). Also, it showed that 
quercetin, emodin and resveratrol can inhibit the activation of NFkB, which can aid 
chemotherapy agents by the modification of drug resistance pathways in cancer cells (Mohan 
et al, 2013).
There are however two contradictory studies, showing that polyphenols can block the activity 
of standard chemotherapeutic agents (CTipak et al, 2003; Kim et al, 2009). Cvipak et al, 2003 
reported that apigenin, galangin and chrysin inhibited the activity of cisplatin and doxorubicin, 
producing an antagonistic effect on cytotoxicity and induced of apoptosis in murine leukaemia 
L1210 cells (CTipak et al, 2003). Similarly, Kim et al, 2009 reported that rutin hydrate, 
quercetin dehydrate, hydrocaffeic acid, gallic acid and tannic acid antagonised the induction of 
apoptosis caused by bortezomib in multiple myeloma cell lines (MC/CAR, RPMI8226 and 
U266) (Kim et al, 2009). It was suggested that the structure of the polyphenols was a key 
factor responsible for their antagonistic effect on bortezomib (Kim et al, 2009).
These findings suggested that polyphenols can differentially modulate the efficacy of some 
chemotherapeutics agents. Still there is no clear study on combination effects of polyphenols 
and a variety of standard chemotherapy agents used in the treatment of leukaemia. Thus, it is 
essential to determine the possible impacts of polyphenols on chemotherapeutic agents. Here, 
chemotherapeutic agents were selected to represent the different classes of chemotherapies, 
and were used to identify any synergistic or indeed inhibitory actions between polyphenols and 
chemotherapy agents.
3.1.1 Hypothesis
This study tested the hypothesis that: polyphenols have a synergistic effect when combined 
with standard chemotherapeutic agents in leukaemia cell lines.
3.1.2 Aims
The major aims of this study were to examine the effects of the most active polyphenols 
selected from Chapter 2 and chemotherapeutic agents alone or in combination on: (1) ATP
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levels using CellTiter-Glo® luminescent cell viability assay; (2) apoptosis using the NucView 
caspase 3 activity assay and flow cytometry; and morphological assessment with Hoechst 
33342/PI stained cells and (3) progression of the cell cycle using PI staining and flow 
cytometry in two lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) and two myeloid 
leukaemia cell lines (THP-1 and KGla). Additionally this study aimed to determine the nature 
of interactions of the polyphenols with the standard chemotherapeutic agents.
3.2 M ethods a n d  M ateria ls
3.2.1 Experimental Design
Four human leukaemia cell lines were used for this study: two lymphoid leukaemia cell lines 
(JURKAT (peripheral blood T cell leukaemia) and CCRF-CEM (acute lymphoblastic 
leukaemia)) (Section 1.3.1) which were previously shown to have high sensitivity to 
polyphenols treatment (Chapter 2); and two myeloid leukaemia cell lines (THP-1 (acute 
monocytic leukaemia) and KG-la (acute myelogenous leukaemia)) (Section 1.3.2) that were 
the most resistant cell lines to polyphenols treatment (Chapter 2). All cell lines were tested 
regularly for mycoplasma contamination using the MycoAlert TM mycoplasma detection kit 
(Lonza) (Section 2.2.2.1) and were all tested negative throughout the study. Cells were 
cultured as previously described (Chapter 2; Section 2.2.2) and incubated at 37°C with 5% CO2 
in a humidified incubator.
Polyphenols which were the most effective at reducing cell ATP levels and induction of 
apoptosis were selected to determine interaction with chemotherapeutic agents (Chapter 2). 
These included: quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) and c/s-stilbene 
(CIS) (Sigma), which were prepared as described in Chapter 2 and Section 2.2.1.
Nine standard chemotherapy agents were selected for this polyphenol combination study: 
cyclophosphamide (CYCLO), chlorambucil (CLB), 5-fluorouracil (5-FLU), doxorubicin 
(DOX), imatinib (IM), cisplatin (CSP), etoposide, (ETP), methotrexate (MTX) and 
mercaptopurine (6 -MP). These are commonly used for leukaemia treatment. Each selected 
chemotherapy agent was chosen as each had a different chemical structure, target and 
mechanism of action (Chapter 1; Section 1.7).
3.2.2 Treatment Regimes
Chemotherapeutic agents: cyclophosphamide (CYCLO), chlorambucil (CLB), 5-fluorouracil 
(5-FLU), doxorubicin (DOX) and imatinib (IM) were dissolved in water. Cisplatin (CSP) and 
etoposide, (ETP) were dissolved in 1:1 v/v water: ethanol; and finally methotrexate (MTX) and 
mercaptopurine (6 -MP) were dissolved in 0.1M of NaOH alkylating solution. All
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chemotherapy drugs were supplied by Sigma. A stock solution of 25mM was prepared with 
10% (v/v) ethanol (Sigma) in serum free media (Invitrogen) to generate treatment 
concentrations of 0.005, 0.01, 0.4, 2, 10, 50 pM.
For the combination study, a non-significant dose (NSD) and a lowest significant dose (LSD) 
which reduced ATP levels and induced apoptosis were determined for each standard 
chemotherapy agent and each polyphenol, following 24 h of treatment.
• The NSD was defined as: the treatment dose that did not cause a significant reduction in 
ATP levels or induction of apoptosis when compared to the vehicle control.
• The LSD was defined as: the lowest treatment dose that caused a significant reduction in 
ATP levels or induction of apoptosis that was significantly greater than that of the vehicle 
control.
All p-values were set at <0.05 (Table 3.1; 3.2; 3.3 and 3.4). The NSD and LSD for each 
polyphenols were determined from the data presented in Chapter 2 and are summarised in 
Table 3.1 for cell proliferation analysis and Table 3.2 for apoptosis analysis.
Initially the NSD and LSD was determined for each standard chemotherapy agents alone on 
ATP levels and apoptosis in two lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and two myeloid leukaemia cell lines (THP-1 and KG-la) (Table 3.3 and 3.4).
Once the NSD and LSD levels were determined for each standard chemotherapy agents, these 
doses were then used in combination with the NSD and LSD for the polyphenols (Table 3.1 
and 3.2) on cells proliferation, apoptosis and cell cycle progression within the four selected 
leukaemia cell lines.
The Polyphenol Non-Significant Doses (NSD) and Lowest Significant Doses (LSD) (pM) 
Determined by Reducing the ATP Levels Comparing to the Vehicle Control at 24 h
Polyphenols
Classification Polyphenols Doses
Lymphoid Leukaemia Myeloid Leukaemia
JURKAT CCRF-CEM THP-1 KGla
Flavonoids
Quercetin NSD 0.4 0.4 0.4 0.4LSD 2 2 2 2
Apigenin NSD 10 2 2 2LSD 50 10 10 10
Anthraquinones
Emodin NSD 0.4 0.4 0.4 0.4LSD 2 2 2 2
Rhein NSD 10 10 10 10LSD 50 50 50 50
Stilbenoid Cis- Stilbenc NSD 0.4 2 0.4 0.4LSD 2 10 2 2
Table 3.1: The non-significant doses (NSD) and lowest significant doses (LSD) of selected 
polyphenols (pM) at which there was non-significant and lowest significant reduction of ATP 
levels, respectively, compared to the vehicle control at 24 h for two lymphoid leukaemia 
(JURKAT and CCRF-CEM) and two myeloid leukaemia (THP-1 and KG-la) cell lines 
(Chapter 2; Figure 2.8). These NSD and LSD were used for combination work with standard 
chemotherapy agents for analysis of cell proliferation. Statistical significance was set at p<0.05.
142
3.2.3 CellTiter-Glo® Luminescent Cell Viability Assay
The CellTiter-Glo® Luminescent Cell Viability Assay Kit (Promega) (Section 2.2.3) was used 
to measure ATP levels, which are directly proportional to the number of metabolically active 
cells and hence indicative of cell proliferation. Firstly, this assay was used to examine the 
effect of eight chemotherapy drugs alone (CYCLO, CLB, CSP, MTX, 6 -MP, 5-FLU, DOX, 
ETP, IM) (Sigma) on the ATP levels of two lymphoid leukaemia cell lines (JURKAT and 
CCRF-CEM) and two myeloid leukaemia cell lines (THP-1 and KG-la). The treatment doses 
used were 0, 0.005, 0.01, 0.4, 2, 10, 50 pMol for 24 h. This wide range of treatment doses were 
selected so that it would be possible to determine the non-significant doses (NSD) and lowest- 
significant doses (LSD) that reduction ATP levels, for each chemotherapy agent; in each cell 
line (Table 3.3). These NSD and LSD (Table 3.3) were then used in subsequent combination 
work with the NSD and LSD of selected polyphenols (QUE, AP, EMO, RH, CIS) (Sigma) 
(Table 3.1).
The Polyphenol Non-Significant Doses (NSD) and Lowest Significant Doses (LSD) (pM) 
Determined by Induction of Capase 3 Activity Comparing to the Vehicle Control at 24 h
Polyphenols Polyphenols Doses Lymphoid Leukaemia Myeloid LeukaemiaClassification JURKAT CCRF-CEM THP-1 KGla
Quercetin NSD 0.4 0.4 2 2
Flavonoids LSD 2 2 10 10
Apigenin NSD 10 2 2 2LSD 50 10 10 10
Emodin NSD 0.4 2 0.4 0.4
Anthraquinones LSD 2 10 2 2
Rhein NSD 10 10 10 10LSD 50 50 50 50
Stilbenoid Cis- Stilbene NSD 2 10 10 2LSD 10 50 50 10
Table 3.2: The non-significant doses (NSD) and lowest significant doses (LSD) of selected 
polyphenols (pM) ) at which there was non-significant and lowest significant induction of 
apoptosis respectively, compared to the vehicle control at 24 h for two lymphoid leukaemia 
(JURKAT and CCRF-CEM) and two myeloid leukaemia (THP-1 and KG-la) cell lines 
(Chapter 2; Figure 2.11). The NSD and LSD were used for combination work with standard 
chemotherapy agents to analysis the apoptosis. Statistical significance was set at p<0.05.
3.2.4 Apoptosis Analysis
3.2.4.1 NucView Caspase 3 Activity Assay by Flow Cytometiy
The NucView caspase 3 activity assay and flow cytometry (Section 2.2.4.1) was used to 
determine the non-significant doses (NSD) and lowest-significant doses (LSD) of each 
chemotherapy drugs alone (CYCLO, CLB, CSP, MTX, 6 -MP, 5-FLU, DOX, ETP, IM) on the 
induction of caspase 3 activity and early stage apoptosis in two lymphoid leukaemia (JURKAT 
and CCRF-CEM) and two myeloid leukaemia (THP-1 and KG-la) cell lines. The treatment 
doses used were 0, 0.005, 0.01, 0.4, 2, 10, and 50 pMol for 24 h. These capase 3 NSD and
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LSD were then used in subsequent combination studies with the NSD and LSD of selected 
polyphenols (QUE, AP, EMO, RH, CIS) for 24 h (Table 3.2). From this the LSD for apoptosis 
determined by NucView caspase 3 activity assay for each polyphenol (Table 3.2) and 
chemotherapy drugs (Table 3.4) were then used for analysis the nuclear morphological of cells 
using double staining Hoechst 33342/PI by fluorescence microscopy.
S.2.4.2 N uclear M orphological Analysis using D ouble S ta in ing  o f  H oechst 33342/PI and  
Fluorescence M icroscopy
The effects of the combined chemotherapy agents and polyphenols on apoptosis were further 
investigated via analysis the nuclear morphological changes of cells using Hoechst 33342 and 
PI staining and fluorescence microscopy. Using these stains, it is possible to distinguish normal, 
apoptotic and dead cell populations. Particularly, Hoechst 33342 (a blue fluorescence dye) 
stains the condensed chromatin in apoptotic cells more brightly than the chromatin in normal 
cells; whilst PI (a red fluorescence dye) only permeates late apoptotic and dead cells. Hence 
normal cells appear round and pale blue; apoptotic cells appear bright blue with the 
characteristic feature of apoptosis and late apoptotic and dead cells appear red. This nuclear 
morphological analysis was used to confirm the results of caspase 3 activity assay.
The two lymphoid leukaemia (JURKAT and CCRF-CEM) and two myeloid leukaemia (THP-1 
and KG-la) cell lines were seeded in 12 well plates 0.5 x 106 cells per ml and treated for 24 h 
with each chemotherapy drug (CYCLO, CLB, CSP, MTX, 6 -MP, 5-FLU, DOX, ETP, IM) and 
each polyphenol (QUE, AP, EMO, RH, CIS) (Sigma) alone and in combination at their LSD 
(Table 3.2 and 3.4). An ethanol vehicle controls at 0.1 % (v/v) was also included. Following 24 
h of treatments, 1 0 0  pi of cells was transferred from each culture well of 1 2  well plate to 
labelled 96-well plates (Fisher Scientific). Then, 10 pi of 2 pg/ml Hoescht 33342 dye (Sigma) 
was added to each well and incubated for 5 min in the dark place. Next 10 pi of 2 pg/ml PI dye 
(Sigma) was added to each well and was incubated for a further 15 min in the dark. Plates were 
examined using inverted fluorescence microscope (Olympus). Two hundred cells (live and 
apoptotic) were counted and the percentage of apoptotic nuclei determined for each sample. 
Images were captured using Cell-F software, Olympus).
3.2.5 Cell Cycle Analysis using Propidium Iodide (PI) and Flow Cytometry
The effects of the combined standard chemotherapy agents and polyphenols were also 
examined on the progression of cell cycle using Propidium Iodide (PI) staining and flow 
cytometric analysis as described previously (Section 2.2.5). Two lymphoid leukaemia 
(JURKAT and CCRF-CEM) and two myeloid leukaemia (THP-1 and KG-la) cell lines were 
treated for 24 h with each chemotherapy drugs (CYCLO, CLB, CSP, MTX, 6 -MP, 5-FLU,
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DOX, ETP, IM) and each polyphenols (QUE, AP, EMO, RH, CIS) (Sigma) alone and in 
combined at their LSD (Table 3.1 and 3.3).
3.2.6 Statistical Analysis
The median with range were calculated for CellTiter-Glo®, NucView Caspase 3 Activity, 
Double Staining of Hoechst 33342/PI and Cell Cycle analysis. The Stats Direct software (Stats 
Direct Ltd, England) was used to test whether data followed a normal distribution using a 
Shapiro-Wilke test; which was used to determine whether the data was parametric or non- 
parametric. As the data was non-parametric, a Kruskal-Wallis and Conover-Inman post hoc 
test was used to determine statistical significance of the data. Results were considered 
statistically significant whenp  < 0.05.
3.2.6.1 Analysis of Effect of Combination Treatments on ATP level and Apoptosis
The effects of the combination treatments were categorised using the following criteria:
• Reduction of ATP levels or induction of apoptosis by a polyphenol = X
• Reduction of ATP levels or induction of apoptosis by chemotherapy agent = Y
• Reduction of ATP levels or induction of apoptosis by combined polyphenol and 
chemotherapy agent treatment = Z
• X+Y were calculated and described as our Expected Value
The effect of combination chemotherapy and polyphenols treatments was classified as: 
Additive or Synergistic or Competitive Antagonistic or Antagonistic according to their 
statistical analysis. The combination effects were classified and defined as follows:
1. Additive (ADD): the effect of combination treatments (Z) is equal to the sum of the 
effect of the two treatments alone. This is an Additive Response if: the combined effect 
(Z) is significantly greater than the effect of each treatment X and Y alone, as well as, 
significantly greater than the control, but not significant greater than the Expected 
value (X + Y).
2. Synergistic (SYN): the effect of combination treatments is higher than the sum of the 
effect of the two treatments alone. A Synergist Response is seen if: the combined effect 
(Z) is significantly greater than the control, each drug alone (X alone, Y alone) and the 
Expected Value (X+Y).
3. Competitive Antagonistic (C-ANTG): the effect of combination treatments is equal 
to the effect of one of two treatments. A Competitive Antagonistic Response is seen if: 
the combined effect (Z) is significantly lower than the Expected Value (X+Y) and has
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a similar response to the effect of one treatment alone (X or Y alone) with no 
significant difference.
4. Antagonistic (ANTG): the effect of combination treatments is lower than the sum of 
the effect of the two treatments and individual treatments. An Antagonistic Response 
seen if: the combined effect (Z) is significantly lower than the effect of each treatment 
alone and the Expected Values (X alone, Y alone and X+Y).
3.2.6.2 Analysis of Effect of Combination Treatments on Cell Cycle
The percentage of cells in each phase was analysed with FlowJo software using the Watson 
pragmatic model. The data was expressed as medians with ranges (n=4). The statistical 
significance of individual drugs was determined firstly in comparison to the vehicle control. 
Then, the statistical significance of combined drugs was determined in comparison to the 
vehicle control and individual treatments. The effect of combination treatments on cell cycle 
was classified either having an Interactive, Non- interactive or Antagonistic effect. These 
classifications are defined as:
1. Interactive Effect: the combination treatments induce a highly significant increase of 
cell accumulation in any phase of cell cycle, when compared to the vehicle control and 
effect of the individual treatment alone (p<0.05)
2. Non-Inter active Effect: the combination treatments induced a significant increase of 
cell accumulation in any phase of cell cycle when compared to the vehicle control; but 
this was not significant greater than that seen with one or both of treatments when used 
alone (p<0.05)
3. Antagonistic Effect: the combination treatments had no significant differences 
compared to the vehicle control (p<0.05) and also had a significant decrease of cell 
accumulation compared to the phases arrested by individual treatments alone (p<0.05).
3.3 Results
3.3.1 Effect of Chemotherapy Agents Treatment on ATP levels and Apoptosis in 
Leukaemia Cell Lines following 24 h treatments
The most effective chemotherapy agents at reducing ATP levels and induction of apoptosis in 
all leukaemia cell lines were: DOX, ETP, CSP, IM (Figure 3.1 and 3.2). The least effective 
agents were CYCLO, MTX, 6 -MP and 5-FLU (Figure 3.1 and 3.2). The NSD and LSD for 
each chemotherapy agents in each cell line are shown in Table 3.3 and 3.4. These NSD and 
LSD which were used in subsequent polyphenols: chemotherapy combination studies (Table
3.1 and 3.2).
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Figure 3.1: Effect of nine chemotherapy agents on ATP levels in two lymphoid leukaemia 
(CCRF-CEM and JURKAT; red lines), and two myeloid leukaemia (THP-1 and KG-la; blue 
lines) cell lines. Cells were treated with each chemotherapy agent at 0, 0.005, 0.01, 0.4, 2, 10, 50 
pM for 24 h. All data was normalised to the vehicle-only control, which was assigned 100% cell 
viability, and each data was in triplicate. Non-significant dose (NSD) and lowest significant dose 
(LSD) that reduced ATP levels for each chemotherapy drug in each cell lines are determined 
(Table 3.3). Statistical significance was set at p<0.05 compared to vehicle control.
The Chemother 
Determinec
apy Non-Significant Doses C 
by Reducing the ATP Leve
VSD) and Lowest Significant Doses (LSD) (pM) 
Comparing to the Vehicle Control at 24 h.
Chemotherapy Chemotherapy
Doses
Lymphoid Leukaemia Myeloid Leukaemia
Classification Agents JURKAT CCRF-CEM THP-1 KGla
Cyclophosphamide
NSD 0.4 2 0.4 10
LSD 2 10 2 50
Alkylating
Chlorambucil
NSD 2 0.005 0.01 2
Agents LSD 10 0.01 0.4 10
Cisplatin
NSD 0.005 0.4 0.005 0.4
LSD 0.01 2 0.01 2
Methotrexate
NSD 0.005 0.01 0.005 0.01
LSD 0.01 0.4 0.01 0.4
Anti-metabolites
Mercaptopurinc
NSD 0.005 0.005 0.005 10
Agents LSD 0.01 0.01 0.01 50
5-FluorouraciI
NSD 0.005 0.4 0.005 0.01
LSD 0.01 2 0.01 0.4
Topoisomerase
Inhibitors
Etoposide
NSD 0.005 0.005 0.005 0.01
LSD 0.01 0.01 0.01 0.4
Agents Doxorubicin
NSD 0.005 0.005 0.005 0.01
LSD 0.01 0.01 0.01 0.4
Tyrosine Kinase
Imatinib
NSD 0.4 0.4 0.005 0.005
Inhibitors Agent LSD 2 2 0.01 0.01
Table 3.3: The non-significant doses (NSD) and lowest significant doses (LSD) of each 
chemotherapy agent (pM) at which there was a non-significant and lowest significant 
reduction of ATP levels compared to the vehicle control at 24 h for two lymphoid leukaemia 
(JURKAT and CCRF-CEM) and two myeloid leukaemia (THP-1 and KG-la) cell lines.
Statistical significance was set at p<0.05.
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Figure 3.2: Effect of nine chemotherapy agents on caspase 3 activity in two lymphoid 
leukaemia (CCRF-CEM and JURKAT; red lines), and two myeloid leukaemia (THP-1 and 
KG-la; blue lines) cell lines. Cells were treated with each chemotherapy agent at 0, 0.005, 0.01, 
0.4, 2, 10, 50 pM for 24 h. All data was normalised to the vehicle-only control, which was assigned 
a 0% apoptotic level, and each data was in triplicate. Non-significant dose (NSD) and lowest 
significant dose (LSD) that induced caspase 3 activity for each chemotherapy in each cell line are 
determined in (Table 3.4). Statistical significance was set at p<0.05 compared to vehicle control.
The Chemotherapy Non-Significant Doses (NSD) and Lowest Significant Doses (LSD) (pM)
Determined by Induction of Capase 3 Activity Comparing to the Vehicle Control at 24 h
Chemotherapy
Classification
Chemotherapy
Agents
Doses
Lymphoid Leukaemia Myeloid Leukaemia
JURKAT CCRF-CEM THP-1 KGla
Alkylating
Agents
Cyclophosphamide
NSD 2 2 0.4 10
LSD 10 10 2 50
Chlorambucil
NSD 2 2 0.01 2
LSD 10 10 0.4 10
Cisplatin
NSD 0.005 0.01 0.005 0.4
LSD 0.01 0.4 0.01 2
Anti-metabolites
Agents
Methotrexate
NSD 0.005 0.4 0.005 0.01
LSD 0.01 2 0.01 0.4
Mercaptopurine
NSD 0.005 0.01 0.4 10
LSD 0.01 0.4 2 50
5-Fluorouracil
NSD 0.005 2 0.01 0.4
LSD 0.01 10 0.4 2
Topoisomerase
Inhibitors
Agents
Etoposide
NSD 0.005 0.005 0.005 0.4
LSD 0.01 0.01 0.01 2
Doxorubicin
NSD 0.005 0.005 0.01 0.01
LSD 0.01 0.01 0.4 0.4
Tyrosine Kinase 
Inhibitors Agent
Imatinib
NSD 0.01 0.4 0.005 0.005
LSD 0.4 2 0.01 0.01
Table 3.4: The non-significant doses (NSD) and lowest significant doses (LSD) of each
chemotherapy agent (pM) at which there was a non-significant and lowest significant 
increase in apoptosis compared to the vehicle control at 24 h for two lymphoid leukaemia 
(JURKAT and CCRF-CEM) and two myeloid leukaemia (THP-1 and KG-la) cell lines.
Statistical significance was set atp<0.05.
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3.3.2 Effect of Chemotherapy Agents and Polyphenols Combination Treatment in 
Leukaemia Cell Lines following 24 h
3.3.2.1 Effects of Topoisomerase Inhibitors Combined with Polyphenols
3.3.2.1.1 Doxorubicin (DOX)
(A) Effects o f  Doxorubicin (DOX) Combined with Polyphenols on ATP Levels
DOX when used in combination with QUE caused a synergistic reduction of ATP levels 
(p<0.05) in both lymphoid and myeloid cell lines (Figure 3.3 and Table 3.5). Similarly, when 
DOX was combined with AP there was a synergistic reduction in ATP level in three out of 
four leukaemia cell lines (CCRF-CEM, JURKAT and THP-1) and an additive effect on KG la, 
(p<0.05) (Figure 3.3 and Table 3.5). When DOX was used in combination with EMO, RH or 
CIS it also caused a synergistic reduction in ATP levels, but only in the lymphoid leukaemia 
cell lines (Figure 3.3 and Table 3.5). In contrast, when DOX was combined with EMO or RH it 
produced a competitive antagonistic effect, which significantly increasing ATP levels in the 
myeloid leukaemia cell lines (p<0.05) (Figure 3.3 and Table 3.5).
(B) Effects o f  Doxorubicin (DOX) Combined with Polyphenols on Apoptosis
DOX when used in combination with QUE caused a synergistic effect on induction of 
apoptosis in all leukaemia cell lines (P<0.05) (Figure 3.4, 3.5 and Table 3.5). Similarly, DOX 
when used in combination with AP synergistically induced apoptosis in three out of four of the 
leukaemia cell lines (CCRF-CEM, JURKAT and THP-1) (Figure 3.4 and 3.5). Whilst only 
additive effects were seen in the KGla myeloid cell lines (Figure 3.4, 3.5 and Table 3.5). DOX 
when used in combination with EMO, RH or CIS synergistically induced apoptosis in the two 
lymphoid leukaemia cell lines (Figure 3.4, 3.5 and Table 3.5). However, EMO and RH when 
used in combination with DOX produced either a competitive antagonistic or antagonistic 
effect on apoptosis; significantly reducing the levels of caspase 3 activity (Figure 3.4) and 
percentage of cells undergoing apoptosis (Figure 3.5) in the myeloid leukaemia (THP-1 and 
KGla) cell lines (p<0.05) (Figure 3.4, 3.5 and Table 3.5). An example of the morphological 
assessment of apoptosis following DOX and polyphenols (QUE, AP, EMO, RH, CIS) 
treatment alone and in combination at their LSD for 24 h on THP-1 myeloid leukaemia cell 
line are showed in Figure 3.6.
(C) Effects o f  Doxorubicin (DOX) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase of cell accumulation in G2 /M 
phase caused by DOX, in S phase caused by QUE or AP, in Go/Gj phase caused by EMO or 
RH when compared to the vehicle control (p<0.05). There was however no significant increase 
of cell accumulation in any phases of the cell cycle when treated with CIS (Figure 3.7). 
Treatment of JURKAT cells with DOX in combination with QUE, AP, EMO, RH or CIS
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caused an interactive effect on cell cycle; with all combination treatments inducing a 
significant increase in cell accumulation in the G2/M phase of the cell cycle, when compared to 
the vehicle control and individual effects of each treatment (p<0.05) (Figure 3.7 and Table 3.5).
CCRF-CEM lymphoid leukaemia cells had a significant increase of cell accumulation in S 
phase caused by DOX, QUE, EMO and RH, and G2/M phase caused by AP. However there 
was no significant increase in accumulation in any phases of cell cycle caused by CIS when 
compared to the vehicle control (p<0.05) (Figure 3.7). Treatment of CCRF-CEM cells with 
DOX in combination with QUE, AP, EMO, RH or CIS had an interactive effect on cell cycle; 
with all combination treatments inducing a significant increase of cell accumulation in S 
phase when compared to the vehicle control and the individual effects if each treatment alone 
(p<0.05) (Figure 3.7 and Table 3.5).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in S and G2/M 
phases caused by DOX and AP, in G2/M phase caused by QUE or CIS; while they had no 
significant increase of cell accumulation in any phases of cell cycle caused by EMO or RH 
when compared to the vehicle control (p<0.05) (Figure 3.7). Treatment of THP-1 cells with 
DOX in combination with QUE, AP and CIS had an interactive effect on cell cycle; with the 
combination treatments inducing either a highly significant increase of cell accumulation in S 
or G2/M phases when compared to the effects caused by the vehicle control and individual 
treatments alone (p<0.05) (Figure 3.7 and Table 3.5). However, treatment of THP-1 cells with 
DOX in combination with EMO or RH had an antagonistic effect on cell cycle, there was no 
significant differences compared to the vehicle control (p<0.05) and but a significant decrease 
of cell accumulation compared to the phases arrested by individual treatments alone (p<0.05) 
(Figure 3.7 and Table 3.5).
KG-la myeloid leukaemia cells had a significant increase in cells accumulated in S and G2/M 
phases following treatment with DOX, G0/G1 phase caused by AP, while they had no 
significant increase of cell accumulation in any phases of cell cycle caused by QUE, EMO, RH 
or CIS when compared to the vehicle control (p<0.05) (Figure 3.7). Treatment of KG-la cells 
with DOX in combination with QUE, AP and CIS had an interactive effect on cell cycle 
causing a significant increase of cell accumulation in S and G2/M phases when compared to the 
vehicle control; but this was not significant when compared to effect caused by DOX alone 
(p<0.05) (Figure 3.7 and Table 3.5). In contrast, treatment of KG-la cells with DOX in 
combination with EMO or RH had an antagonistic effect on cell cycle. These combinations 
had no significant effect compared to the vehicle control (p<0.05) but they did significant 
decrease of cell accumulation compared to the phases arrested by individual treatments alone 
(p<0.05) (Figure 3.7 and Table 3.5).
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Effect of Doxorubicin (DOX) in Combination with Polyphenols at their Low est Significant Doses (LSD)
__________ on ATP level of Leukaemia Cell Lines Following 24 h of Treatment._______________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.3: The effect of DOX when used in combination with QUE, AP, EMO, RH or CIS on 
ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with DOX and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of Doxorubicin (DOX) in Combination with Polyphenols at their Lowest Significant Doses (LSD) 
____________ on Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment.____________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.4: The effect of DOX when used in combination with QUE, AP, EMO, RH or CIS on 
caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with DOX and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. 
The data was expressed as medians with ranges (n=4). The black bars show the vehicle controls 
and treatments alone; the white bar shows the expected effect of the combined treatments on 
caspase 3 activity; the coloured bars indicate significant additive effects in brown, synergistic 
effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. 
Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of Doxorubicin (DOX) in Combination with Polyphenols at their Lowest Significant Doses (LSD)
on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment._____
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.5: The effect of DOX when used in combination with QUE, AP, EMO, RH or CIS on 
apoptosis morphological changes of leukaemia cell lines. This was evaluated by double staining 
with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with DOX and 
polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the vehicle- 
only control, which was assigned a 0% apoptotic level. The data was expressed as medians with 
ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar shows 
the expected level of percentage apoptosis; the coloured bars indicate a significant additive effects 
in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 3.6: An example of morphological assessment of apoptosis using Hoechst 33342/PI for 
THP-1 myeloid leukaemia cells when treated with LSDs of DOX and polyphenols (QUE, AP, 
EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 pm.
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(A)Effect of Doxorubicin (DOX) in Combination with Polyphenols at their Lowest 
Significant Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines 
______________________ Following 24 h of Treatment.______________________
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(B) Effect of Doxorubicin (DOX) in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines
_________________________ Following 24 h of Treatment._________________ _______
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Figure 3.7: The effect of DOX when used in combination with QUE, AP, EMO, RH or CIS on 
cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) and 
(B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with DOX and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.5.
Assays Targets
Com bination of 
Doxorubicin
The Significant Effects o f D oxorubicin (DOX) and 
Polyphenols C om bination T reatm ent on ATP Levels, 
Apoptosis and Cell Cycle Progression a t 24 h.
and Polyphenols Lym phoid Leukaem ia M yeloid Leukaem ia
JU RK A T CCRF-CEM THP-1 K G la
CellTiter- ATP Level DOX + QUE (NSD) 1 SYN SYN SYN SYNGlow DOX + QUE (LSD) 1 SYN SYN SYN SYN
Caspase 3 Apoptosis 1 DOX + QUE (NSD) SYN SYN ■ SYN SYNActivity DOX + QUE (LSD) I SYN SYN SYN SYN
Hoechst/ PI Apoptosis DOX + QUE (LSD) I SYN SYN SYN SYN
Cell
Cycle/PI Cell Cycle DOX + QUE (LSD) | Interaction Interaction Interaction Non Interaction
CellTiter- ATP Level DOX + AP (NSD) 1 SYN SYN SYN ADDGlow DOX + AP (LSD) I SYN SYN SYN ADD
Caspase 3 Apoptosis DOX + AP (NSD) SYN SYN SYN ADDActivity DOX + AP (LSD) SYN SYN SYN ADD
Hoechst/ PI Apoptosis DOX + AP (LSD) SYN SYN SYN ADD
Cell
Cycle/PI Cell Cycle DOX + AP (LSD) Interaction Interaction Interaction Non Interaction
CellTiter- ATP Level DOX + EMO (NSD) SYN SYN C-ANTG C-ANTGGlow DOX + EMO (LSD) SYN SYN C-ANTG C-ANTG
Caspase 3 Apoptosis DOX + EMO (NSD) SYN SYN C-ANTG C-ANTGActivity DOX + EMO (LSD) | SYN SYN C-ANTG C-ANTG
Hoechst/ PI Apoptosis DOX + EMO (LSD) SYN SYN C-ANTG C-ANTG
Cell
Cycle/PI Cell Cycle DOX + EMO (LS) Interaction Interaction ANTG ANTG
CellTiter- ATP Level DOX + RH (NSD) SYN SYN C-ANTG C-ANTGGlow DOX + RH (LSD) SYN SYN C-ANTG C-ANTG
Caspase 3 Apoptosis DOX + RH (NSD) SYN SYN C-ANTG C-ANTGActivity DOX + RH (LSD) SYN SYN ANTG C-ANTG
Hoechst/ PI Apoptosis DOX + RH (LSD) SYN SYN C-ANTG C-ANTG
Cell
Cycle/PI Cell Cycle DOX + RH (LSD) Interaction Interaction ANTG ANTG
CellTiter- ATP Level DOX + CIS (NSD) SYN SYN ADD ADDGlow DOX + CIS (LSD) SYN SYN ADD ADD
Caspase 3 Apoptosis
DOX + CIS (NSD) SYN SYN ADD ADD
Activity DOX + CIS (LSD) SYN SYN ADD ADD
Hoechst/ PI Apoptosis DOX + CIS (LSD) SYN SYN ADD ADD
Cell
Cycle/PI Cell Cycle | DOX + CIS (LSD) Interaction Interaction Interaction Non Interaction
Table 3.5: A sum m ary of the effects of doxorubicin (DOX) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EM O), rhein, (RH) or cis-stilbene (CIS)] com bination trea tm ents on ATP 
level, apoptosis and cell cycle progression in two lymphoid leukaem ia cell lines (JU RK A T and 
CCRF-CEM ) and two myeloid leukaem ia cell lines (T H P -land  K G la ) a t 24 h. Combination 
treatments were investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note 
that the combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.2.1.2 Etoposide (ETP)
(A) Effect o f  Etoposide (ETP) Combined with Polyphenols on ATP levels
ETP when used in combination with QUE produced a synergistic reduction of ATP levels 
(p<0.05) in both lymphoid and myeloid cell lines (JURKAT, CCRF-CEM, THP-1, KGla) 
(Figure 3.9 and Table 3.6). ETP when used in combination with AP produced an additive 
effects in most leukaemia cell lines (p<0.05), the only exception was seen in THP-1 myeloid 
cell lines in which there as a synergistic reduction in ATP level (p<0.05) (Figure 3.9 and Table
3.6). ETP when used in combination with EMO produced a synergistic reduction in ATP level 
in the lymphoid leukaemia cell lines only (JURKAT and CCRF-CEM) (Figure 3.8 and Table
3.6); and an additive effects in myeloid leukaemia cell lines (THP-1 and KGla) (p<0.05) 
(Figure 3.8 and Table 3.6). ETP when used in combination with RH or CIS produced 
synergistic effects significantly reducing ATP levels in the lymphoid leukaemia cell lines only 
(JURKAT and CCRF-CEM) (Figure 3.8 and Table 3.6). In the myeloid leukaemia (THP-1 and 
KGla) cell lines a competitively antagonistic or antagonistic effects was seen with a 
significantly increase ATP level (p<0.05) (Figure 3.8 and Table 3.6).
(B) Effect o f  Etoposide (ETP) Combined with Polyphenols on Apoptosis
ETP when used in combination with QUE produced a synergistic increase in caspase 3 activity 
(Figure 3.9) and the percentage of cells undergoing apoptosis (Figure 3.10) in all cell lines 
(JURKAT, CCRF-CEM, THP-1, KGla) (p<0.05) (Figure 3.9, 3.10and Table 3.6). ETP when 
used in combination with AP produced an additive effects in most leukaemia cell lines 
(p<0.05), the only exception was seen in THP-1 myeloid cell lines in which there as a 
synergistic induction on caspase 3 activity and percentage apoptosis (p<0.05) (Figure 3.9, 3.10 
and Table 3.6). ETP when used in combination with EMO produced a synergistic effects on 
caspase 3 activity (Figure 3.9) and percentage apoptosis (Figure 3.10) (p<0.05) in the 
lymphoid leukaemia cell lines only (JURKAT and CCRF-CEM) (Figure 3.9, 3.10 and Table
3.6); and an additive effects in myeloid leukaemia cell lines (THP-1 and KGla) (p<0.05) 
(Figure 3.9, 3.10 and Table 3.6). Similarly ETP when used in combination with RH or CIS 
produced a synergistic effects on caspase 3 activity (Figure 3.9) and percentage apoptosis 
(Figure 3.10) (p<0.05) in the lymphoid leukaemia cell lines (Figure 3.9, 3.10 and Table 3.6). 
However, they were produced either a competitively antagonistic or antagonistic effects on 
capase 3 activity (Figure 3.9) and percentage apoptosis (Figure 3.10) in the myeloid leukaemia 
(THP-1 and KGla) cell lines (p<0.05) (Figure 3.9, 3.10 and Table 3.6). An example of the 
morphological assessment of apoptosis for ETP and polyphenols (QUE, AP, EMO, RH and 
CIS) alone and in combination at their LSD for 24 h on THP-1 myeloid leukaemia cell lines is 
showed in Figure 3.11.
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(C) Effect o f Etoposide (ETP) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase of cell accumulation in S and 
G2/M phases caused by ETP, in S phase caused by QUE and AP, in Go/Gi phase caused by 
EMO and RH; whilst there was no significant increase of cell accumulation in any phases of 
cell cycle caused by CIS (p<0.05) (Figure 3.12). Treatment of JURKAT cells with ETP in 
combination with QUE, EMO, RH or CIS had an interactive effect on cell cycle; causing a 
highly significant increase of cell accumulation in G2/M phase with all these treatment 
combinations (p<0.05) (Figure 3.12 and Table 3.6). The only variation was seen when 
JURKAT cells were treated with a combination of ETP and AP, which caused an interactive 
effect and cell accumulation was seen in S phase (p<0.05) (Figure 3.12 and Table 3.6).
CCRF-CEM lymphoid leukaemia cells had a significant increase of cell accumulation in S and 
G2/M phases caused by ETP, in S phase caused by QUE, EMO or RH, and in G2/M phase 
caused by AP; there was however no significant increase of cell accumulation in any phases of 
cell cycle caused by CIS (p<0.05) (Figure 3.12). Treatment of CCRF-CEM cells with ETP in 
combination with QUE, AP, EMO, RH or CIS had an interactive effect on cell cycle each 
inducing a highly significant increase of cell accumulation in S phase (p<0.05) (Figure 3.12 
and Table 3.6). In addition, CCRF-CEM cells when treated with ETP in combination with 
QUE, AP or EMO also caused a significant increase of cell accumulation in G2/M phase when 
compared to the vehicle control and polyphenols alone, but no significant increase of cell 
accumulation in this phase when compared to effect of ETP alone (Figure 3.12 and Table 3.6).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in S phase 
caused by ETP, in G2/M phase caused by QUE and by CIS; and in S and G2/M phases caused 
by AP. No significant increase of cell accumulation in any phases of cell cycle was caused by 
EMO or by RH (p<0.05) (Figure 3.12). Treatment of THP-1 cells with ETP in combination 
with QUE and AP had an interactive effect causing a significant increase of cell accumulation 
in S and G2/M phases (p<0.05) (Figure 3.12 and Table 3.6). The combination of ETP and 
EMO had a non-interactive effect on cell cycle; there was an increase of cell accumulation in S 
and G2/M phases when compared to the vehicle control (p<0.05); but this was not significantly 
greater that that seen by the individual treatments alone (Figure 3.12 and Table 3.6). In contrast, 
when THP-1 cells were treated with ETP in combination with RH or CIS there was an 
antagonistic effect on cell cycle, there was a significant decrease of cell accumulation 
compared to the phases arrested by individual treatments alone (p<0.05) (Figure 3.12 and 
Table 3.6).
KG-la myeloid leukaemia cells had a significant increase of cells in S and G2/M phases 
caused by ETP, Go/Gj phase caused by AP; while there was no significant increase of cell
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accumulation in any phases of cell cycle caused by QUE, EMO, RH or CIS (p<0.05) (Figure 
3.12). Treatment of KG-la cells with combination of ETP and AP had an interactive effect on 
cell cycle and induced a highly significant increase of cell accumulation in G2/M phase 
(p<0.05) (Figure 3.12 and Table 3.6). In contrast, treatment of KG-la cells with ETP in 
combination with QUE, EMO or CIS had a non-interactive effect on cell cycle, there were 
significant increases in cell accumulation in S and G2/M phases when compared to the vehicle 
control; but there not when compared to phases arrested by ETP alone (p<0.05) (Figure 3.12 
and Table 3.6). Furthermore, when KG-la cells were treated with ETP in combination with 
RH or CIS there was an antagonistic effect on cell cycle, there were no significant differences 
compared to the vehicle control (p<0.05); but a significant decrease of cell accumulation 
caused by the individual treatment alone (p<0.05) (Figure 3.12 and Table 3.6).
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Effect of Etoposide (ETP) in Combination with Polyphenols at their Lowest Significant Doses (LSD) on
____________ ATP level of Leukaemia Cell Lines Following 24 h of Treatment._________________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
JURKAT CCRF-CEM THP-1 KG-la
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Figure 3.8: The effect of ETP when used in combination with QUE, AP, EMO, RH or CIS on 
ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with ETP and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of Etoposide (ETP) in Combination with Polyphenols at their Lowest Significant Doses (LSD) on
_________Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment._____________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
JURKAT CCRF-CEM THP-1 KG-la
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Figure 3.9: The effect of ETP when used in combination with QUE, AP, EMO, RH or CIS on 
caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with ETP and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. 
The data was expressed as medians with ranges (n=4). The black bars show the vehicle controls 
and treatments alone; the white bar shows the expected effect of the combined treatments on 
caspase 3 activity; the coloured bars indicate significant additive effects in brown, synergistic 
effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. 
Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of Etoposide (ETP) in Combination with Polyphenols at their Lowest Significant Doses (LSD) 
on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment. 
________ Lymphoid Leukaemia Cell Lines.________________ Myeloid Leukaemia Cell Lines._____
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Figure 3.10: The effect of ETP when used combination with QUE, AP, EMO, RH or CIS on 
apoptosis morphological changes of leukaemia cell lines. This was evaluated by double staining 
with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with ETP and 
polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the vehicle- 
only control, which was assigned a 0% apoptotic level. The data was expressed as medians with 
ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar shows 
the expected level of percentage apoptosis; the coloured bars indicate a significant additive effects 
in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 3.11: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of ETP and polyphenols (QUE, 
AP, EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 pm.
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(A)Effect of Etoposide (ETP) in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines
____________________________Following 24 h of Treatment.__________________________
Drugs JURKAT CCRF-CEM
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(B) Effect of Etoposide (ETP) in Combination with Polyphenols at their Lowest Significant 
Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines 
____________________________ Following 24 h of Treatment.____________________________
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Figure 3.12: The effect of ETP when used in combination with QUE, AP, EMO, RH or CIS 
on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with ETP and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.6.
Assays Targets
Combination of 
Etoposide
The Significant Effects o f Etoposide (ETP) and 
Polyphenols Combination Treatment on ATP Levels, 
Apoptosis and Cell Cycle Progression at 24 h.
and Polyphenols Lymphoid Leukaemia | Myeloid Leukaemia
JURKAT CCRF-CEM | THP-1 KGla
CellTiter- ATP ETP + QUE (NSD) SYN SYN SYN SYN
Glow Level ETP + QUE (LSD) SYN SYN SYN SYN
Caspase 3 Apoptosis ETP + QUE (NSD) SYN SYN SYN SYNActivity ETP + QUE (LSD) SYN SYN SYN SYN
Hoechst/ PI Apoptosis ETP + QUE (LSD) SYN SYN SYN SYN
Cell
Cycle/PI
Cell
Cycle ETP + QUE (LSD) Interaction Interaction Interaction
Non
Interaction
CcilTiter- ATP ETP + AP (NSD) ADD ADD 1 SYN ADD
Glow Level ETP + AP (LSD) ADD ADD I SYN ADD
Caspase 3 Apoptosis ETP + AP (NSD) ADD ADD SYN ADDActivity ETP + AP (LSD) ADD ADD SYN ADD
Hoechst/ PI Apoptosis ETP + AP (LSD) SYN SYN SYN SYN
Ceil
Cycle/PI
Cell
Cycle ETP + AP (LSD) Interaction Interaction Interaction Interaction
CellTiter- ATP ETP + EMO (NSD) SYN SYN ADD ADD
Glow Level 1 ETP + EMO (LSD) SYN SYN ADD ADD
Caspase 3 Apoptosis ETP + EMO (NSD) SYN SYN ADD ADDActivity ETP + EMO (LSD) SYN SYN ADD ADD
Hoechst/ PI Apoptosis ETP + EMO (LSD) SYN SYN ADD ADD
Cell
Cycle/PI
Cell
Cycle ETP + EMO (LSD) Interaction Interaction Non Interaction
Non
Interaction
CellTiter- ATP ETP + RH (NSD) SYN SYN C-ANTG C-ANTG
Glow Level ETP + RH (LSD) SYN SYN ANTG C-ANTG
Caspase 3 Apoptosis ETP + RH (NSD) SYN SYN C-ANTG C-ANTGActivity ETP + RH (LSD) SYN SYN ANTG C-ANTG
Hoechst/ PI Apoptosis ETP + RH (LSD) SYN SYN C-ANTG C-ANTG
Cell
Cycle/PI
Cell
Cycle ETP + RH (LSD) Interaction Interaction ANTG ANTG
CellTiter- ATP ETP + CIS (NSD) SYN SYN C-ANTG C-ANTG
Glow Level ETP + CIS (LSD) SYN SYN ANTG ANTG
Caspase 3 Apoptosis ETP + CIS (NSD) SYN SYN C-ANTG C-ANTGActivity ETP + CIS (LSD) SYN SYN ANTG C-ANTG
Hoechst/ PI Apoptosis ETP + CIS (LSD) SYN SYN ANTG ANTG
Cell
Cycle/PI
Cell
Cycle ETP + CIS (LSD) Interaction Interaction ANTG ANTG
Table 3.6: A summary of the effects of etoposide (ETP) and polyphenols [quercetin (QUE), apigenin 
(AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on ATP level, 
apoptosis and cell cycle progression in two lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM) and two myeloid leukaemia cell lines (THP-1 and K G la) at 24 h. Combination treatments were 
investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note that the 
combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.2.2 Effects of Alkylating Chemotherapy agents in Combined with Polyphenols 
3.3.2.2.1 Cyclophosphamide (CYCLO)
(A) Effect o f  Cyclophosphamide (CYCLO) Combined with Polyphenols on ATP Levels
CYCLO when used in combination with AP caused a synergistic reduction in ATP levels 
(p<0.05) in both lymphoid and myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1, 
KGla) (Figure 3.13 and Table 3.7). Furthermore, CYCLO when used in combination with 
QUE, EMO or RH caused a synergistic reduction in ATP levels (p<0.05) in lymphoid 
leukaemia cell lines only (JURKAT, CCRF-CEM) (p<0.05) (Figure 3.13 and Table 3.7); 
whilst they were produced a competitively antagonistic or antagonistic effect and significantly 
increased ATP levels in the myeloid leukaemia cell lines (THP-1, KGla) (p<0.05) (Figure 3.13 
and Table 3.7). In contrast, CYCLO when used in combination with CIS produced a 
competitive antagonistic or antagonistic effect and significantly increased the ATP levels in all 
lymphoid and myeloid leukaemia cell lines (p<0.05) (Figure 3.13 and Table 3.7).
(B) Effect o f  Cyclophosphamide (CYCLO) Combined with Polyphenols on Apoptosis
CYCLO when used in combination with AP produced a synergistic increases in caspase 3 
activity (Figure 3.14) and percentage apoptosis (Figure 3.15) (p<0.05) in both lymphoid and 
myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KGla) (Figure 3.14 and 
Figure 3.15). In addition, CYCLO when used in combination with QUE, EMO or RH 
produced a synergistic increases in caspase 3 activity (Figure 3.14) and percentage apoptosis 
(Figure 3.15) in the lymphoid leukaemia cell lines only (JURKAT and CCRF-CEM) (p<0.05); 
whilst they were produced a competitively antagonistic or antagonistic effects and significantly 
reduced caspase 3 activity (Figure 3.14) and percentage apoptosis (Figure 3.15) in the myeloid 
leukaemia cell lines (THP-1 and KGla) (p<0.05) (Figure 3.14, 3.15 and Table 3.7). On the 
other hand, when CYCLO was used in combination with CIS it produced a competitive 
antagonistic or antagonistic effects and significantly decreased caspase 3 activity (Figure 3.14) 
and the level of apoptosis (Figure 3.15); this time in both the lymphoid and myeloid leukaemia 
cell lines (p<0.05) (Figure 3.14, 3.15 and Table 3.7). An example of the morphological 
assessment of apoptosis for CYCLO and the polyphenols (QUE, AP, EMO, RH and CIS) alone 
and in combined at their LSD for 24 h on THP-1 myeloid leukaemia cell lines is showed in 
Figure 3.16.
(C) Effect o f  Cyclophosphamide (CYCLO) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had no significant increase of cell accumulation in any
phases of cell cycle following CYCLO treatment. However there was a significant increase of
cell accumulation in S phase caused by QUE, and AP, in Go/G] phase caused by EMO, in
Go/Gi phase caused by RH; and there was no significant increase of cell accumulation in any
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phases of cell cycle caused by CIS (p<0.05) (Figure 3.17). Treatment of JURKAT cells with 
CYCLO in combination with QUE or AP had an interactive effect on cell cycle causing a 
highly significant increase of cell accumulation in S phase (p<0.05) (Figure 3.17 and Table
3.7). In addition, treatment of JURKAT cells with CYCLO in combination with EMO or RH 
had an interactive effect causing a significant increase of cell accumulation in Go/Gi phase 
(p<0.05) (Figure 3.17 and Table 3.7). However, treatment of JURKAT cells with CYCLO in 
combination with CIS had an antagonistic effect on the cell cycle, however this was not 
significantly different from that of the vehicle control and individual drugs alone (p<0.05) 
(Figure 3.17 and Table 3.7). CCRF-CEM lymphoid leukaemia cells had a significant increase 
of cell accumulation in S phase caused by CYCLO, QUE, EMO and RH; in G2/M phase 
caused by AP; whilst there was no significant increase of cell accumulation in any phases of 
cell cycle caused by CIS (p<0.05) (Figure 3.17). Treatment of CCRF-CEM cells with CYCLO 
in combination with QUE, AP, EMO or RH had an interactive effect on cell cycle causing a 
significant increase of cell accumulation in S phase (p<0.05) (Figure 3.17 and Table 3.7). 
However, treatment of CCRF-CEM cells with CYCLO in combination with CIS had an 
antagonistic effect on cell cycle, this was however not significantly different from that of the 
vehicle control (p<0.05), but was significantly less when compared to the phases arrested by 
individual treatments alone (p<0.05) (Figure 3.17 and Table 3.7).
THP-1 myeloid leukaemia cells had no significant increase of cell accumulation caused by 
CYCLO, EMO or RH; while they had a significant increase of cell accumulation in G2 /M 
phase caused by QUE, in S and G2/M phases caused by AP and in G2/M phase caused by CIS 
(p<0.05) (Figure 3.17). Treatment of THP-1 cells with CYCLO in combination with AP had 
an interactive effect on cell cycle causing a highly significant increase of cell accumulation in 
S and G2/M phases (p<0.05) (Figure 3.17 and Table 3.7). In contrast, treatment of THP-1 cells 
with CYCLO in combination with QUE, EMO or RH had an antagonistic effect on cell cycle. 
These combination treatments caused no significant differences compared to the vehicle 
control (p<0.05) but a significant decrease of cell accumulation compared to the phases 
arrested by individual treatments alone (p<0.05) (Figure 3.17 and Table 3.7). KG-la myeloid 
leukaemia cells had a significant increase of cell accumulation in Go/Gi phase caused by 
CYCLO and AP; while there was no significant increase of cell accumulation in any phases of 
cell cycle caused by QUE, EMO, RH or CIS (p<0.05) (Figure 3.17). Treatment of KG-la 
cells with CYCLO in combination with AP showed the only interactive effect on cell cycle, 
causing a highly significant increase of cell accumulation in Go/Gi phase (p<0.05) (Figure 
3.17 and Table 3.7). Treatment of KG-la cells with CYCLO in combination with QUE, EMO 
or RH had an antagonistic effect which was not significantly different from the vehicle control
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( p < 0 . 0 5 )  b u t  c e l l  a c c u m u l a t i o n  w a s  s i g n i f i c a n t l y  l e s s  w h e n  c o m p a r e d  t o  t h e  p h a s e s  a r r e s t e d  b y  
i n d i v i d u a l  t r e a t m e n t s  a l o n e  ( p < 0 . 0 5 )  ( F i g u r e  3 . 1 7  a n d  T a b l e  3 . 7 ) .
Effect of Cyclophosphamide (CYCLO) in Combination with Polyphenols at their Lowest Significant
 Doses (LSD) on ATP level of Leukaemia Cell Lines Following 24 h of Treatment._________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.13: The effect of CYCLO when used in combination with QUE, AP, EMO, RH or
CIS on ATP levels of leukaemia cell lines. T h i s  w a s  e v a l u a t e d  b y  C e l l T i t e r - G l o ®  a s s a y .  C e l l s  
w e r e  t r e a t e d  w i t h  C Y C L O  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  D a t a  
w a s  n o r m a l i s e d  t o  t h e  v e h i c l e  c o n t r o l  w h i c h  w a s  a s s i g n e d  1 0 0 %  c e l l  v i a b i l i t y .  T h e  d a t a  w a s  
e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  t r e a t m e n t s  
a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  A T P  l e v e l s  ;  t h e  
c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  i n  b r o w n ,  s y n e r g i s t i c  e f f e c t s  i n  y e l l o w ,  
c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n  a n t a g o n i s t i c  e f f e c t s  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  
w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Effect of Cyclophosphamide (CYCLO) in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment._____
________ Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
JURKAT CCRF-CEM THP-1 K G -la
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Figure 3.14: The effect of CYCLO when used in combination with QUE, AP, EMO, RH or 
CIS on caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 
activity assay. Cells were treated with CYCLO and polyphenols alone and in combined for 24 h 
using their LSD. Data was normalised to the vehicle-only control, which was assigned a 0% 
apoptotic level. The data was expressed as medians with ranges (n=4). The black bars show the 
vehicle controls and treatments alone; the white bar shows the expected effect of the combined 
treatments on caspase 3 activity; the coloured bars indicate significant additive effects in brown, 
synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic effects in 
pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone
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Effect of Cyclophosphamide (CYCLO) in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.15: The effect of CYCLO when used in combination with QUE, AP, EMO, RH or 
CIS on apoptosis morphological changes of leukaemia cell lines. This was evaluated by double 
staining with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with CYCLO 
and polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the 
vehicle-only control, which was assigned a 0% apoptotic level. The data was expressed as medians 
with ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar 
shows the expected level of percentage apoptosis; the coloured bars indicate a significant additive 
effects in brown, synergistic effects in yellow, competitive antagonistic effects in purple and 
antagonistic effects in pink. Statistical significant was set at p<0.05 compared to vehicle control 
and drugs alone.
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Figure 3.16: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of CYCLO and polyphenols 
(QUE, AP, EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified 
by their irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the 
formation of apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic 
cells and dead cells appear pink. Scale bar = 100 pm.
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(A)Effect of Cyclophosphamide (CYCLO) in Combination with Polyphenols at their Lowest 
Significant Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines 
_____________________________ Following 24 h of Treatment._____________________________
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(A)Effect of Cyclophosphamide (CYCLO) in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines
__________________________ Following 24 h of Treatment. __________
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Figure 3.17: The effect of CYCLO when used in combination with QUE, AP, EMO, RH or 
CIS on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM) and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was 
analysed following propidium iodide staining using flow cytometry. Cells were treated with 
CYCLO and polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) 
as determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.7.
Assays Targets
Combination of 
Cyclophosphamide 
and Polyphenols
The Significant Effects of Cyclophosphamide 
(CYCLO) and Polyphenols Combination Treatment 
on ATP Levels, Apoptosis and Cell Cycle Progression 
at 24 h.
Lymphoid Leukaemia | Myeloid Leukaemia
JURKAT CCRF-CEM | THP-1 KGla
CellTiter- ATP CYCLO + QUE (NSD) SYN SYN C-ANTG C-ANTG
Glow Level CYCLO + QUE (LSD) SYN SYN C-ANTG C-ANTG
Caspase 3 Apoptosis CYCLO + QUE (NSD) SYN SYN C-ANTG C-ANTGActivity CYCLO + QUE (LSD) SYN SYN C-ANTG C-ANTG
Hocchst/ PI Apoptosis CYCLO + QUE (LSD) SYN SYN C-ANTG C-ANTG
Cell Cycle/PI CellCycle CYCLO + QUE (LSD) Interaction Interaction ANTG ANTG
CellTitcr- ATP CYCLO + AP (NSD) SYN SYN SYN SYN
Glow Level CYCLO+ AP (LSD) SYN SYN SYN SYN
Caspase 3 Apoptosis CYCLO + AP (NSD) SYN SYN SYN SYNActivity CYCLO + AP (LSD) SYN SYN SYN SYN
Hoechst/ PI Apoptosis CYCLO + AP (LSD) SYN SYN SYN SYN
Cell Cycle/PI CellCycle CYCLO + AP (LSD) Interaction Interaction Interaction Interaction
CellTiter- ATP CYCLO + EMO (NSD) SYN SYN C-ANTG C-ANTG
Glow Level CYCLO + EMO (LSD) SYN SYN C-ANTG C-ANTG
Caspase 3 Apoptosis CYCLO + EMO (NSD) SYN SYN C-ANTG C-ANTGActivity CYCLO + EMO (LSD) SYN SYN C-ANTG C-ANTG
Hoechst/ PI Apoptosis CYCLO + EMO (LSD) SYN SYN C-ANTG C-ANTG
Cell Cycle/PI CellCycle CYCLO + EMO (LSD) Interaction Interaction ANTG ANTG
CellTiter- ATP CYCLO+ RH (NSD) SYN SYN C-ANTG C-ANTG
GIow Level CYCLO+ RH (LSD) SYN SYN ANTG ANTG
Caspase 3 Apoptosis CYCLO+ RH (NSD) SYN SYN ANTG C-ANTGActivity CYCLO + RH (LSD) SYN SYN ANTG ANTG
Hoechst/ PI Apoptosis CYCLO + RH (LSD) SYN SYN ANTG ANTG
Cell Cycle/PI CellCycle CYCLO + RH (LSD) Interaction Interaction ANTG ANTG
CellTiter- ATP CYCLO + CIS (NSD) C-ANTG C-ANTG ANTG C-ANTG
Glow Level CYCLO + CIS (LSD) ANTG ANTG ANTG C-ANTG
Caspase 3 Apoptosis CYCLO + CIS (NSD) C-ANTG C-ANTG ANTG C-ANTGActivity CYCLO + CIS (LSD) ANTG C-ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis CYCLO + CIS (LSD) | ANTG ANTG ANTG ANTG
Cell Cycle/PI CellCycle CYCLO + CIS (LSD) ANTG ANTG ANTG ANTG
Table 3.7: A summary of the effects of cyclophosphamide (CYCLO) and polyphenols [quercetin 
(QUE), apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on 
ATP level, apoptosis and cell cycle progression in two lymphoid leukaemia cell lines (JURKAT and 
CCRF-CEM) and two myeloid leukaemia cell lines (THP-land K G la) at 24 h. Combination 
treatments were investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note 
that the combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.2.2.2 Chlorambucil (CLB)
(A) Effect o f  Chlorambucil (CLB) Combined with Polyphenols on ATP Levels
CLB when used in combination with AP produced a synergistic reduction in ATP level in both 
lymphoid and myeloid leukaemia cell lines (p<0.05) (Figure 3.18 and Table 3.8). CLB when 
combined with QUE and EMO produced an additive effects reducing ATP level in both 
lymphoid and myeloid (p<0.05) (Figure 3.18 and Table 3.8). However when CLB was 
combined with RH, they produced a synergistic reduction in ATP levels in lymphoid 
leukaemia cell lines (JURKAT, CCRF-CEM) (p<0.05) (Figure 3.18 and Table 3.8); whilst 
produced a competitive antagonistic or antagonistic effects significantly increasing ATP levels 
in the myeloid leukaemia cell lines (p<0.05) (Figure 3.18 and Table 3.8). The later effect was 
also seen when CLB was combined with CIS; here they produced a competitive antagonistic or 
antagonistic effects, significantly increasing ATP levels this time in both the lymphoid and 
myeloid leukaemia cell lines (p<0.05) (Figure 3.18 and Table 3.8).
(B) Effect o f  Chlorambucil (CLB) Combined with Polyphenols on Apoptosis
CLB interacted with AP producing synergistic effects that significantly increased the caspase 
3 activity (Figure 3.19) and the percentage of cells undergoing apoptosis (Figure 3.20) 
(p<0.05) in both lymphoid and myeloid leukaemia cell lines (Figure 3.19, 3.20 and Table 3.8). 
CLB when used in combination with QUE and EMO caused an additive effects on apoptosis in 
both lymphoid and myeloid cell lines (p<0.05) (Figure 3.19, 3.20 and Table 3.8). However 
when CLB was used in combination with RH, there was a synergistic increased the caspase 3 
activity (Figure 3.19) and percentage apoptosis (Figure 3.20) in lymphoid leukaemia cell lines 
(JURKAT and CCRF-CEM) (p<0.05) (Table 3.8); but a competitive antagonistic or 
antagonistic effects and significantly decreased the caspase 3 activity (Figure 3.19) and the 
level of apoptosis (Figure 3.20) in myeloid leukaemia cell lines (THP-1 and KGla) (p<0.05) 
(Table 3.8). Likewise, when CLB was combined with CIS they also produced a competitive 
antagonistic or antagonistic effects on apoptosis this time in both the lymphoid and myeloid 
leukaemia cell lines (p<0.05) (Figure 3.19, 3.20 and Table 3.8). An example of the 
morphological assessment of apoptosis for CLB and polyphenols (QUE, AP, EMO, RH or 
CIS) alone and in combination at their LSD for 24 h on THP-1 myeloid leukaemia cell lines is 
showed in Figure 3.21.
(C) Effect o f  Chlorambucil (CLB) Combined with Polyphenols on Cell Cycle
Neither CLB or CIS induced cell cycle arrest in any phase in the JURKAT lymphoid 
leukaemia cells; however there was a significant increase of cell accumulation in S phase 
caused by QUE and AP, in Go/Gi phase caused by EMO and RH (p<0.05) (Figure 3.22).
Treatment of JURKAT cells with CLB in combination with AP or RH had an interactive effect 
on cell cycle inducing a highly significant increase of cell accumulation in S phase and GO/Gl 
phase (p<0.05) (Figure 3.22 and Table 3.8). JURKAT cells when treated with CLB in 
combination with QUE or EMO had a limited interactive effect on cell cycle; these treatment 
combinations induced a significant increase of cell accumulation in S phase and Go/Gi phase, 
respectively, when compared to the vehicle control and CLB alone, but this was not 
significantly different from the QUE or EMO treatment alone (p<0.05) (Figure 3.22 and Table
3.8). In contrast, treatment of JURKAT cells with combination of (CLB and CIS) had non­
interactive effect on cell cycle (p<0.05) (Figure 3.22 and Table 3.8).
In CCRF-CEM lymphoid leukaemia cells, CLB, EMO, RH, and QUE when used alone caused 
a significant increase of cell accumulation in S phase of the cell cycle; whilst there was G2 /M 
phase accumulation caused by AP. There was however no significant increase of cell 
accumulation in any phases of cell cycle caused by CIS (p<0.05) (Figure 3.22). Treatment of 
CCRF-CEM cells with CLB in combination with QUE, AP, EMO or RH had an interactive 
effect on cell cycle each inducing a significant increase of cell accumulation in S phase 
(p<0.05) (Figure 3.22 and Table 3.8). In contrast, treatment of CCRF-CEM cells with 
combination of CLB and CIS had an antagonistic effect which was not significantly different 
to the vehicle control (p<0.05) but was significantly less than the effect of the individual 
treatments alone (p<0.05) (Figure 3.22 and Table 3.8).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in G2/M phase 
caused by CLB, QUE and CIS, in S and G2/M phases caused by AP; and in S phase caused by 
EMO, and RH (p<0.05) (Figure 3.22). Treatment of THP-1 cells with CLB in combination 
with QUE, AP or EMO had an interactive effect on cell cycle causing a highly significant 
increase of cell accumulation in G2/M phase (p<0.05) (Figure 3.22 and Table 3.8). In contrast, 
treatment of THP-1 cells with CLB in combination with RH or CIS had an antagonistic effect 
on cell cycle, which was not significantly different from the vehicle control (p<0.05), but was 
significantly reduced compared to levels of cell cycle arrested caused by individual treatments 
alone (p<0.05) (Figure 3.22 and Table 3.8).
KG-la myeloid leukaemia cells had no significant increase of cell accumulation in any phases 
of the cell cycle when treated with by CLB, QUE, EMO, RH or CIS. However, there was a 
significant increase of cell accumulation in G0/G 1 phase caused by AP (p<0.05) (Figure 3.22). 
Treatment of KG-la cells with CLB in combination with QUE or AP had an interactive effect 
causing a highly significant increase of cell accumulation in S phase and G0/G 1 phase, 
respectively, (p<0.05) (Figure 3.22 and Table 3.8). In contrast, treatment of KG-la cells with 
CLB in combination with EMO, RH or CIS had a non-interactive effect on the cell cycle; there
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were no significant different between these combination treatments and the vehicle control 
(p<0.05), and between these combination treatments and the individual treatments alone 
(p<0.05) (Figure 3.22 and Table 3.8).
Effect of Chlorambucil (CLB) in Combination with Polyphenols at their Lowest Significant Doses
________(LSD) on ATP level of Leukaemia Cell Lines Following 24 h of Treatment.___________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.18: The effect of CLB when used in combination with QUE, AP, EMO, RH or CIS 
on ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with CLB and polyphenols alone and in combined for 24 h using their LSD. Data was 
nonnalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of Chlorambucil (CLB) in Combination with Polyphenols at their Lowest Significant Doses 
______ (LSD) on Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment._______
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.19: The effect of CLB when used in combination with QUE, AP, EMO, RH or CIS 
on caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with CLB and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. 
The data was expressed as medians with ranges (n=4). The black bars show the vehicle controls 
and treatments alone; the white bar shows the expected effect of the combined treatments on 
caspase 3 activity; the coloured bars indicate significant additive effects in brown, synergistic 
effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. 
Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of Chlorambucil (CLB) in Combination with Polyphenols at their Lowest Significant Doses
(LSD) on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.20: The effect of CLB when used in combination with QUE, AP, EMO, RH or CIS 
on apoptosis morphological changes of leukaemia cell lines. This was evaluated by double 
staining with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with CLB and 
polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the vehicle- 
only control, which was assigned a 0% apoptotic level. The data was expressed as medians with 
ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar shows 
the expected level of percentage apoptosis; the coloured bars indicate a significant additive effects 
in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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CONTROL
Figure 3.21: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of CLB and polyphenols (QUE, 
AP, EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 pin.
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(A)Effect of Chlorambucil (CLB) in Combination with Polyphenols at their Lowest 
Significant Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines 
_______________________ Following 24 h of Treatment______________________
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(B) Effect of Chloram bucil (CLB) in Com bination with Polyphenols a t their Low est
Significant Doses (LSD) on Cell Cycle of Myeloid Leukaem ia Cell Lines
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Figure 3.22: The effect of CLB when used in combination with QUE, AP, EMO, RH or CIS 
on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with CLB and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
Flow Jo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.8.
The Significant Effects of Chlorambucil (CLB) and
Combination of Polyphenols Combination Treatment on ATP Levels,
Assays Targets Chlorambucil Apoptosis and Cell Cycle Progression at 24 h.
and Polyphenols Lymphoid Leukaemia Myeloid Leukaemia
JURKAT CCRF-CEM THP-1 KGla
CellTiter- ATP CLB + QUE (NSD) ADD ADD ADD ADD
GIow Level CLB + QUE (LSD) ADD ADD ADD ADD
Caspase 3 Apoptosis CLB + QUE (NSD) ADD ADD ADD ADDActivity CLB + QUE (LSD) ADD ADD ADD ADD
Hoechst/ PI Apoptosis CLB + QUE (LSD) ADD ADD ADD ADD
Cell Cycle/PI CellCycle CLB + QUE (LSD)
Non
Interaction Interaction Interaction Interaction
CcllTitcr- ATP CLB + AP (NSD) SYN SYN SYN ADD
Glow Level CLB + AP (LSD) SYN SYN SYN SYN
Caspase 3 Apoptosis CLB + AP (NSD) SYN SYN SYN ADDActivity CLB + AP (LSD) SYN SYN SYN SYN
Hoechst/ PI Apoptosis CLB + AP (LSD) SYN SYN SYN SYN
Cell Cycle/PI CellCycle CLB + AP (LSD) Interaction Interaction Interaction Interaction
CellTiter- ATP CLB + EMO (NSD) ADD ADD ADD ADD
Glow Level | CLB + EMO (LSD) ADD ADD ADD ADD
Caspase 3 Apoptosis CLB + EMO (NSD) ADD ADD ADD ADDActivity CLB + EMO (LSD) ADD ADD ADD ADD
Hoechst/ PI Apoptosis CLB + EMO (LSD) ADD ADD ADD ADD
Cell Cycle/PI CellCycle CLB + EMO (LSD)
Non
Interaction Interaction Interaction
Non
Interaction
CellTiter- ATP CLB + RH (NSD) SYN SYN C-ANTG C-ANTG
Glow Level CLB + RH (LSD) SYN SYN ANTG ANTG
Caspase 3 Apoptosis CLB + RH (NSD) SYN SYN C-ANTG C-ANTGActivity CLB + RH (LSD) SYN SYN ANTG C-ANTG
Hoechst/ PI Apoptosis | CLB + RH (LSD) SYN SYN C-ANTG C-ANTG
Cell Cycle/PI CellCycle CLB + RH (LSD) Interaction Interaction ANTG
Non
Interaction
CellTiter- ATP CLB + CIS (NSD) C-ANTG C-ANTG C-ANTG ANTG
Glow Level CLB + CIS (LSD) C-ANTG C-ANTG ANTG ANTG
Caspase 3 CLB + CIS (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
Activity CLB + CIS (LSD) C-ANTG C-ANTG | C-ANTG ANTG
Hoechst/ PI Apoptosis 1 CLB + CIS (LSD) C-ANTG C-ANTG | ANTG ANTG
Cell Cycle/PI Cell 1 Cycle 1 CLB + CIS (LSD) ANTG ANTG | ANTG
Non
Interaction
Table 3.8: A summary of the effects of chlorambucil (CLB) and polyphenols [quercetin (QUE),
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on ATP
level, apoptosis and cell cycle progression in two lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM) and two myeloid leukaemia cell lines (THP-land K G la) at 24 h. Combination treatments were
investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note that the 
combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN =
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.2.2.3 Cisplatin (CSP)
(A) Effect o f  Cisplatin (CSP) Combined with Polyphenols on ATP Levels
CSP effectively interacted with QUE, and caused a synergistic reduced in ATP levels in both 
lymphoid and myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) 
(p<0.05) (Figure 3.23 and Table 3.9). Furthermore, when CSP was used in combination with 
EMO, RH, or CIS, it caused a synergistic reduced in ATP levels in the lymphoid leukaemia 
cell lines only (JURKAT and CCRF-CEM) (p<0.05) (Figure 3.23 and Table 3.9). In contrast, 
when CSP was used in combination with EMO, RH, or CIS, it caused a competitive 
antagonistic or antagonistic effects and significantly increased ATP level in myeloid leukaemia 
cell lines (THP-1 and KG-la) (p<0.05) (Figure 3.23 and Table 3.9). The only exception was 
shown when CSP was combined with AP, here there was an additive reduction of ATP level in 
both lymphoid and myeloid leukaemia cell lines, (p<0.05) (Figure 3.23 and Table 3.9).
(B) Effect o f  Cisplatin (CSP) Combined with Polyphenols on Apoptosis
CSP effectively interacted with QUE, which they caused a synergistic increased in caspase 3 
activity (Figure 3.24) and percentage of apoptosis (Figure 3.25) in both lymphoid and myeloid 
leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) (p<0.05) (Figure 3.24, 3.25 
and Table 3.9). In addition, when CSP was used in combination with EMO, RH, or CIS it 
caused a synergistic increased caspase 3 activity (Figure 3.24) and percentage of apoptosis 
(Figure 3.25) in the lymphoid leukaemia cell lines only (JURKAT, CCRF-CEM) (p<0.05) 
(Figure 3.24, 3.25 and Table 3.9). Once again in the myeloid cell lines (THP-1 and KG-la), 
when CSP was combined with EMO, RH, or CIS it caused a competitive antagonistic or 
antagonistic effects; and significantly decreased caspase 3 activity (p<0.05) and the percentage 
of cells undergoing apoptosis (p<0.05) (Figure 3.24, 3.25 and Table 3.9). CSP when used in 
combination with AP this produced an additive effects on apoptosis in both lymphoid and 
myeloid leukaemia cell lines, (p<0.05) (Figure 3.24, 3.25 and Table 3.9). An example of the 
morphological assessment of apoptosis for CSP and polyphenols (QUE, AP, EMO, RH or CIS) 
alone and in combined at their LSD for 24 h on THP-1 myeloid leukaemia cell lines is showed 
in Figure 3.26.
(C) Effect o f  Cisplatin (CSP) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase of cell accumulation in S phase 
caused by CSP, QUE and AP, in Go/Gj phase caused by EMO and RH; while they had no 
significant increase of cell accumulation in any phases of cell cycle caused by CIS when 
compared to the vehicle control (p<0.05) (Figure 3.27). Treatment of JURKAT cells with CSP 
in combination with QUE, AP, EMO, RH or CIS had an interactive effect causing a highly
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significant increase of cell accumulation in S phase of the cell cycle (p<0.05) (Figure 3.27 and 
Table 3.9).
CCRF-CEM lymphoid leukaemia cells had a significant increase of cell accumulation in S 
phase caused by CSP, QUE, EMO, and RH, and in G2/M phase caused by AP; while they had 
no significant increase of cell accumulation in any phases of cell cycle caused by CIS when 
compared to the vehicle control (p<0.05) (Figure 3.27). Treatment of CCRF-CEM cells with 
CSP in combination with QUE, AP, EMO, RH or CIS had an interactive effect causing a 
highly significant increase of cell accumulation in S phase (p<0.05) (Figure 3.27 and Table
3.9).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in G2/M phase 
caused by CSP, QUE, EMO, RH and CIS; and in S and G2 /M phases caused by AP when 
compared to the vehicle control (p<0.05) (Figure 3.27). Treatment of THP-1 cells with CSP in 
combination with QUE or AP had an interactive effect causing a significantly increase of cell 
accumulation in G2/M phase (p<0.05) (Figure 3.27 and Table 3.9). In contrast, treatment of 
THP-1 cells with CSP in combination with EMO, RH or CIS had an antagonistic effect on cell 
cycle significantly decreasing cell accumulation; there was no significant different when 
compared to the vehicle control (p<0.05) and they were significantly reduced cell 
accumulation compared to the phases arrested by individual treatments alone (p<0.05) (Figure 
3.27 and Table 3.9).
KG-la myeloid leukaemia cells had a significant increase of cell accumulation in G2/M phase 
caused by CSP, in G0/G1 phase caused by AP; while they had no significant increase of cell 
accumulation in any phases of cell cycle caused by QUE, EMO, RH or CIS when compared to 
the vehicle control (p<0.05) (Figure 3.27). Treatment of KG-la cells with CSP in combination 
with QUE or AP had an interactive effect on cell cycle which significantly increasing cell 
accumulation in G2 /M phase (p<0.05) (Figure 3.27 and Table 3.9). In contrast, treatment of 
KG-la cells when treated with CSP in combination with EMO, RH or CIS had an antagonistic 
effect on cell cycle; there was no significant different when compared to the vehicle control 
(p<0.05) and they were significantly reduced when compared to the phases arrested by 
individual treatments alone (p<0.05) (Figure 3.27 and Table 3.9).
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i Effect of Cisplatin (CSP) in Combination with Polyphenols at their Low est Significant Doses (LSD) on
____________ATP level of Leukaemia Cell Lines Following 24 h of Treatment._________________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.23: The effect of CSP when used in combination with QUE, AP, EMO, RH or CIS 
on ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with CSP and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of Cisplatin (CSP) in Combination with Polyphenols at their Lowest Significant Doses (LSD) on 
_____________ Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment._____________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.24: The effect of CSP when used in combination with QUE, AP, EMO, RH or CIS 
on caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with CSP and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. 
The data was expressed as medians with ranges (n=4). The black bars show the vehicle controls 
and treatments alone; the white bar shows the expected effect of the combined treatments on 
caspase 3 activity; the coloured bars indicate significant additive effects in brown, synergistic 
effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. 
Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of Cisplatin (CSP) in Combination with Polyphenols at their Lowest Significant Doses (LSD)
on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.25: Effect of CSP when used in combination with QUE, AP, EMO, RH or CIS on 
apoptosis morphological changes of leukaemia cell lines. This was evaluated by double staining 
with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with CSP and 
polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the vehicle- 
only control, which was assigned a 0% apoptotic level. The data was expressed as medians with 
ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar shows 
the expected level of percentage apoptosis; the coloured bars indicate a significant additive effects 
in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 3.26: : An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of CSP and polyphenols (QUE, 
AP, EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 pm.
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(A)Effect of Cisplatin (CSP) in Combination with Polyphenols at their Low est Significant 
Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines 
_________________________ Following 24 h of Treatment._________________________
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(B) Effect of Cisplatin (CSP) in Combination with Polyphenols at their Lowest Significant 
Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines 
_________________________ Following 24 h of Treatment._________________________
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Figure 3.27: The effect of CSP when used in combination with QUE, AP, EMO, RH or CIS 
on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with CSP and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.9.
Assays Targets
Combination of 
Cisplatin 
and 
Polyphenols
The Significant Effects of Cisplatin (CSP) and 
Polyphenols Combination Treatment on ATP Levels, 
Apoptosis and Cell Cycle Progression at 24 h.
| Lymphoid Leukaemia I Myeloid Leukaemia
| JURKAT CCRF-CEM | THP-1 KGla
CellTiter- ATP Level CSP + QUE (NSD) SYN SYN 1 SYN ADDGlow CSP + QUE (LSD) SYN SYN | SYN SYN
Caspase 3 Apoptosis CSP + QUE (NSD) SYN SYN SYN ADDActivity CSP + QUE (LSD) SYN SYN SYN SYN
Hoechst/ PI Apoptosis CSP + QUE (LSD) SYN SYN | SYN SYN
Cell
Cycle/PI Cell Cycle CSP + QUE (LSD) Interaction Interaction Interaction Interaction
CellTiter- ATP Level CSP + AP (NSD) ADD ADD ADD ADDGlow CSP + AP (LSD) ADD ADD ADD ADD
Caspase 3 Apoptosis CSP + AP (NSD) ADD ADD ADD ADDActivity CSP + AP (LSD) ADD ADD ADD ADD
Hoechst/ PI Apoptosis CSP + AP (LSD) ADD ADD ADD ADD
Cell
Cycle/PI Cell Cycle CSP + AP (LSD) Interaction Interaction Interaction Interaction
CellTitcr- ATP Level CSP + EMO (NSD) ADD SYN C-ANTG C-ANTGGlow CSP + EMO (LSD) SYN SYN C-ANTG C-ANTG
Caspase 3 Apoptosis CSP + EMO (NSD) ADD SYN C-ANTG C-ANTGActivity CSP + EMO (LSD) SYN SYN C-ANTG C-ANTG
Hoechst/ PI Apoptosis CSP + EMO (LSD) SYN SYN C-ANTG C-ANTG
Cell
Cycle/PI Cell Cycle CSP + EMO (LSD) Interaction Interaction ANTG ANTG
CellTiter- ATP Level CSP + RH (NSD) SYN SYN C-ANTG C-ANTGGIow CSP + RH (LSD) SYN SYN ANTG C-ANTG
Caspase 3 Apoptosis CSP + RH (NSD) SYN SYN C-ANTG C-ANTGActivity CSP + RH (LSD) SYN SYN ANTG C-ANTG
Hoechst/ PI Apoptosis | CSP + RH (LSD) | SYN SYN ANTG C-ANTG
Cell
Cycle/PI Cell Cycle CSP + RH (LSD) | ANTG ANTG
CellTiter- ATP Level CSP + CIS (NSD)
SYN SYN C-ANTG C-ANTG
Glow CSP + CIS (LSD) SYN SYN ANTG C-ANTG
Caspase 3 Apoptosis CSP + CIS (NS) ADD SYN C-ANTG C-ANTGActivity CSP + CIS (LSD) SYN SYN ANTG C-ANTG
Hoechst/ PI Apoptosis CSP + CIS (LSD) SYN SYN | ANTG C-ANTG
Cell cycle/PI Cell Cycle CSP + CIS (LSD) Interaction Interaction | ANTG ANTG
Table 3.9: A summary of the effects of cisplatin (CSP) and polyphenols [quercetin (QUE), apigenin 
(AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on ATP level, 
apoptosis and cell cycle progression in two lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM) and two myeloid leukaemia cell lines (THP-1 and K G la) at 24 h. Combination treatments were 
investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note that the 
combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.2.3 Effects of Anti-Metabolites Chemotherapy Agents in Combined with Polyphenols 
3.3.2.3.1 Methotrexate (MTX)
(A) Effect o f  Methotrexate (MTX) Combined with Polyphenols on ATP Levels
MTX when used in combination with all polyphenols (QUE, AP, EMO, RH or CIS) caused a 
competitively antagonistic and/or antagonistic effects significantly increasing the ATP levels 
in both lymphoid and myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG­
la) (p<0.05) (Figure 3.28 and Table 3.10).
(B) Effect o f  Methotrexate (MTX) Combined with Polyphenols on Apoptosis
Similarly, when MTX used in combination with all polyphenols (QUE, AP, EMO, RH or CIS) 
caused a competitively antagonistic and/or antagonistic effects significantly decreasing caspase 
3 activity (Figure 3.29) and the percentage of cells undergoing apoptosis (Figure 3.30) in both 
lymphoid and myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) 
(p<0.05) (Figure 3.29, 3.30 and Table 3.10). An example of the morphological assessment of 
apoptosis for MTX and polyphenols (QUE, AP, EMO, RH or CIS) alone and in combination at 
their LSD for 24 h on THP-1 myeloid leukaemia cell lines is showed in Figure 3.31.
(C) Effect o f  Methotrexate (MTX) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase of cell accumulation in S phase 
following treated with MTX, QUE or AP alone, and in Go/Gi phase with EMO or RH alone; 
while there was no significant increase of cell accumulation in any phases of cell cycle 
following treatment with CIS (p<0.05) (Figure 3.32). Treatment of JURKAT cells with MTX 
in combination with QUE, AP, EMO, RH or CIS, caused an antagonistic effect; there were no 
significant differences compared to the vehicle control (p<0.05), but there were significant 
decrease of cell accumulation compared to the phases arrested by the individual treatments 
alone (p<0.05) (Figure 3.32 and Table 3.10).
CCRF-CEM lymphoid leukaemia cells had a significant increase of cells in S phase following 
treatment with MTX, QUE, EMO or RH alone; and in G2/M phase following treatment with 
AP alone; whilst they had no significant increase of cell accumulation in any phases of cell 
cycle following CIS treatment alone (p<0.05) (Figure 3.32). Treatment of CCRF-CEM cells 
with MTX in a combination QUE, AP, EMO, RH or CIS had an antagonistic effect on cell 
cycle accumulation; there were no significant differences compared to the vehicle control 
(p<0.05), but there was a significant decrease of cell accumulation compared to the phases 
arrested by individual treatments alone (p<0.05) (Figure 3.32 and Table 3.10).
THP-1 myeloid leukaemia cells had a significant increase in accumulation of cells in the S and
G2 /M phases of the cell cycle following treatment with MTX and AP alone (p<0.05); in G2/M
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phase following treatment of with QUE and CIS alone (p<0.05); whilst they had no significant 
increase of cell accumulation in any phases of the cell cycle following treatment with EMO or 
RH alone (p<0.05) (Figure 3.32). Treatment of THP-1 cells with MTX in combination with 
QUE, AP, EMO, RH or CIS had an antagonistic effect on the cell cycle; there were no 
significant differences compared to the vehicle control (p<0.05), but there was a significant 
decrease in cell accumulation compared to the phases arrested by individual treatments alone 
(p<0.05) (Figure 3.32 and Table 3.10).
KG-la myeloid leukaemia cells had a significant increase of cells in Go/Gi and S phases when 
treated with MTX alone, and in Go/Gi phase only when treated with AP alone; while they had 
no significant increase of cell accumulation in any phases of cell cycle when treated with QUE, 
EMO, RH or CIS alone (p<0.05) (Figure 3.32). Treatment of KG-la cells with MTX in 
combination with QUE, AP, EMO, RH or CIS had an antagonistic effect on cell cycle 
accumulation, there were no significant differences compared to the vehicle control (p<0.05) 
but there were significant decreases of cell accumulation compared to the phases arrested by 
individual treatments alone (p<0.05) (Figure 3.32 and Table 3.10).
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Effect of Methotrexate (MTX) in Combination with Polyphenols at their Lowest Significant Doses 
(LSD) on ATP level of Leukaemia Cell Lines Following 24 h of Treatment.
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Figure 3.28: The effect of MTX when used in combination with QUE, AP, EMO, RH or CIS 
on ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with MTX and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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j Effect of M ethotrexate (MTX) in Combination with Polyphenols at their Lowest Significant Doses 
I__________(LSD) on Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment._______
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.29: The effect of MTX when used in combination with QUE, AP, EMO, RH or CIS 
on caspase 3 activity in leukaemia cell lines. T h i s  w a s  e v a l u a t e d  b y  N u c V i e w  c a s p a s e  3  a c t i v i t y  
a s s a y .  C e l l s  w e r e  t r e a t e d  w i t h  M T X  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  
L S D .  D a t a  w a s  n o r m a l i s e d  t o  t h e  v e h i c l e - o n l y  c o n t r o l ,  w h i c h  w a s  a s s i g n e d  a  0 %  a p o p t o t i c  l e v e l .  
T h e  d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  w i t h  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  
a n d  t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w s  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  
c a s p a s e  3  a c t i v i t y ;  t h e  c o l o u r e d  b a r s  i n d i c a t e  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  i n  b r o w n ,  s y n e r g i s t i c  
e f f e c t s  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n t a g o n i s t i c  e f f e c t s  i n  p i n k .  
S t a t i s t i c a l  s i g n i f i c a n t  w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Effect of M ethotrexate (MTX) in Combination with Polyphenols at their Lowest Significant Doses 
(LSD) on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.30: The effect of MTX in combination with QUE, AP, EMO, RH or CIS on 
apoptosis morphological changes of leukaemia cell lines. T h i s  w a s  e v a l u a t e d  b y  d o u b l e  s t a i n i n g  
w i t h  H o e c h s t  3 3 3 4 2 / P I  u s i n g  f l u o r e s c e n c e  m i c r o s c o p y .  C e l l s  w e r e  t r e a t e d  w i t h  M T X  a n d  
p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  D a t a  w a s  n o r m a l i s e d  t o  t h e  v e h i c l e -  
o n l y  c o n t r o l ,  w h i c h  w a s  a s s i g n e d  a  0 %  a p o p t o t i c  l e v e l .  T h e  d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  w i t h  
r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w s  t h e  v e h i c l e  c o n t r o l s  a n d  t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w s  
t h e  e x p e c t e d  l e v e l  o f  p e r c e n t a g e  a p o p t o s i s ;  t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  
i n  b r o w n ,  s y n e r g i s t i c  e f f e c t s  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n t a g o n i s t i c  
e f f e c t s  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Figure 3.31: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of MTX and polyphenols (QUE, 
AP, EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 pm.
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(A)Effect of M ethotrexate (MTX) in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines
__________________ Following 24 h of Treatment.______________________
Drugs JURKAT CCRF-CEM
CONTROL 
QUE,2nM 
MTX,0.01 uM 
QUE + MTX
c 100
GO/GI G2/M
Phases
c  100
Go/Gi
Phases
CONTROL 
AP,50ixM 
MTX,0.01mM 
AP + MTX
s  100
G0/G1 G2/M
Phases
= 100
G 0/G1 G2/M
Phases
c 100
G0/G1 G2/M
Phases
s  100
G2/MG0/G1
Phases
b  100
G0/G1 G2/M
Phases
= 100 CONTROL 
RH,50ilM 
MTX,0.4fCV1 
RH + MTX
G0/G1 G 2/M
Phases
U
c 100
G0/G1 G 2A I
c  100
G0/G1 G 2/M
P hases
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(B) Effect of M ethotrexate (MTX) in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines
__________________ Following 24 h of Treatment.
Drugs THP-1 K G -la
P
P
O'
GO/GI G2/M
Phases
CONTROL 
QUE,2pM 
MTX,0.01piM 
QUE + MTX
s  1 0 0
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G2/M
<
CONTROL 
AP.IO^M 
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s  1 0 0
GO/GI G2/M
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MTX,0.4uM 
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G0/G1 G 2 /\l
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EMO,2fiM 
MTX,0.01fiM 
EMO + MTX
£ 100
G0/G1 G2/M
Phases
c  1 0 0
G0/G1 G2/M
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50 
u  25 
0
M CONTROL 
S  RH,50uM 
— MTX,0T4hM 
RH + MTX
G 0/G1 S
P hases
G 2/M
= 100
G0/G1
Phases
c 100
G0/G1
Phases
CONTROL 
CIS,2jiM 
MTX,0.4uM 
CIS + DOX
G 2/M
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Figure 3.32: The effect of MTX when used in combination with QUE, AP, EMO, RH or CIS 
on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with MTX and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
Flow Jo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.10.
Assays Targets
Com bination of 
M ethotrexate 
and Polyphenols
The Significant Effects of M ethotrexate (MTX) and 
Polyphenols Com bination T reatm ent on ATP Levels, 
Apoptosis and Cell Cycle Progression at 24 h.
Lymphoid Leukaemia Myeloid Leukaemia
JURKAT CCRF-CEM T H P -1 KGla
CellTiter-
Glow ATP Level
MTX + QUE (NSD) | C-ANTG C-ANTG C-ANTG ANTG
MTX + QUE (LSD) C-ANTG C-ANTG C-ANTG ANTG
Caspase 3 
Activity Apoptosis
MTX + QUE (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
MTX + QUE (LSD) C-ANTG C-ANTG C-ANTG C-ANTG
Hoechst/ PI Apoptosis MTX + QUE (LSD) C-ANTG C-ANTG ANTG ANTG
Cell Cycle/PI Cell Cycle MTX + QUE (LSD) ANTG ANTG ANTG ANTG
CellTiter-
Glow ATP Level
MTX + AP (NSD) C-ANTG C-ANTG ANTG C-ANTG
MTX + AP (LSD) ANTG C-ANTG ANTG C-ANTG
Caspase 3 
Activity Apoptosis
MTX + AP (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
MTX + AP (LSD) ANTG C-ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis MTX + AP (LSD) | ANTG ANTG ANTG ANTG
Cell Cycle/PI Cell Cycle MTX + AP (LSD) ANTG ANTG | ANTG ANTG
CellTiter-
Glow ATP Level
MTX + EMO (NSD) C-ANTG C-ANTG ANTG ANTG
MTX + EMO (LSD) ANTG C-ANTG ANTG ANTG
Caspase 3 
Activity Apoptosis
MTX + EMO (NS) C-ANTG C-ANTG ANTG C-ANTG
MTX + EMO (LS) ANTG C-ANTG ANTG ANTG
Hoechst/ PI Apoptosis MTX + EMO (LS) ANTG C-ANTG ANTG ANTG
Cell Cycle/PI Cell Cycle MTX + EMO (LS) ANTG ANTG ANTG ANTG
CellTiter-
Glow ATP Level
MTX + RH (NSD) C-ANTG C-ANTG ANTG C-ANTG
MTX + RH (LSD) ANTG C-ANTG ANTG ANTG
Caspase 3 
Activity Apoptosis
MTX + RH (NSD) C-ANTG C-ANTG | C-ANTG C-ANTG
MTX + RH (LSD) C-ANTG C-ANTG ANTG ANTG
Hoechst/ PI Apoptosis MTX + RH (LSD) ANTG C-ANTG ANTG ANTG
Cell Cycle/PI Cell Cycle M TX + RH (LSD) ANTG ANTG ANTG ANTG
CellTiter-
Glow ATP Level
MTX + CIS (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
MTX + CIS (LSD) ANTG C-ANTG ANTG C-ANTG |
Caspase 3 
Activity Apoptosis
MTX + CIS (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
MTX + CIS (LSD) ANTG C-ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis MTX + CIS (LSD) ANTG ANTG ANTG ANTG
Cell Cvcle/PI | Cell Cycle MTX + CIS (LSD) ANTG ANTG ANTG ANTG
Table 3.10: A sum m ary of the effects of m ethotrexate (MTX) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] com bination treatm ents oil ATP 
level, apoptosis and cell cycle progression in two lymphoid leukaem ia cell lines (JURKAT and 
CCRF-CEM ) and two myeloid leukaem ia cell lines (T H P -land  K G la) at 24 h. Combination 
treatments were investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note 
that the combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic. ;
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3.3.2.3.2 6-Mercaptopurine (6-MP)
(A) Effect o f  6 -Mercaptopurine (6 -MP) Combined with Polyphenols on ATP Levels
6 -MP when used in combination with all polyphenols (QUE, AP, EMO, RH or CIS) produced 
a competitive antagonistic and/or antagonistic effects significantly increasing the ATP levels in 
both lymphoid and myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) 
(p<0.05) (Figure 3.33 and Table 3.11).
(B) Effect o f  6 -Mercaptopurine (6 -MP) Combined with Polyphenols on Apoptosis
6 -MP when used in combination with all polyphenols (QUE, AP, EMO, RH or CIS) produced 
a competitive antagonistic and/or antagonistic effects on apoptosis significantly decreasing the 
caspase 3 activity and the percentage of cells undergoing apoptosis in both lymphoid and 
myeloid leukaemia cell lines(p<0.05) (Figure 3.34, 3.35 and Table 3.11). An example of the 
morphological assessment of apoptosis for 6 -MP and polyphenols (QUE, AP, EMO, RH or 
CIS) alone and in combination at their LSD for 24 h on THP-1 myeloid leukaemia cell lines is 
showed in Figure 3.36.
(C) Effect o f  6 -Mercaptopurine (6 -MP) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase in cell accumulation in S phase 
when treated with 6 -MP, QUE or AP alone, and in Go/Gj phase when treated with EMO or RH 
alone; while there was no increase in cell accumulation in any phases of cell cycle when 
treated with CIS alone (p<0.05) (Figure 3.37). Treatment of JURKAT cells with 6 -MP in 
combination with QUE, AP, EMO, RH or CIS had an antagonistic effect, there were no 
significant difference compared to the vehicle control (p<0.05), but there was a significant 
decrease of cell accumulation compared to the phases arrested by individual treatments alone 
(p<0.05) (Figure 3.37 and Table 3.11).
CCRF-CEM lymphoid leukaemia cells had a significant increase in cell accumulation in S 
phase when treated with 6 -MP, QUE, EMO or RH alone; and in G2/M phase when treated 
with AP alone; while there was no significant increase of cell accumulation in any phases of 
cell cycle when treated with CIS alone (p<0.05) (Figure 3.37). Treatment of CCRF-CEM cells 
with 6 -MP in combination with QUE, AP, EMO, RH or CIS had an antagonistic effect on cell 
cycle; there were no significant differences compared to the vehicle control (p<0.05) but there 
was a significant decrease in cell accumulation compared to the phases arrested by individual 
treatments alone (p<0.05) (Figure 3.37 and Table 3.11).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in S and G2/M 
phases when treated with 6 -MP or AP alone; in G2/M phase when treated with QUE or CIS 
alone; however there was no significant increase of cell accumulation in any phases of cell
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cycle when treated with EMO or RH alone (p<0.05) (Figure 3.37). Treatment of THP-1 cells 
with 6 -MP in combination with QUE, AP, EMO, RH or CIS had an antagonistic effect on cell 
cycle; there were no significant differences between the combination treatment and the vehicle 
control (p<0.05), but there were significant decreases in the cell accumulation compared to the 
phases arrested by individual treatments alone (p<0.05(Figure 3.37 and Table 3.11).
KG-la myeloid leukaemia cells had a significant increase of cell accumulation in Go/Gj and S 
phases when treated with 6 -MP or AP alone; while there was no significant increase of cell 
accumulation in any phases of cell cycle when treated with QUE, EMO, RH or CIS alone 
(p<0.05) (Figure 3.37). Treatment of KG-la cells with 6 -MP in combination with QUE, AP, 
EMO, RH or CIS had an antagonistic effect on cell cycle; there were no significant differences 
compared to the vehicle control (p<0.05) but there were significantly decreased when 
compared to the phases arrested by individual treatments alone (p<0.05) (Figure 3.37 and 
Table 3.11).
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Effect of Mercaptopurine (6-MP) in Combination with Polyphenols at their Lowest Significant Doses
_______ (LSD) on ATP level of Leukaemia Cell Lines Following 24 h of Treatment.____________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.33: The effect of 6 -MP used in combination with QUE, AP, EMO, RH or CIS on 
ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with 6-MP and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of 6-M ercaptopurine (6-MP) in Combination with Polyphenols a t their Lowest Significant Doses 
(LSD) on Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment.
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Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.34: The effect of 6 -MP used in combination with QUE, AP, EMO, RH or CIS on 
caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with 6-MP and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. 
The data was expressed as medians with ranges (n=4). The black bars show the vehicle controls 
and treatments alone; the white bar shows the expected effect of the combined treatments on 
caspase 3 activity; the coloured bars indicate significant additive effects in brown, synergistic 
effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. 
Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of 6-M ercaptopurine (6-MP) in Combination with Polyphenols at their Lowest Significant Doses 
(LSD) on Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.35: The effect of 6 -MP in combination with QUE, AP, EMO, RH or CIS on 
apoptosis morphological changes of leukaemia cell lines. This was evaluated by double staining 
with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with 6-MP and 
polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the vehicle- 
only control, which was assigned a 0% apoptotic level. The data was expressed as medians with 
ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar shows 
the expected level of percentage apoptosis; the coloured bars indicate a significant additive effects 
in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 3.36: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of 6 -MP and polyphenols (QUE, 
AP, EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 pm.
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(A) Effect of 6 -Mercaptopurine (6 -MP) in Combination with Polyphenols at their Lowest 
Significant Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines 
_________________________ Following 24 h of Treatment._________________________
Drugs JURKAT CCRF-CEM
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2! 6-MP,0.01 uM 
3  CIS + 6-MP
s 100c  1 0 0
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Phases Phases
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(B) Effect of 6-M ercaptopurine (6-MP) in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines
__________________ Following 24 h of Treatment. ______________
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Figure 3.37: The effect of 6-MP when used in combination with QUE, AP, EMO, RH or CIS 
on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with 6 -MP and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.11.
Assays Targets
Combination of 
Mercaptopurine 
and Polyphenols
The Significant Effects of Mercaptopurine (6-MP) and 
Polyphenols Combination Treatment on ATP Levels, 
Apoptosis and Cell Cycle Progression at 24 h. 
Lymphoid Leukaemia | Myeloid Leukaemia
JURKAT CCRF-CEM THP-1 K G la
CellTiter- ATP Level
6-MP + QUE (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
GIow 6-MP + QUE (LSD) C-ANTG C-ANTG C-ANTG C-ANTG
Caspase 3 Apoptosis 6-MP + QUE (NSD) C-ANTG C-ANTG C-ANTG
C-ANTG
Activity 6-MP + QUE (LSD) C-ANTG C-ANTG C-ANTG C-ANTG
Hoechst/ PI Apoptosis 6-MP + QUE (LSD) C-ANTG C-ANTG ANTG ANTG
Ceil
Cycle/PI Cell Cycle 6-MP + QUE (LSD)
ANTG ANTG ANTG ANTG
CcllTitcr- ATP Level 6-MP + AP (NSD) C-ANTG C-ANTG C-ANTG
C-ANTG
Glow 6-MP + AP (LSD) ANTG ANTG ANTG C-ANTG
Caspase 3 Apoptosis
6-M P+ AP (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
Activity 6-MP + AP (LSD) ANTG ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis | 6-M P+ AP (LSD) | ANTG C-ANTG ANTG ANTG
Cell
Cycle/PI Cell Cycle 6-M P+ AP (LSD)
ANTG ANTG ANTG ANTG
CellTiter- ATP Level 6-MP + EMO (NSD) C-ANTG ANTG C-ANTG
C-ANTG
Glow 6-MP + EMO (LSD) ANTG ANTG ANTG C-ANTG
Caspase 3 Apoptosis
6-MP + EMO (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
Activity 6-MP + EMO (LSD) ANTG ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis 6-MP + EMO (LSD) ANTG ANTG ANTG ANTG
Cell
Cycle/PI Cell Cycle 6-MP + EMO (LSD)
ANTG ANTG ANTG ANTG
CellTiter- ATP Level 6-MP + RH (NSD) 1 C-ANTG C-ANTG C-ANTG
C-ANTG
GIow 6-MP + RH (LSD) I C-ANTG ANTG ANTG C-ANTG
Caspase 3 Apoptosis 6-MP + RH (NSD) C-ANTG C-ANTG C-ANTG
C-ANTG
Activity 6-M P+ RH (LSD) ANTG ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis 1 6-MP + RH (LSD) | ANTG ANTG ANTG ANTG
Cell
Cycle/PI Cell Cycle 6-M P+ RH (LSD)
ANTG ANTG ANTG ANTG
CellTiter- ATP Level 6-MP + CIS (NSD) C-ANTG C-ANTG C-ANTG
C-ANTG
Glovv 6-MP + CIS (LSD) ANTG ANTG ANTG C-ANTG
Caspase 3 Apoptosis 6-MP + CIS (NSD) C-ANTG C-ANTG C-ANTG
C-ANTG
Activity 6-MP + CIS (LSD) ANTG ANTG ANTG C-ANTG
Hoechst/ PI Apoptosis 6-MP + CIS (LSD) ANTG ANTG ANTG ANTG
Cell
Cycle/PI Cell Cycle 6-MP + CIS (LSD)
ANTG ANTG ANTG ANTG
Table 3.11: A summary of the effects of mercaptopurine (6-MP) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on ATP 
level, apoptosis and cell cycle progression in two lymphoid leukaemia cell lines (JURKAT and 
CCRF-CEM) and two myeloid leukaemia cell lines (THP-land K G la) at 24 h. Combination 
treatments were investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note 
that the combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN 
= Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.2.3.3 5-Fluorouracil (5-FLU)
(A) Effect o f  5-Fluorouracil (5-FLU) Combined with Polyphenols on ATP Levels
5-FLU when used in combination with QUE and EMO produced an additive effect 
significantly decreasing the ATP levels in both lymphoid and myeloid leukaemia cell lines 
(Figure 3.38 and Table 3.12). The most potent effect was seen when 5-FLU was combined 
with AP, this combination caused a synergistic reduction in ATP levels in all the leukaemia 
cell lines (p<0.05) (Figure 3.38 and Table 3.12). Similarly, 5-FLU also had a synergistic 
interaction with RH in lymphoid leukaemia cell lines (p<0.05); whilst it was antagonistically 
interacted in myeloid leukaemia cell lines, (p<0.05) (Figure 3.38 and Table 3.12). However, 5- 
FLU when used in combination with CIS produced a competitive antagonistic or antagonistic 
effects significantly increased ATP level in both lymphoid and myeloid leukaemia cell lines 
(p<0.05) (Figure 3.45 and Table 3.12).
(B) Effect o f  5-Fluorouracil (5-FLU) Combined with Polyphenols on Apoptosis
5-FLU when used in combination with QUE and EMO produced an additive effect on 
apoptosis with both the lymphoid and myeloid leukaemia cell lines (Figure 3.39, 3.40 and 
Table 3.12). The most potent affect was shown when 5-FLU was combined with AP, there was 
a synergistic increase in caspase 3 activity (Figure 3.39) and the percentage of cells 
undergoing apoptosis (Figure 3.40) in both lymphoid and myeloid leukaemia cell lines(p<0.05) 
(Figure 3.39, 3.40 and Table 3.12). Similarly, 5-FLU acted synergistically when combined 
with RH increasing apoptosis in the lymphoid leukaemia cell lines, (p<0.05); whilst they were 
found to have an antagonistic effect on apoptosis in myeloid leukaemia cell lines (p<0.05) 
(Figure 3.39, 3.40 and Table 3.12). This competitive antagonistic or antagonistic effects was 
also seen when 5-FLU used in combination with CIS once again there was a significantly 
decreased in the caspase 3 activity (Figure 3.39) and the percentage of cell undergoing 
apoptosis (Figure 3.40) in both lymphoid and myeloid leukaemia cell lines(p<0.05) (Figure 
3.39, 3.40 and Table 3.12). An example of the morphological assessment of apoptosis for 5- 
FLU and polyphenols (QUE, AP, EMO, RH or CIS) alone and in combined at their LSD for 24 
h on THP-1 myeloid leukaemia cell lines is showed in Figure 3.41.
(C) Effect o f  5-Fluorouracil (5-FLU) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase of cell accumulation in S phase 
following treatment with 5-FLU, QUE or AP alone; and in Go/Gj phase following treatment 
with EMO or RH alone; while there were no significant increase of cell accumulation in any 
phases of cell cycle following treatment with CIS alone, (p<0.05) (Figure 3.42). Treatment of 
JURKAT cells with 5-FLU in combination with AP or RH had an interactive effect causing a 
significant increase of cell accumulation in S phase (p<0.05) (Figure 3.42 and Table 3.12). In
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addition, treatment of JURKAT cells with 5-FLU in combination with QUE or EMO had a 
non-interactive effect, there were significant increases in cell accumulation in S phase when 
compared to the vehicle control; but this was not significant when compared to the phases of 
arrest caused by individual treatments alone (p<0.05) (Figure 3.42 and Table 3.12). In contrast, 
treatment of JURKAT cells with combination of 5-FLU and CIS had an antagonistic effect on 
cell cycle, although there were no significant differences compared to the vehicle control 
(p<0.05), but there were significant decreases in the cell accumulation compared to the phases 
arrested by individual treatment alone (p<0.05) (Figure 3.42 and Table 3.12).
CCRF-CEM lymphoid leukaemia cells had a significant increase of cell accumulation in S 
phase following treatment with 5-FLU, QUE, EMO or RH alone, and in G2/M phase following 
treatment with AP alone; while they had no significant increase of cell accumulation in any 
phases of cell cycle following treatment with CIS alone, when compared to the vehicle control 
(p<0.05) (Figure 3.42). Treatment of CCRF-CEM cells with 5-FLU in combination with AP or 
RH had an interactive effect causing a significant increase of cell accumulation in S phase 
(p<0.05) (Figure 3.42 and Table 3.12). In addition, treatment of CCRF-CEM cells with 5-FLU 
in combination with QUE or EMO had a non-interactive effect, there were significant 
increases in cell accumulation in S phase when compared to the vehicle control; but these were 
not significant when compared to the phases arrested by individual treatments alone (p<0.05) 
(Figure 3.42 and Table 3.12). On the other hand, treatment of CCRF-CEM cells with 
combination of 5-FLU and CIS had an antagonistic effect on cell cycle, although there were no 
significant differences compared to the vehicle control (p<0.05) but there were significant 
decreases in the cell accumulation compared to the phases arrested by individual treatment 
alone (p<0.05) (Figure 3.42 and Table 3.12).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in Go/Gi phase 
following treatment with 5-FLU alone, in G2/M phase following treatment with QUE or CIS 
alone, and in S and G2/M phases following treatment with AP alone. There were no significant 
increases of cell accumulation in any phases of cell cycle following treatment with EMO or 
RH alone, when compared to the vehicle control (p<0.05) (Figure 3.42). Treatment of THP-1 
cells with combination of 5-FLU and AP had an interactive effect causing a significant 
increase of cell accumulation in Go/Gi phase when compared to the vehicle control and 
individual treatments (p<0.05) (Figure 3.42 and Table 3.12). In addition, treatment of THP-1 
cells with 5-FLU in combination with QUE or EMO had a non-interactive effect, there were 
significant increases in cell accumulation in Go/Gi when compared to the vehicle control; but 
these were not significant when compared to phases arrested by individual treatments alone 
effect (p<0.05) (Figure 3.42 and Table 3.12). In contrast, treatment of THP-1 cells with 5-FLU 
in combination with RH or CIS had an antagonistic effect, there were no significant differences
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compared to the vehicle control (p<0.05), but there were significant decreases in the cell 
accumulation compared to the phases arrested by individual treatment alone (p<0.05) (Figure 
3.42 and Table 3.12).
KG-la myeloid leukaemia cells had a significant increase of cell accumulation in Go/Gi phase 
following treatment with 5-FLU and AP alone; while they had no significant increase of cell 
accumulation in any phases of cell cycle following treatment with QUE, EMO, RH or CIS 
alone when compared to the vehicle control (p<0.05) (Figure 3.42). Treatment of KG-la cells 
with combination of 5-FLU and AP had an interactive effect causing a significant increase of 
cell accumulation in Go/G] phase when compared to the vehicle control and individual drugs 
treatments (p<0.05) (Figure 3.42 and Table 3.12). In contrast, treatment of KG-la cells with 5- 
FLU in combination with QUE or EMO had a non-interactive effect there were significant 
increases in cell accumulation in Go/Gi when compared to the vehicle control; but these were 
not significant when compared to phases arrested by individual treatments alone (p<0.05) 
(Figure 3.42 and Table 3.12). Alternatively, treatment of KG-la cells with 5-FLU in 
combination with RH or CIS had an antagonistic effect, although there were no significant 
differences compared to the vehicle control (p<0.05), there were significant decreases in the 
cell accumulation compared to the phases arrested by individual treatment alone (p<0.05) 
(Figure 3.42 and Table 3.12).
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Effect of 5-FIuorouraciI (5-FLU) in Combination with Polyphenols at their Lowest Significant Doses
________(LSD) on ATP level of Leukaemia Cell Lines Following 24 h of Treatment.___________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.38: The effect of 5-FLU when used in combination with QUE, AP, EMO, RH or CIS 
on ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with 5-FLU and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of 5-Fluorouracil (5-FLU) in Combination with Polyphenols at their Lowest Significant Doses 
________ (LSD) on Caspase 3 Activity of Leukaemia Cell Lines Follow ing 24 h of Treatment.________
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.39: The effect of 5-FLU used in combination with QUE, AP, EMO, RH or CIS on 
caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with 5-FLU and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. 
The data was expressed as medians with ranges (n=4). The black bars show the vehicle controls 
and treatments alone; the white bar shows the expected effect of the combined treatments on 
caspase 3 activity; the coloured bars indicate significant additive effects in brown, synergistic 
effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. 
Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of 5-Fluorouracil (5-FLD) in Combination with Polyphenols at their Lowest Significant Doses 
(LSD) on Apoptosis Morphological Changes of Leukaemia Cell Lines Follow ing 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.40: The Effect of 5-FLU when used in combination with QUE, AP, EMO, RH or CIS 
on apoptosis morphological changes of leukaemia cell lines. This was evaluated by double 
staining with Hoechst 33342/PI using fluorescence microscopy. Cells were treated with 5-FLU and 
polyphenols alone and in combined for 24 h using their LSD. Data was normalised to the vehicle- 
only control, which was assigned a 0% apoptotic level. The data was expressed as medians with 
ranges (n=4). The black bars shows the vehicle controls and treatments alone; the white bar shows 
the expected level of percentage apoptosis; the coloured bars indicate a significant additive effects 
in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 3.41: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of 5-FLU and polyphenols (QUE, 
AP, EMO, RH or CIS) alone and in combined for 24 h. A poptotic cells w ere identified  by their 
irregular shape, in tensely  bright blue stained nuclei, chrom atin  condensation, and the form ation o f  
apoptotic bodies. N orm al cells w ere round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar = 100 ju m .
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(A)Effect of 5-FIuorouracil (5-FLU) in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines
Following 24 h of Treatment. __________
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(B) Effect of 5-Fluorouracil (5-FLU) in Combination with Polyphenols at their Lowest 
Significant Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines 
________________________Following 24 h of Treatment.________________________
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figure a.4 z: m e enect ot s - e lu  wben used in combination with QUE, AF, EMO, KH or CIS 
on cell cycle progression in: (A) lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) 
and (B) Myeloid leukaemia cell lines (THP-1 and KG-la). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with 5-FLU and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.12.
Assays Targets
Com bination of 
Fluorouracil 
and Polyphenols
The Significant Effects of 5-Fluorouracil and 
Polyphenols Com bination T reatm ent on ATP Levels, 
Apoptosis and Cell Cycle Progression at 24 h
Lymphoid Leukaemia Myeloid Leukaemia
JURKAT CCRF-CEM THP-1 KGla
CellTiter-
Glow ATP Level
1 5-FLU + QUE (NSD) ADD ADD ADD SYN
5-FLU + QUE (LSD) ADD ADD ADD SYN
Caspase 3 
Activity Apoptosis
5-FLU + QUE (NSD) ADD ADD ADD SYN
| 5-FLU + QUE (LSD) ADD ADD ADD SYN
Hoechst/ PI Apoptosis [ 5-FLU + QUE (LSD) ADD ADD ADD SYN
Cell Cvcle/PI Cell Cycle 5-FLU + QUE (LSD) Non
Interaction
Non
Interaction
Non
Interaction
Non
Interaction
CellTitcr-
Glow ATP Level
5-FLU + AP (NSD) SYN SYN SYN SYN
5-F L U +  AP (LSD) SYN SYN SYN SYN
Caspase 3 
Activity Apoptosis
5-FLU + AP (NSD) SYN SYN SYN SYN
5-FLU + AP (LSD) SYN SYN SYN SYN
Hoechst/ PI Apoptosis 5-FLU + AP (LSD) SYN SYN SYN SYN
Cell Cycle/PI Cell Cycle 5-FLU + AP (LSD) Interaction Interaction Interaction Interaction
CellTiter-
Glow ATP Level
5-FLU + EMO (NSD) ADD ADD ADD ADD
5-FLU + EMO (LSD) ADD ADD ADD ADD
Caspase 3 
Activitv Apoptosis
5-FLU + EMO (NSD) ADD ADD ADD ADD
5-FLU + EMO (LSD) ADD ADD ADD ADD
Hoechst/ PI Apoptosis 5-FLU + EMO (LSD) ADD ADD ADD ADD
Cell Cycle/PI Cell Cycle 5-FLU + EMO (LSD) NonInteraction
Non
Interaction
Non
Interaction
Non
Interaction
CellTiter-
Glow ATP Level
5-FLU + RH (NSD) SYN SYN C-ANTG C-ANTG
5-FLU + RH (LSD) SYN SYN ANTG ANTG
Caspase 3 
Activity Apoptosis
5-FLU + RH (NSD) SYN SYN C-ANTG C-ANTG
5-FLU + RH (LSD) SYN SYN ANTG ANTG
Hoechst/ PI Apoptosis 5-FLU + RH (LSD) SYN SYN C-ANTG ANTG
Cell Cycle/PI Cell Cvcle 5-FLU + RH (LSD) Interaction Interaction ANTG ANTG
CellTiter-
Glow ATP Level
5-FLU + CIS (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
5-FLU + CIS (LSD) C-ANTG C-ANTG ANTG ANTG
Caspase 3 
Activitv
Apoptosis
5-FLU + CIS (NSD) C-ANTG C-ANTG C-ANTG C-ANTG
5-FLU + CIS (LSD) C-ANTG C-ANTG ANTG ANTG
Hoechst/ PI Apoptosis 5-FLU + CIS (LSD) C-ANTG C-ANTG ANTG ANTG
Cell Cvcle/PI Cell Cvcle 5-FLU + CIS (LSD) ANTG ANTG ANTG ANTG
Table 3.12: A sum m ary of the effects of 5-fluorouracil (5-FLU) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EM O), rhein, (RH) or cis-stilbene (CIS)] com bination treatm ents on ATP 
level, apoptosis and cell cycle progression in two lymphoid leukaem ia cell lines (JU RK A T and 
CCRF-CEM ) and two myeloid leukaemia cell lines (T H P -land  K G la) at 24 h. Combination treatments 
were investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note that the 
combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3.3.Z.4 Effects of Tyrosine Kinase Inhibitors Agent in Combined with Polyphenols
3.3.2.4.1 Imatinib (IM)
(A) Effect o f  Imatinib (IM) Combined with Polyphenols on ATP Levels
IM was caused a significant synergistic reduction of ATP levels when used in combination 
with AP in the myeloid cell lines (THP-1 and KGla) (p<0.05). In contrast, in the lymphoid cell 
lines (JURKAT and CCRF-CEM), this combination caused a competitively antagonistic or 
antagonistic effects, significantly increased ATP level when compared to the expected values 
and individual drugs (p<0.05) (Figure 3.43 and Table 3.13). IM when combined with EMO 
produced an additive effects on reduction of ATP level in both the lymphoid and myeloid 
leukaemia cell lines (p<0.05) (Figure 3.43 and Table 3.13). In addition, IM when used in 
combination with RH produced additive effects on reduction of ATP level while only in the 
lymphoid cell lines (JURKAT, CCRF-CEM) (p<0.05); however, they produced competitively 
antagonistic or antagonistic effects causing significantly increased in ATP level in the myeloid 
leukaemia cell lines (THP-1 and KGla) (p<0.05) (Figure 3.43 and Table 3.13). Similarly, IM 
in combination with QUE and CIS produced competitively antagonistic or antagonistic effects 
causing significantly increased ATP level when compared to the expected values and 
individual drugs, but this time in both lymphoid and myeloid leukaemia cell lines (p<0.05) 
(Figure 3.43 and Table 3.13).
(B) Effect o f  Imatinib (IM) Combined with Polyphenols on Apoptosis
IM when used in combination with AP produced a synergistic effects on apoptosis in myeloid
cell lines (THP-1 and KGla), significantly increasing caspase 3 activity and the percentage of
cell undergoing apoptosis (p<0.05) (Figure 3.44, 3.45 and Table 3.13). However, in lymphoid
leukaemia cell lines (JURKAT and CCRF-CEM) the combination of IM and AP produced
competitively antagonistic or antagonistic effects, significantly decreasing the caspase 3
activity and the percentage of cells undergoing apoptosis, when compared to the individual
treatments alone and the expected value (p<0.05) (Figure 3.44, 3.45 and Table 3.13). IM when
used in combination with EMO produced an additive effect on caspase 3 activity and the
percentage of cell undergoing apoptosis in both lymphoid and myeloid leukaemia cell lines
(p<0.05) (Figure 3.44, 3.45 and Table 3.13). Furthermore, IM in combination with RH also
produced additive effects on apoptosis, however only in the lymphoid cell lines (JURKAT and
CCRF-CEM). In the myeloid leukaemia cell lines (THP-1 and KGla) this combination
produced a competitively antagonistic or antagonistic effects on apoptosis (p<0.05) (Figure
3.44, 3.45 and Table 3.13). Similarly, IM when used combination with QUE or CIS in both
lymphoid and myeloid leukaemia cell lines, produced competitively antagonistic or
antagonistic effects, significantly decreasing caspase 3 activity and the percentage of a cell
undergoing apoptosis when compared to the individual treatments alone and the expected
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values (p<0.05) (Figure 3.44, 3.45 and Table 3.13). An example of the morphological 
assessment of apoptosis for IM and polyphenols (QUE, AP, EMO, RH or CIS) alone and in 
combination at their LSD for 24 h on THP-1 myeloid leukaemia cell lines is showed in Figure 
3.46.
(C) Effect o f  Imatinib (IM) Combined with Polyphenols on Cell Cycle
JURKAT lymphoid leukaemia cells had a significant increase of cell accumulation in G2/M 
phase when treated with IM alone, in S phase when treated with QUE or AP alone, and in 
Go/Gi phase when treated with EMO or RH alone; while they had no significant increase of 
cell accumulation in any phases of cell cycle when treated with CIS alone, when compared to 
the vehicle control (p<0.05) (Figure 3.47). Treatment of JURKAT cells with IM in 
combination with EMO or RH had an interactive effect that significantly increased the cell 
accumulation in Go/Gj phase when compared to the vehicle control; but this was not significant 
when compared to phases arrested by EMO or RH alone effect (p<0.05) (Figure 3.47 and 
Table 3.13). In contrast, treatment of JURKAT cells with IM in combination with QUE, AP or 
CIS had an antagonistic effect, there were no significant differences compared to the vehicle 
control (p<0.05), but there was a significant decrease in cell accumulation compared to the 
phases arrested by individual treatments alone (p<0.05) (Figure 3.47 and Table 3.13).
CCRF-CEM lymphoid leukaemia cells had a significant increase of cell accumulation in S 
phase when treated with IM, QUE, EMO or RH alone, in G2/M phase when treated with AP 
alone; but there was no significant increase in cell accumulation in any phases of cell cycle 
when treated with CIS alone, when compared to the vehicle control (p<0.05) (Figure 3.47). 
Treatment of CCRF-CEM cells with IM in combination with EMO or RH had an interactive 
effect significantly increasing cell accumulation in S phase when compared to the vehicle 
control; but not when compared to phases arrested by EMO or RH alone (p<0.05) (Figure 3.47 
and Table 3.13). In contrast when CCRF-CEM cells were treated with IM in combination with 
QUE, AP or CIS there was an antagonistic effect, there were no significant differences 
compared to the vehicle control (p<0.05) but there was a significant decrease of cell 
accumulation compared to the phases arrested by individual treatments alone (p<0.05) (Figure 
3.47 and Table 3.13).
THP-1 myeloid leukaemia cells had a significant increase of cell accumulation in S phase 
when treated with IM alone, in G2/M phase when treated with QUE or CIS alone, and in S and 
G2/M phases when treated with AP alone; while they had no significant increase of cell 
accumulation in any phases of cell cycle when treated with EMO or RH alone when compared 
to the vehicle control (p<0.05) (Figure 3.47). Treatment of THP-1 cells with IM in 
combination with AP or EMO had an interactive effect which significantly increased the cell
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accumulation in S phase when compared to the vehicle control; but this was not significant 
when compared to phases arrested by individual treatments alone (p<0.05) (Figure 3.47 and 
Table 3.13). In contrast when THP-1 cells were treated with IM in combination with QUE, RH 
or CIS there was an antagonistic effect, there were no significant differences compared to the 
vehicle control (p<0.05) but there was a significant decrease of cell accumulation compared to 
the phases arrested by the individual treatments alone (p<0.05) (Figure 3.47 and Table 3.13).
KG-la myeloid leukaemia cells had a significant increase of cell accumulation in Go/Gi phase 
when treated with IM or AP alone; while they had no significant increase of cell 
accumulation in any phases of cell cycle when treated with QUE, EMO, RH or CIS alone 
when compared to the vehicle control (p<0.05) (Figure 3.47). Treatment of KG-la cells with 
IM in combination with AP or EMO had an interactive effect which significantly increased the 
cell accumulation in Go/Gi phase when compared to the vehicle control; but this was not 
significant when compared to phases arrested by the individual treatments alone (p<0.05) 
(Figure 3.47 and Table 3.13). On other hand, the treatment of KG-la cells with IM in 
combination with QUE, RH or CIS had an antagonistic effect, there were no significant 
differences compared to the vehicle control (p<0.05), but there were significant decreases in 
cell accumulation compared to the phases arrested by the individual treatments alone (p<0.05) 
(Figure 3.47 and Table 3.13).
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Effect of Imatinib (EM) in Combination with Polyphenols at their Lowest Significant Doses (LSD) on
____________ATP level of Leukaemia Cell Lines Following 24 h of Treatment.________________
Lymphoid Leukaemia Cell Lines. Mveloid Leukaemia Cell Lines.
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Figure 3.43: The effect of IM when used in combination with QUE, AP, EMO, RH or CIS on 
ATP levels of leukaemia cell lines. This was evaluated by CellTiter-Glo® assay. Cells were 
treated with IM and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% cell viability. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on ATP levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Effect of Imatinib (IM) in Combination with Polyphenols at their Lowest Significant Doses (LSD)
_______ on Caspase 3 Activity of Leukaemia Cell Lines Following 24 h of Treatment._________
Lymphoid Leukaemia Cell Lines Myeloid Leukaemia Cell Lines.
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Figure 3.44: The effect of IM used in combination with QUE, AP, EMO, RH or CIS on 
caspase 3 activity in leukaemia cell lines. This was evaluated by NucView caspase 3 activity 
assay. Cells were treated with IM and polyphenols alone and in combined for 24 h using their LSD. 
Data was normalised to the vehicle-only control, which was assigned a 0% apoptotic level. The 
data was expressed as medians with ranges (n=4). The black bars show the vehicle controls and 
treatments alone; the white bar shows the expected effect of the combined treatments on caspase 3 
activity; the coloured bars indicate significant additive effects in brown, synergistic effects in 
yellow, competitive antagonistic effects in purple and antagonistic effects in pink. Statistical 
significant was set at p<0.05 compared to vehicle control and drugs alone.
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Effect of Imatinib (IM) in Combination with Polyphenols at their Lowest Significant Doses (LSD) on
Apoptosis Morphological Changes of Leukaemia Cell Lines Following 24 h of Treatment._____
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 3.45: The effect of IM in combination with QUE, AP, EMO, RH or CIS on apoptosis 
morphological changes of leukaemia cell lines. This was evaluated by double staining with 
Hoechst 33342/PI using fluorescence microscopy. Cells were treated with IM and polyphenols 
alone and in combined for 24 h using their LSD. Data was normalised to the vehicle-only control, 
which was assigned a 0% apoptotic level. The data was expressed as medians with ranges (n=4). 
The black bars shows the vehicle controls and treatments alone; the white bar shows the expected 
level of percentage apoptosis; the coloured bars indicate a significant additive effects in brown, 
synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic effects in 
pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 3.46: An example of morphological assessment of apoptosis using Hoechst 33342/PI 
for THP-1 myeloid leukaemia cells when treated with LSDs of IM and polyphenols (QUE, AP, 
EMO, RH or CIS) alone and in combined for 24 h. Apoptotic cells were identified by their 
irregular shape, intensely bright blue stained nuclei, chromatin condensation, and the formation of 
apoptotic bodies. Normal cells were round and pale blue stained, and late apoptotic cells and dead 
cells appear pink. Scale bar= 100 pm.
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(A)Effect of Imatinib (IM) in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on Cell Cycle of Lymphoid Leukaemia Cell Lines
__________________ Following 24 h of Treatment.___________________________
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(B) Effect of Imatinib (IM) in Combination with Polyphenols at their Lowest Significant 
Doses (LSD) on Cell Cycle of Myeloid Leukaemia Cell Lines 
_________________________Following 24 h of Treatment._________________________
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Figure 3.47: i  he effect o f  IM  w hen used in com bination  w ith  Q U E , A P, E M O , RH or CIS on 
cell cycle progression  in: (A) lym phoid  leukaem ia cell lines (JU R K A T  and C C R F -C E M ) and
(B) M yeloid  leukaem ia cell lines (TH P-1 and K G -la ). Cell cycle progression was analysed 
following propidium iodide staining using flow cytometry. Cells were treated with IM and 
polyphenols alone and in combined for 24 h using the lowest-significant doses (LSD) as 
determined by CellTiter-Glo assay. The percentage of cells in each phase was analysed with 
FlowJo software using Waston pragmatic model. The data was expressed as medians with ranges 
(n=4). The statistical significance of individual drugs and combined drugs was determined by 
comparison with the vehicle control. Statistical significance of the combined treatments was 
determined by comparison with the effect of the individual treatments alone. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone. The Green star (*) is used to 
indicate a significant increase in cell accumulation in a phase of the cell cycle; whilst the Black star 
(*) is used to indicate a significant decrease in cell accumulation in a phase of the cell cycle. The 
effects of combination treatments on cell cycle were classified as interactive or non-interactive as 
described in Section 3.2.5.2; and are summarised in Table 3.13.
Assays Targets
Com bination of 
Im atinib 
and Polyphenols
The Significant Effects of m atinib 
(IM) and Polyphenols C om bination T reatm ent on 
ATP Levels, Apoptosis and Cell Cycle Progression 
at 24 h.
Lymphoid Leukaemia Myeloid Leukaemia !
JURKAT CCRF-CEM THP-1 KGla
CellTiter-
Glow ATP Level
IM + QUE (NSD) C-ANTG ADD C-ANTG C-ANTG
IM + QUE (LSD) ANTG ADD C-ANTG C-ANTG
Caspase 3 
Activitv Apoptosis
IM + QUE (NSD) C-ANTG ADD C-ANTG C-ANTG
IM + QUE (LSD) C-ANTG ADD C-ANTG C-ANTG
Hoechst/ PI Apoptosis IM + QUE (LSD) ANTG ADD ANTG C-ANTG
Cell
Cvcle/PI Cell Cycle IM + QUE (LSD) ANTG ANTG ANTG ANTG
CellTitcr-
Glow ATP Level
IM + AP (NSD) C-ANTG C-ANTG SYN SYN
IM + AP (LSD) C-ANTG C-ANTG SYN SYN
Caspase 3 
Activity
Apoptosis
IM + AP (NSD) C-ANTG C-ANTG SYN SYN
IM + A P  (LSD) C-ANTG C-ANTG SYN SYN
Hoechst/ PI Apoptosis IM + AP (LSD) C-ANTG C-ANTG ADD SYN
Cell
Cycle/PI Cell Cycle IM + AP (LSD) ANTG ANTG ADD ADD
CellTiter-
Glow ATP Level
IM + EMO (NSD) ADD ADD ADD ADD
IM + EMO (LSD) ADD ADD ADD ADD
Caspase 3 
Activity Apoptosis
IM + EMO (NSD) ADD ADD ADD ADD
IM + EMO (LSD) ADD ADD ADD ADD
Hoechst/ PI Apoptosis IM + EMO (LSD) ADD ADD ADD ADD
Cell
Cycle/PI Cell Cycle IM + EMO (LSD)
Non
Interaction
Non
Interaction
Non
Interaction
Non
Interaction
CellTiter-
GIow ATP Level
IM + RH (NSD) ADD ADD C-ANTG C-ANTG
IM + RH (LSD) ADD ADD ANTG C-ANTG
Caspase 3 
Activity Apoptosis
IM + RH (NSD) ADD ADD C-ANTG C-ANTG
IM + RH (LSD) ADD ADD ANTG C-ANTG
Hoechst/ PI Apoptosis IM + RH (LSD) ADD ADD ANTG C-ANTG
Cell
Cycle/PI Cell Cycle IM + RH (LSD)
Non
Interaction
Non
Interaction ANTG ANTG
CellTiter-
Glow ATP Level
IM + CIS (NSD) C-ANTG C-ANTG C-ANTG ADD
IM + CIS (LSD) ANTG ANTG C-ANTG ADD
Caspase 3 
Activity Apoptosis
IM + CIS (NSD) C-ANTG C-ANTG C-ANTG ADD
IM + CIS (LSD) ANTG C-ANTG C-ANTG ADD
Hoechst/ PI Apoptosis IM + CIS (LSD) ANTG C-ANTG ANTG ADD
Cell
Cvcle/PI Cell Cycle IM + CIS (LSD) ANTG ANTG ANTG ANTG
Table 3.13: A sum m ary of the effects of im atinib (IM) and polyphenols [quercetin (QUE), apigenin 
(AP), emodin (EM O), rhein, (RH) or cis-stilbene (CIS)] com bination treatm ents on ATP level, 
apoptosis and cell cycle progression in two lymphoid leukaemia cell lines (JU RK A T and C CRF- 
CEM ) and two myeloid leukaemia cell lines (T H P -land  K G la) a t 24 h. Combination treatments were 
investigated at their non-significant dose (NSD) and lowest significant dose (LSD). Note that the 
combination effects o f drugs were determined statistically as described as in Section 2.5.2. SYN = 
Synergistic, ADD = Additive, C-ANTG= Competitive Antagonistic, ANTG= Antagonistic.
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3,4 Discussion
Clinically, polyphenols have been shown to enhance the efficacy of chemotherapy agents. 
These polyphenols have also been shown to decrease the occurrence of drug resistance, 
toxicity and treatment related side effects in cancer patients (Wu, 2006; Florea and Busselberg, 
2011; Sandeep et al, 2012; Mohan et al, 2013). This study has investigated the combination 
effects of nine standard chemotherapy agents and five polyphenols (identified in Chapter 2). 
Here we have demonstrated how each of these chemotherapy agents and polyphenols can be 
used in combination to inhibit cell proliferation, induce apoptosis and arrest the cell cycle in 
leukaemia cell lines. In order to study the molecular interaction of these polyphenols and 
chemotherapy agent; they need to be combined in micromolar concentrations.
Here these concentrations were defined as the non-significant dose (NSD) and lowest 
significant dose (LSD) that inhbited cell proliferation and induced apoptosis following 24 h 
treatment. Only at these low doses it is possible to measure how drug interactions 
mechanistically, and enable the evaluation of the effects of treatment combinations as 
synergistic, additive, etc. The use of IC50 doses would obscure these effects. This study 
demonstrated that the efficacy chemotherapeutic agents were differential modulated by 
polyphenols within the leukaemia cell lines. These differential combination effects could be 
dependent on the type of chemotherapy agents, the polyphenol used, and/or cell lineage. This 
section will discuss our combination results according to the chemotherapy classifications as 
described previously.
3.4.1 Toposiomerase Inhibitor Agents in Combination with Polyphenols
The topoisomerase inhibitor agents: DOX and ETP displayed synergistic effects on reduction 
of ATP levels, induction of apoptosis and arresting the cell cycle when combined with each of 
the polyphenols investigated (QUE, AP, EMO, RH or CIS) in lymphoid leukaemia cell lines 
(JURKAT and CCRF-CEM) (Table 3.5 and 3.6). However, DOX and ETP displayed 
differential effects either synergistic or additive or antagonistic effects when combined with 
the polyphenols (QUE, AP, EMO, RH or CIS) in myeloid leukaemia cell lines (THP-1 and 
KG-la) (Table 3.5 and 3.6). Most importantly, DOX and ETP when combined with QUE; and 
DOX when combined with AP produced synergistic effects in both lymphoid and myeloid 
leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) (Table 3.5 and 3.6).
Previously DOX combined with QUE was shown to be highly effective against breast cancer 
cell lines (Du et al, 2010; Staedler et al, 2011; Li et al, 2013). Du et al, 2010 demonstrated 
using a xenograft murine breast cancer cell (4T1) model that intra-tumoural injection of 
quercetin and doxorubicin synergistically suppressed tumour growth and metastasis, and 
induced persistent T-cell tumour-specific responses through an increase in IFN-y and IL-2
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levels, a reduced IL-4 and IL-10 and an induction of apoptosis of CD4+ or CD8 + T cells (Du 
et al, 2010). This study reported that that tumour-specific T cells play a vital role in tumour 
immunosurveillance and immunorejection, the characteristics of immune responses are mainly 
directed by the activity of T-helper (Th) cell sub-populations and their cytokine product (Du et 
al, 2010). The type 1 cytokines such as IL-2 and IFN-y are immunostimulants and are able to 
limit tumour growth (Du et al, 2010). Alternatively, the type 2 cytokines such as IL-4 and IL- 
10 are immunoinhibitory and thus able of drive tumour growth (Du et al, 2010). It was found 
that DOX-induced tumour cell death and quercetin was an effective immunoregulator which 
increased IFN-y and IL-2 and decreased IL-4 and IL-10 with the host serum and tumour (Du et 
al, 2010). In addition, this study found quercetin was capable of modulation of the immune 
system and sensitize the tumour to chemotherapy, by the inducing immunogenic cancer cell 
death, and synergistic induction of long lasting tumour-specific immunity (Du et al, 2010). It 
was concluded that the combination of quercetin with intratumoral doxorubicin may represent 
a novel and highly effective strategy for inducing immune responses against tumours, plus help 
to reduce chemotherapy treatment doses an hence the toxic side effects seen in breast cancer 
patients treated with doxorubicin (Du et al, 2010). In addition, in human breast cancer cell 
lines (MCF-7, MDA-MB-231, and MCF-10A) the combination of DOX and QUE inhibited 
cells proliferation and induced apoptosis through decreased the cellular thiol level and 
blockage of the PKC5 signalling pathway (Staedler et al, 2011). The treatment of MCF-7 cells 
with combination of DOX and QUE caused inhibition of cell proliferation and invasion via the 
suppression of hypoxia-inducible factor-1 alpha (HIF-la) and P-glycoprotein (P-gp) (Li et al,
2013). Similarly, the treatment of human hepatoma cell lines (SMMC7721 and QGY7701) 
with a combination of DOX and QUE induced apoptosis via accumulation of p53, followed by 
the activation of mitochondrial apoptotic pathway, resulting in activation of caspase 9 and 
caspase 3 (Wang et al, 2012). These studies suggest that the effects of DOX and ETP could be 
enhanced by polyphenols for solid tumours treatment; however studies in vivo may be 
identifying interactions that are different to cell culture models.
Cipak et al, 2003 reported that the antagonistic effects could be related to the anti-oxidant 
activity of the polyphenols, which could act as protective against reactive oxygen species 
(ROS) that are generated by DOX and thus inhibited the apoptosis, through suppressed ROS 
production and the activation of the c-Jun NH2-terminal kinase (JNK) pathway (Cipak et al, 
2003; Somasundaram et al, 2002). This could be a possible explanation the effect caused by 
EMO and RH within the current study, which antagonised the activity of DOX in myeloid cell 
lines (THP-1 and KG-la). EMO and RH may to act as anti-oxidants and mop up ROS 
generated by DOX (Cipak et al, 2003; Somasundaram et al, 2002).
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Finally, it can be summarised that topoisomerase inhibitor agents when combined with 
flavonoid compounds QUE and AP synergistically interacted in both lymphoid and myeloid 
cell lines which could hold promise for leukaemia treatments. However DOX and ETP when 
combined with remaining polyphenols EMO, RH or CIS synergistically interacted in lymphoid 
leukaemia cell lines only; whilst in myeloid leukaemia cell lines no synergistic responses were 
observed. This suggests that combination of DOX and ETP with the polyphenols investigated 
here (QUE, AP, EMO, RH and CIS) could be promising for the treatment of lymphoid 
leukaemias. However, more importantly, patients with myeloid leukaemia treated with DOX 
should avoid anthraquinones such as EMO and RH; whilst patients given ETP therapy should 
avoid anthraquinones such as RH and stilbenoide such as CIS; or indeed any foods rich in 
these polyphenols that could potentially have an antagonistic effect on their chemotherapy 
treatment. These findings suggest that additional in vivo experiments require to be performed 
to determine whether diet-based EMO, RH or CIS could potentially affect DOX or ETP 
activity.
3.4.2 Alkylating Agents in Combination with Polyphenols
In this study, the alkylating agents CSP and CYCLO, followed by CLB were the next most 
effective chemotherapeutics to interact with the polyphenols. CSP and CYCLO demonstrated a 
potent synergistic effect when combined with 4 out of 5 polyphenols in the lymphoid cell lines 
(Table 3.7 and 3.9). Similarly CLB had a synergistic effect when combined with 2 out 5 
polyphenols, but only in the lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) (Table 
3.8). These synergistic effects were through the inhibition of ATP levels and induction of early 
apoptosis via increase the caspase 3 activation, plus morphological evidence of the late 
apoptosis and arresting the cell cycle mainly at S phase, and some combination at Go/Gi phase 
when compared to control and drugs alone. While, they had differential effects either 
synergistic or additive or antagonistic effects when combined with the 5 polyphenols (QUE, 
AP, EMO, RH, or CIS) in myeloid leukaemia cell lines (THP-1 and KG-la) (Table 3.7, 3.8 
and 3.8).
In summary, the significant observations on the combination of alkylating agents (CSP, 
CYCLO and CLB) with polyphenols were as follows: (1) the combination of CSP with QUE, 
CYCLO with AP and CLB with AP were interacted synergistically in both lymphoid and 
myeloid leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) and could be very 
promising for leukaemia treatment; however, (2) the combination of CYCLO and CLB with 
CIS had an antagonistic interaction in both lymphoid and myeloid leukaemia cell lines 
(JURKAT, CCRF-CE, THP-1 and KG-la). So, leukaemia patients given CYCLO or CLB 
therapy should avoid CIS supplementation or foods containing this type of polyphenol. Results
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suggest that further in vivo experiments need to be performed to determine whether diet-based 
CIS could potentially affect CYCLO or CLB activity.
3.4.2.1 CSP in Combination with Polyphenols
The synergistic interaction between CSP and QUE in leukaemia cell lines occurred through the 
inhibition of ATP levels, induction of early apoptosis via upregulation the actvity of caspase 3 
activity, plus morphological evidence of late apoptosis and arresting the cell cycle at S phase 
for lymphoid cell lines and at G2/M phase for myeloid cell lines. This was confirmed by 
previous studies. CSP has been one of the most investigated chemotherapy drugs in 
combination with QUE in different cancer cell lines although mainly in solid tumour cells. 
Earlier work has shown that CSP and QUE when used in combination caused a synergistic 
inhibition of cell proliferation and induction of apoptosis in a number of cell lines: murine 
leukaemia cells (LI 210) (Cipak et al, 2003), small cell lung cancer cells (SW1271), pulmonary 
adenocarcinoma cells (A549) (Borska et al, 2004), human non-small cell lung carcinoma cells 
(NCL-H-520) (Kuhar et al, 2006), human laryngeal carcinoma cells (Hep-2) (Kuhar et al, 
2007), human malignant mesothelioma cells (SPC212 and SPC111) (Zergeroglu et al, 2010), 
ovarian cancer cells (A2780) (Meher et al, 2011), nasopharyngeal carcinoma cells (HK1 and 
C666-1) (Darker et al, 2012) and human hepatoculallular carcinoma cells (HepG2) (Zhao et al,
2014). Mechanistically, studies by Kuhar et al, in 2006 and 2007 and by Zergeroglu et al, in 
2010 suggested that the synergistic effect induced by the combination of CSP and QUE was 
caused by the activation of the intrinsic apoptotic pathway by the down regulation of Bcl-xl 
and Bcl-2; and an increase in cytochrome c and caspase 3 activity Furthermore, it was found 
that CSP when used in combination with QUE synergistically arrested the cell cycle at S and 
G2/M phases in murine leukaemia cell lines (LI 210) (Cipak et al, 2003), at S phase only 
human malignant mesothelioma cell lines (SPC212 and SPC111) (Zergeroglu et al, 2010), and 
at Go/Gi phase by elevation of p i 6  expression in human hepatocellular carcinoma cell lines 
(HepG2) (Zhao et al, 2014). These earlier studies along with the evidence shown here support 
the theory that the combination of CSP and QUE could have promise in the treatment of a 
number of cancers including leukaemia.
However, there is a recent study by Li et al, 2014 who showed that when CSP was combined 
with low concentrations (5 pM-30 pM) of QUE, it could induce an antagonistic effect via 
inhibition the apoptosis. However, when CSP was combined with higher concentrations of 
QUE (40 pM-100 pM) this resulted in synergistic effects in human epithelial ovarian cancer 
cell lines (C l3* and SKOV3) (Li et al, 2014). It was suggested that the therapeutic effects of 
CSP in combination with QUE, can be influenced by dose, with the lower concentrations of 
QUE causing suppression of ROS-induced injury, reduce intracellular ROS level and
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increasing the expression of endogenous antioxidant enzymes such as glutathione enzymes, 
leading to a reduced therapeutic efficacy of CSP in human epithelial ovarian cancer cell lines 
(Li et al, 2014). Thus it is essential that if CSP and QUE are to be used together, the dose need 
to be sufficient to drive their pro-apoptotic effect, and may require ex vivo testing on a patient- 
by-patient basis. Consideration of QUE in diet is particularly important given the fact that diet- 
derived QUE can accumulate at levels that inhibit bortezomib via a direct antagonistic 
mechanisms-dependent on a direct chemical interaction between the vicinal diol of quercetin 
and the boronic acid of bortezomib, which converting the active triangular boronic acid of 
bortezomib to an inactive tetrahedral in human multiple myeloma cell lines (MC/CAR, 
RPMI8226 and U266) (Kim et al, 2009).
In this study, CSP was found to interact with AP in both lymphoid and myeloid leukaemia cell 
lines (JURKAT, CCRF-CEM, THP-1, and KG-la). In previous studies CSP when used in 
combination with AP has caused a synergistic inhibition of cells proliferation and induction of 
apoptosis in head and neck squamous cell carcinoma cell lines (SCC25) through the increase 
in intracellular ROS levels, reduce the levels of glutathione (GSH), and increased Bcl-2- 
mediated caspase production (Chan et al, 2012); in human nasopharyngeal carcinoma cell lines 
(CNE-2Z) through up-regulation of Bax expression and down-regulation of Bcl-2 expression 
(Yong et al, 2012); and finally in human laryngeal carcinoma cell lines (Hep-2) through 
inhibition of glucose transporter-1 (GLUT-1) and PI3K/Akt expression (Xu et al, 2014).
Furthermore, here CSP has also been shown to act synergistically with all the remaining 
polyphenols (EMO, RH and CIS), however only in lymphoid leukaemia cell lines (JURKAT 
and CCRF-CEM) as showed by reduced ATP levels, induction of caspase 3 activity and 
apoptosis; plus arrest of the cell cycle at S phase. However, in the myeloid cell lines (THP-1 
and KG-la) CSP had an antagonistic effect when combined with EMO, RH or CIS. There was 
an elevation of ATP levels, a reduction in capase 3 and an inhibition the apoptosis; with no 
effect been seen on the cell cycle profile. Thus it would seem that the therapeutic effects of 
CSP in combination EMO, RH or CIS appears to be dependent on the cell lineage; which lead 
to the suggestion that the use of CSP in combination with polyphenols is only usefttl in the 
treatment of lymphoid leukaemia, but not myeloid leukaemia.
Many studies have been reported that CSP can be potentiated by EMO, producing synergistic 
effects on inhibition of cells proliferation and induction of apoptosis in non-small cell lung 
cancer (NSCLC) with HER-2/neu-overexpressing (Zhang and Hung, 1996; Ko et al, 2010), in 
merkel cell carcinoma (MCC) (Fenig et al, 2004), human ovarian tumour cell lines (A2780) 
(Kurokawa et al, 2010), and finally in gallbladder carcinoma cell lines (SGC996) through the 
depletion of glutathione (GSH) that related to ROS-mechanisms; and down-regulation the
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expression of survivin protein and multidrug resistance-related protein 1 (MRP1) (Wang et al, 
2010; Wang et al, 2011). To date there are no studies of the effect of CSP combination 
treatments with RH or CIS.
In general, the results show that CSP was differently modulated by polyphenols within the 
leukaemia cell lines. This is in agreement with the finding of Cvipak et al, 2003, who 
demonstrated in murine leukaemia cell lines (LI 210) that CSP can be differently modulated by 
polyphenols: having a synergistic effect with quercetin or luteolin, an additive effect with 
apigenin and an antagonistic effect with galangin and chrysin on cells proliferation and 
apoptosis (Cvipak et al, 2003).
3.4.2.2 CYCLO in Combination with Polyphenols
CYCLO differently interacted with each polyphenols (Table 3.7): CYCLO when combined 
with AP only produced a synergistic effect in both lymphoid and myeloid leukaemia. Likewise 
when CYCLO was combined QUE, EMO or RH it also produced synergistic effects and but 
only in the lymphoid leukaemia cells. In the myeloid leukaemia treatment these combinations 
produced antagonistic effects. Finally, when CYCLO was used in combined with CIS this 
caused an antagonistic effect in both lymphoid and myeloid leukaemia cells. This 
demonstrated that CYCLO is influenced by the polyphenol type and the lineage of the cells. 
Thus the most effective polyphenol to work in combination with CYCLO is AP for all 
leukaemia types; whilst CYCLO activity is inhibited when combined with QUE, EMO, RH 
and CIS in myeloid leukaemia type. Findings suggest that further in vivo investigations require 
to be performed to determine whether diet-based QUE, EMO, RH and CIS could potentially 
affect CYCLO activity.
There are two previous studies that show that the efficacy of CYCLO can be differentially 
modulated by natural agents such as curcumin and resveratrol in human breast cancer cell lines 
(Somasundaram et al, 2002; Singh et al, 2011). It was reported that the CYCLO activity was 
blocked by curcumin in human breast cancer cell lines (MCF-7, MDA-MB-231, and BT-474). 
It caused an antagonistic inhibition of apoptosis via the reduction of reactive oxygen species 
(ROS) production and the inhibition of the c-Jun NH2-terminal kinase (JNK) pathway 
(Somasundaram et al, 2002). Alternatively, when CYCLO was combined with resveratrol in 
human breast cancer cell lines (MCF-7) it caused a synergistic inhibition of cells proliferation 
and induced apoptosis (Singh et al,2012). This supported the findings of this study that the 
efficacy of CYCLO is differently modulated by polyphenols, dependent on polyphenol type 
and/or cell lineage.
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3.4.2.3 CLB in Combination with Polyphenols
In comparison with the alkylating agents (CSP and CYCLO), the efficacy of CLB had the least 
synergistic effects. Synergy was only observed when CLB was combined with 2 out 5 
polyphenols: with AP in both lymphoid and myeloid leukaemia cell lines, and with RH in 
lymphoid leukaemia cell lines only. Similar to CYCLO combination work, CLB 
synergistically interacted with AP, and an antagonistic effect with CIS in all the leukaemia cell 
lines (JURKAT, CCRF-CEM, THP-1, and KG-la). According to CLB combination results, 
CLB had differential effects either synergistic or additive or antagonistic effects when 
combined with polyphenols within the leukaemia cell lines. The differential combination 
effects of CLB with polyphenols could be dependent on polyphenol type. In particular CLB 
when combined with flavonoides (QUE and AP) and anthraquinones (EMO and RH) there was 
either additive or synergistic interaction. Alternatively when CLB was combined with 
stilbenoide (CIS) there was an antagonistic interacted within all the leukaemia cell lines. To 
date there is only one study investigating the interaction of CLB with polyphenols. CLB when 
combined with QUE was shown to synergistically reduced glutathione (GSH) levels and 
induced apoptosis in human colon adenocarcinoma cell lines (SW480) (Zhang et al, 2003). A 
similar effect is shown here, the combination of CLB with QUE had an additive effect 
reduction ATP levels and inducing apoptosis in leukaemia cell lines.
3.4.3 Anti-Metabolites Agents in Combination with Polyphenols
3.4.3.1 M TX and 6-MP in Combination with Polyphenols
In this study, the anti-metabolite chemotherapy agents such as MTX and 6 -MP were the least 
effective chemotherapy agents when combined with polyphenols within the leukaemia cell 
lines. Particularly, MTX and 6 -MP when combined with all polyphenols (QUE, AP, EMO, RH, 
or CIS) had an antagonistic effect increasing ATP levels and inhibiting caspase 3 activity and 
apoptosis; as well as having no effect on cell cycle profile (Table 3.10 and 3.11). This study is 
the first study to investigate MTX and 6 -MP in combined with polyphenols; suggesting a 
further in vivo experiment is urgently needed to determine whether diet-based polyphenols 
(QUE, AP, EMO, RH and CIS) could potentially affect MTX or 6 -MP activity.
3.4.3.2 5-FLU in Combination with Polyphenols
5-FLU had a varied effects when combined with polyphenols, producing either synergistic or 
additive or antagonistic effects depending on the polyphenol type and the leukaemia lineage 
(Table 3.12). The most promising combination for 5-FLU was with AP in which they were 
effectively interacted in both lymphoid and myeloid leukaemia cell lines and a synergistic
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reduced of ATP levels, an increase in capase 3 activity and apoptosis; plus arrest of the cell 
cycle at S phase in the lymphoid cell lines and in Go/Gi for the myeloid cell line.
These results are consistent with previous finding in which 5-FLU was shown to 
synergistically interacted with three polyphenols: (1) AP in head and neck squamous cell 
carcinoma cell lines (SCC25) through increase in intracellular ROS levels, reduction of GSH 
and increase caspase 3 activation (Chan et al, 2012); (2) QUE in colorectal cancer cell lines 
(HCT116), prostate cancer cell lines (PPC1) (Samuel et al, 2012) and human epithelial ovarian 
cancer cell lines (C l3* and SKOV3) (Li et al, 2014) through the inhibition of cell 
proliferation and the induction of apoptosis through the up-regulation of p53, p21, BAX and 
down regulation of cyclin B1 and survivin , and arrested of the cell cycle at S and G2/M 
phases (Samuel et al, 2012; Li et al, 2014); (3) EMO in non-small cell lung cancer cell lines 
(NSCLC) via decreased tyrosine phosphorylation of HER-2/neu which then preferentially 
suppressed proliferation of HER-2/neu-overexpressing NSCLC cells (Zhang and Hung, 1996). 
Most of these earlier studies suggested 5-FLU in combination with polyphenols could be 
promising for cancer treatment. However, in our study 5-FLU acted antagonistically with CIS 
in all leukaemia cell lines; and with RH in the myeloid leukaemia cell lines (Table 3.12). This 
suggesting that 5-FLU can be differential modulated by polyphenols according to polyphenol 
type or cell lineage.
3.4.4 Tyrosine Kinase Inhibitor Agent -  Imatinib (IM)
In this study, tyrosine kinase inhibitor agent such IM, were found to be one of the least 
effective therapy when used in combination with the selected polyphenols; most likely reason 
as only active against BCR-ABL + ve or fairly specific with limited activity against other 
RTKs. The IM polyphenol combination treatment produced manly additive and antagonistic 
responses within the leukaemia cell lines. The only exception was seen when IM used in 
combination with AP, were it produced a synergistic effects; although this was only seem in 
the myeloid leukaemia cell lines (THP-1 and KGla). This is the first time a study has been 
made of the interaction between IM and polyphenols, but these results do not identify any 
potential IM/polyphenol combination therapies that could be useful in the treatments of 
leukaemia.
3.5 Conclusions
The majority of prior studies suggest that the activity of chemotherapeutic agents can be 
enhanced by polyphenols, however, there are a few studies which have demonstrated 
inhibitory actions of polyphenols on chemotherapeutic agents, responses have been shown to 
be dependent on the polyphenols chemical structure (Golden et al, 2009; Kim et al, 2009;
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Perrone et al, 2009), anti-oxidant functions (Somasundaram et al, 2002; Cipak et al, 2003; 
Kim et al, 2009; Davalli et al, 2012) or administration dose (Li et al, 2014). Furthermore, this 
highlights that urgent investigations are now required to determine whether cancer patients 
undergoing chemotherapy could successfully respond to polyphenols; or should avoid 
polyphenols supplementation, and possibly even limit their exposure to polyphenols- 
containing foods.
Our study has shown that the efficacy of standard chemotherapeutic drugs were differentially 
modulated by polyphenols, producing either synergistic, additive or competitive 
antagonistic/antagonistic effects within the lymphoid and myeloid leukaemia cell lines, which 
was dependent on type of polyphenol, chemotherapy agent and cell line. The combined effect 
of polyphenols on reduction of ATP levels, induction of early and late apoptosis, and cell cycle 
arrest indicate some of these agents could be useful in improving leukaemia therapies; however 
combination therapies could also prevent the actions of chemotherapeutic agents. Identification 
of interaction between polyphenolic compounds and chemotherapy drugs may provide new 
pathways to target cancerous cells. As a result, since some polyphenols enhance the activity of 
chemotherapy, and some inhibit the activity of chemotherapy, it is essential to consider these 
interactions for dietary advice during therapy of cancer patients.
The exact mechanism, by which these differential effects of polyphenols have on the activity 
of chemotherapeutics are still unknown. Some studies have proposed that polyphenols can 
enhance the chemotherapeutic agents through their ability to inhibit kinases such as PKC that 
are involved in phosphorylation of topo II enzyme which can lead to inhibition of cell 
proliferation, induce apoptosis and arrest the cell cycle in cancer cells (Cvipak et al, 2003). 
Furthermore polyphenols which block chemotherapeutic agents have been proposed to act via 
their anti-oxidative activity which is proposed to be cytoprotective for the cancer cells against 
the reactive oxygen species (ROS) which are generated from chemotherapeutic agents 
(Somasundaram et al, 2002; Cipak et al, 2003; Kim et al, 2009; Davalli et al, 2012), or 
through direct chemical interaction between the polyphenols and anti-cancer agents (Golden et 
al, 2009; Kim et al, 2009; Perrone et al, 2009). In addition, it is known that polyphenols are 
powerful antioxidants and free radical scavengers and may modulate the activity of phase I and 
II enzymes, in particular glutathione (GSH)-related enzymes, which are the major enzymes 
responsible for antioxidant functions (Luceri et al, 2002). Moreover, usually cancer cells 
express high levels of glutathione ^-transferase (GST), which are commonly associated with 
the failure of cancer chemotherapy and poor patient survival (Luceri et al, 2002). Thus, the 
resulting synergistic or antagonistic effects from combination of polyphenols with 
chemotherapy drugs could be dependent on a modulation in glutathione (GSH) level within the 
leukaemia cells, which requires further study.
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Chapter 4
Mechanism of Polyphenol Induced 
Modulation of Chemotherapy Agent 
Activity.
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4,1 Introduction
The polyphenols studied here have been shown to induce apoptosis in leukaemia cell lines 
(Chapter 2). Furthermore they can be ranked from the most to the least to effectiveness at 
inducing apoptosis (emodin> quercetin > cw-stilbene = apigenin > rhein = aloe-emodin > 
^rans'-stilbene). These polyphenols have been shown to act synergistically with some 
chemotherapeutic agents such as toposiomerase inhibitor agents DOX or ETP in lymphoid cell 
lines. However these same polyphenols have been shown to have an antagonistic when used in 
combination with anti-metabolites agents MTX and 6 -MP in both the lymphoid and myeloid 
leukaemia cell lines (Chapter 3). This leads to the suggestion that the effects of polyphenols 
alone and in combination with chemotherapeutic agents in leukaemia cell lines is clearly 
dependent of the polyphenol, the chemotherapy type, the cell lineage and/or the doses used 
(Chapter 3).
Here, the potential mechanisms of apoptosis were investigated. Firstly, it was important to 
determine whether polyphenols alone and in combination with chemotherapeutic agents 
induced apoptosis via the extrinsic or intrinsic pathways, as this could impact on the potential 
apoptosis regulatory molecules that polyphenols may modulate. Secondly, it was important to 
identify whether the sensitivity and resistance of leukaemia cell lines to polyphenols alone and 
in combined with chemotherapeutics occurred based on the changing basal glutathione (GSH) 
content in cells. Thirdly, it was important also to demonstrate whether the combination of 
polyphenols and chemotherapeutic agents caused differential effects (synergetic, additive or 
antagonistic effects) on apoptosis induction through the modulation in glutathione (GSH) 
levels. Finally, it was necessary also to confirm whether the combination of polyphenols and 
chemotherapeutic agents induced apoptosis, as well as, arrested cell cycle at S phase and/or 
G2/M phase by high expression of y-H2AX foci (a hallmark of DNA damage). The rationale 
being that polyphenols may deplete GSH, resulting in enhanced chemotherapy-induced DNA 
damage, as determined by y-H2AX. These results may give clues to how polyphenols may 
overcome drug resistance.
4.1.1 Extrinsic Verse Intrinsic Apoptotic Pathways
Apoptotic cell death is a key regulator of cell growth; aberrant apoptosis is crucially involved 
in formation of leukaemia thus its control and regulation is crucial it determining treatments 
(Belloc et al, 2000; Lavrik et al, 2005; Elmore, 2007; Wong, 2011). Currently, most anti­
cancer agents work by driving apoptosis either through the activation of the extrinsic and/or 
intrinsic pathways (Belloc et al, 2000; Lavrik et al, 2005; Elmore, 2007; Wong, 2011). The 
extrinsic pathway is initiated from outside the cell by pro-apoptotic ligands that interact with 
specialised cell surface death receptors (DRs) (Chapter 1; Section 1.6.1.1) (Elmore, 2007;
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Wong, 2011). In contrast, the intrinsic pathway is activated from inside the cells by members 
of Bcl-2 protein family which increase the permeability of the outer mitochondrial membrane 
leading to caspases activation (Chapter 1; Section 1.6.1.2) (Elmore, 2007; Wong, 2011). Both 
pathways activate the enzymatic caspase cascade, which carries out numerous proteolytic 
events that mediate the apoptotic cell death programme (Elmore, 2007; Wong, 2011).
These caspases are a family of cysteine proteases that play crucial roles in regulating apoptosis 
and synthesised as inactive zymogens in cytoplasm (Elmore, 2007; Wong, 2011). They are 
both the initiators and executioners that are responsible for destruction of the cell (Belloc et al, 
2000; Lavrik et al, 2005; Elmore, 2007; Wong, 2011). Caspase 8  and 9 are believed to be the 
initiator caspases which are the first to be activated the executioner caspase 3 (Belloc et al, 
2000; Lavrik et al, 2005; Elmore, 2007; Wong, 2011). Caspase 8  is activated during the 
extrinsic apoptotic pathway and responsible for elimination of unwanted cells during the 
development and other stimulation signals (Elmore, 2007; Wong, 2011). On the other hand, 
caspase 9 is activated during the intrinsic/mitochondrial apoptotic pathway in response to a 
variety of stimuli such as y- and UV-radiation, DNA damage and cytotoxic drugs (Elmore, 
2007; Wong, 2011). Cell death receptor (extrinsic) and mitochondrial (intrinsic) apoptotic 
pathways are initiated by recruitment of caspase 8  into the DISC or caspase 9 into apoptosome 
(Elmore, 2007; Wong, 2011). These initiator caspases undergo then self-activation to start the 
caspase signalling cascade. Subsequently, these two pathways converge and trigger the 
execution pathway through the activation of caspase 3 (Elmore, 2007; Wong, 2011). However 
it is important to note that the exact mechanism for the activation of initiator caspases is still 
not clear.
Activation of apoptosis is considered as the key molecular mechanism responsible for the anti­
cancer action of most of the currently studied potential anti-cancer agents, including 
polyphenols (Patel et al, 2007; Sharif et al, 2010; Shukla et al, 2010). However, polyphenols 
initiate apoptosis and its mechanism of action remains poorly understood in leukaemia. Some 
earlier works have demonstrated the pro-apoptotic activity of polyphenols in solid tumours cell 
lines of the breast, lung and cervix (Dai et al, 2013; Han et al, 2007; Jaganathan et al, 2009; 
Patel et al, 2007; Sharif et al, 2010; Shukla et al, 2010). Here, they demonstrated that 
polyphenols could induce apoptosis by the direct activation of the caspase cascade (Dai et al, 
2013; Han et al, 2007; Jaganathan et al, 2009; Patel et al, 2007; Sharif et al, 2010; Shukla et 
al, 2 0 1 0 ).
4.1.2 Glutathione (GSH)
Glutathione (GSH) is the most abundant non-protein thiol intracellular antioxidant molecules, 
in the cell Wilson et al, 2006; Franco et al, 2007; Franco and Cidlowski, 2009; Abdalla, 2011;
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Ortega et al, 2011; Traverso et al, 2013). It has an important role in cellular defence against 
oxidant aggression, redox regulation of proteins thiols and maintaining redox homeostasis. 
GSH is critical to regulate several metabolic processes including enzyme activity, transport 
activity, signal transduction and gene expression through redox-sensitive nuclear transcription 
factors such as NFkB and p53 (Traverso et al, 2013). GSH is required for proper cellular 
function, including DNA and protein synthesis, cell differentiation, cell proliferation and 
apoptosis (Wilson et al, 2006; Franco et al, 2007; Franco and Cidlowski, 2009; Abdalla, 2011; 
Ortega et al, 2011; Traverso et al, 2013).
GSH accounts for greater than 90% of the cellular thiol content (Wilson et al, 2006; Murphy et 
al, 2008; Abdalla, 2011; Ortega et al, 2011; Traverso et al, 2013); of this 90% is found in the 
cytosol, while nearly 1 0  % is found in the mitochondria and a tiny amount is found in 
endoplasmic reticulum (Abdalla, 2011; Traverso et al, 2013). GSH is known as a ubiquitous 
tripeptide glutathione, which is formed by glutamic acid, cysteine, and glycine (Abdalla, 2011; 
Traverso et al, 2013). These peptides are assembled into active GSH in the presence of y- 
glutamylcysteine synthetase (GCS), glutathione synthetase (GS), GSH reductase (GR), GSH 
synthetase (GSS), gamma glutamyltransferase (GTT) and glutathione S-transferases (GSTs) 
(Abdalla, 2011; Brechbuhl et al, 2012; Traverso et al, 2013; Irwin et al, 2013). These enzymes 
play an important role in synthesis, turnover, homeostasis and maintenance of intracellular 
GSH concentration (Brechbuhl et al, 2012; Irwin et al, 2013). Due to nucleophilic thiol group 
of tripeptide glutathione it can detoxify substances within the cell in one of three ways: ( 1 ) 
conjugation of glutathione to substrates catalyzed by glutathione S-transferases (GSTs); (2) 
chemical reaction with a reactive metabolite to form a conjugate; and (3) donation protons or 
hydrogen atoms to reactive metabolites or free radicals (Durgo et al, 2007). The action GSH 
and its enzymes are regulated by the specific transcription factor called nuclear factor E2- 
related factor 2 (Nrf2) (Abdalla, 2011; Traverso et al, 2013).
GSH is usually present in two forms: the reduced form GSH and the oxidized form GSSG 
(Abdalla, 2011; Traverso et al, 2013). The reduced form (GSH) represents the majority of 
GSH range between 1 and 10 mM and this form can be converted to the oxidized form (GSSG) 
during oxidative stress; which is estimated to be less than 1% of the total GSH (Abdalla, 2011; 
Traverso et al, 2013). The majority of GSH within the cell is found in a reduced form 
(Traverso et al, 2013; Irwin et al, 2013). Normally, maintaining optimal GSH: GSSG ratios in 
the cell are critical for cell survival, and a deficiency of GSH can result in oxidative damage 
(Abdalla, 2011; Traverso et al, 2013; Irwin et al, 2013). Their disruptions are contributed to 
development of many human diseases including neurodegenerative disorders, cystic fibrosis 
and aging and cancers including leukaemia, melanoma, hepatoma and ovarian cancer (Abdalla, 
2011; Traverso et al, 2013).
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In both normal and cancer cells, increased GSH level is associated with a proliferative 
response and is essential for cell cycle progression (Traverso et al, 2013). Particularly in 
normal healthy cells, a higher level of GSH is important for: (1) protecting cells from reactive 
oxygen species (ROS), toxins, mutagens, carcinogens and drugs, (2) normal cellular functions 
including signal transduction, and (3) regulation of gene expression, cell survival, apoptosis, 
and membrane transportation (Meurette et al, 2005; Murphy et al, 2008; Abdalla, 2011; Ortega 
et al, 2 0 1 1 ).
However, in cancerous cells, GSH plays an important role in regulating mutagenic and 
carcinogenic mechanisms including: continual DNA synthesis, cell growth, prevention of cell 
death, cell sensitivity or resistance against cytotoxic drugs; and multidrug and radiation 
resistance (Meurette et al, 2005; Murphy et al, 2008; Abdalla, 2011; Ortega et al, 2011; 
Traverso et al, 2013). Many cancers, including lung, ovarian breast, colon, larynx and 
haematological malignancies have high levels of GSH (Abdalla, 2011; Traverso et al, 2013). 
This high GSH level increases the antioxidant capacity of the cancerous cell preventing 
oxidative stress, repaired the DNA damage and inhibited cell death process; and as a result this 
can lead to resistance to cancer treatments (Abdalla, 2011; Traverso et al, 2013). Irwin et al, 
2013 reported that GSH and its associated enzymes, such as GST are commonly highly present 
in AML, CML and CLL patients compared with healthy individuals (Irwin et al, 2013). It is 
believed that this high GSH level protecting these leukaemia cells from oxidative stress and 
DNA damage chemotherapeutics (Irwin et al, 2013; Traverso et al, 2013). It is reported that 
the GSH system is capable of removing ROS from leukaemia cells (Traverso et al, 2013). It is 
also reported that an elevated GSH in these types of leukaemia patients is correlated with 
increased risk of disease relapse and resistance to the chemotherapeutics (Irwin et al, 2013). In 
particular, it has been found that AML, CML and CLL patients with high GSH levels is 
associated with resistance to anti-cancer agents such as cisplatin, doxorubicin, daunorubicin 
and melphalan (Irwin et al, 2013). In contrast, some types of cancers such as melanoma have 
low intracellular GSH levels, which decreases the cellular antioxidant capacity and increased 
oxidative stress via excessive production of ROS, which can cause DNA damage and 
ultimately leads to cell death; this event consequently increased the sensitivity of cancer cells 
to the treatment (Abdalla, 2011; Traverso et al, 2013). In this regard, measurment of the basal 
levels of GSH in cancer cells and detection of GSH is relevant to understanding the 
mechanisms of action of many cancer treatments, since many earlier reports show that 
depletion of GSH level sensitizes cancer cells to chemotherapy (Meurette et al, 2005; Murphy 
et al, 2008; Abdalla, 2011; Ortega et al, 2011; Traverso et al, 2013).
Several studies suggest that increased levels of glutathione (GSH) and its enzymes is 
considered as one of the major contributing factors to increase chemo-resistance in cancer cells
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(Wilson et al, 2006; Abdalla, 2011; Ortega et al, 2011; Traverso et al, 2013). Cisplatin, 
oxaliplatin, doxorubicin, and 5-fluorouracil are examples of chemotherapeutic agents which 
have an ability to conjugate with the thiol glutathione (GSH) (Wilson et al, 2006; Traverso et 
al, 2013). From earlier studies, the proposed mechanisms for the role of GSH in regulating 
chemotherapy agents’ resistance are: (1) GSH may serve as a cofactor in facilitating multidrug 
resistance protein (MRP)-mediated chemotherapy agents efflux in cells; (2) GSH may serve as 
a redox regulating cytoprotector based on the observations that many chemotherapy agents 
such as cisplatin and doxorubicin-resistant cells overexpress GSH; (3) high GSH levels in 
cancer cells can increase the rate of conjugation and detoxification of chemotherapy agents; 
and (4) GSH may function as a copper (Cu) chelator, thus reducing their effectiveness (Wilson 
et al, 2006; Abdalla, 2011; Ortega et al, 2011; Brechbuhl et al, 2012; Traverso et al, 2013). 
These reports suggested that in order to increasing chemotherapy efficacy and limit multi-drug 
resistance (MDR), the GSH levels may be depleted in cancer cells (Wilson et al, 2006; Abdalla, 
2011; Ortega et al, 2011; Brechbuhl et al, 2012; Traverso et al, 2013).
Pervious work has shown isothiocyanates such as sulforaphane and p-phenylethyl 
isothiocyanate (Andelova et al, 2007; Hu et al, 2010; Traverso et al, 2013; Irwin et al, 2013); 
and polyphenols such as quercetin (Tsao,2010; Khan et al, 2012) are the strongest natural 
inducer of phase II detoxifying enzymes such as GST (Andelova et al, 2007; Hu et al, 2010; 
Tsao,2010; Khan et al, 2012; Traverso et al, 2013; Irwin et al, 2013). It has been shown that 
both isothiocyanate and polyphenol can serve as either antioxidants or pro-oxidants depending 
on cellular conditions, requirement and doses; thus they can help in the modulation of 
antioxidant redox system such as glutathione (GSH) (Andelova et al, 2007; Hu et al, 2010; 
Tsao,2010; Khan et al, 2012; Traverso et al, 2013; Irwin et al, 2013). In addition, it has been 
reported that the antioxidant activity of isocyanates and polyphenols play a crucial role in their 
chemopreventive effect; whilst their pro-oxidant action may be important for their anti- 
cancerous effects (Andelova et al, 2007; Hu et al, 2010; Khan et al, 2012; Traverso et al, 2013; 
Irwin et al, 2013).
Currently, all the present studies reported that GSH depletion in cells is strongly correlated to 
restore apoptosis induction, and this action could be very useful to increase the therapeutic 
efficacy of cancer treatment (Franco et al, 2007; Franco and Cidlowski, 2009; Ortega et al, 
2011; Traverso et al, 2013; Irwin et al, 2013; Rocha et al, 2014). They reported that GSH 
depletion has been shown to regulate both extrinsic and intrinsic apoptotic signalling cascades 
at distinct checkpoints (Franco et al, 2007; Franco and Cidlowski, 2009; Ortega et al, 2011). 
Particularly, GSH depletion can predispose cells to apoptosis or directly trigger cell death by 
modulation of both the permeability transition pore formation and the activation of execution 
caspases (Franco et al, 2007; Franco and Cidlowski, 2009; Ortega et al, 2011). Also, it has
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been reported that a reduction in the GSH content is necessary for the formation of the 
apoptosome and activates the intrinsic apoptotic pathway initiator by its oxidation-dependent 
dimerization (Franco et al, 2007; Franco and Cidlowski, 2009; Ortega et al, 2011). 
Furthermore, GSH depletion has also been shown to trigger cytochrome c release and it has 
been proposed that released cytochrome c from the mitochondria requires to be oxidized for its 
pro-apoptotic action, which would need cytosolic GSH levels to be depleted (Franco and 
Cidlowski, 2009). Also, it is reported that the GSH depletion during apoptosis can occur 
through distinct mechanisms: (1) by its extrusion across the plasma membrane through GSH 
transporters or pumps, which can lead then to activate the death receptors or caspases; (2 ) by 
its oxidation to GSSG which can lead to activate the intrinsic pathways of apoptosis because of 
the generation of reactive oxygen species (ROS) that arise from impairment of mitochondrial 
function; (3) by both its direct oxidation and/or conjugation, which then activated the apoptotic 
signals arising from pro-oxidant stimuli mediate GSH depletion; or finally by (4) impairment 
of GSH synthesis and recycling, which might also contribute to induce apoptosis (Wilson et al, 
2006; Traverso et al, 2013). Many studies showed that the antioxidant property of GSH is 
strongly linked to overexpression of anti-apoptotic Bcl-2, which inhibits mitochondrial- 
induced apoptosis (Franco et al, 2007; Franco and Cidlowski, 2009; Abdalla, 2011; Ortega et 
al, 2 0 1 1 ).
In fact, the modulation of cellular GSH is a double-edged sword, both sides of which have 
been exploited for potential therapeutic benefits (Abdalla, 2011; Traverso et al, 2013; Irwin et 
al, 2013; Rocha et al, 2014). Enhancing the capacity of GSH and its associated enzymes, in 
order to protect cells from redox related changes or environmental toxins, represents a 
persistent aim in the search for cytoprotective strategies against cancer (Abdalla, 2011; 
Traverso et al, 2013; Irwin et al, 2013; Rocha et al, 2014). On the contrary, the strategy of 
depleting GSH and GSH-related detoxification pathways is aimed at sensitizing cancer cells to 
chemotherapy, the so-called chemosensitization (Abdalla, 2011; Traverso et al, 2013; Irwin et 
al, 2013; Rocha et al, 2014). Finally, all these studies suggested that understanding the GSH- 
driven molecular pathways could be crucial to design new therapeutic strategies for 
overcoming cancer cell progression and chemoresistance, and increasing chemosensitivity 
(Abdalla, 2011; Traverso et al, 2013; Irwin et al, 2013; Rocha et al, 2014). To date, little work 
has looked at the GSH levels in leukaemia cells; and how these are affected by polyphenols 
alone and in combination with standard chemotherapy agents. Here a study of GSH levels is 
undertaken in order to determine whether GSH is a key to mechanism of action of polyphenols 
and chemotherapy agents in leukaemia cells and whether it can be used to explain the 
synergistic and antagonist effects observed when polyphenols and chemotherapy agents are 
used in combination.
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4.1.3 Hallmark of DNA Damage: y-H2AX Foci Formation
It is known that DNA wraps around an octameric complex of core histones H2A, H2B, H3 and 
H4 to form nucleosomes (Kuo and Yang, 2008; Fragkos et al, 2009; Rajendran et al, 2011). 
These histones are highly basic proteins that complex with DNA to form chromatin (Kuo and 
Yang, 2008; Fragkos et al, 2009; Rajendran et al, 2011). H2AX is a member of the H2A 
histone family and its phosphorylation is considered as a hallmark of DNA damage (Solier and 
Pommier, 2009; Rajendran et al, 2011). Studies have reported when cells are exposure to DNA 
damaging agents such as ionizing radiation, UV light or chemotherapies (e.g. 
cyclophosphamid, cisplatin, etoposide and doxorubicin) this causes a rapid phosphorylation of 
a serine-139 residue (also known as y-H2AX) (Rakiman et al, 2008; Kuo and Yang, 2008; 
Fragkos et al, 2009; Rajendran et al, 2011). This directly recruits clusters of proteins at the site 
of DNA damage, called DNA damage response foci (Rakiman et al, 2008; Kuo and Yang, 
2008; Fragkos et al, 2009; Rajendran et al, 2011). The rapid phosphorylation of serine 139 (y- 
H2AX) recruits a variety of proteins commonly associated with DNA damage/repair and cell 
cycle check points (Fragkos et al, 2009; Rajendran et al, 2011). Indeed, H2AX is 
phosphorylated by phosphatidylinositol-3 kinase (PI3K)-like kinases, including ATM, ATM- 
Rad3-related (ATR), ATM related kinase (ATX) and other cell cycle checkpoint factors such 
as Chkl and Chk2 (Fragkos et al, 2009; Rajendran et al, 2011). So, phosphorylated yH2AX 
plays an important role the recruitment and localization of DNA proteins, and cell cycle 
checkpoint factors to the DNA-damaged sites; the latter being the main effector for the 
induction of apoptosis (Kuo and Yang, 2008; Fragkos et al, 2009; Solier and Pommier, 2009; 
Rajendran et al, 2011). Thus the presence of y-H2AX foci are an excellent marker of DNA 
damage caused by cytotoxic agents or cancer treatments (Kuo and Yang, 2008; Fragkos et al, 
2009; Solier and Pommier, 2009; Rajendran et al, 2011).
Some earlier studies in solid tumours have reported that dietary agents including: 
isothiocyanates (such as sulforaphane) (Singh et al, 2004; Zhang et al, 2006; Andelova et al, 
2007; Sekine-Suzuki et al, 2008) and polyphenols (such as quercetin, genistein, curcumin and 
resveratrol) (Tan et al, 2009; Ouyang et al, 2009; Sahu et al, 2009; Leone et al, 2010) can 
cause DNA damage response, resulting in the formation of y-H2AX foci (Singh et al, 2004; 
Zhang et al, 2006; Andelova et al, 2007; Sekine-Suzuki et al, 2008; Tan et al, 2009; Ouyang 
et al, 2009; Sahu et al, 2009; Leone et al, 2010; Rajendran et al, 2011). For example, 
sulforaphane has been shown to induce DNA damage associated with the elevation in the 
expression of y-H2AX levels, which also caused an increase in ROS generation, a depletion of 
GSH, an activation of G2 /M checkpoint and cell death in cancer cell lines of prostate (PC-3) 
(Singh et al, 2004), colon (SW620 and HCT116) (Andelova et al, 2007) and cervical (HeLa) 
(Sekine-Suzuki et al, 2008). Likewise, the polyphenols: quercetin, genistein, curcumin and
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resveratrol have been shown to cause direct DNA damage in association with an increase of 
H2AX phosphorylation through the activation of the ATM/ATR and CHK1/2 pathway- 
mediated S or G2/M cell cycle arrest and apoptosis; in cancer cell lines of lung (A549) (Tan et 
al, 2009), ovarian (HO-8910 and Ovcar-3) (Tyagi et al, 2005; Ouyang et al, 2009) and 
pancreas (BxPC-3) (Sahu et al, 2009).
Rajendran et al, (2011) suggested that combination agents could be very effective and 
produced synergistic actions when used to target DNA damage and interfer with DNA repair in 
cancer cells (Rajendran et al, 2011). There are only four studies examining the effects of 
combination anti-cancer agents on DNA damage. The combination used included: benzyl 
isothiocyanate and y-irradiation (Sahu et al, 2009), P-phenylethyl isothiocyanate and vorinostat 
(Hu et al, 2010), sulforaphane and the HD AC inhibitor, panobinostat (LBH589) (Pettazzoni et 
al, 2011) and resveratrol and the purine analogs (fludarabine or cladribine) (Podhorecka et al, 
2011). Each combination caused a synergistic cytotoxicity, G2 /M phase arrest and apoptosis 
associated with increase the expression of y-H2AX in pancreatic cancer cell lines (BxPC-3) 
(Sahu et al, 2009), a prostate cancer cell lines (PC3) (Pettazzoni et al, 2011) a leukaemia cell 
lines (HL60) (Hu et al, 2010) and chronic lymphocytic leukaemia (CLL) cells taken from a 
patients (Podhorecka et al, 2011). It was reported that the synergestic effect seen in each study 
was attributed to an increase in y-H2AX foci which occurred through the activation of 
ATM/ATR, Chk2, Cdc25C, and Cdk-1, and induction of p21 (Sahu et al, 2009; Hu et al, 2010; 
Pettazzoni et al, 2011; Podhorecka et al, 2011); and the inhibition of GSH (Hu et al, 2010). 
Therefore the measurement of y-H2AX foci is useful indicator to identify the most effective 
agents that induce the DNA damage (in particular DSBs) (Kuo and Yang, 2008). y-H2AX can 
also be useful for elucidating the pharmacodynamics of cytotoxic drugs and tumour killing 
drugs (Kuo and Yang, 2008). The foci can be measured to elucidate whether or not drugs reach 
the tumour, whether or not drugs reach their activated forms, and whether or not the drugs 
affect the DNA (Kuo and Yang, 2008). Finally, agents that targeted the DNA and then caused 
DNA damage through an increased in the formation of y-H2AX foci can be very effective for 
cancer treatment; because presence of y-H2AX foci after treatment indicate the induction of 
cell cycle arrest and/or apoptosis in cancer (Kuo and Yang, 2008; Rajendran et al, 2011).
4.1.4 Hypothesis
It is hypothesised that the induction of apoptosis observed following polyphenol treatment is 
caused by the activation of the intrinsic apoptotic pathway through the up-regulation of caspase 
9 and/or the extrinsic apoptotic pathway via the up-regulation of caspase 8  in part, via 
reduction of glutathione, which normally protects cells against oxidative stress and apoptosis.
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Further to this, it is hypothesised that polyphenols alone and in combination with 
chemotherapy agents can alter DNA damage and subsequent apoptosis.
4.1.5 Aims
The major aims of this study were to investigate the effects of the polyphenols and 
chemotherapeutic agents alone or in combination on: (1) activity of initiator caspase 8  and 9 of 
apoptosis using Caspase-Glo 8  and 9 luminescent assays, (2) glutahione (GSH) levels using the 
GSH-Glo™ glutathione luminescent assay and CellTracker GSH-Green 5- 
chloromethylfluorescein diacetate (CMFDA) stain and (3) y-H2AX foci formation using 
immuneflurocant staining called Alexa Fluor® 647 Mouse anti-H2AX (pS139) in two human 
lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) and two human myeloid leukaemia 
cell lines (THP-1 and KG la).
4.2 Methods and Materials
4.2.1 Experimental Design
The effects of polyphenols alone (quercetin, apigenin, chrysin, emodin, aloe-emodin, rhein, 
cis-stilbene and trans-stilbene) and in combination with standard chemotherapy agents were 
investigated to determine effects on caspase 8  and 9 activity; glutathione (GSH) levels and the 
induction of DNA damage. Initially, the effect of each polyphenol alone (quercetin, apigenin, 
chrysin, emodin, aloe-emodin, rhein, c/s-stilbene and /raws-stilbene) was examined on the 
levels of caspase 8  and 9 activity, glutathione (GSH) levels and DNA damage.
For the polyphenol/chemotherapy agent combination work, only those combinations which 
induced a synergistic reduction in ATP levels and induction of apoptosis were investigated 
further these included: quercetin (QUE); apigenin (AP); emodin (EMO); rhein (RH) and cis- 
stilbene (CIS) (Sigma) (Chapter 2). Likewise only those chemotherapy agents which 
significantly interacted with polyphenols which were identified in Chapter 3 were investigated 
further. These included: two topoisomerase inhibitor agents (doxorubicin (DOX) and etoposide, 
(ETP)), two alkylating agents (cyclophosphamide (CYCLO) and cisplatin (CSP)), and two 
anti-metabolite agents (methotrexate (MTX) and 6 -mercaptopurine (6 -MP)) (Sigma). All 
polyphenols were prepared as described in Chapter 2. All chemotherapy agents were prepared 
as described in Chapter 3. The effect of these selected polyphenols and chemotherapy agents 
were examined alone and in combination, on the caspase 8  and 9 activity, glutathione (GSH) 
levels and DNA damage.
Four human leukaemia cell lines were used for this study: two lymphoid leukaemia cell lines: 
JURKAT and CCRF-CEM, and two myeloid leukaemia cell lines: THP-1 and KG-la (Chapter 
2). All cell lines were tested regularly for mycoplasma contamination using the MycoAlert TM
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mycoplasma detection kit (Lonza) and were all tested negative throughout the study. Cells 
were cultured as previously described (Chapter 2) and incubated at 37°C with 5% CO2 in a 
humidified incubator.
4.2.2 Caspases-Glo ® Luminescent 8  and 9 Assays
Caspases play a key role in the induction of apoptosis (Lavrik et al, 2005; Belloc et al, 2000). 
Caspase 3 which was shown to be up-regulated by polyphenols (Chapter 2) is commonly 
initiated and activated by either caspase 8  via the extrinsic pathway, or by caspase 9 via the 
intrinsic pathway (Belloc et al, 2000). Thus here Caspase-Glo 8  and 9 assays (Promega) were 
used to determine the effects of polyphenols and chemotherapy agents on the induction of 
caspases 8  and 9 to determine whether apoptosis was activated via the intrinsic and/or extrinsic 
pathway. The Caspase-Glo 8  and 9 assays (Promega) contains a luminogenic substrate: 
tetrapeptide Z-LETD-aminoluciferin for caspase 8  and tetrapeptide (Z-LEHD-aminoluciferin 
for caspase 9. These substrates combine with a thermostable luciferase in the presence of 
caspase 8  or caspase 9; this causes cell lysis and the release of ATP. Each released ATP 
combines with a free aminoluciferin molecule, which in the presence of oxygen (O2), 
magnesium (Mg2+) and luciferase is catalysed to oxyluciferin, AMP, PPi and carbon dioxide. 
The energy formed during this reaction produces a luminescent signal (Figure 4.1) which can 
be measured by a luminometer. The resulting luminescent signal is directly proportional to the 
amount of caspase 8  or 9 activity.
Caspase-Glo® 8  and 9 assays (Promega) were used to examine: 1) the effect of all polyphenols 
alone (quercetin, apigenin, chrysin, emodin, aloe-emodin, rhein, c/s-stilbene and frww-stilbene 
(Sigma)) in four leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) following 6  
and 24 h. Quercetin, apigenin, emodin, rhein and c/s-stilbene were investigated at their NSD, 
LSD (as determined earlier in Chapter 3), and their AP5 0 doses (Chapter 2). The less potent 
polyphenols: chrysin, aloe-emodin and Jrans'-stilbene were tested only at their AP50 doses 
(Chapter 2); 2) the effects of selected polyphenols (quercetin (QUE), apigenin (AP), emodin 
(EMO), rhein (RH) and c/s-stilbene (CIS)) (Sigma) were investigated in combination with four 
chemotherapy drugs (etoposide, doxorubicin, cyclophosphamide, cisplatin (CSP)) (Sigma). 
Doses were selected as the LSDs that could induce apoptosis from the results from Chapter 3. 
A summary of the treatment regimens is shown in Table 4.1. Cells were seeded into white 96- 
well plates (Fisher Scientific) at 2.5 X 103 cells per well and treated. All treatments were 
performed in triplicate. An ethanol vehicle controls at 0.1 % (v/v) ethanol was also included.
Following treatments Caspase 8  and 9 activity was measured using the Caspase-Glo 8  and 9 
assays (Promega). Plates containing cells were removed from the incubator and equilibrated to 
room temperature for 30 minutes. Fifty microlitres Caspase-Glo reagent (Promega) with
proteasome inhibitor (MG-132) were added to each well and gently mixed on a plate shaker at 
400 rpm for 30 seconds. The plate was then incubated at room temperature for 90 min. The 
luminescence was measured using a Wallac Victor 2 1420 luminescence detector. The average 
luminescence readings were calculated and all treated samples were normalised to the vehicle 
controls.
Figure 4.1: Schematic of the 
Caspases-Glo 8  and 9
Assays. Caspase 8 or 9 
cleaves their luminogenic 
substrate (Z-LETD or Z- 
LEHD respectively) causing 
the production of free 
aminoluciferin. The free 
aminoluciferin reactions with 
ATP, oxygen (0 2) and 
magnesium (Mg2+) in the 
presence of luciferase to 
production luminescence, 
which can be detected by a 
luminometer.
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The Polyphenols/Chemotherapy Combinations Used to Investigate Caspase 8  and 9 Activity.
Com bination Treatm ents Lymphoid Leukaem ia Cell Lines Myeloid Leukaem ia Cell Lines
JU RK A T CCRF-CEM THP-1 K G -la
Doxorubicin (DOX) & Polyphenols
DOX + QUE 
DOX + AP 
DOX + EMO 
DOX + RH
DOX + CIS
DOX + QUE 
DOX + AP 
DOX + EMO 
DOX + RH
DOX + CIS
DOX + QUE 
DOX + AP
DOX + QUE 
DOX + AP
Etoposide (ETP) & Polyphenols
ETP + QUE 
ETP + AP 
ETP + EMO 
ETP + RH 
ETP+ CIS
ETP + QUE 
ETP + AP 
ETP + EMO  
ETP + RH 
ETP+ CIS
E T P +  QUE  
ETP + AP
ETP + QUE 
ETP + AP
Cyclophosphamide (CYCLO) & 
Polyphenols
CYCLO + QUE 
CYCLO+ AP 
CYCLO + EMO 
CYCLO + RH
CYCLO + QUE  
CYCLO+ AP 
CYCLO + EMO 
CYCLO + RH
C Y C L O + AP C Y C L O + AP
Cisplatin (CSP) & Polyphenols
CSP + QUE  
CSP + A P  
CSP + EMO  
CSP + RH
CS + CIS
CSP + QUE 
CSP + AP 
CSP + EMO 
CSP + RH
CS + CIS
CSP + QUE 
CSP + AP
CSP + QUE 
CSP + AP
Table 4.1: A summary of the polyphenols/chemotherapy combinations used to investigate 
caspase 8  and 9 activity. The LSDs for each agent was studied in four leukaemia cell lines, 
following 24 h treatment. Only those combinations that had previously induced a synergistic effect 
on caspase 3 activity and the morphological changes of apoptosis (Chapter 3) were studied.
255
4.2.3 Glutathione (GSH) Assays
The detection of GSH is important in understanding the mechanisms of action of any cancer 
treatment. For this reason two glutathione (GSH) assays: 1) GSH-Glo™ Glutathione Assay 
(Promega); and 2) CellTracker GSH-Green 5-chloromethylfluorescein diacetate (CMFDA) 
stain were used to screen the effects of polyphenols and chemotherapies alone and in 
combination. The CellTracker™ Green CMFDA- staining for GSH was used to confirm the 
GSH-Glo™ Glutathione assay results and enable visualisation of GSH in pre-apoptotic cells.
4.2.3.1 GSH-Glo™ Glutathione Assay
The GSH-Glo™ glutathione assay has two steps (Figure 4.2): 1) Initially the luciferin 
derivative substrate proluminogenic Luciferin-NT is converted into luciferin in the presence of 
glutathione S-transferase (GST) which causes cell lysis. During this process, GST detaches a 
non-functional group from a luciferin derivative and couples this to the reduced glutathione. 2) 
Luciferase is then added which converts luciferin in the presence of ATP, oxygen (O2) and 
magnesium (Mg2+) to the oxyluciferin, AMP, carbon dioxide and energy in the form of a 
luminescent signal. This signal can now be measured by a luminometer, and is directly 
proportional to the level of glutathione (GSH) present in the cell.
The GSH-Glo™ Glutathione Luminescent assay (Promega) was optimised using buthionine 
sulphoximine (BSO) as negative control (GSH inhibitor agent) and N-acetylcysteine (NAC) as 
positive control (GSH induction agent) in four leukaemia cell lines (CCRF-CEM, JURKAT, 
KG la, THP-1) and two normal cell lines (CD133+HSC and CD34+ HSC) following 24 h.
Using this assay the basal GSH levels was determined for the four leukaemia cell lines (CCRF- 
CEM, JURKAT, KG la, THP-1) and the two normal cell lines (CD133+HSC and CD34+ HSC).
Initially the GSH-Glo™ Glutathione Luminescent assay (Promega) was then used to determine 
the effect of all polyphenols alone (quercetin, apigenin, chrysin, emodin, aloe-emodin, rhein, 
cA-stilbene and frYms-stilbene (Sigma)) on GSH levels in four leukaemia cell lines (JURKAT, 
CCRF-CEM, THP-1 and KG-la) at 24 h. Quercetin, apigenin, emodin, rhein and c/s-stilbene 
were examined at their NSD and LSD that reduced ATP levels (as determined in Chapter 3); 
and their dose ranges used to determine the I C 5 0  values (Chapter 2). For chrysin, aloe-emodin 
and frYms'-stilbene these were tested at the dose ranges used to determine their I C 5 0  values 
(Chapter 2).
For the polyphenol/chemotherapy combination work the effect of selected polyphenols 
(quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) and cA-stilbene (CIS)) (Sigma), 
and six chemotherapy drugs (etoposide, doxorubicin, cyclophosphamide, cisplatin (CSP),
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methotrexate (MTX) and 6-mercaptopurine (6-MP)) (Sigma) were investigated alone and in 
combination on GSH levels using their LSDs that reduced ATP levels (Chapter 3) in four 
leukaemia cell lines (JURKAT, CCRF-CEM, THP-1 and KG-la) at 24 h. These polyphenols 
and chemotherapy drugs were selected as they had previously caused synergistic or 
antagonistic effects when used in combination (Chapter 3). A summary of the treatment 
regimens is shown in Table 4.2. Cells were seeded into white 96-well plates (Fisher Scientific) 
at 2.5 X 103 cells per well. Following treatment cells were incubated at 37°C with 5% CO2 for 
24 h. All treatments were performed in triplicate. An ethanol vehicle controls at 0.1 % (v/v) 
ethanol was also included.
Following treatment glutathione levels were measured using the GSH-Glo™ glutathione 
luminescent assay (Promega). Treated cells were initially washed with PBS, resuspended in 50 
pi of PBS in a white 96-well plate (Fisher Scientific). Fifty microliters of GSH-Glo™ reagent 
containing Luciferin-NT substrate and glutathione S-transferase (diluted 1:50 in GSH-Glo™ 
reaction buffer) (Promega) was added to each well. The content was then gently mixed, and 
incubated at RT for 30 min. Next, lOOpl of reconstituted luciferin detection reagent containing 
the luciferase enzyme (Promega) was added to each well. The content was then gently mixed 
using a shaker for 2 min and then further incubated at RT for a further 15 min. The 
luminescent signal was measured using a Wallac Victor 2 1420 luminescence detector. The 
luminescent signal is proportional to the levels of GSH in the sample. The average 
luminescence readings were calculated and all treated samples were normalised to the control.
The Polyphenols/Chemothei
ant
•apy Combinations Used to Investigate Glutathione (GSH) Levels 
DNA Damge (y-H2AX Foci Formation)
The Combination Treaments Lymphoid Leukaemia Cell Lines Myeloid Leukaemia Cell Lines
JURKAT CCRF-CEM THP-1 KG-la
Doxorubicin (DOX) & Polyphenols
DOX + QUE 
DO X +A P  
DOX + EMO 
D O X+RH  
DOX + CIS
DOX + QUE 
DOX + AP 
DOX + EMO 
DOX + RH 
DOX + CIS
DOX + QUE 
DOX + AP 
DOX + EMO 
D O X +R H  
DOX + CIS
DOX + QUE 
DOX + AP 
DOX + EMO 
D O X+RH  
DOX + CIS
Etoposide (ETP) & Polyphenols
ETP + QUE 
ETP + AP 
ETP + EMO 
ETP + RH 
ETP+ CIS
ETP + QUE 
ETP + AP 
ETP + EMO 
ETP + RH 
ETP+ CIS
ETP + QUE 
ETP + AP 
ETP + EMO 
ETP + RH 
ETP+ CIS
ETP + QUE 
ETP + AP 
ETP + EMO 
ETP + RH 
ETP+ CIS
Cyclophosphamide (CYCLO) & 
Polyphenols
CYCLO + QUE 
CYCLO+AP 
CYCLO + EMO 
CYCLO+ RH 
CYCLO + CIS
CYCLO + QUE 
CYCLO+ AP 
CYCLO + EMO 
CYCLO + RH 
CYCLO + CIS
CYCLO + QUE 
CYCLO+ AP 
CYCLO + EMO 
CYCLO + RH 
CYCLO + CIS
CYCLO + QUE 
CYCLO+ AP 
CYCLO + EMO 
CYCLO + RH 
CYCLO + CIS
Cisplatin (CSP) & Polyphenols
CSP + QUE 
CSP + AP 
CSP + EMO 
CSP + RH 
CS + CIS
CSP + QUE 
CSP + AP 
CSP + EMO 
CSP + RH 
CS + CIS
CSP + QUE 
CSP + AP 
CSP + EMO 
CSP + RH 
CS + CIS
CSP + QUE 
CSP + AP 
CSP + EMO 
CSP + RH 
CS + CIS
Table 4.2: A summary of the polyphenols/chemotherapy combinations used to investigate 
glutathione (GSH) levels and the formation of y-H2AX Foci in four leukaemia cell lines, 
following at treatment with the LSDs for 24 h. Note that only those combinations that produced a 
synergistic, additive, competitive antagonistic or antagonistic effects at reduction of ATP levels; or 
caused an interactive, non-Interactive or antagonistic effects on cell cycle (Chapter 3) were 
investigated.
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Figure 4.2: Schematic of the 
GSH-Glo™ Glutathione Assay.
The assay is based on the 
conversion of a luciferin NT- 
substrate into luciferin in the 
presence of glutathione and 
glutathione S-transferase (GST). 
Free luciferin is converted in the 
presence of luciferase, ATP, 
oxygen (0 2) and magnesium 
(Mg2_) to oxyluciferin, AMP, 
carbon dioxide (C 02) and energy 
in the form of a luminescent 
signal which can be measured by 
luminometer.
4.2.3.2 Cell Tracker™  Green 5-Chloromethylfluorescein Diacetate (CMFDA)- 
Glutathione Staining and Fluorescence Microscopy.
The Cell Tracker Green 5-chloromethyl fluorescein diacetate (CMFDA) dye is an excellent 
tool for long-term measurement of intracellular thiol levels to assess cell viability, cytotoxicity 
and drugs sensitivity and resistance (West et al, 2001; Christian et al, 2008). Cell Tracker 
Green CMFDA dye (Molecular Probe) is a thiol-reactive cytoplasmic fluorescent probe (Lantz 
et al, 2001; West et al, 2001). The CMFA stain freely diffuses through the cell membrane of 
live cells (Lantz et al, 2001; West et al, 2001; Christian et al, 2008). Once in the cell, the 
acetate group of the CMFDA stain is cleaved by cytoplasmic esterases. The chloromethyl 
group of CMFDA then reacts with the sulfhydryl (SH) group of any glutathione in the presence 
o f glutathione transferase (GST). This makes the cell impermeable, trapping green fluorescent 
5-chloromethyl-fluorescein dye in the cell cytoplasm which can be visualised by fluorescence 
microscope (Figure 4.3) (Lantz et al, 2001; West et al, 2001; Christian et al, 2008). It is 
important to note that the levels of GST affect the levels of staining and fluorescence (Lantz et 
al, 2001). However the CMFDA dye does not fluorescence until it is cleaved by cytoplasmic
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esterase and conjugation with glutathione (West et al, 2001). This dye has a relatively low pKa 
value which exhibits bright green fluorescence in the cytoplasm at all physiological pH levels 
(Lantz et al, 2001; West et al, 2001). CMFDA is commonly used in conjunction with Hoechst 
33342 staining, as this is an effective way of analysing intracellular glutathione levels using the 
CMFDA, as well as being able to discriminate between live and apoptotic cells which have 
reduced intracellular glutathione and the morphological characteristic of apoptosis which is 
shown by the CMFDA and Hoechst 3342 staining respectively (Lantz et al, 2001; West et al, 
2001; Christian et al, 2008).
The Cell Tracker™ Green 5-chloromethylfluorescein diacetate (CMFDA)-GSH stain was used 
to measure the percentage of cells with GSH activity, when treated with selected polyphenols 
(quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) and cA-stilbene (CIS)) (Sigma); 
and chemotherapy agents (doxorubicin (DOX), etoposide (ETP), cyclophosphamide 
(CYCLO), cisplatin (CSP), methotrexate (MTX) and 6-mercaptopurine (6-MP)) (Sigma) when 
used alone, and in combination at their LSDs (Chapter 3). The selected polyphenols and 
chemotherapy drugs were selected as they had previously demonstrated a synergistic or 
antagonistic effect when used in combination (Chapter 2). A summary of the treatment 
regimens is shown in Table 4.2.This investigation was made in four leukaemia cell lines 
(JURKAT, CCRF-CEM, THP-1 and KG-la) following 24 h treatment. Cells were seeded into 
white 24-well plates (Fisher Scientific) at 1.0 X 103 cells per well and treated. Finally, treated 
cells incubated at 37°C with 5% C 02 for 24 h. All treatments were performed in triplicate, an 
ethanol vehicle controls at 0.1 % (v/v) ethanol was also included.
Following polyphenol and chemotherapy treatments, cells were stained with Cell Tracker™ 
Green CMFDA (Molecular Probes) to detect and quantify GSH levels (specificity 95%) and 
counterstained with Hoechst 33342 stain (Sigma) to localize the cell nuclei. The cells were 
harvested and transferred to labelled centrifuge tube and spun at 400 g for 5 min. The cells 
were then gently resuspended in 2 ml of 0.5 pM pre-warmed Cell Tracker™ Green CMFDA 
dye working solution prepared in serum-free medium and incubation at 37C° with 5% CO2 for 
45 min, this was then replaced with 2 ml fresh pre-warmed serum-free medium and incubation 
at 37C° with 5% CO2 for a further 30 min. The cells were then washed twice in PBS and 
transferred to a 96 well plate (Fisher Scientific). Ten microliteres of 2 pg/ml of Hoechst 33342 
(Sigma) was added in each well and incubated for 15 min. Stained cells were observed and 
analysed under inverted fluorescence microscopy (Olympus, Ix2-UCB) using CellF imaging 
software (Olympus). CMFDA and Hoechst 33342 stains were examined using the FITC 
(green) and DAPI (blue) fluorescent filters. The excitation wavelengths were 488 nm for 
CMFDA and 364 nm for Hoechst 33342. The emission wavelengths for fluorescence detection 
were 510-540 nm for CMFDA and 380- 485 nm for Hoechst 33342.
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Stained cells were examined under an inverted fluorescence microscopy (Olympus, Ix2-UCB). 
Using the monocamera and dual excitation settings images were captures using the FITC filter 
for CMFDA green staining and the DAPI filter for Hoechst 33342 staining (Figure 4.4). 
Images were captured using CellF imaging software (Olympus). CMFDA green staining was 
localised mainly in cytoplasm, as well in nucleus of the live cells only, which commonly have 
high glutathione level, while it is depleted in apoptotic and dead cells (Figure X). Hoechst 
33342 blue staining was commonly localised in the nuclei of both live and dead cells (Figure 
X). Two hundred cells (green and blue) were counted and then percentage of (green stained) 
GSH positive cells was determined for each sample.
Figure 4.3: Schematic of the 
CellTracker™ 5-chloromethyl 
fluorescein diacetate (CMFDA) 
stain. CMFDA dye freely 
diffuses through the cell 
membrane of live cells. Once the 
dye diffused into the cells, 
cytoplasmic esterases cleave the 
acetate groups of CMFDA dye, 
then the chloromethyl group of 
CMFDA reacting with sulfhydryl 
(SH) group of glutathione in the 
presence of glutathione 
transferase (GST) making a cell 
impenneable and trapping 5- 
chloromethyl-fluorescein dye 
within the cell which 
fluorescence green and can be 
visualised using a fluorescence 
microscope.
CH2CI
5-chloromethyl fluorescein diacetate (CMFDA)
Cytoplasmic Esterases: 
Cleave the acetate groups of 
CMFDA.
coot <
CH2CI
Free 5-chloromethvl fluorescein
GSH
GS-R
Glutathione S-Transferase 
(GST)
5-chloromethyl group reacting with sulfhydryl (SH) group of 
glutathione
G r e e n  
F l u o r e s c e n c e
COOH
C H ^-G lutath ione
Fluorescent 5-chloromethvl -fluorescein
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Figure 4.4: An example of glutathione 
(GSH) assessment uses dual staining of 
CMFDA (green) and Hoechst 33342 (blue) 
for THP-1 myeloid cell lines after treated 
with a combination of DOX and QUE at 
their LSDs for 24 h. From the picture, it can 
be seen that Hoechst 33342 blue staining (blue 
arrows) localised the nuclei of both living and 
dead cells, while CMFDA green staining 
(green arrows) was localised in the cell 
cytoplasm and nucleus of only live cells.
4.2.4 y-H2AX Immunofluorescent Detection using Alexa Fluor® 647 Mouse anti-H2AX 
(pS139) Staining and Fluorescence Microscopy
Cytotoxic agents and radiation commonly cause DNA damage. They cause double-stranded 
breaks (DSBs) in DNA which is followed by rapid formation of thousands of gamma-H2AX 
foci. These trigger serine 139 phosphorylation in the chromatin flanking the DSB site. This is 
normally excised during post-translational processing and is included in amino acid sequence 
numbering. Immunofluorescent staining can be used to identify H2AX (pS139)-containing 
foci. As such, y-H2AX (pS139) immunofluorescence localization serves as a biomarker for 
DNA damage. This is the most sensitive method to detect the y-H2AX and enables the 
quantification of single foci in individual cells. Here by using y-H2AX immunofluorescent 
staining, it was possible to confirm the previous cell cycle results, by quantifying the cells with 
foci in each sample after treatment with polyphenols and chemotherapy alone and in 
combination.
Alexa Fluor® 647 Mouse anti-H2AX (pS139) is specific designed for the phosphorylation of 
Ser-139 at the C-terminal region of H2AX enabling the visualisation of yH2AX by 
immunofluorescence microscopy. This direct immunofluorescence method uses a single 
primary antibody which recognizes and binds to the targeted antigen epitope (Figure 4.5). The 
antibody is conjugated to a fluorophore, which can be excited and visualised by fluorescent 
microscope. This immunofluoresence can be used in combination with non-antibody methods 
of fluorescent staining such as Hoechst 33342 to label DNA.
The y-H2AX immunofluorescent stain (BD Pharmingen™) was used to measure the DNA 
damage (measured as y-H2AX foci) in four leukaemia cell lines (JURKAT, CCRF-CEM, 
THP-1 and KG-la), when treated with selected polyphenols (quercetin (QUE), apigenin (AP), 
emodin (EMO), rhein (RH) and cis-stilbene (CIS)) (Sigma); and six chemotherapy drugs 
(doxorubicin (DOX), etoposide (ETP), cyclophosphamide (CYCLO), cisplatin (CSP), 
methotrexate (MTX) and 6-mercaptopurine (6-MP)) (Sigma) alone and in combination at their
\ > \  * \
\
\
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LSDs (Chapter 3) for 24 h. These polyphenols and chemotherapy treatments were selected as 
they previously caused a synergistic or antagonistic effect on ATP levels and apoptosis; plus 
they had an interactive or antagonistic effect on cell cycle (Chapter 3). Table 4.2 summarises 
the combination treatments investigated here. All cells were seeded into a BD Falcon™ 96- 
well Imaging Plate (BD Pharmingen™) at 1.0 X 10‘" cells per well and treated. Treated cells 
incubated at 37°C with 5% CCT for 24 h. All treatments were performed in triplicate. An 
ethanol vehicle control at 0.1 % (v/v) ethanol was also included.
Following treatments, the cells were removed from the wells, centrifuged at 400g for 10 
minutes and washed twice with 100 pi of PBS (Sigma). Cells were fixed for 10 minutes in 100 
pi BD Cytofix™ fixation buffer (BD Pharmingen™). The fixative was removed, and cells 
washed twice with 100 pi of PBS. Cells were then permeabilised using 100 pi of -20°C 90% 
methanol (Sigma) and incubated at RT for 5 min, permeabilisation buffer was then removed, 
and the cells were washed twice in 100 pi of PBS. Fifty microliters of diluted Alexa Fluor® 
647 Mouse anti-H2AX (pS139) (1:10 v/v) (BD Pharmingen™) was added to the cells and they 
were incubated at RT for 60 min in the dark. Following incubation cells were washed three 
times in PBS. After the final wash, cells were counter-stained in 100 pi 2 mg/ml Hoechst 
33342 (Sigma) and incubated for 15 min before imaging. Stained cells were visualised using 
an inverted fluorescence microscopy (Olympus, 1x2-UCB) using the monocamera using dual 
excitation settings for Texas Red (for y-H2AX foci) which were stained red and for DAPI (for 
Hoechst 33342) blue staining of the cell nuclear material (Figure 4.6). Those cells with 6 and 
more y-H2AX foci were considered as cells with DNA damage (Rakiman et al, 2008). Two 
hundred cells (cells with >6 foci and cells with <6 foci) were counted and the percentage of 
cells with >6 foci was determined for each sample. Images were captured using (Cell-F 
software, Olympus).
DNA
DNA
Damage
Primary Antibody
Phosphorylation 
of Histone
(gp I ® ®
Fluorochrome
Figure 4.5: The Principle Method of H2AX Immunofluorescent Detection.
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Figure 4.6: Immunofluorescent detection 
of DNA damage (measured as y-H2AX 
foci) assessment using Alexa Fluor® 647 
Mouse anti-H2AX (pS139) and Hoechst 
33342 staining of JURKAT lymphoid cell 
lines after treatment with a combination 
of ETP and QUE at their LSD for 24 h.
4.2.5 Statistical Analysis
Using the Stats Direct software a Shapiro-Wilke test was used to determine whether the data 
was parametric or non-parametric. As the data was non-parametric, a Kruskal-Wallis and 
Conover-Inman post hoc test was used. Statistical significance was set at p < 0.05.
4.2.5.1 Analysis o f  Effect o f  Polyphenols Alone on Caspase Activity and GSH Levels
The caspase 8  and 9 activity and GSH level following polyphenol treatment alone was 
normalised to the vehicle-only control, and each data point (n=3) was plotted. A statistical 
comparison was made between the polyphenols treatment and the vehicle controls.
4.2.5.2 Analysis o f  Effect o f  Combination Treatments on Caspase Activity, GSH Levels and 
y-H2AX Foci Formation
Data of combination work was normalised to the vehicle-only control. The median and ranges 
were calculated for all the assays. The effects of the combination treatments were categorised 
using the following criteria:
• An increase in the levels of caspase ( 8  or 9) activity or depletion of GSH levels or induction 
of y-H2AX foci formation by a polyphenol = X
• An increase the levels of caspase ( 8  or 9) activity or depletion of GSH levels or induction of 
y-H2AX foci formation by chemotherapy agent = Y
• An increase the levels of caspase ( 8  or 9) activity or depletion of GSH levels or induction of 
y-H2AX foci formation by combined polyphenol and chemotherapy agent treatment = Z
X+Y were calculated and described as our Expected Value. The effect of combination 
chemotherapy and polyphenols treatments was classified as: Additive or Synergistic or 
Competitive Antagonistic or Antagonistic according to their statistical analysis. The 
combination effects were classified and defined as desribed in Chapter 3 and Section 3.2.6.
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4.3 Results
4.3.1 Caspase 8 and 9 Activity
4.3.1.1 Effect of Polyphenols on Caspase 8 and 9 Activity
Flavonoid compounds: quercetin, apigenin and chrysin caused a significant increased in both 
caspase 8  and 9 activity at 24 h in all lymphoid and myeloid leukaemia cell lines (Figure 4.7, 
4.8, 4.9 and Table 4.3). Following 6  and 24 h, both quercetin and apigenin significantly 
increased caspase 8  and 9 activity in the lymphoid leukaemia cell lines (p<0.05), whilst in 
myeloid leukaemia cell lines a significant increase was only seen at 24 h (p<0.05) (Figure 4.7, 
4.8 and Table 4.3). Chrysin, however did not significantly affect caspase 8  or 9 activity at 
either 6  or 24 h in KG-la cells (p<0.05); while it caused a significant increase in caspase 8  and 
9 activity at 6  and 24 h in Jurkat cells (p<0.05) (Figure 4.9 and Table 4.3). Whilst CCRF-CEM 
and THP-1 had both caspase 8  and 9 activity at 24h, but not at 6  h (p<0.05) (Figure 4.9 and 
Table 4.3).
Anthraquinone compounds: emodin, rhein and aloe-emodin in general did not affect caspase 8  
activity; but significantly increased caspase 9 activity in all the leukaemia cell lines 
investigated (p<0.05) (Figure 4.10, 4.11, 4.12 and Table 4.3). In particular following 6  h and 
24 h, emodin, rhein (used at their NSD, LSD and IC50 doses), and aloe-emodin (used at its 
I C 5 0 )  significantly increased caspase 9 but had no effect on caspase 8  activity in Jurkat, CCRF- 
CEM and THP-1 cells (p<0.05) (Figure 4.10, 4.11, 4.12 and Table 4.3). Whist KGla cells 
treated with emodin for 6  and 24 h did not affect either caspase 8  or 9 activity (Figure 4.10 and 
Table 4.3). Similarly, KGla cells and THP-1 cells were treated with rhein at the NSD and LSD 
at 6  h and 24 h, there was no significant effect on caspase 8  or 9 activity. However there was a 
significant effect increase in caspase 9 activity when rhein was used at its I C 5 0  treatment dose at 
both 6  and 24 h (p<0.05) (Figure 4.11 and Table 4.3). Aloe-emodin stimulation at its I C 5 0  dose 
did not affect caspase 8  activity, but significantly increased caspase 9 activity in all the 
leukaemia cell lines investigated at both 6  h and 24 h (p<0.05) (Figure 4.12 and Table 4.3).
Stilbene compounds: c/s-stilbene and rraws-stilbene in general caused a significant increase in 
both caspase 8  and 9 activity following 24 h in all leukaemia cell lines investigated (Figure 
4.13, 4.14 and Table 4.3). In particularly c/s-stilbene over all doses significantly increased 
caspase 8  and 9 activity in the lymphoid leukaemia cell lines following 6  h and 24 h, (p<0.05); 
and in the myeloid leukaemia cell lines following 24 h (p<0.05) (Figure 4.13 and Table 4.3). 
Trans-stilbene was only investigated at the I C 5 0  doses, which did not show any effect on 
caspase activity at 6  h, but it did significantly increase both caspase 8  and 9 activity at 24 h in 
all leukaemia cell lines (p<0.05) (Figure 4.14 and Table 4.3).
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In summary, flavonoids (quercetin, apigenin and chrysin) and stilbenes (c/s-stilbene and trans- 
stilbene) increased caspase 8 and 9 activity in all leukaemia cell lines, most significantly at 24 
h (Table 4.3). The anthraquinone compounds: emodin, rhein and aloe-emodin increased 
caspase 9 activity following both 6 h and 24 h in lymphoid cell lines, and following 24 h in the 
myeloid cell lines (Table 4.3).
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Figure 4.7: Effect of quercetin on initiator caspases 8 (A) or 9 (B) in two lymphoid leukaemia 
(JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell lines 
following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each data 
point plotted (n=3). * = p<0.05 compared to vehicle control.
265
(A) Caspase 8 Activity
JU RK A T
•J — S os
Z  .2
> c ’■S ©
2 u oo "3 % 2 
SB «a. >
500-3
400
300-j
200 4 
100 4 
0 i i m i |
0.1
l a•2 j  500-5 &H “
£ 2,400- 
Z  js
£> |  300- 
e
5  U 200<  4i 
00 ~S 2 100-
1 1.0 100 
Apigenin (pM)
C CRF-CEM
CS «a > 0J rmrp
0.1
THP-1
•2 j  500- ■ 3 S *£ 2,400- 
z  »
£  1300-j '> a 
•S o2 U200-
2 1 0 0 -01
O 0- i i i iinij—T i  r m ^  i i Jliii|— m  imi|
0.1 1 1.0 100 1000 
Apigenin (pM )
•  6hr 
A 24hr
1000
•  6hr 
A 24hr
J 10 100 1000
Apigenin (pM ) [log scale]
#  6hr 
A 24hr
K G -la
.§3
1« *- © o ^
Z  JS 
* 2
<  o 
00 ~
& >
500
400-
300-
200-j
100
0
•  6hr 
A 24hr
TTTT7|-
0.1
" T  1 ' ™""l 1 1.0 100 
Apigenin (pM )
T™1
1000
(B) Caspase 9 Activity
© ^ 
•J= -J
s e
Z  J2
'?  e  *5 O
4? u 2
J! '■= 
a  >  
x 2 
U
500
400-1
300
200
100-1
0
JU RK A T
•  6hr
A 24hr
0.1
TTTTT| 1 I rillll|
1 1.0 
Apigenin (pM)
TTj 1 I I lllllj
100 1000
a  3  
•.= — 9 M 
£ ® u o  e  -—- 
Z  JS
*£ '> e 
'S oy u
500
400-1
300
200
100-j
a  >
C CRF-CEM
•  6hr 
A 24hr
i i i niii|— i i i iini|— r i 111ni|— i  ...... .
0.1 1 10 100 1000 
Apigenin (pM )
THP-1
j  500- 
os
£ 4 0 0 -
JS
• 1300- 
e
0  200- 2
2  100 -11.>
2 0 -
6hr
24hr
0.1
mii| W i i —i i W|—
1 1.0 100 
Apigenin (pM )
K G -la
TTTTTj
1000
£  j  500-
ax£ 2,400- 
Z  J2
£> 2 300- 
> e
1 a 2oo-ii
s |  iooHSB A1a  >x 2 0O
•  6hr 
A 24hr
i ■ mi|—V i i rrriW i i mni|— w  i in ii|
0.1 1 . 1.0 100 1000 
Apigenin (pM )
Figure 4.8: Effect of apigenin on initiator caspases 8 (A) or 9 (B) in two lymphoid leukaemia 
(JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell lines 
following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each data 
point plotted (n=3). * = p<0.05 compared to vehicle control.
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Figure 4.9: Effect of chrysin on initiator caspases 8 (A) or 9 (B) in two lymphoid leukaemia 
(JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell lines 
following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each data 
point plotted (n=3). * = p<0.05 compared to vehicle control.
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Figure 4.10: Effect of emodin on initiator caspases 8 (A) or 9 (B) in two lymphoid leukaemia 
(JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell lines 
following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each data 
point plotted (n=3). * = p<0.05 compared to vehicle control.
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Figure 4.11: Effect of rhein on initiator caspases 8 (A) or 9 (B) in two lymphoid leukaemia 
(JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell lines 
following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each data 
point plotted (n=3). * = p<0.05 compared to vehicle control.
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Figure 4.12: Effect of aloe-emodin on initiator caspases 8 (A) or 9 (B) in two lymphoid 
leukaemia (JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell 
lines following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each 
data point plotted (n=3). * = p<0.05 compared to vehicle control.
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Figure 4.13: Effect of c/s-stilbene on initiator caspases 8 (A) or 9 (B) in two lymphoid 
leukaemia (JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell 
lines following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each 
data point plotted (n=3). * = p<0.05 compared to vehicle control.
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Figure 4.14: Effect of fra/is-stilbene on initiator caspases 8 (A) or 9 (B) in two lymphoid 
leukaemia (JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and KG-la) cell 
lines following 6 and 24 h. Data normalised to vehicle-control which was set to 0 RLU, and each 
data point plotted (n=3). * = p<0.05 compared to vehicle control.
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Polyphenols Targets Doses
The Significant Effects of Polyphenols Alone on In itiator 
Caspase 8 and 9 Activity following 6 h and 24 h in 
Leukaem ia Cell Lines.
Lymphoid Leukaemia Myeloid Leukaemia
JURKAT CCRF-CEM THP-1 KG-la
6 h 24 h 6 h 24 h 6 h 24 h 6 h 24 h
Quercetin
Caspase 8 
Activity
NSD * * * * — * * *
LSD * * * * — * *
ic50 * * * * * * * *
Caspase 9 
Activity
NSD He * * ❖ — — *
LSD * '3' * * — * — He
IC50 * * * * He * — H=
Apigenin
Caspase 8 
Activity
NSD * * * * — * — He
LSD * * * * — * — He
ic50 * * * * * * — He
Caspase 9 
Activity
NSD * * * He — He — He
LSD * * * * — He — He
»C50 * * * * — * — He
Chrysin
Caspase 8 
Activity ic50 * * — * — * — —
Caspase 9 
Activity ICso
* * — * — H= — —
Emodin
Caspase 8 
Activity
NSD — — — — — — — —
LSD — — — — — — — —
IC50 — — — — — — — —
Caspase 9 
Activity
NSD — * — — * — —
LSD * * * * — —
ic50 * ❖ * * * * — —
Rhein
Caspase 8 
Activity
NSD — — — — — — — —
LSD — — — — — — — —
IC 5o — — — — — — — —
Caspase 9 
Activity
NSD * sjc * * — * — —
LSD * % ❖ * — * — —
ICso * * * * * * * He
Aloe -Emodin
Caspase 8 
Activity ICso — — — — — — — —
Caspase 9 
Activity ICso
* He * * ❖ ■fi * He
C i s -  Stilbene
Caspase 8 
Activity
NSD * * * * — * — —
LSD * * * * — * — —
ICso * * * * — * — He 1
Caspase 9 
Activity
NSD He He * ❖ — * — —
LSD sjs * -i- — * — —
ICso He * He * — He
7ra/fs-Stilbene
Caspase 8 
Activity ICso —
* — * — * — He
Caspase 9 
Activity ICso —
* — ❖ — He — He
Table 4.3: A summary of the significant effect of eight polyphenols (quercetin, apigenin, 
chrysin, rhein, emodin, aloe-emodin, c/s-stilbene and trans-stilbene) alone on initiator 
caspase 8 and caspase 9 activity in two lymphoid leukaemia (JURKAT and CCRF-CEM), 
and two myeloid leukaemia (THP-1 and KGla) cell lines at 6 h and 24 h. This was evaluated 
by the Caspase-Glo® 8 and 9 Assays. Quercetin, apigenin, emodin, rhein and cz.s-stilbene were 
investigated at their NSD, LSD and IC50 treatment ranges, while chrysin, aloe-emodin and t r a n s -  
stilbene were investigated only at their IC50 treatment ranges. * = p<0.05 (Kruskal-Wallis and 
Conover-Inman post hoc test). — = no activity.
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4.3.1.2 Effects of Topoisom erase Inh ib ito rs C om bined with Polyphenols on C aspase 8 and
9 Activity
(A) Effects o f  Doxorubicin (DOX) Combined with Polyphenols on Initiator Caspase Activity
DOX alone used at its LSD for 24 h significantly increased both caspase 8 and caspase 9 
activity in most leukaemia cell lines (JURKAT, THP-1 and KGla) (p<0.05) (Figure 4.15). 
However in the CCRF-CEM lymphoid cell lines, DOX alone significantly increased caspase 9 
activity (p<0.05); there was no change in caspase 8 activity (Figure 4.15). DOX treatment 
combined with QUE or AP treatment generally induced an additive induction in caspase 8 
activity and a synergistic induction in caspase 9 activity in all leukaemia cell lines (p<0.05) 
(Figure 4.15 and Table 4.4). With the exception that CCRF-CEM cells treated with DOX 
together with QUE induced a synergistic increase in caspase 8 and caspase 9 activity (p<0.05) 
(Figure 4.15 and Table 4.4). Furthermore, when DOX was used in combined with EMO, RH or 
CIS there was a additive increase in caspase 8 activity, and synergistic increase in caspase 9 
activity in both lymphoid leukaemia cell lines (p<0.05) (Figure 4.15 and Table 4.4).
(B) Effects o f Etoposide (ETP) Combined with Polyphenols on Initiator Caspase Activity
ETP alone used at its LSD for 24 h significantly increased both caspase 8 and caspase 9 
activity in most leukaemia cell lines (JURKAT, THP-1 and KGla) (p<0.05) (Figure 4.16). 
However in CCRF-CEM lymphoid cell lines, ETP alone only significantly increased caspase 9 
activity (p<0.05) (Figure 4.16). ETP when combined with QUE or AP mainly caused an 
additive increase in caspase 8 activity, and a synergistic increase in caspase 9 activity in all the 
leukaemia cell lines (p<0.05) (Figure 4.16 and Table 4.5). ETP when used in combination with 
EMO or RH caused an additive increase in caspase 8 activity on three leukaemia cell lines 
(JURKAT, THP-1 and KG-1 a), whilst it caused a synergistic increase in caspase 8 activity in 
CCRF-CEM cell line (p<0.05) (Figure 4.16 and Table 4.5). Additionally, ETP when used in 
combination with EMO or RH caused a synergistic increase in caspase 9 activity in the 
lymphoid leukaemia cell lines (JURJAT and CCRF-CEM) (p<0.05) (Figure 4.16 and Table 
4.5). Likewise, when ETP was used in combined with CIS it caused an additive increase in 
caspase 8 activity, and a synergistic increase in caspase 9 activity in the lymphoid leukaemia 
cell lines (JURKAT and CCRF-CEM) (p<0.05) (Figure 4.16 and Table 4.5).
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(A) Effect of Doxorubicin (DOX) When Used in Combination with Polyphenols at their Lowest Significant Doses
(LSD) on Initiator Caspases Activity of Lymphoid Leukaemia Cell Lines Following 24 h of Treatment.
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(B) E ffect o f  Doxorubicin (D O X ) W hen U sed in C om bination w ith P olyphenols at their L ow est Significant D oses 
(LSD ) on In itiator C aspases A ctivity o f  M yeloid L eukaem ia Cell L ines Follow ing 24 h o f  Treatm ent.
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Figure 4.15: The effect of DOX on caspase 8 and 9 activity: (A) When used in combination 
with QUE, AP, EMO, RH or CIS in lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM); and (B) When used in combination with QUE or AP in myeloid leukaemia cell lines 
(THP-1 and KG-la). Cells were treated with DOX and polyphenols alone and in combined for 24 
h using their LSD. Data was normalised to the vehicle-control, which was assigned a 0 RLU. The 
data was expressed as medians with ranges (n=4). The black bars show the vehicle controls and 
treatments alone; the white bar shows the expected effect of the combined treatments on caspase 8 
and 9 activity; the coloured bars indicate significant additive effects in brown, synergistic effects in 
yellow, competitive antagonistic effects in purple and antagonistic effects in pink. Statistical 
significant was set at p<0.05 compared to vehicle control and drugs alone.
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(A) Effect of Etoposide (ETP) When Used in Combination with Polyphenols at their Lowest Significant Doses
(LSD) on Initiator Caspases Activity of Lymphoid Leukaemia Cell Lines Following 24 h of Treatment.
Caspase 8 Activity. Caspase 9 Activity.
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(B) Effect of Etoposide (ETP) When Used in Combination with Polyphenols at their Lowest Significant Doses
(LSD) on Initiator Caspases Activity of Myeloid Leukaemia Cell Lines Following 24 h of Treatment.
Caspase 8 Activity. Caspase 9 Activity.
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Figure 4.16: The effect of ETP on caspase 8  and 9 activity: (A) When used in combination 
with QUE, AP, EMO, RH or CIS in lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM); and (B) When used in combination with QUE or AP in myeloid leukaemia cell lines 
(THP-1 and KG-la). Cells were treated with ETP and polyphenols alone and in combined for 24 h 
using their LSD. Data was normalised to the vehicle-control, which was assigned a 0 RLU. The 
data was expressed as medians with ranges (n=4). The black bars show the vehicle controls and 
treatments alone; the white bar shows the expected effect o f the combined treatments on caspase 8 
and 9 activity; the coloured bars indicate significant additive effects in brown, synergistic effects in 
yellow, competitive antagonistic effects in purple and antagonistic effects in pink. Statistical 
significant was set at p<0.05 compared to vehicle control and drugs alone.
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4.3.1.3 Effects of Alkylating Chemotherapy Agents Combined with Polyphenols on
Caspase 8 and 9 Activity
(A) Effects o f Cyclophosphamide (CYCLO) Combined with Polyphenols on Initiator 
Caspase Activity
CYCLO alone used at its LSD for 24 h significantly increased both caspase 8 and caspase 9 
activity in all leukaemia cell lines (p<0.05) (Figure 4.17). CYCLO when used in combination 
with QUE or AP caused a synergistic increase in both caspase 8 and caspase 9 activity in the 
lymphoid leukaemia cell lines (p<0.05) (Figure 4.17 and Table 4.6). However, when CYCLO 
was used in combination with EMO or RH there was an additive increase in caspase 8 activity, 
and a synergistic increase in caspase 9 activity in the lymphoid leukaemia cell lines (JURKAT 
and CCRF-CEM) (p<0.05) (Figure 4.17 and Table 4.6).
(B) Effects o f Cisplatin (CSP) Combined with Polyphenols on Initiator Caspase Activity
CSP alone used at its LSD for 24 h significantly increased both caspase 8 and caspase 9 
activity in all leukaemia cell lines (p<0.05) (Figure 4.18). CSP when used in combined with 
QUE or AP caused a synergistic increase in both caspase 8 and caspase 9 activity in all 
leukaemia cell lines (p<0.05) (Figure 4.18 and Table 4.7). Whilst CSP in combined with CIS 
caused a synergistic increase in caspase 8 and caspase 9 activity only in the lymphoid 
leukaemia cell lines (p<0.05) (Figure 4.18 and Table 4.7). When CSP was combined with 
EMO or RH there was a additive increase in caspase 8 activity, and a synergistic increase 
caspase 9 activity in the lymphoid leukaemia cell lines (p<0.05) (Figure 4.18 and Table 4.7).
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(A) Effect of Cyclophosphamide (CYCLO) When Used in Combination with Polyphenols at their Lowest Significant
Doses (LSD) 011 Initiator Caspases Activity of Lymphoid Leukaemia Cell Lines Following 24 h of Treatment.
Caspase 8 Activity. Caspase 9 Activity.
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(B) Effect of Cyclophosphamide (CYCLO) When Used in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on Initiator Caspases Activity of Myeloid Leukaemia Cell Lines Following 24 h of Treatment.
C a s p a s e  8  A c t i v i t y . C a s p a s e  9  A c t i v i t y .
K G - 1 A T H P - 1
Figure 4.17: The effect of CYCLO on caspases 8  and 9 activity: (A) when used in combination 
with QUE, AP, EMO or RH in lymphoid leukaemia cell lines (JURKAT and CCRF-CEM); 
and (B) When used in combination with AP in myeloid leukaemia cell lines (THP-1 and KG­
la). Cells were treated with CYCLO and polyphenols alone and in combined for 24 h using their 
LSD. Data was normalised to the vehicle-control, which was assigned a 0 RLU. The data was 
expressed as medians with ranges (n=4). The black bars show the vehicle controls and treatments 
alone; the white bar shows the expected effect of the combined treatments on caspase 8 and 9 
activity; the coloured bars indicate significant additive effects in brown, synergistic effects in 
yellow, competitive antagonistic effects in purple and antagonistic effects in pink. Statistical 
significant was set at p<0.05 compared to vehicle control and drugs alone.
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(A) Effect of Cisplatin (CSP) When Used in Combination with Polyphenols at their Lowest Significant Doses (LSD)
on Initiator Caspases Activity of Lymphoid Leukaemia Cell Lines Following 24 h of Treatment.________
Caspase 8 Activity. Caspase 9 Activity.
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(B) Effect of Cisplatin (CSP) When Used in Combination with Polyphenols at their Lowest Significant Doses
(LSD) on Initiator Caspases Activity of Myeloid Leukaemia Cell Lines Following 24 h of Treatment.
Caspase 8 Activity. Caspase 9 Activity.
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Figure 4.18: The effect of CSP on caspases 8  and 9 activity: (A) when used in combination 
with QUE, AP, EMO, RH or CIS in lymphoid leukaemia cell lines (JURKAT and CCRF- 
CEM); and (B) When used in combination with QUE or AP in myeloid leukaemia cell lines 
(THP-1 and KG-la). Cells were treated with CSP and polyphenols alone and in combined for 24 h 
using their LSD. Data was normalised to the vehicle-control, which was assigned a 0 RLU. The 
data was expressed as medians with ranges (n=4). The black bars show the vehicle controls and 
treatments alone; the white bar shows the expected effect o f the combined treatments on caspase 8 
and 9 activity; the coloured bars indicate significant additive effects in brown, synergistic effects in 
yellow, competitive antagonistic effects in purple and antagonistic effects in pink. Statistical 
significant was set at p<0.05 compared to vehicle control and drugs alone.
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4.3.2 Gluathione (GSH) Activity
4.3.2.1 Basal Glutathione (GSH) Levels in Normal and Leukaemia Cell Lines
In order to evaluate the significance o f any changes in glutathione (GSH) levels it is essential 
to establish the basal GSH level presence in each untreated cell line. It was found that he GSH 
levels varied between cell lines. These cell lines could be ranked in order o f GSH levels from 
the lowest to the highest levels: CCRF-CEM  < JURKAT < CD34+ HSC < THP-1 < K G -la  < 
CD 133 HSC (p<0.05) (Figure 4.19). As a result, the lymphoid leukaemia cell lines had 
significantly lower GSH levels compared to myeloid leukaemia cell lines and normal cells 
(CD34 HSC and CD 133' HSC) (p<0.05) (Figure 4.19).
In addition, when leukaemia cell lines and normal cells were treated with 50 pM  GSH inhibitor 
(buthionine sulfoximine (BSO)) for 24 h, there was a significant decrease in GSH levels in all 
leukaemia and normal cell lines when compared to untreated cells (p<0.05) (Figure 4.19). 
Alternatively, when cells were treated with GSH inducer agent (N-acetyle cysteine (NAC)) for 
24 h, there was a significant increase in GSH levels in the lymphoid leukaemia cell lines only 
when compared to untreated cells (p<0.05) (Figure 4.19).
Low GSH Level 
(1) C C R F-C EM  
(2) JU R K A T 
(3) CD34+ HSC
(4) THP-1
(5) K G -la
(6) CD 133+ HSC
High GSH Level
The significant o rd e r of 
un trea ted  cell lines according 
to  th e ir  basal GSH levels from  
low to high level when 
com pared to each others.
200
B a s a l  L e v e l  o f  G S H  i n  
L e u k e a m i a  a n d  N o r m a l  C e l l  L i n e s
l U ntreated  □  BSO (50pM ) ■  NAC (50pM )
CCRF-CEM JURKAT THP-1 K G -la CD133+HSC CD34+ HSC
Cell Type
Figure 4.19: Basal level of glutathione (GSH) in two lymphoid leukaemia (CCRF-CEM and 
JURKAT), two myeloid leukaemia (THP-1 and K G-la) cell lines; and two normal 
(CD133+HSC and CD34+ HSC) cell lines. Cells were untreated, treated with GSH inhibitor agent 
(buthionine sulfoximine (BSO)) and with GSH inducer agent (N-acetyle cysteine (NAC)) for 24 h. 
This was evaluated by the GSH-Glo™ Glutathione Assay. The data is expressed as median with 
range in triplicate. * = p<0.05.
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4.3.2.2 Effect of Polyphenols Alone on Glutathione (GSH) Levels
The NSDs and LSDs o f  polyphenols showed differential effects on GSH levels within the 
leukaemia cell lines at 24 h (Table 4.8). At the NSDs o f  quercetin (Figure 4.20), apigenin 
(Figure 4.20), emodin (Figure 4.21) and rhein (Figure 4.21) there was no significant effect on 
GSH levels. However, the LSDs caused a significant decrease GSH levels in the lymphoid cell 
lines and one myeloid cell line (THP-1) (p<0.05) (Table 4.8). Quercetin was the only 
polyphenol when used at its LSD caused a significant depletion on GSH level in the K G-la  
myeloid cell lines (p<0.05) (Figure 4.20 and Table 4.8). In contrast, apigenin (Figure 4.20), 
emodin (Figure 4.21) and rhein (Figure 4.21) significantly increased GSH levels in one 
myeloid (KG-la) cell line, when used at its NSDs and LSDs (p<0.05). Cis-stilbene when used 
at the NSDs and LSDs did not show any significant effect on GSH levels within the two 
lymphoid cell lines (Figure 4.22 and Table 4.8); but did significantly increase GSH levels in 
the two myeloid cell lines (p<0.05) (Figure 4.22 and Table 4.8).
At the IC50 treatment doses, all polyphenols (quercetin, apigenin, chrysin (Figure 4.20), 
emodin, rhein, aloe-emodin (Figure 4.21), cis-stilbene and trans-stilbene (Figure 4.22)) 
significantly depleted the GSH levels in all the leukaemia cell lines (p<0.05) (Table 4.8). The 
only exception was seen with trans-stilbene which was significantly elevated GSH levels in 
K G -la cells when compared to vehicle-control (p<0.05) (Figure 4.22 and Table 4.8).
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Figure 4.20: Effect of polyphenols: (A) quercetin, (B) apigenin and (C) chrysin on GSH levels 
in two lymphoid leukaemia (JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 
and KG-la) cell lines. Cells were treated with quercetin and apigenin at their NSD, LSD and IC50 
treatment ranges; while chrysin was only used at its IC50 treatment ranges for 24 h. This was 
evaluated by the GSH-GIo™ Glutathione Assay. Data was normalised to the vehicle-control which 
was assigned 1.0 RLU of GSH level, and each data point plotted (n=3). * = p<0.05.
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Figure 4.21: Effect of polyphenols: (A) emodin, (B) rhein and (C) aloe-emodin on GSH levels 
in two lymphoid leukaemia (JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 
and KG-la) cell lines. Cells were treated with emodin and rhein at their NSD, LSD and IC50 
treatment ranges; while aloe-emodin was only used at its IC50 treatment ranges for 24 h. This was 
evaluated by the GSH-Glo™ Glutathione Assay. Data was normalised to the vehicle-control which 
was assigned 1.0 RLU of GSH level, and each data point plotted (n=3). * = p<0.05.
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Figure 4.22: Effect of polyphenols: (A) c/s-stilbene and (B) trans-stilbene on GSH levels in two 
lymphoid leukaemia (JURKAT and CCRF-CEM), and two myeloid leukaemia (THP-1 and 
KG-la) cell lines. Cells were treated with m -stilbene at their NSD, LSD and IC50 treatment 
ranges; while trans-stilbene was only used at its IC50 treatment ranges for 24 h. This was evaluated 
by the GSH-Glo™ Glutathione Assay. Data was normalised to the vehicle-control which was 
assigned 1.0 RLU of GSH level, and each data point plotted (n=3). * = p<0.05.
P olyph en ols In vestigated
T he S ign ifican t E ffects o f  24 h P o lyp h en o l T reatm en t on  
G SH  L evels.
D oses L ym phoid  L eu k aem ia M yelo id  L eu kaem ia
JU R K A T C C R F -C E M TH P -1 K G la
N SD — — — —
Q uercetin L SD sh vh — 4^
IC 50 4, vh 4,
N SD — — t
A p igen in L SD 4, sh t
ICso 4, 4, 4, sh
C hrysin ICso vh 4,
N SD — — — t
E m odin LSD 4/ 4, t
ICso 4/ 4/ 4,
N SD — — — t
R hein L SD 4/ — — t
ICso * 4,
A loe-em odin ICso 4, 4,
N SD — — t *
C is-S tilbene LSD 4, t t
ICso 4/ vh 4, 4/
T ran s-S tilb en e ICso 4/ 4 , t
Table 4.8: A summary of the significant effect of eight polyphenols (quercetin, apigenin,
chrysin, rhein, emodin, aloe-emodin, m -stilbene and trans-stilbene) on GSH levels in two
lymphoid leukaemia cell lines (JURKAT and CCRF-CEM), and two human myeloid
leukaemia cell lines (THP-1 and K G la) at 24 h. This was evaluated by the GSH-Glo™
Glutathione Assay. Quercetin, apigenin, emodin, rhein and c/s-stilbene were investigated at
their NSD, LSD and IC50treatriient ranges, while chrysin, aloe-emodin and trans-stilbene were
investigated only at their IC50 treatment ranges. — 
levels) and \ (significant increase in GSH levels).
(no effect), j  (significant decrease in GSH
291
4.3.2.3 Effects of Topoisomerase Inhibitors Alone and in Combination with Polyphenols
on GSH Levels
(A) Effects o f Doxorubicin (DOX) Combined with Polyphenols on Glutathione (GSH) Levels
DOX alone significantly reduced the level o f GSH in all leukaemia cell lines (JURKAT, 
CCRF-CEM, THP-1 and K G -la) (p<0.05) (Figure 4.23, 4.24, 4.25). DOX in combination with 
QUE or AP caused a synergistic decrease in GSH levels in all lymphoid and myeloid cell lines 
(p<0.05) (Figure 4.23, 4.24 and Table 4.4). W hen DOX was used in combination with EMO, 
RH or CIS it also caused a synergistic reduction in GSH levels, but only in the lymphoid 
leukaemia cell lines (Figure 4.23, 4.24 and Table 4.4). In contrast, in the myeloid cell lines, 
DOX was combined with EMO or RH it produced a competitive antagonistic effect, 
significantly increasing GSH levels (p<0.05) (Figure 4.23, 4.24 and Table 4.4). W hen DOX 
was used in combination with CIS it produced an additive reduction in GSH levels in the 
myeloid leukaemia cell lines (p<0.05) (Figure 4.23, 4.24 and Table 4.4).
(B) Effects o f Etoposide (ETP) Combined with Polyphenols on (Glutathione) GSH Levels
ETP alone significantly reduced the GSH levels in all the leukaemia cell lines (JURKAT, 
CCRF-CEM, THP-1 and K G -la) (p<0.05) (Figure 4.26, 4.27, 4.28). ETP when used in 
combination with QUE or AP produced a synergistic reduction in GSH levels (p<0.05) in all 
the leukaemia cell lines (Figure 4.26, 4.27 and Table 4.5). ETP when used in combination with 
EMO produced a synergistic reduction in GSH level in the lymphoid leukaemia cell lines only 
(Figure 4.26, 4.27 and Table 4.5); and an additive effects in myeloid leukaemia cell lines 
(p<0.05) (Figure 4.26, 4.27 and Table 4.5). ETP when used in combination with RH or CIS 
produced a synergistic reduction in GSH levels in the lymphoid leukaemia cell lines only 
(Figure 4.26, 4.27 and Table 4.5). W hilst in the myeloid leukaemia cell lines ETP combined 
with RH or CIS displayed competitively antagonistic or antagonistic effects with a 
significantly increase GSH levels (p<0.05) (Figure 4.26, 4.27 and Table 4.5).
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Effect of Doxorubicin (DOX) When Used in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on Glutathione (GSH) Level of Leukaemia Cell Lines Following 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 4.23: The effect of DOX used in combination with QUE, AP, EMO, RH or CIS on 
GSH levels of leukaemia cell lines. This was evaluated by the GSH-Glo™ Glutathione Assay.
Cells were treated with DOX and polyphenols alone and in combination for 24 h using their LSD. 
Data was normalised to the vehicle-control which was assigned 100% of GSH Level. The data was 
expressed as medians and ranges (n=4). The black bars show the vehicle-controls and treatments 
alone; the white bar shows the expected effect of the combined treatments on GSH levels; the 
coloured bars indicate a significant additive reduction of GSH levels in brown, synergistic 
reduction in GSH levels in yellow, a competitive antagonistic increase in GSH levels in purple and 
an antagonistic increase in GSH levels in pink. Statistical significant was set at p<0.05 compared to 
vehicle control and drugs alone.
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Figure 4.24: The effect of DOX used in combination with QUE, AP, EMO, RH or CIS on 
intracellular GSH levels of leukaemia cell lines. This was evaluated by double staining with 
the CellTracker GSH- Green CMFDA (5-chloromethylfluorescein diacetate) and blue 
Hoechst 33342 using fluorescence microscopy. Cells were treated with DOX and polyphenols 
alone and in combined for 24 h using their LSD. Data was normalised to the vehicle control which 
was assigned 100% of GSH level. The data was expressed as medians and ranges (n=4). The black 
bars show the vehicle controls and treatments alone; the white bar show the expected effect o f the 
combined treatments on GSH levels; the coloured bars indicate a significant additive effects in 
brown, synergistic effects in yellow, competitive antagonistic effects in purple and an antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
294
CO NTR O L DO X, 0.0 l^ M
100 pun I 101) pm
Figure 4.25: An example of fluorescent detection of cellular glutathione (GSH) for THP-1 
myeloid leukaemia cells when treated with LSDs of DOX and polyphenols (QUE, AP, EMO, 
RH or CIS) alone and in combination for 24 h; using the CellTracker GSH- Green 5- 
chloromethylfluorescein diacetate (CMFDA) and blue Hoechst 33342 stains. Cells with green- 
CMFDA staining indicate the presence o f GSH, while cells with blue Hoechst 33342 staining 
indicate a decrease in G SH .. Scale bar = 100 pm.
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Figure 4.26: The effect of ETP used in combination with QUE, AP, EMO, RH or CIS on GSH 
levels of leukaemia cell lines. This was evaluated by the GSH-Glo™ Glutathione Assay. Cells 
were treated with ETP and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% of GSH level. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on GSH levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical signficant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Figure 4.27: The effect of ETP used in combination with QUE, AP, EMO, RH or CIS on 
intracellular GSH levels of leukaemia cell lines. This was evaluated by double staining with 
the CellTracker GSH- Green CMFDA (5-chloromethylfluorescein diacetate) and blue 
Hoechst 33342 using fluorescence microscopy. Cells were treated with ETP and polyphenols 
alone and in combined for 24 h using their LSD. Data was normalised to the vehicle control which 
was assigned 100% of GSH level. The data was expressed as medians and ranges (n=4). The black 
bars show the vehicle controls and treatments alone; the white bar show the expected effect o f the 
combined treatments on GSH levels; the coloured bars indicate a significant additive effects in 
brown, synergistic effects in yellow, competitive antagonistic effects in purple and an antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 4.28: An example of fluorescent detection of cellular glutathione (GSH) for THP-1 
myeloid leukaemia cells when treated with LSDs of ETP and polyphenols (QUE, AP, EMO, 
RH or CIS) alone and in combination for 24 h; using the CellTracker GSH- Green 5- 
chloromethylfluorescein diacetate (CMFDA) and blue Hoechst 33342 stains. Cells with green- 
CMFDA staining indicate the presence of GSH, while cells with blue Hoechst 33342 staining 
indicate a decrease in G SH .. Scale bar = 100 pm.
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4.3.Z.4 Lttects ot Alkylating Chemotherapy Alone and m Combination with Polyphenols 
on GSH Levels
(A) E ffec ts  o f  Cyclophosphamide (CYCLO) A lone and  in Combination with Polyphenols on 
G lutathione (GSH) Levels
CYCLO alone significantly reduced the level o f  GSH in three leukaemia cell lines (JURKAT, 
CCRF-CEM and THP-1) (p<0.05) (Figure X, X), but had no effect on K G -la cells (Figure 
4.29, 4.30, 4.31). CYCLO when used in combination with AP caused a synergistic reduction in 
GSH levels (p<0.05) in all leukaemia cell lines (Figure 4.29, 4.30 and Table 4.6). However, 
when CYCLO was combined with QUE, EMO or RH a synergistic reduction in GSH levels 
was seen in the lymphoid leukaemia cell lines (p<0.05) (Figure 4.29, 4.30 and Table 4.6); 
whilst in myeloid leukaemia cell lines a competitively antagonistic or antagonistic effect and a 
significant increase in GSH levels was observed (p<0.05) (Figure 4.29, 4.30 and Table 4.6). 
Likewise, when CYCLO used in combination with CIS a competitive antagonistic or 
antagonistic effect was seen in all the leukaemia cell lines (p<0.05) (Figure 4.29, 4.30 and 
Table 4.6).
(B) E ffec ts  o f  Cisplatin (CSP) A lone and  in Combination Polyphenols on G lutathione  
(GSH) Levels
CSP alone significantly reduced the levels o f  GSH in all the leukaemia cell lines (p<0.05) 
(Figure 4.32, 4.33, 4.34). CSP combined with QUE, resulted in a synergistic reduction in GSH 
levels in all leukaemia cell lines (p<0.05) (Figure 4.32, 4.33 and Table 4.7). Likewise, when 
CSP was combined with AP, it produced a synergistic effect on GSH levels in lymphoid 
leukaemia cell lines (p<0.05); as well a synergistic effect or an additive effect on GSH levels in 
myeloid leukaemia cell lines (p<0.05) (Figure 4.32, 4.33 and Table 4.7). Additionally, when 
CSP was used in combination with EMO, RH, or CIS, it caused a synergistic reduced in GSH 
levels in the lymphoid leukaemia cell lines only (p<0.05) (Figure 4.32, 4.33 and Table 4.7). 
However, in myeloid leukaemia cell lines, when CSP was combined with EMO, RH, or CIS, a 
competitive antagonistic or antagonistic effect as seen significantly increasing GSH levels 
(p<0.05) (Figure 4.32, 4.33 and Table 4.7).
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Figure 4.29: The effect of CYCLO used in combination with QUE, AP, EMO, RH or CIS on 
GSH levels of leukaemia cell lines. This was evaluated by the GSH-Glo™ Glutathione Assay.
Cells were treated with CYCLO and polyphenols alone and in combined for 24 h using their LSD. 
Data was normalised to the vehicle control which was assigned 100% of GSH level. The data was 
expressed as medians and ranges (n=4). The black bars show the vehicle controls and treatments 
alone; the white bar show the expected effect of the combined treatments on GSH levels ; the 
coloured bars indicate a significant additive effects in brown, synergistic effects in yellow, 
competitive antagonistic effects in purple and an antagonistic effects in pink. Statistical significant 
was set at p<0.05 compared to vehicle control and drugs alone.
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Figure 4.30: The effect of CYCLO used in combination with QUE, AP, EMO, RH or CIS on 
intracellular GSH levels of leukaemia cell lines. This was evaluated by double staining with 
the CellTracker GSH- Green CMFDA (5-chloromethylfluorescein diacetate) and blue 
Hoechst 33342 using fluorescence microscopy. Cells were treated with CYCLO and polyphenols 
alone and in combined for 24 h using their LSD. Data was normalised to the vehicle control which 
was assigned 100% of GSH level. The data was expressed as medians and ranges (n=4). The black 
bars show the vehicle controls and treatments alone; the white bar show the expected effect o f the 
combined treatments on GSH levels; the coloured bars indicate a significant additive effects in 
brown, synergistic effects in yellow, competitive antagonistic effects in purple and an antagonistic 
effects in pink. The gray bars indicate for no significant effect. Statistical significant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Figure 4.31: An example of fluorescent detection of cellular glutathione (GSH) for THP-1 
myeloid leukaemia cells when treated with LSDs of CYCLO and polyphenols (QUE, AP, 
EMO, RH or CIS) alone and in combination for 24 h; using the CellTracker GSH- Green 5- 
chloromethylfluorescein diacetate (CMFDA) and blue Hoechst 33342 stains. Cells with green- 
CMFDA staining indicate the presence o f GSH, while cells with blue Hoechst 33342 staining 
indicate a decrease in G SH .. Scale bar = 100 pm.
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Figure 4.32: The effect of CSP used in combination with QUE, AP, EMO, RH or CIS on GSH 
levels of leukaemia cell lines. This was evaluated by the GSH-Glo™ Glutathione Assay. Cells 
were treated with CSP and polyphenols alone and in combined for 24 h using their LSD. Data was 
normalised to the vehicle control which was assigned 100% of GSH level. The data was expressed 
as medians and ranges (n=4). The black bars show the vehicle controls and treatments alone; the 
white bar show the expected effect of the combined treatments on GSH levels ; the coloured bars 
indicate a significant additive effects in brown, synergistic effects in yellow, competitive 
antagonistic effects in purple and an antagonistic effects in pink. Statistical signficant was set at 
p<0.05 compared to vehicle control and drugs alone.
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Figure 4.33: The effect of CSP used in combination with QUE, AP, EMO, RH or CIS on 
intracellular GSH levels of leukaemia cell lines. This was evaluated by double staining with 
the CellTracker GSH- Green CMFDA (5-chloromethylfluorescein diacetate) and blue 
Hoechst 33342 using fluorescence microscopy. Cells were treated with CSP and polyphenols 
alone and in combined for 24 h using their LSD. Data was normalised to the vehicle control which 
was assigned 100% of GSH level. The data was expressed as medians and ranges (n=4). The black 
bars show the vehicle controls and treatments alone; the white bar show the expected effect o f the 
combined treatments on GSH levels; the coloured bars indicate a significant additive effects in 
brown, synergistic effects in yellow, competitive antagonistic effects in purple and an antagonistic 
effects in pink. Statistical significant was set at p<0.05 compared to vehicle control and drugs alone.
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HFigure 4.34: An example of fluorescent detection of cellular glutathione (GSH) for THP-1 
myeloid leukaemia cells when treated with LSDs of CSP and polyphenols (QUE, AP, EMO, 
RH or CIS) alone and in combination for 24 h; using the CellTracker GSH- Green 5- 
chloromethylfluorescein diacetate (CMFDA) and blue Hoechst 33342 stains. Cells with green- 
CMFDA staining indicate the presence o f GSH, while cells with blue Hoechst 33342 staining 
indicate a decrease in G SH .. Scale bar=  100 pm.
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4.3.Z.5 Ettects ot Anti-Metabolites Chemotherapy Agents Alone and in Combination with 
Polyphenols on GSH Levels
(A) E ffec t o f  M ethotrexate (M TX) A lone and in Combination with Polyphenols on 
G lutathione (GSH) Levels
MTX alone was significantly reduced the level o f  GSH in all the leukaemia cell lines (p<0.05) 
(Figure 4.35, 4.36, 4.37). MTX when used in combination with all polyphenols (QUE, AP, 
EMO, RH or CIS) caused a competitively antagonistic and/or antagonistic effects significantly 
increasing the GSH levels in all leukaemia cell lines (p<0.05) (Figure 4.35, 4.36 and Table 4.8).
(B) E ffec t o f  6-M ercaptopurine (6-MP) A lone and in Combination with Polyphenols on 
G lutathione (GSH) Levels
6 -MP alone significantly reduced the level o f GSH in three leukaemia cell lines (JURKAT, 
THP-1 and KG-la) (p<0.05), but had no significant effect on CCRF-CEM cells (Figure 4.38, 
4.39, 4.40). 6 -MP when used in combination with all polyphenols (QUE, AP, EMO, RH or 
CIS) caused competitive antagonistic and/or antagonistic effects significantly increasing the 
GSH levels in all leukaemia cell lines (p<0.05) (Figure 4 .38 ,4 .39  and Table 4.9).
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Figure 4.35: The effect of MTX used in combination with QUE, AP, EMO, RH or CIS on 
GSH levels of leukaemia cell lines. This was evaluated by the GSH-Glo™ Glutathione Assay.
C e l l s  w e r e  t r e a t e d  w i t h  M T X  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  
D a t a  w a s  n o r m a l i s e d  t o  t h e  v e h i c l e  c o n t r o l  w h i c h  w a s  a s s i g n e d  1 0 0 %  o f  G S H  l e v e l .  T h e  d a t a  w a s  
e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  t r e a t m e n t s  
a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  G S H  l e v e l s  ;  t h e  
c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  i n  b r o w n ,  s y n e r g i s t i c  e f f e c t s  i n  y e l l o w ,  
c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n  a n t a g o n i s t i c  e f f e c t s  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  
w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Figure 4.36: The effect of MTX used in combination with QUE, AP, EMO, RH or CIS on 
intracellular GSH levels of leukaemia cell lines. This was evaluated by double staining with 
the CellTracker GSH- Green CMFDA (5-chloromethylfluorescein diacetate) and blue 
Hoechst 33342 using fluorescence microscopy. C e l l s  w e r e  t r e a t e d  w i t h  M T X  a n d  p o l y p h e n o l s  
a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  D a t a  w a s  n o r m a l i s e d  t o  t h e  v e h i c l e  c o n t r o l  w h i c h  
w a s  a s s i g n e d  1 0 0 %  o f  G S H  l e v e l .  T h e  d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  
b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  
c o m b i n e d  t r e a t m e n t s  o n  G S H  l e v e l s ;  t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  i n  
b r o w n ,  s y n e r g i s t i c  e f f e c t s  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n  a n t a g o n i s t i c  
e f f e c t s  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Figure 4.37: An example of fluorescent detection of cellular glutathione (GSH) for THP-1 
myeloid leukaemia cells when treated with LSDs of MTX and polyphenols (QUE, AP, EMO, 
RH or CIS) alone and in combination for 24 h; using the CellTracker GSH- Green 5- 
chloromethylfluorescein diacetate (CMFDA) and blue Hoechst 33342 stains. C e l l s  w i t h  g r e e n -  
C M F D A  s t a i n i n g  i n d i c a t e  t h e  p r e s e n c e  o f  G S H ,  w h i l e  c e l l s  w i t h  b l u e  H o e c h s t  3 3 3 4 2  s t a i n i n g  
i n d i c a t e  a  d e c r e a s e  i n  G S H . .  S c a l e  b a r  =  1 0 0  p m .
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Effect o f Mercaptopurine (6-M P) When Used in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Glutathione (GSH) Level o f Leukaemia Cell Lines Following 24 h o f
Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 4.38: The effect of 6 -MP used in combination with QUE, AP, EMO, RH or CIS on 
GSH levels of leukaemia cell lines. This was evaluated by the GSH-Glo™ Glutathione Assay.
C e l l s  w e r e  t r e a t e d  w i t h  6 - M P  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  
D a t a  w a s  n o r m a l i s e d  t o  t h e  v e h i c l e  c o n t r o l  w h i c h  w a s  a s s i g n e d  1 0 0 %  o f  G S H  l e v e l .  T h e  d a t a  w a s  
e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  t r e a t m e n t s  
a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  G S H  l e v e l s  ;  t h e  
c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  i n  b r o w n ,  s y n e r g i s t i c  e f f e c t s  i n  y e l l o w ,  
c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n  a n t a g o n i s t i c  e f f e c t s  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  
w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Effect of Mercaptopurine (6-M P) When Used in Combination with Polyphenols at their Lowest
Significant Doses (LSD) on Glutathione (GSH) Based on Green CM FDA Stain of Leukaemia Cell Lines
______________________________ Following 24 h o f Treatment.__________________________________
Lymphoid Leukaemia Cell Lines. Mveloid Leukaemia Cell Lines.
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Figure 4.39: The effect of 6 -MP used in combination with QUE, AP, EMO, RH or CIS on 
intracellular GSH levels of leukaemia cell lines. This was evaluated by double staining with 
the CellTracker GSH- Green CMFDA (5-chloromethylfluorescein diacetate) and blue 
Hoechst 33342 using fluorescence microscopy. C e l l s  w e r e  t r e a t e d  w i t h  6 - M P  a n d  p o l y p h e n o l s  
a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  D a t a  w a s  n o r m a l i s e d  t o  t h e  v e h i c l e  c o n t r o l  w h i c h  
w a s  a s s i g n e d  1 0 0 %  o f  G S H  l e v e l .  T h e  d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  
b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  
c o m b i n e d  t r e a t m e n t s  o n  G S H  l e v e l s ;  t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t  a d d i t i v e  e f f e c t s  i n  
b r o w n ,  s y n e r g i s t i c  e f f e c t s  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  e f f e c t s  i n  p u r p l e  a n d  a n  a n t a g o n i s t i c  
e f f e c t s  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  w a s  s e t  a t  p < 0 . 0 5  c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Figure 4.40: An example of fluorescent detection of cellular glutathione (GSH) for THP-1 
myeloid leukaemia cells when treated with LSDs of 6 -MP and polyphenols (QUE, AP, EMO, 
RH or CIS) alone and in combination for 24 h; using the CellTracker GSH- Green 5- 
chloromethylfluorescein diacetate (CMFDA) and blue Hoechst 33342 stains. C e l l s  w i t h  g r e e n -  
C M F D A  s t a i n i n g  i n d i c a t e  t h e  p r e s e n c e  o f  G S H ,  w h i l e  c e l l s  w i t h  b l u e  H o e c h s t  3 3 3 4 2  s t a i n i n g  
i n d i c a t e  a  d e c r e a s e  i n  G S H . .  S c a l e  b a r  =  1 0 0  p m .
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4.3.3 Gamma-H2AX (y-H2AX) Foci Formation in Leukaemia Cells
4.3.3.1 Effect of Polyphenols and Chemotherapies Alone on y-H2AX Foci Formation
Polyphenols alone caused different capacities to induce the formation o f  y-H2AX foci within 
the leukaemia cell lines (Figure 4.41; 4.45). In particular at the LSD following 24 h treatment, 
QUE significantly increased the number o f y-H2AX foci in three out o f  four leukaemia cell 
lines (JURKAT, CCRF-CEM and THP-1) (p<0.05) (Figure 4.41; 4.45). However, AP 
significantly increased y-H2AX foci formation in all the leukaemia cell lines (p<0.05) (Figure 
4.41; 4.45). EMO and RH did cause a significant increase in y-H2AX foci in the CCRF-CEM 
lymphoid cell line (p<0.05), but did not show any significant effect on the remaining three 
leukaemia cell lines (JURKAT, THP-1 and KG-la) (p<0.05) (Figure 4.41; 4.45). Whilst, CIS 
did not cause any significant increase in y-H2AX foci in any leukaemia cell lines (p<0.05) 
(Figure 4.41; 4.45). DOX, ETP, CSP, MTX and 6 -MP when used alone at the LSD for 24 h 
caused a significant increase in y-H2AX foci formation in all the leukaemia cell lines (p<0.05) 
(Figure 4.41; 4.45). In contrast, CYCLO when used alone only significant increased y-H2AX  
foci formation in CCRF-CEM lymphoid leukaemia cell lines (p<0.05) (Figure 4.41; 4.45), and 
did not significant affect the remaining leukaemia cell lines (JURKAT, THP-1 and KG la) 
(Figure 4.41; 4.45).
4.3.3.3 Effects of Topoisomerase Inhibitors in Combination with Polyphenols on y-H2AX 
Foci Formation
(A) E ffec ts o f  D oxorubicin (DOX) in Combination with Polyphenols on y-H 2A X  Foci 
Form ation
DOX when used in combination with QUE or AP caused a synergistic increase in y-H2AX foci 
(p<0.05) in both lymphoid and myeloid cell lines (Figure 4.41 and Table 4.4). Likewise, when 
DOX was used in combination with EMO, RH or CIS it also caused a synergistic formation o f  
y-H2AX foci (p<0.05), but only in the lymphoid leukaemia cell lines (Figure 4.41 and Table 
4.4). In contrast, when DOX was combined with EMO or RH it produced a competitive 
antagonistic effect, which significantly decreased y-H2AX foci formation in the myeloid 
leukaemia cell lines (p<0.05) (Figure 4.41 and Table 4.4). When DOX was used combination 
with CIS it produced an additive effect increasing y-H2AX foci formation in the myeloid 
leukaemia cell lines (p<0.05) (Figure 4.41 and Table 4.4).
(B) E ffec ts  o f  Etoposide (ETP) in Combination with Polyphenols on y -H 2A X  Foci 
Form ation
ETP when used in combination with QUE or AP produced a synergistic increase in y-H2AX
foci formation in all leukaemia cell lines (p<0.05) (Figure 4.42 and Table 4.5). Likewise ETP
when used in combination with EMO produced a synergistic increase in y-H2AX foci in the
lymphoid leukaemia cell lines (p<0.05) (Figure 4.42 and Table 4.5); and an additive increase in
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y - H 2 A X  f o c i  i n  t h e  m y e l o i d  l e u k a e m i a  c e l l  l i n e s  ( p < 0 . 0 5 )  ( F i g u r e  4 . 4 2  a n d  T a b l e  4 . 5 ) .  E T P  
w h e n  u s e d  i n  c o m b i n e d  w i t h  R H  o r  C I S  p r o d u c e d  a  s y n e r g i s t i c  i n c r e a s e  i n  t h e  f o r m a t i o n  o f  y -  
F I 2 A X  f o c i  i n  t h e  l y m p h o i d  l e u k a e m i a  c e l l  l i n e s  o n l y  ( F i g u r e  4 . 4 2  a n d  T a b l e  4 . 5 ) .  I n  t h e  
m y e l o i d  l e u k a e m i a  c e l l  l i n e s ,  E T P  w h e n  u s e d  i n  c o m b i n a t i o n  w i t h  R H  o r  C I S  p r o d u c e d  a  
c o m p e t i t i v e l y  a n t a g o n i s t i c  o r  a n t a g o n i s t i c  e f f e c t  s i g n i f i c a n t l y  d e c r e a s i n g  t h e  y - H 2 A X  f o c i  
f o r m a t i o n  o f  ( p < 0 . 0 5 )  ( F i g u r e  4 . 4 2  a n d  T a b l e  4 . 5 ) .
Effect o f D oxorubicin (DOX) W hen Used in C om bination w ith Polyphenols a t th e ir  Low est S ignificant Doses 
(LSD) on yH 2AX Foci Form ation  o f L eukaem ia Cell L ines Following 24 h o f T reatm en t.
Q
U
E
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Figure 4.41: The effect of DOX when used in combination with QUE, AP, EMO, RH or CIS 
on y-H2AX foci formation (DNA damage marker) in four leukaemia cell lines. T h i s  w a s  
e v a l u a t e d  b y  t h e  i m m u n o f l u o r e s c e n t  s t a i n i n g  u s i n g  A l e x a  F l u o r ®  6 4 7  M o u s e  a n t i - H 2 A X  ( p S 1 3 9 ) .  
C e l l s  w e r e  t r e a t e d  w i t h  D O X  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  T h e  
d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  
t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  y - H 2 A X ;  
t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t :  a d d i t i v e  i n c r e a s e  i n  D N A  d a m a g e  i n  b r o w n ,  s y n e r g i s t i c  
i n c r e a s e  i n  D N A  d a m a g e  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p u r p l e  
a n d  a n  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p i n k .  S t a t i s t i c a l  s i g n f i c a n t  w a s  s e t  a t  p < 0 . 0 5  
c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Effect of Etoposide (ETP) When Used in Combination with Polyphenols at their Lowest Significant Doses
________ (LSD) on yH2AX Foci Formation of Leukaemia Cell Lines Following 24 h of Treatment.________
L y m p h o id  L eu k a em ia  C ell L ines. M y elo id  L eu k a em ia  C ell L in es.
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Figure 4.42: The effect of ETP when used in combination with QUE, AP, EMO, RH or CIS 
on y-H2AX foci formation (DNA damage marker) in four leukaemia cell lines. T h i s  w a s  
e v a l u a t e d  b y  t h e  i m m u n o f l u o r e s c e n t  s t a i n i n g  u s i n g  A l e x a  F l u o r ®  6 4 7  M o u s e  a n t i - H 2 A X  ( p S 1 3 9 ) .  
C e l l s  w e r e  t r e a t e d  w i t h  E T P  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  T h e  
d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  
t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  y - H 2 A X ;  
t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t :  a d d i t i v e  i n c r e a s e  i n  D N A  d a m a g e  i n  b r o w n ,  s y n e r g i s t i c  
i n c r e a s e  i n  D N A  d a m a g e  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p u r p l e  
a n d  a n  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  w a s  s e t  a t  p < 0 . 0 5  
c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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4.3.3.4 Effects of Alkylating Chemotherapy Agents in Combination with Polyphenols on
y-H2AX Foci Formation
(A) E ffec ts o f  Cyclophosphamide (CYCLO) in Combination with Polyphenols on y-H 2A X  
F oci Formation
CYCLO when used in combination with AP caused a synergistic increase in y-H2AX foci 
formation (p<0.05) in all the leukaemia cell lines (Figure 4.43 and Table 4.6). Likewise 
CYCLO when used in combination with QUE, EMO or RH caused a synergistic increase in y- 
H2AX foci formation in the lymphoid leukaemia cell lines (p<0.05) (Figure 4.43 and Table 
4.6). In contrast, in the myeloid leukaemia cell lines (THP-1, KGla); when CYCLO was used 
in combination with QUE, EMO or RH if  caused an competitively antagonistic effect, 
significantly decreasing the formation o f  y-H2AX foci (p<0.05) (Figure 4.43 and Table 4.6). 
Additionally, when CYCLO used in combination with CIS caused a competitive antagonistic 
effect and significantly decreased the formation o f  y-H2AX foci in all leukaemia cell lines 
(p<0.05) (Figure 4.43 and Table 4.6).
(B) E ffec ts o f  Cisplatin (CSP) in Combination with Polyphenols on y-H 2A X  F oci Form ation
CSP when use in combination with QUE or AP, caused a synergistic increase in y-H2AX foci 
formation in all the leukaemia cell lines (p<0.05) (Figure 4.4 and Table 4.7). Additionally, 
when CSP was used in combination with EMO, RH, or CIS, it caused a synergistic increase in 
y-H2AX foci formation, but only in the lymphoid leukaemia cell lines (p<0.05) (Figure 4.4 and 
Table 4.7). In contrast, when CSP was used in combination with EMO, RH, or CIS, in myeloid 
leukaemia cell lines this caused a competitive antagonistic effect significantly decreasing y- 
H2AX foci formation (p<0.05) (Figure 4.4 and Table 4.7).
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Effect of Cyclophosphamide (CYCLO) When Used in Combination with Polyphenols at their Lowest
S ig n ific a n t  D o s e s  (L S D ) on  y H 2 A X  F o c i F o r m a tio n  o f  L e u k a e m ia  C e ll L in e s  F o llo w in g  2 4  h o f  T rea tm en t.
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Figure 4.43: The effect of CYCLO when used in combination with QUE, AP, EMO, RH or 
CIS on y-H2AX foci formation (DNA damage marker) in four leukaemia cell lines. T h i s  w a s  
e v a l u a t e d  b y  t h e  i m m u n o f l u o r e s c e n t  s t a i n i n g  u s i n g  A l e x a  F l u o r ®  6 4 7  M o u s e  a n t i - H 2 A X  ( p S 1 3 9 ) .  
C e l l s  w e r e  t r e a t e d  w i t h  C Y C L O  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  
T h e  d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  
t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  y - H 2 A X ;  
t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t :  a d d i t i v e  i n c r e a s e  i n  D N A  d a m a g e  i n  b r o w n ,  s y n e r g i s t i c  
i n c r e a s e  i n  D N A  d a m a g e  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p u r p l e  
a n d  a n  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p i n k .  S t a t i s t i c a l  s i g n i f i c a n t  w a s  s e t  a t  p < 0 . 0 5  
c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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Figure 4.44: The effect of CSP when used in combination with QUE, AP, EMO, RH or CIS 
on y-H2AX foci formation (DNA damage marker) in four leukaemia cell lines. T h i s  w a s  
e v a l u a t e d  b y  t h e  i m m u n o f l u o r e s c e n t  s t a i n i n g  u s i n g  A l e x a  F l u o r ®  6 4 7  M o u s e  a n t i - H 2 A X  ( p S 1 3 9 ) .  
C e l l s  w e r e  t r e a t e d  w i t h  C S P  a n d  p o l y p h e n o l s  a l o n e  a n d  i n  c o m b i n e d  f o r  2 4  h  u s i n g  t h e i r  L S D .  T h e  
d a t a  w a s  e x p r e s s e d  a s  m e d i a n s  a n d  r a n g e s  ( n = 4 ) .  T h e  b l a c k  b a r s  s h o w  t h e  v e h i c l e  c o n t r o l s  a n d  
t r e a t m e n t s  a l o n e ;  t h e  w h i t e  b a r  s h o w  t h e  e x p e c t e d  e f f e c t  o f  t h e  c o m b i n e d  t r e a t m e n t s  o n  y - H 2 A X ;  
t h e  c o l o u r e d  b a r s  i n d i c a t e  a  s i g n i f i c a n t :  a d d i t i v e  i n c r e a s e  i n  D N A  d a m a g e  i n  b r o w n ,  s y n e r g i s t i c  
i n c r e a s e  i n  D N A  d a m a g e  i n  y e l l o w ,  c o m p e t i t i v e  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p u r p l e  
a n d  a n  a n t a g o n i s t i c  d e c r e a s e  i n  D N A  d a m a g e  i n  p i n k .  S t a t i s t i c a l  s i g n f i c a n t  w a s  s e t  a t  p < 0 . 0 5  
c o m p a r e d  t o  v e h i c l e  c o n t r o l  a n d  d r u g s  a l o n e .
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4.3.3.S Effects of Anti-Metabolites Chemotherapy Agents in Combination with
Polyphenols on y-H2AX Foci Formation
(A) E ffec t o f  M ethotrexate (M TX) in Combination with Polyphenols on y -H 2A X  Foci 
Form ation
MTX when used in combination with all polyphenols (QUE, AP, EMO, RH or CIS) caused a 
competitively antagonistic and/or antagonistic effect significantly decreasing the formation o f  
y-H2AX foci in all the leukaemia cell lines (p<0.05) (Figure 4.45 and Table 4.8).
(B) E ffec t o f  6-M ercaptopurine (6-MP) in Combination with Polyphenols on y -H 2A X  F oci 
Form ation
6 -MP when used in combination with all polyphenols (QUE, AP, EMO, RH or CIS) caused a 
competitive antagonistic and/or antagonistic effects significantly decreasing the formation o f  y- 
H2AX foci in all lymphoid and myeloid leukaemia cell lines (p<0.05) (Figure 4.46 and Table 
4.9).
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Effect o f Methotrexate (MTX) When Used in Combination with Polyphenols at their Lowest Significant
Doses (LSD) on yH2AX Foci Formation of Leukaemia Cell Lines Following 24 h of Treatment.
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 4.45: The effect of MTX when used in combination with QUE, AP, EMO, RH or CIS 
on y-H2AX foci formation (DNA damage marker) in four leukaemia cell lines. This was 
evaluated by the immunofluorescent staining using Alexa Fluor® 647 Mouse anti-H2AX (pS139). 
Cells were treated with MTX and polyphenols alone and in combined for 24 h using their LSD. 
The data was expressed as medians and ranges (n=4). The black bars show the vehicle controls and 
treatments alone; the white bar show the expected effect of the combined treatments on y-H2AX; 
the coloured bars indicate a significant: additive increase in DNA damage in brown, synergistic 
increase in DNA damage in yellow, competitive antagonistic decrease in DNA damage in purple 
and an antagonistic decrease in DNA damage in pink. Statistical significant was set at p<0.05 
compared to vehicle control and drugs alone.
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Effect ofMercaptopurine (6-MP) When Used in Combination with Polyphenols at their Lowest Significant
 Doses (LSD) on yH2AX Foci Formation of Leukaemia Cell Lines Following 24 h of Treatment.______
Lymphoid Leukaemia Cell Lines. Myeloid Leukaemia Cell Lines.
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Figure 4.46: The effect of 6-MP when used in combination with QUE, AP, EMO, RH or CIS 
on y-H2AX foci formation (DNA damage marker) in four leukaemia cell lines. This was 
evaluated by the immunofluorescent staining using Alexa Fluor® 647 Mouse anti-H2AX (pS139). 
Cells were treated with 6 -MP and polyphenols alone and in combined for 24 h using their LSD. 
The data was expressed as medians and ranges (n=4). The black bars show the vehicle controls and 
treatments alone; the white bar show the expected effect of the combined treatments on y-H2AX; 
the coloured bars indicate a significant: additive increase in DNA damage in brown, synergistic 
increase in DNA damage in yellow, competitive antagonistic decrease in DNA damage in purple 
and an antagonistic decrease in DNA damage in pink. Statistical significant was set at p<0.05 
compared to vehicle control and drugs alone.
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The Significant Effects of Doxorubicin (DOX) 
and Polyphenols Combination Treatment on 
Caspase 8 and 9 Activity, Glutathione (GSH) 
Levels, H2AX Foci Formation and Cell Cycle 
Arrest at 24 h in Leukaemia Cell Lines.
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Table 4.4: A summary of the effects of doxorubicin (DOX) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on 
caspase 8 and 9 activity, glutathione (GSH) levels, y-H2AX foci formation and cell cycle 
progression (Chapter 3) in two lymphoid leukaemia (JURKAT and CCRF-CEM) and two myeloid 
leukaemia (THP-1 and KGla) cell lines at 24 h. Combination treatments were investigated at their 
lowest significant dose (LSD). Note that the combination effects of drugs were determined statistically 
as described as in Section 4.2.5. SYN = Synergistic, ADD = Additive. NT= non-tested. Cell cycle data 
summarised to enable comparison to results o f y-H2AX formation.
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Table 4.5: A summary of the effects of etoposide (ETP) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on 
caspase 8 and 9 activity, glutathione (GSH) levels, y-H2AX foci formation and cell cycle 
progression (Chapter 3) in two lymphoid leukaemia (JURKAT and CCRF-CEM) and two myeloid 
leukaemia (THP-land KGla) cell lines at 24 h. Combination treatments were investigated at their 
lowest significant dose (LSD). Note that the combination effects of drugs were determined statistically 
as described as in Section 4.2.5. SYN = Synergistic, ADD = Additive. NT= non-tested. Cell cycle data 
summarised to enable comparison to results o f y-H2AX formation.
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C asp ase-G lo®  8  A ssay C asp ase  8 A ctiv ity C Y C L O  +  A P  (L SD ) SY N S Y N SY N S Y N
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity C Y C L O  +  A P  (L SD ) SY N S Y N S Y N S Y N
G S H -G lo ™  G lu ta th ion e  
A ssa y  ' G S H  L evel
C Y C L O  +  A P  (L S D ) S Y N S Y N S Y N S Y N
C eliT ra ck er  G S H -G reen  
C M F D A
%  o f  C ells  w ith  G SH  
Stain
C Y C L O  +  A P  (L S D ) SY N S Y N SY N S Y N
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
Y -H 2A X  F oci 
F O R M A T IO N
C Y C L O  +  A P  (L SD ) SY N S Y N S Y N S Y N
C ell C ycle /P I A rrestin g  P hases C Y C L O  +  A P  (L SD ) S p hase S p h ase s & g 2/mp hases
Go/G,
p h ase
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity C Y C L O  +  E M O  (L SD ) A D D A D D N T N T
C asp ase-G lo®  9  A ssay C asp ase  9 A ctiv ity C Y C L O  +  E M O  (L S D ) SY N S Y N N T N T
G S H -G lo ™  G lu ta th ion e  
A ssay G S H  L eve l
C Y C L O  +  E M O  (L S D ) SY N S Y N C -A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G SH  
S ta in
C Y C L O  +  E M O  (U SD ) SY N S Y N A N T G
N O
E F F E C T
A lexa  F lu or®  6 4 7  M ou se  
an ti-H 2A X
Y -H 2A X  F oci 
F O R M A T IO N
C Y C L O  +  E M O  (L SD ) SY N S Y N C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P hases C Y C L O  +  E M O  (L S D ) Go/G,p hase S p h ase N o  A rrest N o  A rres t
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity C Y C L O  +  R H  (L S D ) A D D A D D N T N T
C asp ase-G lo®  9  A ssay C asp ase 9 A ctiv ity C Y C L O  +  R H  (L S D ) SY N S Y N N T N T
G S H -G lo™  G lu ta th ion e
A ssay G S H  L ev e l
C Y C L O  +  R H  (L S D ) - S Y N S Y N A N T G C -A N T G
C eliT ra ck er  G S H -G reen  
C M F D A
%  o f  C ells  w ith  G S H  
S ta in
C Y C L O  +  R H  (L S D ) ; SY N S Y N C -A N T G
N O
E F F E C T
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
Y -H 2A X  F oci 
F O R M A T IO N
C Y C L O  +  R H  (L S D ) SY N S Y N C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases C Y C L O  +  R H  (L SD ) Go/G,p hase S p h ase N o A rrest N o A rrest
C asp ase-G lo®  8 A ssay C asp ase 8 A ctivity’ C Y C L O  +  C IS  (L S D ) N T N T N T N T
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity C Y C L O  +  C IS  (L SD ) N T N T N T N T
G S H -G lo™  G lu ta th ion e  
A ssay G S H  L evel
C Y C L O  +  C IS  (L S D ) A N T G A N T G C -A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G S H  
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E F F E C T
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C Y C L O  +  C IS  (L SD ) C -A N T G C -A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases C Y C L O  +  C IS  (L SD ) N o A rrest N o A rrest N o  A rrest N o A rres t
Table 4.6: A summary of the effects of cyclophosphamide (CYCLO) and polyphenols 
(QUE), apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination ti 
on caspase 8 and 9 activity, glutathione (GSH) levels, y-H2AX foci formation and 
progression (Chapter 3) in two lymphoid leukaemia (JURKAT and CCRF-CEM) and tw 
leukaemia (THP-land KGla) cell lines at 24 h. Combination treatments were investigate 
lowest significant dose (LSD). Note that the combination effects of drugs were determined si 
as described as in Section 4.2.5. SYN = Synergistic, ADD = Additive. NT= non-tested. Cell 
summarised to enable comparison to results o f y-H2AX formation.
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Assays Targets
Combination of 
Cisplatin 
and Polyphenols
The Significant Effects of Cisplatin (CSP) and 
Polyphenols Combination Treatment on 
Caspase 8 and 9 Activity, Glutathione (GSH) 
Levels, H2AX Foci Formation and Cell Cycle 
Arrest at 24 h in Leukaemia Cell Lines.
L y m p h o id  L e u k a e m ia M y e lo id  L e u k a e m ia
J U R K A T C C R F -C E M T H P -1 K G la
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity C S P  +  Q U E  (L S D ) SY N SY N SY N S Y N
C asp ase-G Io®  9 A ssay C asp ase  9  A ctiv ity C S P  +  Q U E  (L S D ) SY N S Y N  . SY N S Y N
G S H -G lo™  G lu ta th ion e  
A ssay G S H  L eve l C S P  +  Q U E  (L S D )
SY N S Y N S Y N S Y N
C eliT rack er G S H -G reen  
C M F D A
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S ta in C S P  +  Q U E  (L S D )
S Y N ; SY N ; SY N S Y N
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Y -H 2A X  Foci 
F O R M A T IO N C S P  +  Q U E  (L S D )
SY N S Y N SY N S Y N
C ell C ycle/PI A rrestin g  P hases C S P  +  Q U E  (L SD ) S p hase S p hase G^/M p hase G 2/M  p h ase
C asp ase-G Io®  8  A ssay C asp ase  8 A ctiv ity C S P  +  A P  (L SD ) S Y N S Y N SY N S Y N
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity C S P  +  A P  (L S D ) SY N S Y N SY N S Y N
G S H -G lo ™  G lu ta th ion e  
A ssa y G S H  L eve l C S P  +  A P  (L S D )
SY N SY N S Y N S Y N
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G S H  
S tain C S P  +  A P  (L S D )
SY N SY N A D D A D D
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
Y -H 2A X  Foci 
F O R M A T IO N C S P  +  A P  (L SD )
SY N SY N SY N S Y N
C ell C ycle/PI A rrestin g  P hases C SP  +  A P  (L SD ) S p hase S p hase G 2/M  p hase G 2/M  p h ase
C asp ase-G lo®  8 A ssay C asp ase  8  A ctiv ity C S P  +  E M O  (L S D ) A D D A D D N T N T
C asp ase-G lo®  9  A ssay C asp ase  9 A ctiv ity C S P  +  E M O  (L S D ) S Y N S Y N N T N T
G S H -G lo™  G lu ta th ion e  
A ssay G S H  L eve l C S P  +  E M O  (L S D )
S Y N ' S Y N A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G S H  
S tain C S P  +  E M O  (L S D )
S Y N  - S Y N  , A N T G C -A N T G
A lexa  F luor®  647  M ou se  
an ti-H 2A X
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F O R M A T IO N C SP  +  E M O  (L S D )
SY N S Y N C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  Phases C SP  +  E M O  (L SD ) S p hase S p h ase N o A rrest N o A rres t
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity C S P  +  R H  (L SD ) A D D A D D N T N T
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity C SP  +  R H  (L SD ) S Y N S Y N N T N T
G S H -G lo™  G lu ta th ion e  
A ssay G S H  L ev e l C S P  +  R H  (L S D )
SY N  \ S Y N A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G S H  
S ta in C S P  +  R H  (L S D )
SY N S Y N C -A N T G C -A N T G
A lexa  F lu or®  6 47  M ou se  
an ti-H 2A X
Y -H 2A X  F oci 
F O R M A T IO N C S P  +  R H  (L S D )
SY N S Y N C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  Phases C S P  +  R H  (L SD ) S p hase S p h ase N o A rrest N o  A rrest
C asp ase-G Io®  8 A ssay C asp ase  8  A ctiv ity C S P  +  C IS  (L S D ) S Y N S Y N N T N T
C asp ase-G lo®  9  A ssay C asp ase  9 A ctiv ity C S P  +  C IS  (L S D ) SY N S Y N N T N T
G S H -G lo™  G lu ta th ion e  
A ssay G S H  L eve l CSP + a s  (LSD)
S Y N S Y N A N T G A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G SH  
S ta in C S P  +  C IS  (L S D )
S Y N S Y N  . C -A N T G C -A N T G
A lexa  F luor®  64 7  M ou se  
anti-I12A X
Y -H 2A X  F oci 
F O R M A T IO N C S P  +  C IS  (L SD )
SY N S Y N C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P hases C S P  +  C IS  (L S D ) S p hase S p h ase N o A rrest N o  A rrest
Table 4.7: A summary of the effects of cisplatin (CSP) and polyphenols [quercetin (QUE), 
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination treatments on 
caspase 8 and 9 activity, glutathione (GSH) levels, y-H2AX foci formation and cell cycle 
progression (Chapter 3) in two lymphoid leukaemia (JURKAT and CCRF-CEM) and two myeloid 
leukaemia (THP-land KGla) cell lines at 24 h. Combination treatments were investigated at their 
lowest significant dose (LSD). Note that the combination effects of drugs were determined statistically 
as described as in Section 4.2.5. SYN = Synergistic, ADD = Additive. NT= non-tested. Cell cycle data 
summarised to enable comparison to results o f y-H2AX formation.
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Assays Targets
Combination of 
Methotrexate 
and Polyphenols
The Significant Effects of Methotrexate 
(MTX) and Polyphenols Combination 
Treatment on Caspase 8 and 9 Activity, 
Glutathione (GSH) Levels, H2AX Foci 
Formation and Cell Cycle Arrest at 24 h in 
Leukaemia Cell Lines.
L y m p h o id  L e u k a e m ia M y e lo id  L e u k a e m ia
J U R K A T C C R F -C E M T H P -1  | K G la
C asp ase-G Io®  8 A ssay C asp ase  8 A ctiv ity M T X  +  Q U E  (L S D ) N T N T N T N T
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity M T X  +  Q U E  (L S D ) N T N T N T N T
G S H -G lo™  G lu ta th ion e
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S ta in M T X  +  Q U E  (L S D )
A N T G C -A N T G C -A N T G A N T G
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
Y -H 2A X  F oci 
F O R M A T IO N M T X  +  Q U E  (L S D ) C -A N T G A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases M T X  +  Q U E  (L SD ) N o A rrest N o A rrest N o A rrest N o A rrest
C asp ase-G lo®  8  A ssay C asp ase  8 A ctiv ity M T X  +  A P  (L SD ) N T N T N T N T
C asp ase-G Io®  9 A ssay C asp ase  9 A ctiv ity M T X  +  A P  (L SD ) N T N T N T N T
G S H -G lo ™  G lu tath ion e
A ssay G S H  L evel M T X  +  A P  (L S D )
C -A N T G C -A N T G A N T G A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G SH  
S ta in M T X  +  A P (L S D )
C -A N T G C -A N T G A N T G C -A N T G
A lexa  F lu or®  6 4 7  M ou se  
anti-I12A X
Y -H 2A X  Foci 
F O R M A T IO N M T X  +  A P  (L SD ) A N T G C -A N T G A N T G A N T G
C ell C ycle/PI A rrestin g  P h ases M T X  +  A P  (L SD ) N o A rrest N o A rrest N o A rrest N o A rrest
C asp ase-G lo®  8  A ssay C asp ase  8 A ctiv ity M T X  +  E M O  (L SD ) N T N T N T N T
C asp ase-G lo®  9  A ssay C asp ase 9 A ctiv ity M T X  +  E M O  (L SD ) N T N T N T N T
G S H -G lo™  G lu ta th ion e  
A ssay G S H  L evel M T X  +  E M O  (L S D )
A N T G A N T G K  A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G S H  
S tain M T X  +  E M O  (L S D )
A N T G C -A N T G A N T G  > ' C -A N T G
A lexa  F lu or®  647  M ou se  
anti-I12A X
Y -H 2A X  F oci 
F O R M A T IO N M T X  +  E M O  (L SD ) C -A N T G A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P hases M T X  +  E M O  (L SD ) N o A rrest N o  A rrest N o A rrest N o  A rres t
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity M T X  +  R H  (L SD ) N T N T N T N T
C asp ase-G lo®  9 A ssay C asp ase  9  A ctiv ity M T X  +  R H  (L S D ) N T N T N T N T
G S H -G lo ™  G lu ta th ion e  
A ssay G S H  L eve l M T X  +  R H  (L S D )
C -A N T G C -A N T G C -A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G SH  
S ta in M T X  +  RI1 (L S D )
A N T G C -A N T G C -A N T G C -A N T G
A lexa  F lu or®  6 47  M ou se  
an ti-H 2A X
Y -H 2A X  Foci 
F O R M A T IO N M T X  +  R H  (L SD ) C -A N T G A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases M T X  +  R H  (L SD ) N o A rrest N o  A rrest N o A rrest N o A rres t
C asp ase-G lo®  8  A ssay C asp ase  8  A ctiv ity M T X  +  C IS  (L S D ) N T N T N T N T
C asp ase-G lo®  9  A ssay C asp ase  9  Activity' M T X  +  C IS  (L SD ) N T N T N T N T
G S H -G lo™  G lu tath ion e  
A ssay G S H  L evel M T X  +  C IS  (L S D )
C -A N T G C -A N T G C -A N T G C -A N T G
C eliT rack er G S H -G reen  
C M F D A
%  o f  C ells  w ith  G SH  
S ta in M T X  +  C IS  (L S D )
A N T G C -A N T G C -A N T G C -A N T G
A lexa  F lu or®  6 47  M ou se  
anti-I12A X
Y -H 2A X  F oci 
F O R M A T IO N M T X  +  C IS  (L SD ) C -A N T G C -A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases M T X  +  C IS  (L SD ) N o A rrest N o  A rrest N o A rrest N o  A rrest
Table 4.8: A summary of the effects of methotrexate (MTX) anc 
apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (Cl 
caspase 8 and 9 activity, glutathione (GSH) levels, y-H2AX 
progression (Chapter 3) in two lymphoid leukaemia (JURKAT an 
leukaemia (THP-land KGla) cell lines at 24 h. Combination treatmei 
significant dose (LSD). Note that the combination effects of drugs were 
as in Section 4.2.5. SYN = Synergistic, ADD = Additive. NT= non-tes 
enable comparison to results of y-H2AX formation.
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Assays Targets
Combination of 6- 
Mercaptopurine 
and Polyphenols
The Significant Effects of 6-Mercaptopurine (6- 
MP) and Polyphenols Combination Treatment 
on Caspase 8 and 9 Activity, Glutathione (GSH) 
Levels, H2AX Foci Formation and Cell Cycle 
Arrest at 24 h in Leukaemia Cell Lines.
L y m p h o id  L e u k a e m ia M y e lo id  L e u k a e m ia
J U R K A T C C R F -C E M T H P -1 K G la
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A ssay G S H  L eve l 6 -M P  +  Q U E  (L S D )
C -A N T G C -A N T G C -A N T G A N T G
C eliT ra ck er  G S H -G reen  
C M F D A
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S ta in 6 -M P  +  Q U E  (L S D )
A N T G C -A N T G C -A N T G A N T G
A lexa  F lu or®  6 4 7  M ou se  
an ti-H 2A X
y -H 2A X  F oc i 
F O R M A T IO N 6-M P  +  Q U E  (L S D ) C -A N T G A N T G A N T G C -A N T G
C ell C ycle /P I A rrestin g  P hases 6-M P  +  Q U E  (L S D ) N o A rrest N o A rrest N o  A rrest N o A rrest
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity 6 -M P +  A P  (L S D ) N T N T N T N T
C asp ase-G lo®  9  A ssay C asp ase  9 A ctiv ity 6 - M P +  A P  (L S D ) N T N T N T N T
G S H -G lo ™  G lu ta th ion e  
A ssay G S H  L evel 6 - M P +  A P  (L S D )
C -A N T G C -A N T G C -A N T G C -A N T G
C eliT rack er G S H G r e e n  
C M F D A
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S ta in 6 - M P +  A P  (L S D )
A N T G C -A N T G A N T G C -A N T G
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
y -H 2A X  Foci 
F O R M A T IO N 6 -M P +  A P  (L S D ) A N T G A N T G A N T G A N T G
C ell C ycle/PI A rrestin g  P h ases 6 -M P +  A P  (L SD ) N o A rrest N o A rrest N o  A rrest N o A rrest
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity 6 -M P  +  E M O  (L S D ) N T N T N T N T
C asp ase-G lo®  9  A ssay C asp ase  9 A ctiv ity 6-M P  +  E M O  (L S D ) N T N T N T N T
G S H G Io ™  G lu ta th ion e  
A ssay G S H  L evel 6 -M P  +  E M O  (L S D )
■: A N T G C -A N T G A N T G C -A N T G
C eliT rack er G S H G r e e n  
C M F D A
%  o f  C ells w ith  G S H  
Stain 6 -M P  +  E M O  (L S D )
A N T G C -A N T G A N T G C -A N T G
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
y  -H 2A X  Foci 
F O R M A T IO N 6 -M P  +  E M O  (L S D ) C -A N T G A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases 6-M P  +  E M O  (L S D ) N o A rrest N o A rrest N o  A rrest N o  A rrest
C asp ase-G lo®  8 A ssay C asp ase  8 A ctiv ity 6-M P  +  R H  (L S D ) N T N T N T N T
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity 6-M P  +  R H  (L S D ) N T N T N T N T
G S H G Io ™  G lu tath ion e  
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A N T G C -A N T G C -A N T G C -A N T G
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A N T G C -A N T G C -A N T G C -A N T G
A lexa  F lu or®  647  M ou se  
an ti-H 2A X
y -H 2 A X  F oci 
F O R M A T IO N 6 -M P +  R H  (L SD ) C -A N T G C -A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P h ases 6 -M P  +  R H  (L S D ) N o A rrest N o A rrest N o  A rrest N o A rrest
C asp ase-G Io®  8 A ssay C asp ase 8 A ctiv ity 6 -M P  +  C IS  (L S D ) N T N T N T N T
C asp ase-G lo®  9 A ssay C asp ase  9 A ctiv ity 6-M P  +  C IS  (L S D ) N T N T N T N T
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A ssay G S H  L evel 6 -M P  +  C IS  (L S D )
A N T G C -A N T G C -A N T G C -A N T G
C eliT ra ck er  G S H G r e e n  
C M F D A
%  o f  C ells w ith  G SH  
S ta in 6 -M P  +  C IS  (L S D )
A N T G \  ' C -A N T G C -A N T G C -A N T G
A lexa  F lu or®  6 4 7  M ou se  
an ti-H 2A X
y -H 2 A X  Foci 
F O R M A T IO N 6-M P  +  C IS  (L S D ) C -A N T G C -A N T G C -A N T G C -A N T G
C ell C ycle/PI A rrestin g  P hases 6 -M P  +  C IS  (L S D ) N o A rrest N o A rrest N o  A rrest N o A r r e s t
Table 4.9: A summary of the effects of 6-mercaptopurine (6-MP) and polyphenols 
(QUE), apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS)] combination ti 
on caspase 8 and 9 activity, glutathione (GSH) levels, y-H2AX foci formation and 
progression (Chapter 3) in two lymphoid leukaemia (JURKAT and CCRF-CEM) and tw 
leukaemia (THP-land KGla) cell lines at 24 h. Combination treatments were investigated at ti 
significant dose (LSD). Note that the combination effects of drugs were determined statistically as 
as in Section 4.2.5. SYN = Synergistic, ADD = Additive. NT= non-tested. Cell cycle data sum 
enable comparison to results of y-H2AX formation.
quercetin 
reatments 
cell cycle 
o myeloid
leir lowest 
described 
marised to
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4.4 Discussion
4.4.1 The Role of Polyphenols on Extrinsic and Intrinsic Apoptosis Pathways: Caspases 8 
and 9 Activity
4.4.1.1 E ffec t Flavonoids Com pounds: Quercetin, Apigenin and  Chiysin on Caspases 
Activity
(A) Quercetin
Quercetin (used at its NSD, LSD and IC50) caused a significant increase in caspase 8 , 9 and 3 
activity in the lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) at 6  and 24 h, and 
the myeloid leukaemia cell lines (THP-1 and K G-la) at 24h (Table 4.3) (Chapter 2; Mahbub et 
al, 2013); suggesting that quercetin directly activates both the extrinsic and intrinsic apoptotic 
pathways.
These finding are consistent with previous works in solid cancer tumour cells, which showed 
that quercetin treatment induce apoptosis in breast cancer (MDA-MB- 231 following 48 h 
treatment and MCF-7 following 24 h treatment) (Chien et al, 2009; Chou et al, 2010), and a 
recent study using K562 myeloid leukaemia cell line (Chen et al, 2015) via both the intrinsic 
and extrinsic pathways.
In contrast, quercetin treatment o f  human hepatoma cell lines (HepG2) for 18 h (Serrano et al, 
2006) and cervical cancer (HeLa) cell lines for 24 h cuases apoptosis via the intrinsic pathway 
with the activation o f caspase 9 and 3, in the absence o f caspase 8  (Huang et al, 2009; 
Priyadarsini et al, 2010; Zhang et al, 2009).
These finding demonstrate that quercetin is capable o f  inducing apoptosis by the direct 
activation o f  caspases, however whether this leads on to the activation o f  the intrinsic and/or 
extrinsic pathways varies depending to the cancer cell lines; suggesting that the mechanism o f  
action within the apoptotic pathway may be cell lineage- specific.
(B) Apigenin
Apigenin (used at its LSD, NSD and IC5 0) caused a significant increase in caspases 8 , 9 and 3 
activity in both the lymphoid leukaemia (JURKAT and CCRF-CEM) at 6  and 24hrs, and 
myeloid leukaemia cell lines (THP-1 and KG-la) at 24 h (Table 4.3) (Chapter 2; Mahbub et al, 
2013); suggesting once again that apigenin was capable o f  inducing apoptotic via the extrinsic 
and intrinsic pathways.
These results seem to be compatible with two earlier studies which found that apigenin 
treatment for 24 h in breast (MDA-MB-453) and prostate (22Rvl) cancer cell lines causes an 
increase in caspases 8 , 9 and 3, and induced apoptosis via both the intrinsic and extrinsic 
pathways (Choi and Kim, 2009; Shukla and Gupta, 2008).
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There are however two contrasting reports; that show apigenin treatment for 24 h in six 
leukaemia cell lines (THP-1, U937, HL60, JURKAT, K562 and NIH3t3) (Vargo et al, 2006 
and one lung cancer cell lines (H460) (Lu et al, 2010) causes the activation o f  intrinsic 
pathway only; through activation the caspase 9 and 3. There was however no reported 
increases in caspase 8  activity, or up-regulation o f Bax, AIF or cytochrome c. Further to this it 
was reported that this was accompanied by a decreased in the mitochondrial membrane 
potential; and an increase in the level o f  reactive oxygen species (Vargo et al, 2006; Lu et al, 
2010).
These findings demonstrate that apigenin can provide direct activity to promote caspase- 
dependent-apoptosis o f  cancer cells.
(C) Chrysin
Chrysin investigated at its IC50 doses; significantly increased both caspase 8  and 9 activity in 
three out o f  four leukaemia cell lines (JURKAT, CCRF-CEM and THP-1) at 24 h; suggesting 
that chrysin act via both the intrinsic and extrinsic pathways (Table 4.3) (Mahbub et al, 2013; 
Chapter 2). However chrysin did not affect caspase 8  or 9 activity in K G -la myeloid cell lines 
at any studied time points (Table 4.3), consistent with the lack o f  apoptosis seen (Mahbub et al, 
2013; Chapter 2). Since K G-la undergoes apoptosis in other treatment regimes, this suggests 
that K G-la specifically do not respond to crysin, unlike other lines tesed.
Only two published works has investigated the pro-apoptotic potential o f  chrysin in solid 
tumours cell lines. The first study by Li et al, 2011 showed that chrysin treatment for 24 and 
48 h up-regulation o f  caspase 8  and 3 and an induces apoptosis through the extrinsic pathway 
in gastric adenocarcinoma (SGC-7901), colorectal adenocarcinoma (HT-29 and HCT-116), 
cervical cancer (HeLa) and hepatoma (HepG2) cells lines (Li et al, 2011).
In contrast, a recent study by Samarghandian et al, 2014; showed that chrysin treatment for 48 
and 72 h induces apoptosis in lung adenocarcinoma epithelial cell lines (A549) through the 
activation o f  intrinsic pathways only, via an up-regulation the Bax:Bcl-2 ratio and an increase 
in caspase 9 and 3 activity (Samarghandian et al, 2014).
Based on these earlier studies and the results here it can be concluded that chiysin is capable o f  
inducing apoptosis via caspase activation in cancer cells lines; although the mechanisms o f  
induction is cell type specific cancer cell lines.
4.4.1.2 E ffec t o f  Anthraquinones: Em odin, R hein  and  Aloe-Em odin on Caspases A ctivity
Emodin, rhein (when used at their NSD, LSD and IC50) and aloe-emodin (when used at its IC50  
doses) significantly increased caspase 9 activity; but did not affect caspase 8  activity in three
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out o f  four leukaemia cell lines (Table 4.3); suggesting that the observed apoptosis induction 
and caspase 3 activation previously shown by these anthraquinones (Mahbub et al, 2013; 
Chapter 2) caused the activation o f the intrinsic pathway only. The only exception was seen 
once again in the K G -la myeloid cell lines; when treated with emodin failed to increase either 
caspase 8  or 9 activity at any treatment doses (Table 4.3). This would explain earlier findings 
in which emodin failed to induction o f  apoptosis in this cell line (Mahbub et al, 2013).
Previous work in cancer cell lines has shown that emodin treatment for 24 and 48 h in human 
oral squamous cell carcinoma cell lines (SCC-4) (Chen et al, 2010), T-lymphocytic leukaemia 
cell lines (JURKAT) (Wei et al, 2009) and murine leukaemia cell lines (WEHI-3) (Chang et al, 
2 0 1 1 ); were shown to induce apoptosis through the production o f  reactive oxygen species 
(ROS) and activation o f  mitochondria-dependent pathways, which subsequently was increased 
the activity o f  caspase 9, followed by the activation o f  caspase 3 and up-regulation the 
expression o f  PARP (Wei et al, 2009; Chen et al, 2010; Chang et al, 2011). Thus, suggesting 
activation o f  the intrinsic apoptotic pathway only.
A similar effect has been shown by Chen et al 2010, in which human oral squamous cell 
carcinoma cell lines (SCC-4) when treated with either aloe-emodin or rhein for 24 and 48 hr; 
were shown to induce apoptosis through the production o f  reactive oxygen species (ROS) and 
mitochondria-dependent pathway via up regulation the caspase 9 and 3 activity (Chen et al 
2010). Thus again demonstrating that in this cell line only the intrinsic apoptotic pathway was 
activated.
This evidence taken together, suggests that anthraquinones specifically targeted the intrinsic 
apoptotic pathway and activated caspases 9 only in all studied solid tumour and leukaemia cell 
lines.
4.4.1.3 E ffec t o f  Stilbenoid Compounds: Cis-Stilbene and  Trans-Stilbene on Caspases 
Activity
This has been shown here that cis-stilbene and trans-stilbene treatment for 24 h caused a 
significant increased in caspase 8 , 9 and 3 activity within all the lymphoid and myeloid 
leukaemia cell lines (JURKAT, CCRF-CE, THP-1 and KG-la) (Table 4.3) (Mahbub et al, 
2013; Chapter 2). This study is considered as first work investigating the effect o f  cis-stilbene 
and trans-stilbene on initiator caspases in leukaemia; concluding that stilbenoid compounds 
targeted both the extrinsic and intrinsic pathways to induce apoptosis in leukaemia.
In contrast, previous works in lungs (A549 and CH27) (Lee et al, 2004; Weng et al, 2009) and 
prostate (DU145 and PC3) cancer cell lines (Shankar et al, 2007) has shown that cis-stilbene 
and trans-stilbene treatment induce apoptosis via the intrinsic/mitochondrial pathway,
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increasing the Bax: Bcl-2 ratio, caspase 9 and 3 activity, but not caspase 8  or subsequent PARP 
cleavage (Lee et al, 2004; Shankar et al, 2007; Weng et al, 2009). Thus once again it would 
seem that the mechanism o f  induction o f apoptosis by the stilbenes is cell type specific.
4.4.2 The Role of Polyphenols Alone on Major Intracellular Antioxidant Molecule: 
Glutathione (GSH)
4.4.2.1 The B asal Levels o f  Intracellular Glutathione (GSH) Levels in Leukaem ia  Cell L ines
The lymphoid leukaemia cell lines (JURKAT and CCRF-CEM) had a low basal GSH level 
when compared to myeloid (THP-1 and KG-la) and non-tumour cell lines (CD133+ HSC and 
CD34+ HSC). As polyphenols are thought to reduce GSH levels and make cells more 
susceptible to apoptosis (Babich et al, 2011); this can explained why these cell lines were 
usually more sensitive to polyphenol treatment, when used either alone or in combined with 
chemotherapeutic agents.
In contrast, the myeloid leukaemia cell lines (THP-1 and KG-la) had higher basal GSH levels 
compared to lymphoid and non-tumour cell lines. So, this can possible explain why these 
myeloid cell lines were commonly more resistant to polyphenol treatments, either when used 
alone or in combined with chemotherapy agents. From this it can be concluded that the basal 
level o f  glutathione (GSH) in leukaemia cell lines is significantly related to their sensitivity or 
resistance to polyphenols alone or in combined with chemotherapeutic agents.
These findings are consistent with earlier work by Morales et al, 2005 who reported that 
intracellular glutathione levels play an essential role in determine the cancer cell sensitivity to 
apoptosis induction by the anti-neoplastic agent such as retinoid N-(4-hydroxyphenyl) 
retinamide (4-HPR) in melanoma (A375) and leukaemia (JURKAT and CCRF-CEM) cell lines 
(Morales et al, 2005). In fact, they showed that the higher the intracellular GSH levels in 
melanoma cell lines (A375) cells the greater the resistance 4-HPR induced apoptosis. 
Meanwhile the lower the intracellular GSH levels in leukaemia cell lines (JURKAT and 
CCRF-CEM) the greater the sensitivity these cells hade to 4-HPR induce apoptosis (Morales et 
al, 2005). Taken together, these results indicated the glutathione content in cancer cells is 
strongly related and contributed to determining the cancer cells sensitivity or resistance to 
induce apoptosis by anti-cancer agents; such as polyphenols.
4.4.2.2 E ffec t F lavonoids Compounds: Quercetin, Apigenin  and  Chrysin on G SH  Levels
(A) Quercetin
Quercetin has been shown here to act as GSH depleting agent for all the leukaemia cell line, 
when used at both low doses (NSD and LSD) and high doses (IC50) for 24 h (Table 4.8).
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However, some researchers have reported that quercetin can exhibit both antioxidant and/or 
pro-oxidant effects in cancer cell lines depending on the: (1) basal GSH levels in cells (Tsao, 
2010; Khan et al, 2012), (2) the treatment dose (Scharf et al, 2003; Ramos, 2008; Chang et al, 
2009; Granado-Serrano et al, 2012) and/or (3) the treatment duration (Ferraresi et al, 2005). 
However these bimodal effects have observed in solid tumour cancer cells lines; with most 
work being carried out in hepatoma cell lines (Scharf et al, 2003; Ramos, 2008; Chang et al, 
2009; Granado-Serrano et al, 2012); and with very little study being undertaken in leukaemia 
cells (Cipak et al, 2003; Ferraresi et al, 2005). In particular, quercetin when used at a low  
doses this caused an antioxidant effects, increasing GSH levels and reducing ROS generation. 
However at high doses quercetin causes a pro-oxidant effect, decreasing GSH levels and 
increasing ROS; which lead to a reduction in cell proliferation and an increase in apoptosis in 
cell lines o f  hepatoma (HepG2, H epalclc7  and HA22T/VGH (Scharf et al, 2003; Ramos, 
2008; Granado-Serrano et al, 2012; Ramos, 2008 and Chang et al, 2009), laryngeal (HEp2) 
(Durgo et al, 2007); and murine leukaemia cell lines (LI210) (Cipak et al, 2003).
Another study in U937 leukaemia cells reported that short term quercetin exposure (for 2, 4 
and 6  h) causes an antioxidant effect and increases GSH levels. However, during a more 
prolonged exposure (for 12 and 24 h) to quercetin this caused a pro-oxidant effects: a depletion 
o f  GSH levels, an altered mitochondrial permeability and increased cytochrome c release, the 
increase production o f  caspase 9 and 3, S phase cell cycle arrest and apoptosis (Ferraresi et al, 
2005). This study suggested also that depletion GSH levels can act specifically at an early 
event in the apoptotic process through the dissipation o f  the mitochondrial membrane potential 
(Ferraresi et al, 2005).
(B) Apigenin
Similar to quercetin result, apigenin significantly depleted GSH levels when used at all 
treatment doses both low and high in most o f  the leukaemia cell lines (JURKAT, CCRF-CEM 
and THP-1) (p<0.05) (Table 4.8). However in the K G -la myeloid cell lines, there was a 
differential effect on GSH levels dependent on dose (Table 4.8). In particular at the NSD and 
LSD for apigenin there was an elevation o f  GSH levels, while at its IC5o dose the GSH levels 
were depleted (Table 4.8). This effect is not surprising as the K G -la cell line has the highest 
basal GSH level o f  all the studied leukaemia cell lines (Section 4.3.2.1). From this it can be 
concluded that apigenin can act as the anti- or pro-oxidant depending on basal GSH content 
and treatment doses used in the KG-la myeloid cell lines.
Based on earlier works, the effect o f apigenin on GSH has been only studied on solid tumour 
cell lines o f  the liver (HepG2), lungs (A549) and prostate (PC-3 and 22R vl) (Ramos, 2008; 
Kachadourian and Day, 2006 and Shukla and Gupta, 2008). These studied has shown that
apigenin causes a rapid depletion in GSH levels, an increase in ROS generation and an 
activation o f  p53. This was followed by a disruption o f  the mitochondrial membrane potential 
via a decrease in Bcl-xl and Bcl-2, and an increase in Bax. This subsequent resulted in a 
cytosolic release o f  cytochrome c which triggers caspase 9 and 3 activation and apoptosis 
(Kachadourian and Day, 2006; Shukla and Gupta, 2008; Ramos, 2008).
(C) Chrysin
In this study chrysin was only tested at theIC5o which significantly decreased GSH levels all 
the leukaemia cell lines (Table 4.8). This finding is consistent with previous studies which 
demonstrated that chrysin could depleted GSH levels in solid tumours cell lines from non­
small cell lung cancer (A549, H I57, H I975 and H460), and prostate cancer cell lines (PC-3) 
(Kachadourian and Day, 2006; Kachadourian et al, 2007; Brechbuhl et al, 2012; Kachadourian 
and Day, 2006 and Brechbuhl et al, 2012). This work reported that chrysin causes a pro­
oxidant effect, by directly depleting GSH and subsequently increasing caspase 8  and Bid 
activity (Kachadourian and Day, 2006; Kachadourian et al, 2007; Brechbuhl et al, 2012).
4.4.2.S Effect o f  Anthraquinone Compounds: Emodin, Rhein and Aloe-Entodin on GSH  
Levels
In generally, each o f  the anthraquinone (emodin, rhein and aloe-emodin) caused a significant 
depletion in GSH levels at their highest treatment doses (ICsos) in all the leukaemia cell lines 
(Table 4.8). However, emodin and rhein caused a dose-dependent effect on GSH levels (Table
4.8). When used at a low doses (NSD and LSD), emodin and rhein either caused no effect, or 
depletion in GSH levels (Table 4.8). However in the K G -la myeloid cell line, which has the 
highest basal GSH levels, these polyphenols when used at a low dose caused an increase in 
GSH levels (Table 4.8). From this, it can be suggested that emodin and rhein can act as the 
anti- or pro-oxidant effects depending on the treatment dose used, the cell type and/or the basal 
GSH. However it would seem that i f  these anthraquinone are to be used therapeutically that 
need to be used a doses around those o f the IC50 ranges.
This suggestion is confirmed by earlier work which showed that emodin at high dose causes a 
depletion o f  GSH levels, an increase ROS generation and apoptosis in gallbladder (SGC996) 
(Wang et al, 2010) and ovarian carcinoma cell lines (COC1) (Ma et al, 2014). Both studies 
specifically stated that emodin requires a high dose to achieve its growth inhibitory effect or 
induction o f  apoptosis in SGC996 and COC1 cell lines (Wang et al, 2010; Ma et al, 2014).
333
4.4.2.4 Effect o f Stilbenoids: Cis-Stilbene and Trans-Stilbene on GSH Levels
Cis-stilbene and trans-stilbene significantly depleted GSH levels at their LSD and IC50 
treatment doses and did not show any effect at NSD in lymphoid cell lines (JURKAT and 
CCRF-CEM) (Table 4.8). However, these stilbenoids caused dose-dependent differential 
effects in the myeloid leukaemia cell lines (THP-1 and KG-la) (Table 4.8). Specifically, cis- 
stilbene at the lower doses (NSD and LSD) caused a significant elevation in GSH levels; while 
at higher doses (IC50) it caused a significant depletion in GSH in both myeloid cell lines (Table
4.8); suggesting this that the action of cis-stilbene on GSH modulation is strongly dependent 
on doses. Trans-stilbene when used as it IC50 dose significantly depleted GSH levels in THP-1 
cell line, but surprisingly it was caused an elevation on GSH levels in KG-la cells (Table 4.8); 
concluding that the modulating effect of trans-stilbene could be dependent also on doses, cell 
type and/or the basal levels of GSH.
In summary it would seem that both stilbenoids compounds have a pro-oxidant activity in 
lymphoid cell lines, while they have both antioxidant and pro-oxidant activity in myeloid cell 
lines. The results shown that their modulation effects on GSH levels was strongly correlated to 
doses, cell type and/or basal GSH levels.
4.4.3 The Role of the Selected Polyphenols (Quercetin, Apigenin, Emodin, Rhein and Cis- 
Stilbene) Alone on DNA Damage
When investigating the effect of polyphenols of DNA damage only the most potent 
polyphenols were selected (quercetin, apigenin, emodin, rhein and cis-stilbene) and were used 
at their LSDs. Here it was shown polyphenols had differential capacities to induce DNA 
(shown as y-H2AX foci) within the leukaemia cell lines. In particularly, quercetin increased 
the number of y-H2AX foci in three out of four leukaemia cell lines; with only the KGla cell 
line demonstrating some resistance to DNA damage. However, apigenin was shown to increase 
y-H2AX foci formation in all the leukaemia cell lines. Emodin and rhein were less impressive 
as they only caused an increase in y-H2AX foci in the CCRF-CEM lymphoid cell line; whilst 
cis-stilbene did not cause any increase in y-H2AX foci in any leukaemia cell lines.
As a result, these polyphenols seem to cause different capacities to induce the formation of y- 
H2AX foci within the leukaemia cell lines; with the most effective polyphenols being apigenin 
and quercetin and the less effective being emodin rhein and cis-stilbene.
A few earlier studies have reported that polyphenols such as quercetin, genistein, curcumin 
and resveratrol could directly induced DNA damage, with it associated increase of y-H2AX 
phosphorylation through the activation of the ATM/ATR and CHK1/2 pathway-mediated S or 
G2/M cell cycle arrest and apoptosis in solid tumours cell line of the lungs (A549) (Tan et al,
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2009), ovaries (Ovcar-3 and HO-8910) (Tyagi et al, 2005 and Ouyang et al, 2009), and 
pancreas (BxPC-3) (Sahu et al, 2009).
Furthermore in a study by Singh et al, 2004) it has been reported that when DNA damage is 
induced by anti-cancer agents and is associated with the elevation in the expression of y-H2AX 
levels it is causally linked to ROS generation and the depletion of GSH levels, followed by the 
activation of S or G2/M checkpoints and apoptosis. This suggests that differentaial effects seen 
by polyphenols on DNA damage is strongly likned to GSH levels, and once the GSH level are 
depleted may there a progression to DNA damge.
4.4.4 The Mechanisms of Action of Toposiomerase Inhibitor Agents in Combination with 
Polyphenols
Previously, both DOX and ETP have been shown to act synergistically with polyphenols 
reducing ATP levels and inducing apoptosis with the all selected polyphenols (QUE, AP, EMO, 
RH or CIS) in lymphoid leukaemia cell lines (JURKAT and CCRF-CEM); and with QUE and 
AP only in the myeloid leukaemia cell lines (THP-1 and KG-la) (Chapter 3).
A further study of caspase 8  and 9 activity in each of these toposiomerase inhibitor/ polyphenol 
combination treatments was caused by a synergetic activation of caspase 9 and additive 
activation of caspase 8  in all leukaemia cell lines (Table 4.4 and 4.5); suggesting that these 
combination agents were preferably induced apoptosis through the activation of intrinsic 
pathways; but can also activate the extrinsic pathway, most likely via p53-mediated death 
receptor expression. In addition, each of these synergetic combination treatments was 
associated with a synergetic depletion in GSH levels (Table 4.9 and 4.10), as well as, a 
synergetic formation of y-H2AX foci (Table 4.15 and 4.16). In correlation to the previous cell 
cycle results, all those synergistic combination agents had also an interactive effect on cell 
cycle which significantly increased the cell accumulation in S phase and/or G2/M phase; this 
results can be confirmed by the presence of formation of y-H2AX foci as showed here which 
commonly indicated for the presence of DNA damage in particular DSBs (Table 4.15 and 
4.16).
Alternatively, DOX and ETP topoisomerase inhibitor agents have shown either additive or 
antagonistic effects when combined with the EMO, RH or CIS in myeloid leukaemia cell lines 
(THP-1 and KG-la) (Chapter 3). In particular, combination agents that had previously 
additive effects (DOX + CIS) and (ETP + EMO) can be associated also with additive effects 
on the depletion of GSH levels (Table 4.9 and 4.10) and an increase in y-H2AX formation 
(Table 4.15 and 4.16). More importantly, when DOX was combined with EMO or RH, or 
when ETP was combined with RH or CIS an antagonistic and/or competitive antagonistic 
elevated in ATP levels and an inhibited the apoptosis was observed in the myeloid cell lines
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(THP-1 and KG-la) (Chapter 3). Interestingly, those antagonistic combination treatments 
were associated with an elevation in GSH levels (Table 4.9 and 4.10) and no y-H2AX foci 
formation (Table 4.15 and 4.16). This may helps to also explain why there was no arrest of the 
cell cycle following the use of these treatment combinations in the myeloid cell lines.
As a result, the modulation on GSH level and y-H2AX foci formation seem to play important 
role in synergetic and antagonistic effects topoisomerase inhibitor agents (DOX and ETP) 
polyphenols combination treatments in leukaemia cell lines. This suggestion is supported by 
the finding of a small study looking the effects of doxorubicin with quercetin in human breast 
cancer cell lines (MCF-7, MDA-MB-231 and MCF-10A). Here it was shown that synergistic 
inhibition of cell proliferation and induction of apoptosis was through the reduction of cellular 
GSH levels and its enzyme GST (Staedler et al, 2011).
In addition, the synergetic effects of DOX and ETP with polyphenols on apoptosis induction 
seem to be dependent on the activation of caspase cascades, in particular caspase 9 and 3 
through the intrinsic pathway. This is very compatible with finding by Wang et al, 2012 which 
showed that doxorubicin when combined with quercetin causes synergistic induction of 
apoptosis through the accumulation of p53, and the activation of the intrinsic apoptotic 
pathway associated with the activation of caspase 9 and 3 in human hepatoma cell lines 
(SMMC7721 and QGY7701) (Wang et al, 2012).
Here for the first time we have shown the exact mechanisms of synergism and antagonism of 
topoisomerase inhibitor agents DOX and ETP when combined with QUE, AP, EMO, RH or 
CIS based on investigation the GSH levels, caspases cascades and y-H2AX foci formation 
within the lymphoid and myeloid leukaemia cell lines.
4.4.5 The Mechanisms of Action of Alkylating Agents in Combination with Polyphenols
The alkylating agents CSP and CYCL have were the next most effective chemotherapeutics to 
interact with the polyphenols in leukaemia cell lines (Chapter 3). CSP and CYCLO 
demonstrated a potent synergistic effect when combined with 4 out of 5 polyphenols on ATP 
levels, apoptosis and cell cycle in the lymphoid cell lines (JURJAT and CCRF-CEM) (Chapter 
3). However, they had a differential effects either synergistic or additive or antagonistic effects 
when combined with the 5 polyphenols (QUE, AP, EMO, RH, or CIS) in myeloid leukaemia 
cell lines (THP-1 and KG-la) (Chapter 3).
4.4.5.1 Cisplatin (CSP) in Combination with Polyphenols
CSP was shown to synergistically reduced ATP levels and induced apoptosis when combined 
with all the selected polyphenols (QUE, EMO, RH or CIS); and additively interacted with AP
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within the lymphoid leukaemia cell lines (Chapter 3). Similarly, CSP had a synergistic effect 
when combined with QUE and an additive effect when combined with AP in myeloid 
leukaemia cell lines (Chapter 3). Mechanistically CSP when combined with QUE, AP or CIS 
caused a synergistic activated both caspase 8  and 9 (Table 4.7); suggesting an activation of 
both the extrinsic and intrinsic apoptotic pathways all the leukaemia cell lines. While when 
CSP was combined with EMO or RH there was an additive activated the caspase 8  and a 
synergistic activated the caspase 9 in lymphoid leukaemia cell lines (Table 4.7); indicating that 
these combinations preferentially induced apoptosis by the intrinsic pathway, but could also 
activate the extrinsic pathway. Furthermore, all these synergetic combination agents were 
linked with a synergetic depletion in GSH levels (Table 4.12), as well as, with a synergetic 
formation of y-H2AX foci in all the leukaemia cell lines (Table 4.18).
These results are supported by earlier work in which cisplatin was combined with quercetin (Li 
et al, 2014), apigenin (Chan et al, 2012) or emodin (Wang et al, 2010; Ma et al, 2014) and 
caused a synergistic inhibition of cells proliferation, an induction of apoptosis through the 
elevation of intracellular ROS and the reduction GSH levels and down regulation of MRP1 
expression. This caused mitochondrial transmembrane potential dissipation and activated of 
the intrinsic apoptotic pathway via releasing of cytochrome c, down-regulation of Bcl-X(L) 
and up-regulation Bax, followed by caspase 9 and 3 activation and apoptosis in ovarian cancer 
cell lines (Li et al, 2014; Ma et al, 2014), gallbladder (SGC996) (Wang et al, 2010) and head 
and neck squamous carcinoma (SCC25) (Chan et al, 2012).
However in the myeloid cells when CSP was combined with EMO, RH or CIS this caused an 
antagonistic and/or completive antagonistic effects on ATP levels, apoptosis and cell cycle 
(Chapter 3). These antagonistic effects are caused by elevated GSH levels, which were 
significantly greater than those caused by the CSP or the polyphenols alone and/or the vehicle 
controls (Table 4.12). This lead to the suggestion the elevated GSH in the myeloid cells 
prevents a reduction of ATP levels and the induction of apoptosis. In addition, the combination 
of CSP with EMO, RH or CIS in the myeloid also had no y-H2AX foci formation, and hence 
do DNA damage; which is also reflected in the lack of any effect of this treatment combination 
on progression of the cell cycle in the myeloid leukaemia cell lines (Table 4.18).
4.4.S.2 Cyclophosphamide (CYCLO) in Combination with Polyphenols
CYCLO demonstrated before a potent synergistic effect when combined with four out of five 
polyphenols (QUE, AP, EMO or RH) in the lymphoid leukaemia cell lines and with AP only in 
myeloid leukaemia cell lines by inhibition of ATP levels, induction of apoptosis via increased 
the caspase 3 activity and arrest the cell cycle (Chapter 3).
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In the lymphoid leukaemia cell lines the synergetic induction of apoptosis by CYCLO when 
used in combined with QUE or AP was caused by the synergetic activation of both caspase 8  
and 9; whilst when combined with EMO or RH this was caused by the synergetic activation of 
caspase 9 only. Meanwhile, in myeloid leukaemia cell lines the combination of CYCLO with 
AP caused the synergic induction of apoptosis via the activation of both caspase 8  and 9. These 
results show the combination of CYCLO with QUE or AP caused by the activation of both the 
extrinsic and intrinsic pathways; whilst the combination of CYCLO with EMO or RH is 
caused by the activation of the intrinsic pathway in leukaemia cells. Additionally, all those 
synergetic combination agents were associated with a synergetic depletion in GSH levels 
(Table 4.11), as well as, with a synergetic formation of y-H2AX foci (Table 4.17), a reduction 
in ATP levels, induction of apoptosis and arresting the cell cycle (Chapter 3) in all the 
leukaemia cell lines.
Alternatively, CYCLO has been found to have an antagonistic and/or competitive antagonistic 
effect when combined with QUE, EMO, RH or CIS in myeloid leukaemia cell lines; which 
showed significant elevation on ATP levels, inhibition on apoptosis and no effect on cell cycle 
progression (Chapter 3). Here, it was found that antagonistically and/or competitive 
antagonistically effect was linked to a significant elevation in GSH levels, as well as, a lack of 
y-H2AX foci in myeloid leukaemia cell lines. This may explain why there was no apoptosis or 
accumulation of cells at any phases of cell cycle in myeloid cell lines when treated with 
combination of CYCLO with QUE, EMO, RH or CIS (Chapter 3).
There are two previous studies that show that the efficacy of CYCLO can be differentially 
modulated by the natural agents such as curcumin and resveratrol in human breast cancer cell 
lines (MCF-7, MDA-MB-231, and BT-474) (Somasundaram et al, 2002; Singh et al, 2011). 
They concluded that the CYCLO activity was inhibited by curcumin, while it was enhanced by 
resveratrol although the actual mechanism of action was not reported. This study for the first 
time showed that the activity of CYCLO could be modulated by natural agents like 
polyphenols-dependent on their conjugation and interaction with the GSH, as well as, on the 
GSH content the basically present in cancer cells.
4.4.6 The Mechanisms of Action of Anti-Metabolites Agents in Combination with 
Polyphenols
Previously the anti-metabolites agents MTX and 6 -MP when combined with all the selected 
polyphenols (QUE, AP, EMO, RH or CIS) have been caused antagonistic and/or competitive 
antagonistic effects on ATP, apoptosis and cell cycle in both the lymphoid and myeloid 
leukaemia cell lines (JURKAT, CCRF-CEM, THP-1, KG-la) (Chapter 3). This study showed 
the antagonism of MTX and 6 -MP by polyphenols was significantly linked with an elevation 
in GSH level when compared to drugs alone (Table 4.13 and 4.14) and absence the formation
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of y-H2AX (Table 4.19 and 4.20) in all the leukaemia cell lines. Actually, this is first work 
showed the effect of MTX and 6 -MP in combined with polyphenols and their mechanisms of 
action within different type of leukaemia cell lines.
4.5 Conclusion
All eight polyphenols (quercetin, apigenin, chrysin, emodin, rhein, aloe-emodin, c/s-stilbene 
and Jraas'-stilbene) were previously shown to induce caspase 3 activity and morphological 
changes associated with apoptosis all leukaemia cell lines (Mahbub et al, 2013; Chapter 2). 
Here were have shown that the flavonoids (quercetin, apigenin, chrysin) and stilbenoids (cis- 
stilbene and trans-stilbene) (using the IC50 dose as for 24 h) increase both caspase 8  and 9 
activity, thus causing activation both the intrinsic and extrinsic apoptotic pathways. The 
anthraquinones (emodin, rhein, aloe-emodin), however only up-regulated the caspase 9 
activitythus working via the intrinsic pathway only.
When considering GSH levels it has been observed here that the basal level of GSH in 
leukaemia cell lines is related and contributed to their sensitivity or resistance to polyphenols 
treatment. The lymphoid leukaemia cell lines had the lowest basal GSH levels, whilst the 
myeloid leukaemia had higher levels of GSH comparable with or greater than that of non­
tumour control cells. The KG-la myeloid cell lines had the highest GSH levels, which may 
explain why this cell type was considered as the most resistant to polyphenol treatments. In 
this regard, our earlier work reported that myeloid leukaemia cell lines specifically the KG-la 
cells were most resistant cell lines to the most of polyphenolic treatments (quercetin, chrysin, 
emodin, aloe-emodin, c/s-stilbene treatments); while lymphoid leukaemia cell lines (JURKAT 
and CCRF-CEM) were the most sensitive leukaemia cell lines to polyphenol treatment (in 
particular to quercetin, chrysin, apigenin, emodin, aloe-emodin, c/s-stilbene treatments) 
(Mahbub et al, 2013). When polyphenols were investigated at their high doses ( I C 5 0 )  GSH 
levels were depleted. It is thought that this depletion in GSH it seems the major stimulus for 
caspase 8  and/or 9 activities and the induction of apoptosis in all leukaemia cell lines at these 
treatment doses at 24 h. The only exception was seen following stilbene treatment in the 
myeloid cell lines; in which elevated basal GSH levels could not be depleted by the I C 5 0  
treatment doses at 24h. When examining the effects of the most potent polyphenols on DNA 
damage (quercetin, apigenin, emodin, rhein and cis-stilbene) it has been shown that selected 
polyphenols have differential capacities to induce DNA damage in the leukaemia cell lines: 
apigenia and quercetin were the most effective, whilst emodin and rhein were least effective; 
whilst cis-stilbene had no effect.Futhermore, this study has concluded that the synergistic 
induction of apoptosis observed following the combination of chemotherapeutic agents with 
quercetin, apigenin or cis-stilbene was mainly caused by the activation of both intrinsic
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apoptotic pathway through the up-regulation of caspase 9 and the extrinsic apoptotic pathway 
via the up regulation of caspase 8 ; while with emodin and rhein was specifically caused by the 
intrinsic apoptotic pathway via the activation of caspase 9 only within the lymphoid and 
myeloid leukaemia cell line.
Here it was found that the synergistic or antagonistic effects observed following the 
combination of chemotherapies agents and polyphenols were strongly dependent on the 
modulation of the glutathione levels in association with the formation of y-H2AX nuclear foci 
in leukaemia cell lines. In conclusion, it was found the depletion of GSH levels and formation 
of y-H2AX foci were significantly associated with the combination of chemotherapies and 
polyphenols that had previously synergetic inhibition on ATP levels, induction of apoptosis, 
and accumulation of cells at S and/or G2/M phases. On the other hand, it was observed that the 
elevation of GSH levels and lack of y-H2AX foci was linked with the combination of 
chemotherapies and polyphenols that had earlier antagonistic or competitive antagonistic 
effects on ATP, apoptosis and cell cycle. As a result the sensitivity or resistance of leukaemia 
cells to the combination of chemotherapeutic agents with polyphenols is modulated, either by 
increasing or decreasing the intracellular glutathione contents, respectively. Actually, our data 
provide new and interesting information on the role of intracellular GSH in leukaemia cells 
sensitively or resistance to the apoptosis by polyphenol and chemotherapeutic agent 
combinations. Firstly, GSH depletion could be useful to increase the therapeutic efficacy of 
cancer treatment combining the polyphenols with chemotherapeutic drugs. Secondly, a 
polyphenols/chemotherapy agent seems to be more effective to cells with low GSH content 
such as lymphoid cells, while less effective to cells with high GSH content such myeloid cells. 
Finally, cancer cell type and their basal level of GSH specificity should be taken into account 
when designing new clinical chemotherapy approaches using combinations of polyphenols.
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Chapter 5 
General Discussion.
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5.1 Key Findings
5.1.1 The E ffec t o f  Polyphenols Treatm ent on Leukaem ia Cell L ines
This study demonstrated for the first time the specific IC50 and AP50 values at 24 h for eight 
polyphenols on four lymphoid and four myeloid leukaemia cells lines, together with normal 
haematopoietic control cells. This enabled a direct comparison of the anti-proliferative and 
apoptotic effects of each polyphenol, and rank then in order of effectiveness from the most to 
least effect: emodin > quercetin > m-stilbene > apigenin > rhein > aloe-emodin > trans- 
stilbene > chrysin. This ranking did vary between individual cell lines. Polyphenols with 
similar molecular structures such as emodin and aloe-emodin had differential effects on 
leukaemia cells. The effectiveness of polyphenols was lineage dependent suggesting that 
polyphenols molecular mechanism of action may vary between cell lineages. Lymphoid cell 
lines were usually more sensitive to polyphenol treatment than myeloid cell lines. However, 
the most resistant myeloid (KG-la and K562) cell lines, did still respond to emodin and 
quercetin treatment even when treated at low micromolar levels. These differential sensitive 
patterns seen within myeloid and lymphoid cell lines could be due to different cellular origin, 
genetic abnormalities and/or expression of differential proteins by different types of cells. 
However when considering cell-cycle arrest, the majority of polyphenols induce G0/G1 arrest, 
suggesting that they may inhibit CDK4 and/or CDK6  related pathways. This study also 
showed that the effect of the polyphenols was always greater in the leukaemia cells than the 
non-tumour blood progenitor cells.
The findings here together with earlier works on polyphenols in solid tumours suggested that 
polyphenols are promising anti-cancer agents, as they are capable of inhibiting cell 
proliferation, inducing cell cycle arrest and apoptosis; without causing any toxicity to normal 
cells (Dai et al, 2013; Han et al, 2007; Jaganathan et al, 2009; Patel et al, 2007; Sharif et al, 
2010; Shukla et al, 2010). This study demonstrated that all eight polyphenols induced caspase 
3 activity and caused apoptotic morphological changes in all leukaemia cell lines. Quercetin, 
apigenin, chrysin, cis-stilbene and trans-stilbene induced caspases 8  and 9 activity, whilst, 
emodin, rhein and aloe-emodin caused the activation of caspase 9 alone in all leukaemia cell 
lines. From the findings here in leukaemia cell lines, together with earlier studies on solid 
tumours cells, it can be demonstrated that polyphenols can induce apoptosis through the 
differential mechanisms (Dai et al, 2013; Han et al, 2007; Jaganathan et al, 2009; Patel et al, 
2007; Sharif et al, 2010; Shukla et al, 2010).
Most polyphenols when used at their IC50 doses for 24 h caused a decrease of basal GSH levels. 
This depletion in GSH seems to be the major stimulus for caspase 8  and/or 9 activities and the 
induction of apoptosis in all leukaemia cell lines. The only exception was seen following
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stilbene treatments (cis-stilbene and trans-stilbene) in the myeloid cell lines; in which there 
was an elevated basal GSH levels.
These findings are supported by studies in solid cancer cell lines in which GSH depletion was 
strongly correlated with the induction of apoptosis; and believed to regulate both the extrinsic 
and intrinsic apoptotic signalling cascades at distinct checkpoints (Franco et al, 2007; Franco 
and Cidlowski, 2009; Ortega et al, 2011; Traverso et al, 2013; Irwin et al, 2013; Rocha et al, 
2014).
Polyphenols when used at their lower doses (NSD or LSD) caused differential effects on GSH 
levels. Earlier studies have reported that high basal GSH level in cancer cells is associated with 
an increased cell proliferation and antioxidant capacity, preventing oxidative stress, DNA 
repair and inhibiting cell death process; and as a result leads to resistance to cancer treatments 
(Abdalla, 2011; Traverso et al, 2013). Indeed, this study demonstrated that lymphoid cell lines 
(JURKAT and CCRF-CEM) had low basal GSH levels, compared to the myeloid cell lines 
(THP-1 and KG-la); and as a result the lymphoid cell lines were more susceptible of 
polyphenol treatment; whilst the myeloid cell lines were more resistant. Thus it would seem 
that GSH levels contributed to the sensitivity or resistance to polyphenols treatment in 
leukaemia cell lines. Interestingly, KG-la myeloid cell lines had the highest basal GSH levels, 
which may explain why this cell line was considered as the most resistant to most polyphenol 
treatments (quercetin, chrysin, emodin, aloe-emodin, and cA-stilbene treatments).
The most effective polyphenols (quercetin, apigenin, emodin, rhein and cA-stilbene) were also 
shown to induce DNA damage (measured as y-H2AX foci); and thus drive apoptosis. Indeed 
many studies have reported that DNA damage induces cell cycle arrest and/or apoptosis and 
that DNA damaging agents make good anti-cancer therapies (Kuo and Yang, 2008; Rajendran 
et al, 2011). Here, apigenin and quercetin were the most effective polyphenols at inducing 
DNA damage, whilst emodin and rhein were least effective, with cis-stilbene having no effect 
at all. This suggests that the induction of apoptosis caused by these polyphenol is not always 
driven by DNA damage.
5.1.2 The E ffec t o f  Polyphenols and  Chem otherapy Combination Treatm ents on L eukaem ia  
Cell L ines
Here it was demonstrated that the combination of the five most effective polyphenols 
(quercetin, apigenin, emodin, rhein and c/s-stilbene) differentially modulated the efficacy of 
nine chemotherapy agents; producing either synergistic, additive or competitive 
antagonistic/antagonistic effects on ATP levels, apoptosis and cell cycle arrest within the 
lymphoid and myeloid leukaemia cell lines. These differential effects were dependent on the 
type of chemotherapy or polyphenol and/or cell lineage being treated.
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The most effective chemotherapeutics to interact with the polyphenols were doxorubicin, 
etoposide and cisplatin, followed by cyclophosphamide. In general it was shown that when 
these chemotherapeutic agents when combined with each polyphenols caused a synergistic 
affects in the lymphoid leukaemia cell lines (JURKAT and CCRF-CEM). The only exception 
was seen when cyclophosphamide was combined with cis-stilbene, this caused an antagonistic 
effects in the lymphoid cell lines. In contrast however, in the myeloid cell lines (THP-1 and 
KG-la), the polyphenol/chemotherapy combination treatments caused a differential effects, 
producing either synergistic or additive or antagonistic effects.
The results of this study suggest that the use of polyphenols in combination with standard 
chemotherapy agents such as doxorubicin, etoposide, cisplatin, and cyclophosphamide is most 
effective in lymphoid cell lines. Most importantly among those polyphenols investigated, 
quercetin was the most interacted polyphenols with doxorubicin, etoposide and cisplatin; 
whilst apigenin was the most interacted polyphenols with cyclophosphamide; and this 
combination seem to be very promising for the treatment of both lymphoid and myeloid 
leukaemia cells.
These results are consistent with earlier work in which the activity of doxorubicin or cisplatin 
are strongly enhanced by quercetin in breast cancer (MCF-7, MDA-MB-231, and MCF-10A) 
(Staedler et al, 2011), hepatoma (SMMC7721 and QGY7701) (Wang et al, 2012), small cell 
lung cancer (SW1271), pulmonary adenocarcinoma (A549) (Borska et al, 2004), non-small 
cell lung carcinoma (NCL-H-520) (Kuhar et al, 2006), laryngeal carcinoma (Hep-2) (Kuhar et 
al, 2007), human malignant mesothelioma (SPC212 and SPC111) (Zergeroglu et al, 2010) and 
ovarian cancer (A2780) cell lines (Meher et al, 2011). Considering all these results together, it 
would seem that the activity of doxorubicin, etoposide, cisplatin and cyclophosphamide are 
influenced by the polyphenol type and the lineage of the cells being treated.
In contrast, in this study for the first time it has been shown that the combination of anti­
metabolites chemotherapy agents such as methotrexate and 6 -mercaptopurine when used in 
combination with the investigated polyphenols produced an competitive-antagonistic and/or 
antagonistic effects on ATP levels, apoptosis and cell cycle progression in both the lymphoid 
and myeloid leukaemia cell lines. This contradicts the finding of previous studies in which it 
has been suggest that the activity of chemotherapeutic agents is enhanced by polyphenols. 
There are only a few studies which demonstrated inhibitory actions of polyphenols on 
chemotherapeutic agents, which was attributed to the polyphenols chemical structure (Golden 
et al, 2009; Kim et al, 2009; Perrone et al, 2009), administration dose (Li et al, 2014) or the 
polyphenols anti-oxidant capacity (Somasundaram et al, 2002; Cipak et al, 2003; Kim et al, 
2009; Davalli et al, 2012).
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The exact mechanism by which polyphenols can enhance or inhibit the action of these 
chemotherapeutics is unknown. Here it has been shown however that is it is strongly correlated 
with modulation of the cellular GSH levels.
In particular, the synergistic effects from the combination of polyphenols and chemotherapy 
agents possibly occurred via a direct activation of extrinsic and/or intrinsic apoptotic pathways, 
which was associated with a depletion of GSH levels and elevation in levels of DNA damage.
Alternatively, the antagonistic effects produced by the combination of polyphenols and 
chemotherapy agents (e.g. QUE, AP, EMO, RH or CIS in combination with methotrexate and 
6 -mercaptopurine) were commonly associated with an elevation of GSH levels and a lack of y- 
H2AX foci formation. This finding is importance as this suggests that polyphenols can inhibit 
the action of standard chemotherapy such as methotrexate and 6 -mercaptopurine; and that 
patients taking these drugs should be careful about their consumption of polyphenol rich foods. 
Indeed this leads to the suggestion that the use of methotrexate and 6 -mercaptopurine 
therapeutically should be taken alongside a polyphenol free diet.
5.2 Future Directions
In order to test the efficiency and safety of polyphenols alone and in combined with 
chemotherapeutic agents; further in vitro and in vivo research is required. These phases of 
study are necessary prior to clinical approval and the used of these combination treatments in 
leukaemia patients.
5.2.1 E lucidate the M olecular M echanism s o f  Polyphenols
Experimental data obtained from this study has indicated that polyphenols induced apoptosis 
through caspase activation and arrested cell cycle at different phases in leukaemia cell lines. 
Further work is required to further elucidate the mechanism of action of polyphenols and 
chemotherapy agents at a molecular level in leukaemia cell lines. For this it would be 
necessary to: (1) Investigate whether polyphenols have ability to regulate the key pro-apoptotic 
proteins such as Bid, Bim, Noxa, Puma, Bad, Bax, Bak etc and anti-apoptotic proteins such as 
Bcl-2, Bcl-x, B c 1 - X l ,  Bcl-x, etc (Section 1.6.3). This could be investigated by western blot 
analysis using Western Lightning™ Chemiluminescence Reagent Plus (PerkinElmer Life 
Sciences, US). Work by Pesakhov et al, 2010 used western blot analysis to examine the effect 
of curcumin and camosic acid alone and in combination on the levels of Bcl-2 family proteins, 
including the levels of anti-apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1) and pro-apoptotic 
proteins (Bax and Bak) in two myeloid leukemia cell lines (HL-60 and KG-la). They reported 
that treatments alone did not show any change in the expression of Bcl-2 family proteins, while 
in combination with camosic acid caused a down regulation of Bcl-2 and Bcl-xL; and an
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elevated the Bax levels; which they attributed to activation of mitochondrial caspase-9 
(Pesakhov et al, 2010). (2) Investigate whether polyphenols have the ability to activate the 
production of vital apoptotic proteins in leukaemia cells. This would include a study of histone 
acetylation and the inhibition of HD AC and histone deacetylase (HD AC) activity, as these are 
involved in several cellular regulative processes including: transcription, cell cycle progressing, 
gene silencing, cell differentiation, DNA-replication and DNA-damage responses (Groh et al, 
2013). This can be investigated using HD AC chemiluminescent drug discovery kit (Enzo, UK) 
which is designed to measure histone deacetylase (HDAC) activity in cells, nuclear extracts, 
immunoprecipitates or purified enzymes. Indeed recent work by Vargas et al, 2014 showed 
that quercetin has the ability to inhibit HDAC activity and increase reactive oxygen species 
levels in glioma cell lines; (Vargas et al, 2014). In fact, most evidence suggests that agents that 
inhibiting HDAC and/or protesome activity could be used as a potential strategy for cancer 
therapy and could be used in combination with standard chemotherapeutic agents to overcome 
the drug resistance (Almond and Cohen, 2002; Groh et al, 2013; Vargas et al, 2014). (3) 
Investigate the direct effect of polyphenols on proteasome activity, as proteasomes plays a key 
role in cell cycle regulation, tumour growth and cell survival (Almond and Cohen, 2002). This 
can be investigated using proteasome fluorogenic assay kit for drug discovery (Enzo, UK) 
which is designed to measure chymotrypsin-like protease activity of purified 20S proteasome. 
The effects of polyphenols on proteasome activity have not been previously reported. 
However some preliminary examination using each of the polyphenols studied here; has shown 
each to act as proteasome inhibitor activity. This work however, required repeating. (4) 
Investigate the effect of polyphenols on protein kinases activity and cell cycle regulators. This 
would include assessment of cyclin and cyclin-dependent kinase activity which is crucial in the 
regulation of the cell cycle. This can be examined using western blot analysis and/or RT-PCR. 
Both have been previoulsy used by Weng et al, 2005; to identify protein kinases and cell cycle 
regulators that responsible for arresting the cell cycle at Gi phase in C6  glioma cells, following 
treatment with chrysin. They demonstrated that chrysin enhanced p2 l Wafl/Cipl protein levels 
and inhibited CDK4- and CDK2-mediated phosphorylation of Rb (Weng et al, 2005); thus 
understanding the effects of chrysin progression of cell cycle. This is essential for the rational 
design of novel drugs to prevent abnormal cellular proliferation seen during cancer. (5) 
Investigate the effect of polyphenols alone and in combination with chemotherapeutic agents 
on reactive oxygen species (ROS) levels, which is considered to be an important protective 
biomarker and may be a crucial target for anti-cancer therapies by ameliorating oxidative stress 
and thus DNA damage (Babich et al, 2011). The intracellular ROS levels can be investigated 
and determined by the oxidation-sensitive fluorescent probe (DCFH-DA) using flow cytometer. 
Previousl work by Pesakhov et al, 2010 used this assay to measure the levels of ROS in two 
myeloid leukaemia cell lines (HL-60 and KG-la) treated with curcumin, camosic acid and
stilbene, alone and in combination with each other. They did not observed any significant 
elevation of the intracellular ROS levels in leukaemia cells; even when the treatment dose were 
increase to 50 pm (Pesakhov et al, 2010).
5.2.2 In Vivo Animal Studies
Earlier in vivo works using xenograft models has demonstrated the possible use o f polyphenols 
alone or in combination with chemotherapeutic agents in the treatment of cancers (Dai and 
Mumper, 2010; Lewandowska et al, 2014). Genistein has been shown to significantly reduce 
tumour growth of pancreatic carcinoma (BxPC-3) xenografts; when used alone and in 
combination with cisplatin (Lewandowska et al, 2014). Similar Caltagirone et al, 2000 
showed that quercetin and apigenin inhibited growth and metastasis of melanoma cell (B16- 
BL6 ) grown as xenograph on athymic mice. They concluded that quercetin and apigenin had a 
greater anti-cancer effect than the chemotherapy agent tamoxifen (Caltagirone et al, 2000). It is 
clear from these studies that it is important to investigate the anti-cancerous potential of 
polyphenols within an in vivo system; to date this has not been undertaken to study the effects 
of polyphenols alone or in combination with standard chemotherapy agents on leukaemia. 
Thus in order to confirm the current finding, an appropriate animal model or xenograft system 
is required for the further study the effect of polyphenols on leukaemia in vivo. Use of such 
models would be required to determine whether polyphenol treatment is feasible in the whole 
organisms, and if so, which are the most effective treatments, doses and routes of 
administration.
Some recent studies reported that polyphenols when administrated orally under in vivo 
conditions resulting in poor bioavailability, as a result of poor solubility and/or rapid 
metabolism (Bansal et al, 2011; Rodriguez et al, 2013). Rodriguez et al, 2013 reported that 
most polyphenols including quercetin, curcumin, resveratrol and epigallocatechin gallate 
(EGCG) when administrated orally are not absorbed by the intestine in their native form, 
instead they are conjugated before passing into the blood stream (Rodriguez et al, 2013). 
Furthermore, coexisting compounds in the gut lumen lead to inhibit the digestive enzyme 
activity and/or alteration of the intestinal transport system; and hence a reduced intestinal 
absorption (Rodriguez et al, 2013). Once absorbed, polyphenols are further metabolised in the 
liver and then eliminated through urine and bile (Rodriguez et al, 2013). It is known that 
polyphenols are normally subjected to 3 main types of conjugation: methylation, 
glucuronidation and sulphation (Rodriguez et al, 2013). So, this extensive conjugation 
followed by a rapid excretion of the conjugated metabolites is responsible of their poor 
bioavailability of polyphenols (Rodriguez et al, 2013). However, it has been shown that these 
limitations can be circumvented by intravenous administration of polyphenols (Rodriguez et al,
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2013). Study by Bansal et al, 2011 showed that curcumin was rapidly metabolism in the 
intestine and liver; with approximately 60% to 70% of orally given curcumin was eliminated in 
faeces (Bansal et al, 2011). It was reported that when curcumin was administrated orally as an 
aqueous suspension (2 g/kg) the maximum plasma concentration reached was 1 mg/mL within 
1 hour, and this then dropped rapidly to undetectable levels within 5 hours (Bansal et al, 2011). 
Likewise, when curcumin was administrated intraperitoneally in mice at 0.1 g/kg; only 2.25 
mg/mL reached blood plasma within 15 mins; which rapidly dropped to 0.35 mg/mL after only 
1 hour (Bansal et al, 2011). Similarly, intravenous administration of curcumin results in about 
50% elimination in bile within 5 hours (Bansal et al, 2011). It is believed that this poor 
bioavailability of curcumin may be caused by the formation of sulphate and glucuronide 
conjugates which prevent its absorption and sped up its elimination (Bansal et al, 2011). 
Bansal et al, 2011 suggested that the bioavailability of polyphenols such as curcumin, ellagic 
acid, resveratrol and green tea polyphenols may be improved by the use of novel delivery 
systems such as liposomal formulations, nanoparticles, microemulsions and/ or polymeric 
implantable devices; which could deliver therapeutic concentrations directly into the systemic 
circulation (Bansal et al, 2011). These finding however suggest that more work is still needed 
to find the best administration route for polyphenols in vivo models and how these could be 
used in a clinical setting.
5.2.3 In  Vitro H um an Primary Leukaem ia Studies
Once therapeutic doses of polyphenols and chemotherapy drug are determined, the next step is 
evaluate whether these two agents work with the same efficacy on human blood samples taken 
from patients with lymphoid and myeloid leukaemia (Kennedy and Barabe, 2008).
5.2.4 H um an  Clinical Trials
Following investigation of the effect of polyphenols in vitro and in vivo, the next step would be 
to examine the efficacy and safety in humans. Thus the expansion to clinical trials in patients 
with leukaemia would be an essential step towards developing the use of polyphenols in the 
treatment of leukaemia. In addition, it would be essential to evaluate whether combination 
treatments with polyphenols on a large group of patients to determine whether reduced side 
effects were observed compared to the treatment with chemotherapy alone. To date there are 
few clinical trials that have tested the effect polyphenols on cancer. One promising clinical 
study by Cruz-Correa et al, 2006, found that the combination of quercetin and curcumin 
supplements decreased the number and size of pre-cancerous rectal tumours in patients 
suffering from rectal adenomas with familial adenomatous polyposis (FAP). Here they 
supplemented five patients with 480 mg of curcumin and 20 mg of quercetin orally, three times 
a day, for six months. As a result, 5 patients had a remarkable decrease in polyp number and
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size with an average reduction of 60% and 51% respectively, after 6 months; without 
appreciable toxicity (Cruz-Correa et al, 2006). Thus much work is required to further clarify 
the anti-cancer potential of polyphenols clinically in human.
5.3 Final Conclusion
This study has shown that polyphenols hold promise for the treatment of leukaemia. Lymphoid 
leukaemias were shown to be more sensitive than myeloid cell lines and limited effect were 
seen in non-tumour control cells. Selected polyphenols were shown to act differently either 
synergistically, additively or antagonistically with the standard chemotherapeutic agents, 
depending on the level of modulation of glutathione (GSH). Further in vivo investigations into 
polyphenols alone in the treatment of leukaemia are urgently needed to develop these potential 
agents as future treatments. Finally, this study also suggested a further in vivo study is urgently 
required to demonstrate whether diet-based polyphenols (QUE, AP, EMO, RH and CIS) affect 
chemotherapeutics activity.
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